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The development of checkpoint immunotherapy has been a paradigm shift in the treatment of 
cancer, leading to dramatic improvement in treatment outcomes across a broad range of tumor 
types. Nevertheless, our current understanding of the tumor immune microenvironment and 
mediators of resistance to therapy are limited. The recent development of high-throughput 
single-cell RNA-Sequencing (scRNA-Seq) technology has opened up an unprecedented window 
into the transcriptional states of distinct tumor-infiltrating immune and stromal cells. However, 
even this technology has its biological limitations, with very high levels of data dropout induced 
by low total mRNA molecules and capture efficiency.  
This thesis explores the application of a transcriptional regulatory protein activity 
inference approach to single-cell data in order to resolve gene dropout and more deeply 
characterize upstream drivers of cell state within the micro-environment of several distinct tumor 
types. To this end, algorithms for inference of protein activity, drug sensitivity, and cell-cell 
interaction have been adapted to scRNA-Seq data, along with an approach for querying 
enrichment of single-cell-derived population marker gene sets patient-by-patient in larger bulk-
RNA-Seq cohorts. By applying these tools systematically, we have identified distinct cellular 
sub-populations associated with clinical outcome in different tumor types, including a novel 
population of C1Q+/TREM2+/APOE+ macrophages associated with post-surgical tumor 
recurrence in clear cell renal carcinoma, a sub-population of fibroblasts associated with 
 
 
improved response to immunotherapy in head and neck squamous cell carcinoma, tumor cell 
subpopulations with distinct inferred drug sensitivities in cholangiocarcinoma and prostate 
cancer, as well as tumor-specific regulatory T-cells (Tregs), active as a mechanism of 
immunotherapy resistance across a range of tumor types. In ongoing clinical trials from both 
primary and metastatic prostate cancer as well as clear cell renal carcinoma, we are able to assess 
which of these populations are enriched in non-responders to checkpoint immunotherapy. The 
proteomic master regulators of each of these single-cell types have direct utility as potential 
biomarkers for treatment response, but they may also be therapeutically modulated as novel 
targets for combination immunotherapy, potentially improving treatment response rates and 
treatment outcomes in future clinical trials.  
Finally, this thesis also presents a discovery-to-validation platform to accelerate micro-
environment-directed drug repurposing in the context of immunotherapy resistance and rapid 
CRISPRko validation of novel therapeutic targets. This platform has been developed specifically 
to validate newly identified master regulators of tumor-specific immunosuppressive regulatory 
T-cells (Tregs), resulting in discovery of low-dose gemcitabine as a tumor-specific Treg-
modulating drug synergistic with anti-PD1 checkpoint immunotherapy and TRPS1 as a 
proteomic master regulator with clinically significant effect on tumor Treg-infiltrating and tumor 
growth rate. However, the platform itself may be readily extended in future work to prioritize 
agents against immunosuppressive macrophage and fibroblast populations for clinical 
development and trials. As we have discovered, different cancers have different populations of 
cells driving therapy response and resistance. Taken together, the analytical and validation tools 
presented in this thesis represent an opportunity to tailor future immuno-therapies at the single-
cell level to particular tumor types and to individual patients.  
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Checkpoint Inhibitors and the Role of the Tumor Microenvironment 
Solid tumors consist not only of tumor cells, but also of many diverse stromal and immune cell 
types infiltrating the tumor micro-environment. Traditional approaches to cancer therapy have 
commonly focused on killing tumor cells directly, but recent immune checkpoint inhibitor 
immunotherapies have aimed instead to activate anti-tumor immune cells in the tissue. The 
development of checkpoint immunotherapies has been transformative in clinical oncology over 
the past several years, motivating efforts to better profile specific immune cell types in tumors 
under various treatment conditions, in the hope that this will reveal novel therapeutic targets and 
combination therapies.  
Within any solid tumor, there is a complex milieu of stromal cells, including fibroblasts 
and vascular endothelium, as well as immune cells ranging from macrophages and dendritic cells 
which present cancer antigens, to B-cells, cytotoxic T-cells, regulatory T-cells, and various 
immunosuppressive populations. Anti-tumor response relies on infiltration of immune cells into 
the tumor compartment, tumor-cell recognition, and immune-mediated cell death, as well as local 
production of cytokines and clonal expansion of cytotoxic T-cells [1]. Mechanisms of immune 
tolerance in tumors are common, most notably the activity of immune checkpoints that inhibit 
cytotoxic T-cell activity.  
In particular, the interaction between programmed cell death 1 (PD-1) on T-cells and its 
corresponding ligand PD-L1 on tumor cells induces functional T-cell exhaustion and has been 
successfully targeted in the clinic by the anti-PD1 antibodies pembrolizumab and nivolumab to 
reactivate exhausted T-cells and re-engage their tumor-killing capacity. These drugs are now 
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widely used across a range of tumor types. For example, objective responses are seen in 40-45% 
of patients with melanoma given pembrolizumab or nivolumab in the first line setting and in 20% 
of patients with non-small cell lung cancer [2]. Although these and other checkpoint 
immunotherapies can elicit dramatic therapeutic responses, the characteristics of the tumor-
immune microenvironment responsible for response or treatment resistance are incompletely 
described.   
 
Clinical Predictors of Response to Immunotherapy  
To date, the most-utilized biomarker of response to checkpoint immunotherapy has been 
expression of PD-L1 in tumor tissue. However, both PD-L1 negative and PD-L1 positive tumors 
respond to immunotherapy, with different trials showing different levels of biomarker correlation 
with Response Rate (RR) and Progression-Free Survival (PFS) [3, 4]. Negative predictive value 
of PD-L1 staining as a marker for treatment response is as low as 58% for nivolumab, and 45% 
for nivolumab plus ipilimumab in patients with melanoma [2]. Other investigational predictors of 
response to immunotherapy have included Tumor Mutational/Neoantigen Burden, Bulk Immune 
Gene Expression Signatures, and Multiplex Immunohistochemistry staining [2]. These capture 
different potential mechanisms of therapy resistance, but each has significant drawbacks.  
A study of mutational load based on tumor whole-exome sequencing in advanced 
melanoma patients treated with anti-CTLA4 immunotherapy identified that a load of >100 non-
synonymous somatic mutations was associated with longer overall survival (log-rank p-
value=0.04 in discovery cohort, 0.10 in validation cohort) [2]. In non-small-cell lung cancer higher 
mutational burdens were found to be associated with clinical benefit, but intra-tumoral 
heterogeneity of neoantigen load further affects response rate [2].  
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Immunohistochemistry is limited to investigating small sets of pre-specified markers and 
can be very laborious to expand to novel markers. A study of melanoma tumor slides stained for 
CD3, CD8, FOXP3, CD163, and PD-L1 showed that presence of CD8+ T-cells alone was 
insufficient to predict growth of tumor-infiltrating lymphocytes ex vivo, although the ratio of 
CD8+ T-cells to immunosuppressive CD3+FOXP3+ Tregs was associated with tumor-infiltrating 
lymphocyte growth [2].  
Finally, gene expression has been investigated as a predictor of response to 
immunotherapy, identifying panels of immune-related genes that capture multiple aspects of the 
immune response. One 28-gene signature developed in melanoma significantly correlated with 
overall response to immunotherapy and progression-free survival, optimized to a positive 
predictive value of 59% and negative predictive value of 90% [2]. However, such approaches 
suffer from an inability to distinguish which cell types present in the tumor micro-environment are 
responsible for expression of any given gene and are unable to distinguish the distinct contributions 
of different cell types to immunotherapy response across patients, or to identify transcriptional 
regulators specific to those cell types. 
 
Mechanisms of Resistance to Immunotherapy 
Cell-intrinsic mechanisms of immunotherapy resistance are those active in the tumor cells 
themselves, rendering them less susceptible to immune-mediated cell death or less visible to the 
immune system. These include downregulation of antigen presentation, engagement of alternative 
immune checkpoints, secretion of immunosuppressive cytokines, or decrease in tumor mutational 
burden under selective pressure on heterogeneous tumors [5] [6] [7]. Cell-extrinsic mechanisms 
largely involve exclusion of cytotoxic cells and recruitment of immunosuppressive cell types, 
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including regulatory T-cells (Tregs) as well as myeloid-derived suppressor cells (MDSCs), each 
of which interact with each other and with the remainder of the tumor microenvironment and which 
have been associated with poor prognosis across various tumor types [6] [8] [9] [10] [11]. In 
reality, these two categories of resistance mechanisms likely share common regulatory pathways 
and may be modulated by drugs targeting key tumor cell regulators of immune evasion, 
immunosuppressive cell regulators of tumor-infiltration, or interactions between the two.  
 
Immunomodulatory Effects of Conventional and Targeted Cancer Therapies 
A large number of commonly used conventional and targeted cancer therapies have been shown 
to exert immunomodulatory effects on the tumor microenvironment, but the mechanisms of these 
effects and the clinical relevance of each effect in relation to immunotherapy efficacy have not 
been well-studied [12] [1] [13]. This presents an area of great opportunity for exploration of drug 
synergies that may overcome mechanisms of resistance to immunotherapy. Chemotherapies can 
promote tumor immunity by inducing immunogenic cell death, or by disrupting cell-intrinsic 
mechanisms by which tumors evade immune recognition. It may also render tumor cells more 
sensitive to T-cell-mediated lysis through fas, perforin, and granzyme dependent mechanisms [14]. 
Chemotherapy has additionally been shown to exert immunomodulatory effects directly on 
immune cells. For example, low-dose cyclophosphamide depletes circulating naïve and activated 
Tregs [14], and paclitaxel has been shown in mouse models to reprogram tumor macrophages to a 
pro-inflammatory phenotype in a TLR4-dependent manner [15]. Targeted therapies also have 
potentially significant immunomodulatory effects [12]. In mouse models, intra-tumoral Treg 
depletion with an anti-CTLA4 antibody synergizes with androgen deprivation where it would 
otherwise fail to show survival benefit as monotherapy [4, 4]. This leads to the hope that even in 
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cancers otherwise unresponsive to immunotherapy, synergistic approaches that combine 
immunotherapy with drugs targeting resistance mechanisms may provide survival benefit.  
 
Single-Cell RNA-Sequencing as a Tool for Dissecting the Tumor Micro-Environment 
The development of high-throughput droplet-based single-cell RNA sequencing (scRNA-Seq) 
technology [16] presents a significant opportunity in study of the tumor-immune 
microenvironment. scRNA-Seq has an advantage in resolution over traditional bulk RNA 
sequencing and can distinguish the transcriptional states of individual cell types contributing to 
the overall tumor phenotype. This is particularly important for immune populations present at 
relatively low frequency, such as Tregs, and for highly heterogeneous tumors.  
The potential of scRNA-Seq has been shown in recent studies of melanoma, where scRNA-
Seq in one trial of checkpoint immunotherapy identified a distinct TCF7+CD8+ T-cell state 
associated with outcome [17] and scRNA-Seq in another trial identified a tumor-cell-intrinsic 
transcriptional program predictive of response to immunotherapy [18]. In a pre-clinical trial of 
CDK4/CDK6 resistant breast cancer, scRNA-Seq identified a novel population of myeloid cells 
associated with poor response to immunotherapy and enriched in genes targeted by cabozantinib 
[19]. Application to other tumor types and different treatment conditions presents a broad area of 
novel opportunity for scRNA-Seq to elucidate mechanisms of immunotherapy resistance and 
identify context-specific drug synergies.  
However, scRNA-Seq is not without problems. Due to low input RNA, it is common for 
individual cells to capture expression of fewer than 1000 unique genes, yielding gene expression 
matrices that are >90% sparse. This may adequately capture variation in highly expressed genes 
but miss variation in key transcriptional regulators and signaling molecules that have high 
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biological relevance but low gene expression. The Seurat pipeline commonly used for scRNA-Seq 
analysis attempts to resolve this issue by normalizing the raw expression matrix with regularized 
binomial regression and implements anchor-integration for batch-correcting multiple samples 
[20], but remains noisy at the level of individual genes.  
 
Transcriptomics and the Master Regulator Paradigm of Tumor Biology 
Upstream of gene expression at the RNA level, the actual drivers of cell phenotype are 
interactions between proteins and their regulatory/transcriptional targets. The Califano lab has 
developed and widely applied a method to infer transcriptional regulatory protein activity from 
gene expression data using two algorithms- the Algorithm for Reconstruction of Accurate 
Cellular Networks (ARACNe), and Virtual Inference of Protein activity by Enriched Regulon 
analysis (VIPER) [21] [22] [23]. First, ARACNe uses mutual information between genes at the 
expression level to build and prune a gene regulatory network, such that each transcription 
factor, co-transcriptional regulator, signaling molecule, and surface marker has an inferred 
“regulon” of downstream targets with directionality and strength of regulation encoded [23]. 
VIPER can then be used to infer protein activity from the enrichment of each regulon in a gene 





Figure 1: Conceptual Logic of the VIPER Algorithm.  
Where a) indicates the sequence of events between gene expression and biological protein 
activity, b) represents a context in which EGFR (a master regulatory protein) is not active, and its 
downstream targets are consequently not over- or under-expressed, and c) represents a context in 
which EGFR is active, which can be inferred from the upregulation of its positively regulated 
targets and the downregulation of its negatively regulated targets. 
 
 The ability to infer protein activity allows for identification of differentially active protein 
master regulators (MRs) that regulate clinically relevant phenotypes. Clustering of tumor samples 
on inferred protein activity is significantly more robust to noise than clustering on raw gene 
expression [21] and also allows for drug discovery by identification of known drug targets 
(OncoTarget) and by identifying drugs that perturb the transcriptional state in a way that inverts 
MR activity for a specific tumor phenotype (OncoTreat) [24]. Furthermore, an extension of the 
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ARACNe/VIPER pipeline has been developed for Conditional Inference of Network Dynamics 
(CINDy), which infers surface receptors that modulate the activity of MRs based on mutual 
information between MRs and their downstream targets, conditioned on specified surface 
receptors [25].  
These protein activity inference tools have thus far been applied primarily on bulk RNASeq 
data, but they provide significant potential benefit in scRNA-Seq data. Because ARACNe regulons 
infer many downstream targets for each protein, VIPER is less sensitive to single-cell dropout of 
specific genes, and has been shown to robustly infer protein activity from single-cell gene 
expression data using a metaVIPER approach that integrates protein activity inferred from 
ARACNe networks in multiple tissue contexts [26]. By clustering single-cells from patients’ tumor 
microenvironment at the gene expression level, distinct patient-specific and cell-type-specific 
ARACNe networks can be constructed, and leveraged to infer protein activity in tumor cells and 
immune cells for improved clustering resolution, as well as to run the OncoTarget/OncoTreat 
algorithms for identification of druggable targets in tumor cells or immunosuppressive cells 
involved in treatment resistance, and to identify tumor-immune interactions involving receptors 
with high VIPER-inferred activity and matched ligands with high expression in an interacting cell 
type.  
These methods require optimization of parameters for effective application to single-cell 
datasets in a way that is robust to varying levels of dropout and scalable to very high numbers of 
cells produced by modern droplet-based scRNA-Seq technologies. Approaches for optimization 
include repeated sub-sampling as well as pooling transcriptional nearest-neighbor cells for network 
inference, and optimal analytic pipelines may need to be tailored to characteristics of particular 
tumor types. Ultimately, leveraging the Califano Lab suite of network-based protein activity 
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inference methods on clinical datasets of patients profiled by scRNA-Seq with and without 
immunotherapy treatment allows for improved identification of cell-intrinsic and cell-extrinsic 
mechanisms of therapy resistance at single-cell resolution, and may lead to identification of 





Chapter 1: Validation and Benchmarking of an Analysis Pipeline 
for Systematic Protein-Activity Inference from Single-Cell RNA 
Sequencing Data 
The following is adapted from:  
 
Obradovic, A.*, Vlahos, L.*, Laise, P., Worley, J., Tan, X., Wang, A.-L., & Califano, A. (2021). 
PISCES: A pipeline for the systematic, PROTEIN Activity-based analysis of single Cell 
Rna sequencing data. https://doi.org/10.1101/2021.05.20.445002  
 *These authors contributed equally 
 
1.1 Summary 
While single-cell RNA sequencing provides a new window on physiologic and pathologic tissue 
biology and heterogeneity, it suffers from low signal-to-noise ratio and a high dropout rate at the 
individual gene level, thus challenging quantitative analyses.  To address this problem, we 
introduce PISCES (Protein-activity Inference for Single Cell Studies), an integrated analytical 
framework for the protein activity-based analysis of single cell subpopulations. PISCES 
leverages the assembly of lineage-specific gene regulatory networks, to accurately measure 
activity of each protein based on the expression its transcriptional targets (regulon), using the 
ARACNe and metaVIPER algorithms, respectively. It implements novel analytical and 
visualization functions, including activity-based cluster analysis, identification of cell state 
repertoires, and elucidation of master regulators of cell state and cell state transitions, with full 
interoperability with Seurat’s single-cell data format. Accuracy and reproducibility assessment, 
via technical and biological validation assays and by assessing concordance with antibody and 
CITE-Seq-based measurements, show dramatic improvement in the ability to identify rare 






High-throughput, droplet-based single-cell RNA Sequencing (scRNASeq) has recently emerged 
as a valuable tool to elucidate the diverse repertoire of cellular subpopulations comprising a 
broad range of mammalian tissues. Applications of this technology range from study of tissue 
development [27] and tumor micro-environment [28], to the elucidation of tissue heterogeneity 
[29] and even of tissue-level response to infectious diseases, such as COVID-19 [30] [31]. More 
specifically, scRNASeq data allows identification of representative gene expression signatures 
for thousands of individual cells dissociated from a tissue sample [16] [32], thus providing fine-
grain characterization of the transcriptional state of individual cell types contributing to the 
emergence of complex phenotypes, which would be impossible from bulk profiles. This can help 
elucidate the role of rare populations, for instance, whose gene expression signature would be 
diluted below detection limits in bulk samples [20]. Moreover, in contrast to flow cytometry or 
CyTOF, scRNASeq generates genome-wide single cell profiles, without requiring a priori 
selection of a limited number of antibody-based markers. The value of scRNASeq in tumor 
biology has been broadly demonstrated in recent studies of melanoma [17] [18], pancreatic 
cancer [33], breast cancer [34], and renal cell carcinoma [35]. 
 
The key drawback of scRNAseq technologies is that the total number of mRNA molecules per 
cell, combined with low capture efficiency, fundamentally limits the number of distinct mRNA 
molecules that can be detected in each single cell (UMI reads). As a result, scRNASeq profiles 
are extremely sparse, with as many as 90% of all genes producing no reads in any given cell and 
the majority of detected genes producing one or two reads. This phenomenon, commonly known 
12 
 
as gene dropout, greatly hinders downstream analysis, making quantitative assessment of 
differential gene expression extremely challenging. For instance, while broadly different cell 
types can be classified, a majority of biologically relevant genes, including the established 
lineage markers of specific cellular subpopulations, are undetected. As a result, cellular 
subpopulations presenting more subtle differences, such as different fibroblast or macrophage 
subpopulations, may be impossible to differentiate [33] [35]. Even with cutting edge analysis 
tools such as the Seurat analysis pipeline [36], which can often identify individual 
subpopulations, scRNAseq gene expression data remains limited in its ability to elucidate fine-
grain biological mechanisms due to its sparseness. Additionally, interrogation of individual 
genes of interest across cells is significantly impaired, particularly for transcription factors and 
signaling molecules, which do not need to be abundantly transcribed in order to fundamentally 
drive cell phenotype through their downstream effects on transcriptional state. 
 
To address these limitations, we have shown that network-based analysis of protein activity, 
using the VIPER and metaVIPER algorithms [26] [35], can provide accurate, quantitative 
assessment for >6,000 proteins, including transcription factors, co-factors, chromatin remodeling 
enzymes, and signaling proteins. Moreover, we have shown that protein activity-based analysis 
can help identify rare subpopulations that are responsible for the presentation of key macroscopic 
phenotypes, ranging from immune evasion [37] to relapse following surgery [35]. It can also 
help identify master regulator proteins representing mechanistic, causal determinants of cell state 
and cell state transitions, such as to de-differentiation to a pluripotent stem cell state [38] or 
transdifferentiation between distinct tumor cell states [39]. However, these analyses can be 
extremely complex because they require assembly of lineage specific regulatory networks and 
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master regulator analyses that are challenging for biologists who are not trained in network 
biology.  
 
To allow broad access to these methodologies to biologists with relatively limited network-based 
analyses expertise, we introduce a comprehensive pipeline for Protein Activity Inference for 
Single Cell Studies (PISCES), which is made available to the research community via a general-
use R package.  The pipeline automates the optimal generation of lineage specific regulatory 
networks, via ARACNe (Algorithm for Reconstruction of Accurate Cellular Networks) [40] 
[23], measurement of protein activity via VIPER (Virtual Inference of Protein Activity by 
Enriched Regulon Analysis) [21], as well as the identification of molecularly distinct 
subpopulations via a variety of clustering methodologies, and the identification of Master 
Regulators of cell state and cell state transitions (Figure 2). 
 
Figure 2: Single-Cell RNA-Seq Protein Activity Analysis Workflow.  
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Flowchart of overall analysis pipeline, showcasing sequential data transformations from original 
raw RNA-Seq gene expression counts matrix (blue) followed by Quality Control Filtering and 
Normalization (yellow) and data scaling (red), followed by cluster-specific ARACNe and final 
VIPER transformation to generate a single-cell VIPER-inferred protein activity matrix (green). 
 
ARACNe is an information theoretic algorithm for the inference of the direct transcriptional 
targets of transcriptional regulator proteins, as well as the least indirect targets of signal 
transduction proteins. This allows reconstructing the tissue specific repertoire of transcriptional 
targets (regulon) of ~6,500 regulatory and signaling proteins, including surface markers (SMs). 
VIPER computes the activity of each protein based on the differential expression of the genes in 
its regulon, as assessed by weighted gene set enrichment analysis. Since regulons are generally 
large, containing up to several hundred genes, we prune them to include the same number of the 
most likely targets (between 50 and 100), to avoid biasing the statistical significance of the gene 
set enrichment analysis, as discussed in [21]. As a result, even when the specific gene encoding 






Figure 3: Single-Cell RNA-Seq Protein Activity Analysis Workflow.  
Graphical of the gene expression dropout mitigation effect. A theoretical ARACNe-inferred 
regulon of a proteomic master regulator of cell state (MR) and its downstream transcriptional 
targets (g1,g2,g3,g4,….) is shown, along with a matrix showing sparseness of expression for MR 
and each of its targets both in cells with high real activity of MR and cells with low activity. 
From MR expression alone, only a single sample with high MR-activity would be correctly 
identified. However, by integrating the expression values from each target gene, high protein 
activity of MR can be correctly inferred despite the high dropout rate of any single gene target. 
 
Previous work in the Califano lab has shown the accuracy and reproducibility of these algorithms 
when used to analyze bulk data. Indeed, ARACNe and VIPER have been used extensively to 
identify master regulators (MRs) that were experimentally validated as mechanistic determinants 
of diverse biological states, many of which have been extensively validated, see [41] [42] [43] 
[24], just to cite a few, and resulting in two CLIA-approved clinical tests to predict tumor drug 
sensitivity, including OncoTreat [24] and OncoTarget [44]. Most critically, when comparing 
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30M read RNASeq profiles to down-sampled profiles with 10K to 50K reads (similar to typical 
scRNASeq profiles), VIPER-measured protein activity profiles retain high Spearman correlation 
(ρ ≥ 0.8), while correlation of the raw gene expression profiles is extremely poor (ρ ≤ 0.3) [21].  
 
To adapt these tools to the analysis of scRNASeq profiles, PISCES implements three major 
modifications. First, an initial gene expression-based cluster analysis is used to identify 
molecularly distinct cellular subpopulations representing distinct sub-lineages. Fine grain cluster 
analysis is not necessary as we have shown that regulatory networks for closely lineage-related 
cells are virtually indistinguishable [45]. ARACNe is then used to generate distinct regulatory 
networks for each cluster containing at least N = 500 cells. Second, to increase regulon coverage, 
cells within each sub-lineage-related cluster are combined into “meta-cells” using a K-nearest-
neighbors graph analysis. This creates pseudo-bulk samples that can then be analyzed by 
ARACNe, producing networks with more accurate edges, larger regulons, and greater coverage 
of regulatory proteins. Finally, rather than using VIPER for protein activity measurement, we use 
its derivative metaVIPER [26], which is designed to optimally integrate protein activity 
inferences from multiple networks. This allows for the use of multiple single-cell and, when 
available, lineage-matched bulk-tissue-derived networks. Downstream of the ARACNe and 
metaVIPER analyses, PISCES provides access to a variety of novel protein-activity based 
clustering and data visualization algorithms, in addition to implementing interoperability with the 
popular Seurat single-cell data format.  
 
In order to establish the efficacy of these tools and optimal parameters for future benchmarking 
and improvement, we have performed both technical and biological validation experiments, first 
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by evaluating reproducibility of protein activity assessment from progressively down sampled 
data, and then by assessing concordance of gene expression and protein activity to antibody-
based measurements using multiplexed FACS (Cytek) and CITE-Seq [46].  
Taken together, the results of these benchmarks show that the PISCES analytical pipeline 
dramatically outperforms gene expression-based analyses and even outperforms experimental 
assessment via selected antibodies, while allowing essentially proteome-wide activity 
quantitation. As such, these data suggest that PISCES provides a valuable and highly flexible 
tool for the analysis of scRNA-Seq datasets, which greatly improves the granularity of cell 
subpopulation detection, allowing detection of rare yet biologically relevant subpopulations that 
would be missed by gene expression analysis, due to gene dropout issues, and supports accurate 
assessment of Master Regulators of single-cell states.  
 
1.3 Results 
Analytical Pipeline Overview: The PISCES pipeline takes a single-cell Unique Molecular 
Identifier (UMI) count matrix as input, with genes organized by row and cells by column. Initial 
Quality Control filtering is adjustable, with user-defined parameters. By default, it will remove 
cells with fewer than 1,000 UMIs or more than 25% mitochondrial gene UMIs. The gene 
expression matrix is then normalized and scaled to generate a matrix of gene expression 
signatures. By default, this is accomplished by converting counts to 𝐿𝑜𝑔!"(𝐶𝑃𝑀 + 	1), where 
CPM indicates counts per million. However, it can also be implemented via the Seurat 
SCTransform algorithm [20] or any other third-party methods of choice.  
Following normalization, a first-pass clustering is performed on scaled gene expression using 
one of several clustering approaches implemented in the pipeline, including partition around 
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medioids (PAM) [47]or Louvain clustering with resolution-optimization [35]. For each gene 
expression cluster with ≥ 500 cells, by default, metaCells are computed by first selecting 250 
unique cells at random and then transforming their scRNASeq profile into a metaCell by adding 
the UMI counts from the k nearest neighbors (k = 5 by default).  Independent ARACNe networks 
are generated from each cluster using the 𝐿𝑜𝑔!"(𝐶𝑃𝑀 + 	1) values of each metaCell. 
 
In parallel, the normalized gene expression profile is transformed into a gene expression 
signature (GES). This can be done in a number of ways, either with an internal normalization 
against mean and standard deviation of all cells to query differences within the dataset or with an 
external reference to answer experiment-specific questions (i.e. the differences between 
cancerous and healthy cells). By default, PISCES will perform a standard internal normalization 
to generate the gene expression signature, which is then transformed into a matrix of protein 
activity using MetaVIPER. MetaVIPER takes as input the GES and the previously generated 
cluster-specific networks and identifies the best network matches to each sample by maximum 
regulon consensus. Enrichment scores from each matched network are then integrated using a 
weighted average to produce a final enrichment value that can then be used for downstream 
visualization and analysis. The entire pipeline is visualized in Figure 2.  
 
Since every scRNAseq experiment is unique—depending on the specific cell types, the quality of 
the data, or the overarching question driving the research—PISCES allows users to fine tune the 
pipeline to match their specific requirements. For instance, since Seurat represents a widely used 
platform for scRNAseq analysis at the gene expression level, the Seurat batch-correction and 
SCTransform data scaling approach are incorporated as optional pre-processing steps to generate 
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gene expression signatures before they are analyzed by PISCES. These may, however, be 
substituted by any user defined normalization and data scaling routine, such that effect of 
alternative normalization or pre-processing methods may be tested using PISCES’s default 
technical and biological benchmarks. Output from the PISCES pipeline is converted to a Seurat 
object for convenient export into a variety of external visualization or processing tools and 
analyzed by other commonly used tools. In particular, cell type annotation is implemented in 
PISCES at the single-cell level using SingleR [48], which infers cell types represented in the 
dataset by correlation of gene expression to expression of sorted bulk-RNASeq reference 
datasets and stores these labels as metadata for downstream analysis.  
  
Technical Validation Shows Improved Recovery of Data Structure from Low-Depth Cells: To 
benchmark PISCES reproducibility relative to gene expression and to establish an optimal UMI 
depth for user-driven adjustment of metacell parameters, we executed the entire pipeline using 
progressively down-sampled profiles from relatively high-depth scRNAseq data. For this 
purpose, we used the SNU-16 cell line, a relatively homogenous stomach adenocarcinoma model 
that is transcriptionally complex and produces high UMI counts per cell (i.e., 40,000-50,000), on 
the high end of the typical yield for cell lines and significantly above the yield produced by 
clinical samples. Average UMI count in our dataset was 41,915 across 6157 single cells. To 
create synthetic data with lower depth, we down-sampled this data by first drawing each cell’s 
total UMI-count from a multinomial distribution with mean target depth manually specified and 
a uniform probability weight over all cells, then drawing the gene-specific counts from a second 
multinomial with probabilities given by the proportions of genes in the original, full depth profile 
for each cell. This procedure was applied with target depths between one and ten thousand UMIs 
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at a step-size of 1,000 and between 10,000 and 40,000 UMIs at a step-size of 5,000. We then 
generated meta-cells using a consistent sub-set of 500 cells for each down-sampled matrix with 
depth of 10,000 UMIs or fewer. These data were used to generate 27 ARACNe networks in total; 
one for the full data, 16 from each of the down-sampled gene expression profiles, and 10 from 
each of the meta-cell matrices. 
 
To generate gene expression signatures, we normalized each down-sampled matrix against the 
Cancer Cell Line Encyclopedia (CCLE) from The Broad. Because this data is from bulk-
sequencing, we first had to apply the previously described down-sampling scheme in order to 
generate depth-matched reference samples for each single-cell matrix. Gene expression profiles 
were then normalized gene-by-gene by subtracting the mean expression from CCLE, then 
dividing by the standard deviation of the expression in CCLE. Finally, we generated VIPER 
matrices for all pairwise combinations of GES and regulatory networks, culminating in 459 





Figure 4: Flowchart of Technical Validation Down-Sampling Approach 
 
To assess the reproducibility of gene expression and protein activity signatures at different 
depths, we computed the cell-by-cell Pearson correlation between each down-sampled matrix 
and the full depth data. In each cell, we subset the comparison to those genes or proteins with 
significantly different expression or activity (p-value < 0.05 with Bonferroni correction) in the 
full-depth data, then computed the correlation coefficients cell-by-cell between full-depth and 
down-sampled data using this subset. This reduction was performed in order to avoid inflation of 
correlation values based on non-significant data. In protein activity signatures generated fully 
from down-sampled data (down-sampled GEP as input to ARACNe, down-sampled GES as 
input to VIPER), we observe a statistically significant improvement in correlation to full-depth 
data relative to gene expression signature at all depths above 5,000 UMIs (Figure 5A; p-value < 
0.05 by Wilcoxon signed rank test). Strikingly, when an ARACNe network generated from full-
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depth GEP is applied to down-sampled GES as input to VIPER, correlation to original full—
depth VIPER signature is strongly conserved even at extremely low UMI counts, remaining 
above 0.75 on average at UMI depth of 1000, where average correlation of gene expression 
signature to full-depth data is below 0.1. This emphasizes the importance of constructing a high-
quality ARACNe network in the VIPER inference pipeline, such that applying high-quality 
networks inferred for a given cell type from one dataset to a matched cell type in lower-quality 
data is likely to provide a significant boost to the power of protein activity inference even from 
very-low-depth data. Additionally, we find a significant improvement in correlation values when 
constructing metaCell-based ARACNe networks from lower-depth data (Figure 5B), such that 
metaCell networks applied to run VIPER on GES matrices with mean UMI count of 3000 
approach the inference quality seen when running ARACNe and VIPER on gene expression 
matrices with a mean UMI count of 20,000. However, at the very low mean depth of 1000 
UMI/cell this breaks down, and metaCell ARACNe network inference no longer offers any 
statistically significant improvement over inference on low-depth data. Therefore, we strongly 
recommend applying the metaCell ARACNe network inference option in PISCES for any 





Figure 5: Technical Benchmarking Shows Increased Recovery of Original Data 
Structure from Down-sampled Matrices by VIPER vs Gene Expression 
A) Boxplot showing distribution across single cells of Pearson correlation between sub-sampled 
and original full-depth cells. Along the x-axis is the UMI/cell downsampling quotient. In purple, 
correlation between downsampled and original gene expression is shown to rapidly degrade, to a 
median consistently below 0.5, and below 0.25 even by the relatively high depth of 10,000 
UMI/cell. In red, correlation is shown between VIPER inference on down-sampled gene 
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expression signature with full-depth ARACNe network vs VIPER inference on full-depth gene 
expression signature using full-depth ARACNe network, such that correlation remains high even 
at extremely low sample depth, with a median above 0.75 even at 1000 UMI/cell. In green, 
correlation is shown between VIPER inference on full-depth gene expression signature using 
ARACNe networks derived from full-depth vs down-sampled data, and in blue correlation is 
shown between full-depth VIPER inference using full-depth ARACNe networks and VIPER 
inference on down-sampled gene expression signature using down-sampled ARACNe network. 
In all cases protein activity improves on gene expression, and down-sampling of both VIPER 
and ARACNe simultaneously still improves correlation relative to gene expression down to a 
depth of 5000 UMI/cell, with Bonferroni-corrected p-values by paired Wilcox test < 0.05.  B) 
For UMI depths ranging from 1000 to 10000, correlation between full-depth VIPER matrix using 
full-depth ARACNe network and VIPER matrices computed on on down-sampled gene 
expression signatures with either full-depth or metaCell ARACNe. metaCell ARACNe 
significantly improves on correlation with full-depth data for all depths >1000 UMI/cell, by 
paired Wilcox test p-values < 0.05. Mean correlation at low-depth with metaCell ARACNe 
network approaches 0.75, seen only at UMI depths >20000 without applying the metaCell 
ARACNe inference approach. 
 
Overall, these data show that the correlation between full-depth and down-sampled gene 
expression signatures is poor even at relatively high depth, and decays rapidly to a median value 
of less than 0.25 even at depths of 10,000 UMIs/cell (purple bars, Figure 5A). Protein activity, 
by comparison, is much more robust, significantly outperforming gene expression at all depths 
above 5,000 UMIs/cell. Interestingly, down-sampling only the gene expression signature input to 
VIPER while retaining a full-depth ARACNe network had little effect (red bars, Figure 5A) on 
protein activities robustness, while down-sampling either the data using to generate ARACNe 
networks or both ARACNe data and gene expression signature (green and blue bars respectively) 
had a much more significant effect on correlation to original full-depth VIPER matrix, which 
was partially rescued by metaCell ARACNe. The full heatmap showing mean correlation across 
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cells comparing all VIPER matrices against full depth data is available in the Figure 6. These 
findings indicate that the quality of the ARACNe networks is the driving force behind protein 
activity signatures’ ability to retain signal at low UMI depths and supports the idea of using 
metacells to rescue signal within the ARACNe network or use context-appropriate bulk networks 
where available. 
 
Figure 6: Pairwise Down-sampling Correlation Matrix 
Heatmap of mean correlation values compared to original full-depth VIPER matrix with full-
depth ARACNe network for each combination of down-sampled ARACNe and VIPER gene 
expression signature depth. Each row corresponds to depth of gene expression signature input to 
VIPER, and each column corresponds to depth of gene expression input to ARACNe. 
Correlation is subset to proteins differentially up-regulated or down-regulated (p<0.05) within 
26 
 
original full-depth VIPER matrix, on a cell-by-cell basis, and mean correlation across all cells is 
plotted for each box on the heatmap corresponding to a particular down-sampling approach. 
 
Biological Validation Shows Improved Concordance with Antibody Profiling: To assess 
whether protein activities measured by PISCES effectively track with direct assessment of 
protein abundance in single cells, thus providing improved mechanistic understanding of single 
cell processes, we compared PISCES-measured protein activity to CITE-Seq single-cell 
measurements of protein abundance in a publicly available dataset of cord blood-derived 
mononuclear cells (CBMCs) [46].  
 
Single cell clustering based on CITE-Seq measurements, using a pre-selected antibody panel, 
yields six major cell type clusters, including CD4 T-cells, CD8 T-cells, Monocytes, NK Cells, B-
cells, and Hematopoietic Stem Cells (HSCs) (Figure 7C). In sharp contrast, gene expression-
based clustering by Seurat identified only four distinct cell clusters, with NK cells and HSCs 
subsumed into the other major cell types. Protein activity-based clustering by PISCES not only 
recapitulated all six clusters identified by antibody measurement but also identified many 
additional proteins representing established lineage markers of these sub-populations, which 
were completely missed by gene expression analysis. Indeed, the most differentially active 
proteins in each cluster present a highly cluster-specific activity pattern not visible by gene 
expression alone.  
 
Furthermore, when gene expression-based clustering was limited only to the genes encoding for 
the proteins in the CITE-Seq panel, the single-cell RNA-Seq dropout problem was so severe that 
cluster structure was completely lost (Figure 7D). This suggests that critical proteins, whose role 
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in the biology of these populations is extremely well established, are completely missed in terms 
of their gene expression. In sharp contrast, PISCES analysis fully recapitulated the 
experimentally assessed cluster structure when the analysis was limited to the proteins 
represented on the CITE-Seq panel (Figure 7E).  
 
Critically, the coefficients of variation (i.e., 𝐶𝑂𝑉 = 𝜎/𝜇), as computed for gene-expression, 
antibody-measured protein abundance, and VIPER-measured protein activity, shows that 
VIPER-measured activity dramatically outperforms gene expression (p=0.0004 by paired t-test 
across the entire panel) and even antibody measurements for most proteins (p = 0.0083 across the 
entire panel), indicating a significant improvement in reproducibility and signal-to-noise ratio 
(Figure 7A). Finally, we assessed correlation between either gene expression or VIPER-
measured protein activity against protein abundance as assessed by CITE-Seq. Across the board 
VIPER significantly outperformed gene expression (Figure 7B), with strong visual cluster-
separation even on single genes (Figure 7F), and pairwise plots of VIPER activity vs paired 





Figure 7: Biological Benchmarking Shows Dramatically Increased Concordance with 
CITE-Seq Antibody Profiling by VIPER vs Gene Expression 
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A) Coefficient of Variation (computed as σ/μ) for each gene profiled by the CITE-Seq antibody 
panel, shown for antibody staining (red), Gene Expression (green), and VIPER-inferred protein 
activity (blue), with higher Coefficient indicating lower signal-to-noise ratio. B) Spearman 
Correlation between Gene Expression vs Antibody (red) and VIPER vs Antibody (blue) 
computed across cells for each gene profiled by the CITE-Seq antibody panel. C) UMAP 
projection and clustering of CITE-Seq antibody staining panel, labelled with cell types inferred 
from SingleR and validated by staining for known markers. Row-scaled heatmap is shown below 
with antibody staining intensity grouped by cluster. D) UMAP projection and clustering of Gene 
Expression for the subset of genes concurrently profiled by CITE-Seq antibody staining 
panel.  Row-scaled heatmap is shown below, with excessive noise for meaningful clustering due 
to single-cell RNA-Seq dropout effect. E) UMAP projection and clustering of VIPER protein 
activity, labelled with cell types as in 3C.  Row-scaled heatmap is shown below with VIPER 
activity grouped by cluster, for the subset of genes concurrently profiled by CITE-Seq antibody 
staining panel with activity inferred by VIPER. F) Representative Correlation plots of Gene 
Expression vs Antibody and VIPER vs Antibody, showing greater concordance of CD3D VIPER 





Figure 8: Pairwise CITE-Seq Antibody vs VIPER Correlation Plots 
A) Correlation Plots of CD3D Gene Expression vs Antibody Intensity (left) and VIPER vs 
Antibody Intensity (right). B) Correlation Plots of CD3E Gene Expression vs Antibody Intensity 
(left) and VIPER vs Antibody Intensity (right). C) Correlation Plots of CD3G Gene Expression 
vs Antibody Intensity (left) and VIPER vs Antibody Intensity (right). D) Correlation Plots of 
CD4 Gene Expression vs Antibody Intensity (left) and VIPER vs Antibody Intensity (right). E) 
Correlation Plots of CD8B Gene Expression vs Antibody Intensity (left) and VIPER vs Antibody 
Intensity (right). F) Correlation Plots of CD14 Gene Expression vs Antibody Intensity (left) and 
VIPER vs Antibody Intensity (right). G) Correlation Plots of FCGR3A (CD16) Gene Expression 
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vs Antibody Intensity (left) and VIPER vs Antibody Intensity (right). H) Correlation Plots of 
PTPRC (CD45) Gene Expression vs Antibody Intensity (left) and VIPER vs Antibody Intensity 
(right). 
 
Furthermore, we would like to point out that protein abundance, as assessed by antibodies, is a 
poor proxy for protein activity. This is because, even after a protein is expressed, its activity is 
manifested only when it is effectively post-translationally modified, it is translocated into the 
appropriate sub-cellular compartment, and it has formed complexes with critical cognate binding 
partners. By measuring activity via expression of highly multiplexed gene reporter assay, VIPER 
can effectively report on the activity of proteins, which has been so far elusive, especially in 
single cells. In a separate analysis of CD45+ cells that were isolated from renal clear cell 
carcinoma, then split and profiled at the single cell level using both scRNA-Seq and a CyTEK 
high-throughput flow cytometry panel of 19 lymphoid and 19 myeloid antibodies [35], the de-
noising effect of PISCES was even more obvious. Not only did these results completely 
recapitulate the results obtained for the CITE-Seq comparison, but, given the larger number of 
experimentally assessed proteins, they provide further evidence of the dramatic improvement 
offered by PISCES analysis over both gene expression and antibody-measured protein 
abundance. This is reflected in three key findings. First, experimentally assessed protein 
abundance (e.g., using the 19 lymphoid markers) was unable to identify the clusters that could be 
identified by VIPER-based measurement of the same 19 proteins, including splitting of the 
myeloid cluster into monocytes and macrophages, the CD8 T cell cluster into CD8 T cells and 




Figure 9: Comparison of VIPER Inferences and Gene Expression to Flow Cytometry in 
Renal Clear Cell Carcinoma Dataset 
A) UMAP projection, clustering, and heatmap by flow cytometry proteins profiled in CyTEK 
Lymphoid Panel. B) UMAP and clustering by scRNASeq gene expression subset to the proteins 
profiled in A, showing noise-induced decrease in clustering resolution. C) UMAP and clustering 
by VIPER-inferred protein activity using PISCES, subset to the proteins profiled in A. D) UMAP 
and clustering by flow cytometry proteins profiled in CyTEK myeloid panel. E) UMAP and 
clustering by scRNA-Seq gene expression, subset to the proteins profiled in D. F) UMAP and 
clustering by VIPER-inferred protein activity using PISCES, subset to the proteins profiled in D. 






Second, proteins not expressed on the surface of the cell, such as FOXP3, a canonical marker of 
regulatory T cells, could not be reliably detected by antibody measurements but were clearly 
detected in the correct sub-population by VIPER. Indeed, taken together, only 4 of 38 proteins 
assessed by VIPER and antibody measurement were not effectively and correctly detected by 
VIPER in the specific cellular sub-populations for which they represent an established lineage 
marker (NT5E/CD73, FCGR3B/CD16b, PTGDR2/CD294, CD33). In contrast, 9 of 38 proteins 
could not be consistently detected by antibody measurement or were not restricted to the 
associated sub-populations due to noisy background staining (CD14, CD127, FOXP3, CD38, 
CD25, CXCR3, CD161, CTLA4, CD39). Indeed, clustering on the full set of proteins identified 
by PISCES on this dataset [35] led to identification of rare cellular subpopulations that play a 
critical role in post-surgical tumor recurrence, and for which PISCES-inferred markers were 
validated by immunohistochemistry.  
 
This indicates amplification of biologically meaningful rather than artifactual signal from single 
cells by PISCES, and its ability to enable interrogation of individual genes of interest without 
data dropout. In fact, while CITE-Seq is limited by time-consuming antibody titration and panel 
optimization, ultimately profiling relatively few proteins in most experiments, PISCES typically 
captures several orders of magnitude more unique proteins, enabling interrogation of intracellular 
proteins which would otherwise be difficult to stain for without losing cellular RNA, as well as 
select surface markers of interest. Nevertheless, the cell-matched profiling of both gene 
expression and protein abundance by CITE-Seq enables direct comparison of PISCES inferences 
to measured protein abundance for a subset of proteins within the same cells, which may be used 
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as a benchmark of the high concordance between PISCES and measured protein abundance, and 




The PISCES package for analysis of single-cell RNA-Sequencing data represents a 
comprehensive and highly generalizable pipeline for inference of protein activity to maximize 
utility of single-cell datasets. We have demonstrated its ability to mitigate the single-cell RNA-
Seq data dropout problem and recapitulate high-depth data structure even from low UMI counts. 
We have also demonstrated its ability to recapitulate biological structure from CITE-Seq 
antibody-based protein profiling with much better gene-by-gene signal than gene expression. 
These technical and biological validations also serve as benchmarks for further refinement of the 
pipeline by which any changes can be comprehensively assessed.  
 
For biological validation benchmarking, protein selection was based on pre-defined protein 
panels from CITE-Seq experiments. As a result, this represents a completely unbiased set of 
proteins that was not selected to skew performance in VIPER’s favor. While we limited the 
comparison only to the CITE-Seq panel of proteins, PISCES produced activity profiles for 6,500 
proteins. Thus, if these results are further confirmed in follow-up studies, PISCES would provide 
the equivalent of a single cell FACS with 6,500 antibodies, remedying the need to select and 
validate antibodies for specific cellular populations. Indeed, VIPER was originally developed for 
the analysis of proteins that directly control gene expression on the chromatin (i.e., TFs and co-
TFs). As a result, accuracy and reproducibility of VIPER-based measurement of surface markers 
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is likely to be significantly outperformed for TFs and co-TFs, which represent the most critical 
class of lineage markers.  
 
In addition to the technical benchmarking of correlation between down-sampled and full-depth 
data, the extent of improvement by PISCES in coefficient of variation, number of genes 
recovered, and gene-by-gene correlation to matched antibody profiling represent a critical 
biological benchmark for alternative workflows by PISCES users as new pre-processing methods 
are incorporated and existing algorithms are refined. The pipeline has been consciously designed 
to be highly modular, with customizable workflows and parameter optimization enabled by 
separate pre-processing, meta-cell, and clustering steps and interoperability with the popular 
Seurat workflow. We recommend targeting a median UMI depth / cell of no less than 5000, with 
the crucial step being inference of ARACNe network from high-depth data, applying the 
metaCell algorithm to improve sample depth for ARACNe network inference. Wherever a high-
depth-derived ARACNe net is available, inference fidelity is high even on extremely low-depth 
datasets, so the increased availability of single-cell RNA-Seq datasets across a broad range of 
tissue contexts will continually allow construction of an expanding library of ARACNe networks 
which can be broadly applied to new data.  
 
PISCES is chiefly limited by the fraction of 6,500+ total proteins recoverable at low UMI depth, 
although the number of proteins recovered nearly always compares favorably to CITE-Seq, 
which requires time-consuming antibody titration and is limited to predefined cell surface 
proteins, whereas PISCES captures proteins with the strongest signal-to-noise from the data and 
can infer both cell surface and intracellular protein activity. Applying metaCell ARACNe 
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network inference addresses this to some degree, such that nearly 100% of all proteins 
recoverable at full depth in SNU-16 cell line sequencing data were recovered at a UMI depth of 
10,000, where only half of the proteins inferred at full-depth were recoverable without metaCell, 
and over half of proteins remained recoverable with metaCell even at critically low UMI depth 
of 1,000 (Figure 10). Future iterations of the pipeline will continue to improve on the fraction of 
recoverable proteins by integrating and testing novel pre-processing procedures and optimization 
of the ARACNe and VIPER inference steps. The development version of the PISCES R package 
will be continually available at https://github.com/califano-lab/PISCES.  
 
 
Figure 10: ARACNe Network Size at Variable Depth with and without Meta-Cell 
 On the left, fraction of Total ARACNe network regulons (y-axis) recovered at each down-
sampling depth (x-axis) relative to full-depth data, such that fraction decreases log-linearly with 
down-sampling depth. On the right, fraction of Total ARACNe network regulons relative to full-
depth data (y-axis) recovered at each down-sampling depth from 1000 to 10000 UMI/cell, with 






Quality Control, Normalization, and Scaling: As a pre-processing step, low quality cells and 
genes lacking enough data to be useful are removed from the analysis. Cell quality is determined 
by two primary factors – read depth and mitochondrial gene percentage. Samples with too many 
or too few reads are likely sequencing errors (doublets or empty droplets), while a high 
mitochondrial gene percentage is indicative of cell stress or damage. This latter group of cells 
will typically have a biased transcriptome not representative of the actual cell state. For most 
data sets, PISCES will simply remove genes with no reads at all. For larger data sets, genes that 
appear in less than 1% of the total cells will be removed in order to optimize computational 
complexity. Cells with fewer than 1000 total UMIs or mitochondrial transcript fraction greater 
than 25% are also removed in quality-control filtering. Filtered data are then normalized to 
log10(counts per million + 1). A gene expression signature is then generated from the 
normalized data using either double rank transformation or Seurat SCTransform scaling function. 
 
Seurat Pre-Processing Workflow: Gene Expression UMI count matrices for each sample are 
processed in R using the Seurat SCTransform command to perform a regularized negative 
binomial regression based on the 3000 most variable genes. For datasets combining samples 
across multiple patients, normalized datasets may be integrated using the 
FindIntegrationAnchors and IntegrateData functions in Seurat. The resulting data are projected 
into their first 50 principal components, and further reduced into a 2-dimensional visualization 
space using the RunUMAP function with method umap-learn and Pearson correlation as the 
distance metric between cells. Differential Gene Expression between clusters is computed by the 
MAST hurdle model for single-cell gene expression modeling, as implemented in the Seurat 
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FindAllMarkers command, with log fold change threshold of 0.5 and minimum fractional 
expression threshold of 0.25, indicating that the resulting gene markers for each cluster are 
restricted to those with log fold change greater than 0 and non-zero expression in at least 25% of 
the cells in the cluster. 
 
Initial Clustering and MetaCells: In order to generate accurate, robust networks, ARACNe 
requires data from a population that shares the majority of its transcriptional architecture. In the 
context of single cells, this requires separating the data into coarse cell type clusters before 
network generation. These clusters can be generated in a number of ways; any of the popular 
gene expression methods for clustering will work, as will a simple clustering based on the first 
30 principle components in gene expression space. We have implemented clustering on gene 
expression signature by Partition Around Medioids (PAM), Multi-Way K-Means, and Louvain 
with Resolution Optimization. Once the data have been clustered, meta-cells can be generated 
for input to ARACNe. By pooling cells that are close together in either gene expression or 
VIPER space within a cluster, the number of interactions inferred using ARACNe can be 
increased. PISCES uses a simple K-nearest-neighbors approach to pool cells, then sums reads 
across neighbors and re-normalizing. This data then serves as the input to ARACNe. 
 
ARACNe Network Generation: A full guide for utilizing ARACNe is available on the Califano 
Lab Github at https://github.com/califano-lab/PISCES. For each gene expression cluster, 250 
metaCells are sampled to compute a regulatory network. All networks are reverse engineered by 
the ARACNe algorithm, run with 100 bootstrap iterations using 1785 transcription factors (genes 
annotated in gene ontology molecular function database as GO:0003700, “transcription factor 
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activity”, or as GO:0003677, “DNA binding” and GO:0030528, “transcription regulator 
activity”, or as GO:0003677 and GO:0045449, “regulation of transcription”), 668 transcriptional 
cofactors (a manually curated list, not overlapping with the transcription factor list, built upon 
genes annotated as GO:0003712, “transcription cofactor activity”, or GO:0030528 or 
GO:0045449), 3455 signaling pathway related genes (annotated in GO biological process 
database as GO:0007165, “signal transduction” and in GO cellular component database as 
GO:0005622, “intracellular” or GO:0005886, “plasma membrane”), and 3620 surface markers 
(annotated as GO:0005886 or as GO:0009986, “cell surface”). Each regulator set is run 
separately, as different types of proteins will have different mutual information thresholds. Once 
a set of regulons has been inferred for each group of regulators, the results are combined into a 
single network. ARACNe is only run on these gene sets so as to limit protein activity inference 
to proteins with biologically meaningful downstream regulatory targets, and we do not apply 
ARACNe to infer regulatory networks for proteins with no known signaling or transcriptional 
activity, for which protein activity may be difficult to biologically interpret. Parameters are set to 
zero DPI (Data Processing Inequality) tolerance and MI (Mutual Information) p-value threshold 
of 10-8, computed by permuting the original dataset as a null model. Each gene list used to run 
ARACNe is available on github. 
 
VIPER Analysis and Re-clustering: Once cluster-specific networks have been generated, they 
will serve as the input to a final VIPER run. More accurate networks will naturally lead to more 
accurate inferences of protein activity, which in turn allows for more robust downstream 
analyses. Bulk networks can also be incorporated to fill in any gaps present in the single-cell 
networks, as ARACNe will typically be unable to infer regulons for some proteins even with the 
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implementation of MetaCells. These protein activities inferred from bulk should be considered 
less accurate, but they can be used to follow-up on previously known proteins of interest, for 
instance. Once a final VIPER matrix has been inferred, the data can be re-clustered. VIPER-
space will typically allow for the parsing of smaller, more transcriptionally distinct populations. 
These classifications can then be used for a master regulator analysis that identifies the driving 
regulators of the differential cell state. This can be done in several ways, with a Bootstrapped 
Mann Whitney-U test being the most robust. Cluster-specific Stouffer integration or a data-wide 
ANOVA or Kruskal-Wallis test are also viable alternatives and implemented within PISCES.  
 
Weighted VIPER: Previously, MetaVIPER was developed as an initial adaptation of VIPER to 
single-cell data. By using multiple networks, MetaVIPER sought to accurately recapitulate 
protein activity in populations for which no context-specific network was available. To briefly 
explain this method, protein activity would be inferred from a given gene expression 
signature using multiple networks, which would then be integrated on a protein-by-protein basis 
using the square of the NES. Since a non-relevant network would generate a protein activity NES 
close to zero under the null model, networks that generate more extreme NES’s can be 
interpreted to more accurately match the given biological context and were thus weighted more 
heavily. This approach has been improved on further in PISCES. Rather than relying on the 
square of the NES to integrate networks in a protein-by-protein manner, Weighted VIPER 
utilizes all the proteins in a given sample to determine network accuracy. For each sample, the 
NES’s generated by the set of networks for each protein are ranked, and the ranks are totaled 
across proteins. Networks are then weighted based on their frequency as the most-accurate 
network. As an example, if network A generates the most extreme NES for 50% of the proteins 
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in a sample and network B generates the most extreme NES for 25% of the proteins, network A 
will be weighted twice as heavily in the integration. This technique utilizes all proteins as a 
multiplexed reporter of network accuracy, allowing for more accurate matching of samples and 
the most-context specific network available. 
 
Single Cell Visualization Functionality: Visualizing data with thousands of dimensions is a 
fundamental challenge of transcriptomics. PISCES has a number of pre-built plotting functions 
to aid in the visualization of results. Scatter plots are based in UMAP coordinates, with the 
starting features filtered by the most significant proteins within each sample. Functions within 
PISCES allow for the visualization of clustering schemes, protein activity, or gene expression in 
UMAP space, along with density plotting. Additionally, we provide heatmap functionality for 
more tractable succinct visualization of a set of genes or proteins grouped by cluster, such as a 
set of known markers or a list of candidate master regulators.  
 
Resolution-Optimized Louvain Clustering Algorithm: The default clustering method 
implemented in Seurat is Partitioning Around Medioids (PAM). However, for large datasets 
aggregating hundreds of thousands of single-cells, PAM is computationally slow, requiring more 
computational power than is available to the average user and computation of pairwise distance 
matrices exceeding the vector size limit in R. In such cases, it is preferable to run a network-
based Louvain clustering, as implemented in Seurat, which optimizes network modularity score. 
However, practical implementations of Louvain clustering include a user-adjustable resolution 
parameter which allows over-clustering and under-clustering without an objective cluster quality 
metric. To solve this problem, we have implemented a hybrid clustering approach in PISCES 
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which performs cluster assignment in two steps. First, Seurat Louvain clustering is performed 
with resolution values ranging from 0.01 to 1.0 at intervals of 0.01, then cluster quality is 
evaluated at each resolution value to select an optimum in this range. For each resolution value, 
clustered cells are subsampled to 1000, and silhouette score is computed for these 1000 cells and 
their corresponding cluster labels, with correlation distance metric. This procedure is repeated for 
100 random samples to compute a mean and standard deviation of average silhouette score at 
each resolution value. The highest resolution value that maximizes mean silhouette score is 
selected as the optimal resolution at which to cluster the data.  
 
Multi-Way K-Means Clustering Algorithm: In addition to PAM and Louvain with Resolution 
Optimization, PISCES further implements a Multi-Way K-Means Clustering approach. 
Transitioning populations, such as in a differentiation pathway, are extremely common, and such 
relationships will not be accurately characterized by a discrete clustering scheme. To handle this 
set of problems, we adapted the Multiway K-Means algorithm for use in biological settings, 
where samples can be thought of as linear combinations of related phenotypes rather than simply 
belonging to totally distinct populations. Originally developed for clustering speciating 
microbiome populations, Multiway K-Means technique has two primary advantages. First, it 
more accurately captures cluster center (in biological terms, a representative phenotype) for each 
population endpoint. Second, it places cells along a trajectory between cluster centers, providing 
a more accurate representation of cell state and allowing for additional inferences into the drivers 




Semi-Supervised Cell Type Calling: For each single cell gene expression sample, cell-by-cell 
identification of cell types is performed using the SingleR package and the preloaded Blueprint-
ENCODE reference, which includes normalized expression values for 259 bulk RNASeq 
samples generated by Blueprint and ENCODE from 43 distinct cell types representing pure 
populations of stroma and immune cells [49] [50]. The SingleR algorithm computes correlation 
between each individual cell and each of the 259 reference samples, and then assigns both a label 
of the cell type with highest average correlation to the individual cell and a p-value computed by 
wilcox test of correlation to that cell type compared to all other cell types. Cell-by-cell SingleR 
labels with p<0.05 are added as metadata and may be projected onto PISCES-generated UMAP 
space. Unsupervised clusters may then be labelled as a particular cell type based on the most-
represented SingleR cell type label within that cluster. 
 
Data Collection and Down-sampling for Technical Validation: SNU-16, a stomach 
adenocarcinoma cell line, was dissociated into a single-cell suspension and scRNAseq was 
performed using 10X Genomics Chromium platform (3’v3). Libraries were sequenced on an 
illumina Novaseq 6000 according to 10X Genomics’ protocol. In mid-log growth, SNU-16 is a 
transcriptionally complex cell line that will typically have 40,000-50,000 UMIs/cell with 
134,000 reads sequencing. These data were then down-sampled to depths of 10-40,000 at 5,000 
UMI intervals and 1-10,000 at 1,000 UMI intervals. Sample depths were first drawn from a 
uniformly distributed multinomial with n = N*x and p1,...,pn = 1 / N, where N was the number 
of cells and x is the target mean depth. Once sample depths were drawn, UMI counts were drawn 
from a sample-specific multinomial with n = di and p1...pg = 1 / G, where di is the sample depth 




Biological Validation Analysis: A highly used public CITE-Seq dataset of cord blood 
mononuclear cells was downloaded from Gene Expression Omnibus (GEO), and subset to 
human cells only. RNA counts were processed by the standard PISCES workflow, and antibody 
dependent tags (ADTs) were concurrently analyzed. ADT matrix was normalized by Seurat 
Centered Log Ratio “CLR” function, and clustered by PISCES resolution-optimized Louvain 
algorithm. Two-dimensional data representation was computed by RunUMAP, and antibody 
staining of all markers was visualized in a heatmap, with cells grouped by ADT cluster. For 
single-cell sequencing data, both gene expression signature and PISCES-inferred VIPER matrix 
were subset to genes encoding proteins represented in the ADT panel, and data were re-clustered 
on those gene subsets. For genes shared across all three modalities, coefficient of variation was 
computed as standard deviation divided by mean across all cells, and Spearman correlation was 
computed between gene expression or VIPER and corresponding protein-targeting antibody.  
 
Data Availability: The PISCES pipeline is implemented as an R package with all dependencies 
listed and a usage tutorial available at https://github.com/califano-lab/PISCES. All data, 








Chapter 2: Profiling the Renal Cell Carcinoma Microenvironment 
by Protein Activity Inference Reveals Novel Recurrence-Associated 
Macrophages 
The following is adapted from:  
Obradovic, A.*, Chowdhury, N.*, Haake, S. M.*, Ager, C., Wang, V., Vlahos, L., Guo, X. V., 
Aggen, D. H., Rathmell, W. K., Jonasch, E., Johnson, J. E., Roth, M., Beckermann, K. E., 
Rini, B. I., McKiernan, J., Califano, A., & Drake, C. G. (2021). Single-cell protein activity 
analysis identifies recurrence-associated renal tumor macrophages. Cell, 184(11). 
https://doi.org/10.1016/j.cell.2021.04.038  




Clear Cell Renal Carcinoma (ccRCC) is a heterogeneous disease with a variable post-surgical 
course. To assemble a comprehensive ccRCC tumor microenvironment (TME) atlas, we 
performed single-cell RNA sequencing (scRNASeq) of hematopoietic and non-hematopoietic 
subpopulations from tumor and tumor-adjacent tissue of treatment-naïve ccRCC resections. We 
leveraged the VIPER algorithm to quantitate single-cell protein activity and validated this 
approach by comparison to flow cytometry. The analysis identified key TME sub-populations, as 
well as their master regulators and candidate cell-cell interactions, revealing clinically relevant 
populations, undetectable by gene expression analysis. Specifically, we uncovered a tumor-
specific macrophage subpopulation characterized by upregulation of TREM2/APOE/C1Q - 
validated by spatially resolved, quantitative multispectral immunofluorescence.  In a large 
clinical validation cohort, these markers were significantly enriched in tumors from patients who 
recurred following surgery. The study thus identifies TREM2/APOE/C1Q-positive macrophage 





Figure 11: Experimental Design and Major Findings (Graphical Abstract) 
 
2.2 Introduction 
Clear cell renal carcinoma (ccRCC) is the most common histological subtype of renal carcinoma.  
Although primary disease is treated surgically, approximately 40% of resected ccRCC patients 
will relapse and develop metastases [51].  With a 5-year survival of 10% [52] metastatic ccRCC 
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is a lethal disease, underscoring the need to understand the cellular and molecular mechanisms in 
primary lesions that are prognostic for recurrence, both as biomarkers and as potential targets for 
intervention. Although ccRCC is an immunogenic tumor, the tumor-immune cell dynamics that 
regulate effective anti-tumor responses remain incompletely characterized. Consistent with other 
immunogenic tumors, overall immune infiltration and tumor mutation burden are partially 
predictive of response to therapy; yet, the value of these biomarkers in clinical decision making 
remains elusive.  Indeed, the complete picture of anti-tumor immune response drivers is complex 
[53] [54] [55]. Predictors of post-surgical disease recurrence are also limited, with previous gene 
expression studies suggesting CD44 as a marker of recurrence [56].  
 
To date, the most comprehensive studies of the primary ccRCC Tumor Micro-Environment 
(TME) used cytometry by time of flight (CyTOF) to interrogate markers of innate and adaptive 
immunity [57]. These studies showed that expression of T cell exhaustion markers and CD38+ 
myeloid cell infiltration was associated with worse overall outcome. High-throughput droplet-
based single-cell RNA Sequencing (scRNASeq) has recently emerged as a valuable tool to 
catalog the diverse cellular subpopulations that comprise the TME, with the ability to identify 
representative gene expression signatures from thousands of individual cells in a single sample 
[16] [32]. In contrast to bulk RNA-Sequencing, scRNASeq can characterize the transcriptional 
state of individual cell types, highlighting the role of rare populations whose gene expression 
signature would be diluted below the limits of detection in bulk samples [20]. In contrast to flow 
cytometry or CyTOF, scRNASeq generates a genome-wide profile of each individual cell’s 
transcriptome, without requiring selection of predefined markers. The value of scRNASeq has 
been demonstrated in recent studies of melanoma [17] [18] and breast cancer [34]. However, no 
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systematic, single-cell studies have been performed to study tumor tissue vs. adjacent normal in 
ccRCC. 
 
A key technical limitation of scRNASeq is that gene expression profiles are extremely sparse, 
with ~80% - 90% of genes undetected in every cell, a phenomenon known as gene dropout. 
While such data are effective in characterizing more molecularly distinct cellular subpopulations, 
they are not well suited to study specific genes and may also fail to detect more subtle 
differences, for instance due to activation of a few critical lineage markers [33]. Although 
dimensionality reduction tools, such as the Seurat pipeline [36], are successful in identifying 
individual subpopulations, the sparse and noisy nature of the data often prevents elucidation of 
finer-grain biological mechanisms. 
 
To address this issue, we have developed the metaVIPER algorithm  [26] , which leverages 
highly-multiplexed, tissue-specific gene-reporter assays to accurately measure the activity of up 
to ~6,500 regulatory proteins on a single-cell basis, including transcription factors (TFs), co-
factors (co-TFs), signaling proteins (SPs), and surface markers (SMs), based on the expression of 
their downstream regulatory targets (regulon). MetaVIPER extends the VIPER algorithm [21] to 
single-cells, independent of lineage. For simplicity, here we will use the term VIPER to refer to 
its single-cell implementation. Single-cell, tissue-specific regulons are inferred using ARACNe, 
an information theoretic algorithm that has been experimentally validated in multiple tissue 




To comprehensively characterize the interaction of immune- and non-immune cells in the ccRCC 
TME, we generated scRNASeq data from FACS-purified hematopoietic and non-hematopoietic 
cells dissociated from tumor and adjacent non-tumor tissue of 11 treatment-naïve primary 
ccRCC patients. To analyze these data, we developed a VIPER-based scRNASeq analysis 
pipeline to assess single-cell protein activity from single-cell ARACNe networks followed by an 
optimized single-cell clustering approach. These studies revealed a population of tumor-specific 
C1Q+TREM2+APOE+ macrophages associated with early post-surgical disease recurrence, as 
well as a potential target for therapeutic intervention. To validate VIPER predictions, we 
generated spectral flow cytometry and scRNASeq from matched patient samples, as well as 
quantitative, multi-spectral immunofluorescence (qmIF) data for a set of proteins significantly 
activated in a macrophage subpopulation prognostic for post-surgical disease recurrence. Taken 
together, these data provide a comprehensive atlas of primary ccRCC TME subpopulations—
including the Master Regulator (MR) proteins that control their transcriptional state, lineage 
markers, and predicted cell-cell interactions.  
 
2.3 Results 
Protein Activity Analysis of CD45+ TME Cells Reveals Tumor-Specific Immune 
Subpopulations: To study hematopoietic and non-hematopoietic populations in the primary 
ccRCC TME at single cell resolution, we isolated live cells from 11 treatment-naïve resected 
tumors, along with adjacent normal tissue. Expression-based clustering of scRNASeq profiles 




Figure 12: Consistency of Cell Type Clustering Across Patients 
UMAP plots of global gene expression clustering and global VIPER clustering for both CD45+ 
and CD45- cells, split by individual patient identity, such that the overall cell types identified are 
consistent across patients, with minimal batch effect. 
 
We initially focused on the hematopoietic compartment (CD45+), which was visualized 
following UMAP dimensionality reduction and clustered using the Seurat Louvain algorithm 
(Stuart et al., 2019). To optimize often arbitrary clustering while retaining scalability to hundreds 
of thousands of cells, we performed Louvain clustering across a range of 100 resolution values 
and selected optimal clustering resolution by optimizing a bootstrapped mean silhouette score 
(see methods). This clustering approach resolved CD4 and CD8 lymphocytes, regulatory T cells 
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(Tregs), NK cells (two populations), macrophages, monocytes, and small populations of B cells, 
mast cells, and plasma cells (Figure 13A), which were represented in all patient samples.  For 
visualization purposes, we show a heatmap for the top five transcripts most uniquely upregulated 
in each cluster (Figure 13C). These data confirmed SingleR-inferred cellular identify of each 
cluster — including expression of IL7R in CD4 T cells, CD3 and granzyme in CD8 T cells, and 




Figure 13: Deep Profiling of CD45+ Microenvironment by Gene Expression and Protein 









A) UMAP Plots for single-cell gene expression pooled across CD45+ samples, clusters 
visualized and labelled by cell type. Bottom plot is split by Tumor vs Adjacent Normal label B) 
UMAP Plots for VIPER-Inferred protein activity pooled across CD45+ samples. Bottom plot is 
split by Tumor vs Adjacent Normal label C) Heatmap of top5 upregulated genes for each cluster 
by expression; each row represents a gene and each column represents a cell. Legend shows 
cluster identity with cell type inferred by SingleR and Tumor (red) or Adjacent Normal (blue) 
tissue source. D) Heatmap of top5 differentially upregulated proteins for each cluster by VIPER-
inferred activity. Legend as in C. E) Bar plots of patient-by-patient cluster frequency in Tumor 
minus frequency in Adjacent Normal for each Gene Expression cluster, grouped by stage; values 
< 0 (blue) indicate higher frequency in Adjacent Normal and values > 0 (red) indicate higher 
frequency in Tumor. F) Bar plots of patient-by-patient cluster frequency in Tumor minus 
frequency in Adjacent Normal for each VIPER cluster, grouped by stage, as in E. 
 
However, expression-based clustering missed multiple established markers of these 
populations. For example, Tregs did not show differential expression of the canonical FOXP3 
transcription factor; rather the most overexpressed gene was IL-32. While other genes in this 
cluster, e.g., BATF, TIGIT, and TNFRSF18— are expressed in Tregs [58], none is considered a 
canonical marker. Further, expression-based clustering failed to recapitulate the heterogeneity of 
these subpopulations; for example, it distinguished only two populations of myeloid cells 
(Figure 13). Finally, considering intra-cluster statistics, differentially expressed genes had poor 
reproducibility. For instance, average within-cluster standard deviation of classical markers such 
as IL7R, KLRD1, and CD8B was quite high, σIL7R = 3.19, σKLRD1 = 3.79, and σCD8B = 3.01 
respectively, exceeding the mean expression values of the gene: µIL7R = 2.52, µKLRD1 = 3.17, and 




We next proceeded to assess whether protein activity-based clustering, using VIPER, 
would yield additional robustness and biological insight. Since we previously showed that 
regulatory networks of lineage-related cells have >95% overlap [59], we generated (n = 69) 
ARACNe-inferred regulatory models—one for each gene expression cluster in each patient—as 
we expected that finer differences would likely be present within primary lineages. For each 
single cell, we then used the cluster-specific regulatory networks to perform VIPER-based 
protein activity inference. While the resulting clusters were generally consistent with those 
derived by gene expression, protein activity-based clusters showed multiple critical differences 
(Figure 13B, Figure 13D).  For example, the most differentially active protein in the Treg 
cluster was FOXP3, consistent with well-established Treg biology [58] (Figure 13D), and 
Cytotoxic T Lymphocyte Antigen–4 (CTLA-4), which is up-regulated on the surface of tumor 
infiltrating Tregs [60], was inferred as differentially active by VIPER. VIPER identified a 
distinct CD8 T cell population with markers consistent with exhaustion, including differential 
activation of LAG-3, TOX2, and PD1, which had been missed by expression-based analysis 
(Figure 13D, Figure 14A). Additionally, myeloid cells were further stratified by VIPER into 




Figure 14: Known and Novel Tumor-Infiltrating Immune Population Markers 
Discovered from Single-Cell Transcriptomic and Inferred Proteomic Data 
A) Violin plots of VIPER-inferred Proteins upregulated in CD45+ cell subsets corresponding to 
Tregs (FOXP3, CTLA4), Exhausted CD8s (TOX2, LAG3, PD1, CTLA4), and Tumor-specific 





TREM2) specifically up-regulated in Tumor-Infiltrating Macrophages as compared to other cell 
populations as well as non-tumor macrophages. 
 
VIPER analysis identified several populations that were differentially represented as a 
function of tumor stage and localization in tumor vs. adjacent non-tumor; these were 
undetectable by gene expression analysis (Figures 13E,F). Specifically, Treg, CD8 T cell, and 
Macrophage normalized counts were higher in the tumor compared to normal adjacent tissue 
(p = 0.012, p = 0.006, p = 0.013, respectively). In contrast, Monocyte, B cell, and CD4 T cell 
counts were higher in adjacent normal (p = 0.097, p = 0.017, p = 0.018, respectively). Two NK 
cell clusters were identified, one with higher counts in the adjacent normal (NK cell 1) and a 
second with higher counts in tumor (NK cell 2), (p = 0.09, p = 0.008, respectively). Consistent 
with prior data [61], activity-based, but not expression-based clustering identified higher counts 
of exhausted CD8 T cells in tumor vs. adjacent normal (p = 0.0005), and also in stage pT3a vs. 
pT1a tumors (p = 0.015) (Figure 13F). Further, the tumor-specific macrophage population 
identified by inferred protein activity was more significantly enriched in tumor as compared to 
adjacent normal than the coarse macrophage population identified by gene expression, i.e., 
p = 0.0006 vs. p = 0.013.  
Reproducibility of individual markers was also significantly improved by VIPER (Figure 
13D), compared to gene expression (Figure 13C). For example, the standard deviation of the 
classical markers (IL7R,  KLRD1, and CD8B) was much lower, σIL7R = 0.75, σKLRD1 =0.48, and 
σCD8B = 0.49 respectively, whereas their mean activity value was substantially larger µIL7R =5.28, 
µKLRD1 = 6.54, and µCD8B = 5.88, as further confirmed by significant improvement in silhouette 
scores, SC = 0.7 by VIPER as compared to a SC = 0.35 by gene expression based clustering 
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(Figure 15). Thus, based on the coefficient of variation (i.e., σ/μ), reproducibility was increased 
between 8.9-fold (IL7R) and 25.6-fold (CD8B) by VIPER-based clustering. 
 
 
Figure 15: Resolution-Optimized Louvain Clustering Silhouette Scores 
Mean and Standard Deviation of Silhouette Score by Resolution-Optimized Louvain algorithm 
for each resolution value ranging along the x-axis from 0 to 1.0 at intervals of 0.01, showing 
“best” resolution in the top-right as the resolution that maximizes mean silhouette score. Includes 
CD45+ Gene Expression clustering, CD45- Gene Expression clustering, CD45+ VIPER 







Relative Specificity of Tumor Infiltrating Immune Cell Populations: To visualize protein 
activity differences in key cell type markers over-represented in tumor vs. adjacent normal, 
including Macrophages, Tregs, and exhausted CD8 T cells, we generated violin plots (Figure 
14A). As shown, LILRB5 was identified as the most differentially active among VIPER-inferred 
markers of tumor-specific macrophages. These macrophages, as well as the three monocyte 
clusters, showed high APOE activity. Among T-cells, FOXP3 was identified as the most 
activated protein in TIL Treg; relative activation was also noted in tumor associated CD8 T cells.  
CTLA-4 followed a similar pattern, consistent with previous data from bulk TIL Treg studies 
[60].  LAG-3 and PD-1 (PDCD1) showed similar inferred protein activity distributions, with 
higher activity in CD8 T cells and, in particular, in the CD8 TIL cluster (CD8 T cell 1) vs. the 
(CD8 T cell 2) cluster that was also represented in adjacent normal. PD-1 also showed significant 
expression in TIL Treg. Interestingly, we found significant activation of TOX2—a protein 
related to TOX1 which plays a critical role in epigenetic reprogramming of exhausted CD8 T 
cells [62] [63]—in the CD8 TIL cluster, consistent with an exhausted phenotype. We 
complemented these differential activity analyses by examining genes that were differentially 
expressed in the tumor-specific macrophage population, which were only be identified by 
VIPER-based protein activity clustering (Figure 13C). Once a finer-grain cluster structure was 
revealed, with several genes found to be over-expressed in specific clusters, including APOE, 
C1QA-C and TREM2 - demonstrating the ability to integrate both differential protein activity 
and differential gene expression in the analysis (Figure 14B). Notably, differential expression of 
these genes would have gone undetected if the cluster structure produced by gene expression-
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based clustering had been used. As discussed below, we subsequently validated the tumor-
specific macrophage marker proteins identified by these analyses by immunofluorescence and 
correlated those data with clinical outcome. 
 
Master Regulators of Sub-Population Transcriptional State: In addition to recapitulating 
differential activity of established subpopulation markers, VIPER analysis identified novel 
proteins that were differentially active in both common and rare subpopulations. For TFs and co-
TFs, these Master Regulator (MR) proteins represent novel mechanistic drivers of the 
transcriptional state of these cells, while signaling and surface marker proteins may represent 
novel lineage markers for FACS-based isolation, as further confirmed by the protein-based 
validation assays discussed below. Of note, we previously showed that a majority (>70%) of 
VIPER-inferred proteins control the transcriptional state of a cell by direct, physical regulation of 
their transcriptional targets and can be used to efficiently reprogram cell state by ectopic 
expression/co-expression [42] [64] [65] [66]. As a result, these proteins may also represent 
attractive drug targets for modulation of specific sub-populations.  Candidate MR proteins of 
each VIPER-inferred cluster are reported in supplement at Obradovic et al; the top MRs are also 
shown in Figure 13D. In particular, MRs of tumor-enriched cell populations (i.e., Tregs, CD8 T 
1 cells, and Macrophages) included both established drug targets for Tregs or exhausted CD8 T-
cells, such as CTLA-4 and PD-1, as well as less well-characterized markers of Tregs (CNIH1, 
STAM, RAB33A, etc.), exhausted CD8 T cells (TOX2, SNAP47, CD82, SIRT2, LAG-3, etc.), 
and Tumor-Infiltrating Macrophages (LILRB5, FAM120B, CD209, IGF1, TNFRSF11A, etc.). 
As a result, these data provide a valuable resource of proteomic regulators for the full 




VIPER-inferred Protein Activity Recapitulates Flow Cytometry, Overcoming scRNASeq-
related Gene Dropout: To more fully characterize the proteomic profile of the ccRCC TME and 
to benchmark VIPER results, we analyzed a subset of samples for which scRNASeq data was 
available using high-dimensional flow cytometry with a 19-marker lymphoid panel and 19-
marker myeloid panel. Manual gating of specific marker pairs broadly recapitulated the 
populations identified by VIPER-based cluster analysis.  For example, flow cytometry identified 
a population of CD8+/PD1+/CD39+ CD8 T cells, with numerically higher normalized counts in 
tumor vs. adjacent non-tumor samples (p = 0.057), consistent with the cluster of tumor-enriched 
exhausted CD8 T cells identified by VIPER (Figure 16). Cytometry also identified a population 
of CD4+/CD127low/FOXP3+ Tregs, with higher representation in the majority of tumor vs. 
adjacent normal samples (p = 0.072). Similarly, these flow studies confirmed the existence of 
two distinct NK cell subpopulations (i.e., CD56high/CD16low vs CD56low/CD16high), a 
CD11C+/CD163+ macrophage population with higher representation in tumor vs. adjacent 
normal (p = 0.076), and three distinct monocyte subpopulations (CD14+/CD16+, vs. 





Figure 16: Characterization of Immune Infiltrate by Manual Flow Cytometry Gating 
Representative Flow Cytometry Gating in Tumor and Adjacent Normal and frequency plots in 
tumor and adjacent normal for all manually gated populations. Populations of PD1+CD39+ 
exhausted CD8 cells, Tregs, and CD11B+CD163+ Macrophages are of higher frequency in 
Tumor than Adjacent Normal. Representative plots showing two distinct NK cell phenotypes and 
three monocytic sub-phenotypes, consistent with Figure 13B. 
 
While these populations were validated by manual gating of specific proteins, our analysis shows 
that they could not have been inferred directly from the high-dimensional flow cytometry data 
(Figure 17). To test this, we performed unsupervised clustering of the flow cytometry dataset, 
using the Resolution-Optimized Louvain cluster analysis algorithm by which we infer expression 
and activity-based clusters. Based on the lymphoid panel, the analysis identified four distinct 
clusters: CD4 and CD8 T cells, Myeloid cells, and B cells (Figure 17A) while the myeloid panel 
yielded 6 clusters: Lymphoid cells, B cells, 3 monocyte cell types characterized as 




represented in the tumor compartment, with relative over-expression of CD86, CD1D, CD16, 
CD163, CD169, CD56, CXCR2, CD14, and CD33 proteins (Figure 17D).   
 
To assess whether scRNASeq data could recapitulate these findings, we restricted unsupervised 
cluster analysis to genes encoding for proteins represented in the flow cytometry panels (Figure 
17B,E). This analysis failed to reveal biologically relevant clusters due to high gene dropout 
rates, even on markers that should be highly expressed. Indeed, expression of the genes encoding 
for the 19 lymphoid and 19 myeloid proteins was too noisy and sparse to support cluster 
inference consistent with established cell types. This result emphasizes the extremely noisy 
nature of scRNASeq measurements when restricted to specific genes of interest.  
 
We next tested whether analysis of VIPER-inferred activity for lymphoid and myeloid markers 
could recapitulate meaningful cell types. As shown in Figure 3D, the vast majority of proteins in 
the lymphoid flow cytometry panel were well-resolved by VIPER, with the exceptions of 
PTGDR2, FCGR3B, and NT5E. Similarly, the majority of the proteins in the myeloid flow panel 
were also well-resolved by VIPER, with the exception of FCGR3B and CD33 (Figure 17F).  
Taken together, 34 of 39 proteins (77%) were well-represented by VIPER, consistent with the 
70-80% previously reported recovery in protein activity measurements [21]. This was even more 
remarkable because the panel analyzed here included mostly surface markers not directly 
involved in transcriptional regulation, with a few exceptions (e.g. FOXP3). 
 
Protein activity analysis restricted to the lymphoid panel was effective in recovering lymphoid 
cell diversity, and was able to distinguish Monocytes from Macrophages despite limited profiling 
63 
 
of macrophage lineage markers by the lymphoid panel (Figure 17C), thus comparing favorably 
with analysis of flow cytometry data, which only identified 4 of these 7 cell types.  For instance, 
protein activity analysis was effective in identifying Tregs, which were missed by flow-based 
clustering due to low intensity of FOXP3 staining. Comparing protein abundance and activity in 
matched flow-cytometry and VIPER clusters (e.g., CD4 T cells), the reproducibility of activity 
data was approximately 2-fold higher, on average, based on coefficient of variation (CV) 
analysis, defined as the ratio of the standard deviation over the mean. When averaged over the 
top proteins differentially represented in the CD4 and CD8 T cell clusters, flow-based analysis 
produced CVCD4 = 0.206 and CVCD8 = 0.209, while activity-based analysis yielded 





Figure 17: Flow Cytometry is Better Recapitulated by Protein Activity Than by Gene 
Expression 
A) UMAP projection, clustering, and heatmap by flow cytometry proteins profiled in CyTEK 
Lymphoid Panel. B) UMAP and clustering by scRNASeq gene expression subset to the proteins 
profiled in A, showing noise-induced decrease in clustering resolution. C) UMAP and clustering 
by scRNASeq VIPER inference subset to the proteins profiled in A. D) UMAP and clustering by 
flow cytometry proteins profiled in CyTEK myeloid panel. E) UMAP and clustering by scRNA-
Seq gene expression, subset to the proteins profiled in D. F) UMAP and clustering by scRNA-
Seq VIPER inference, subset to the proteins profiled in D. 
 
A) B) C) 
D) E) F) 
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These findings were validated in a public CITE-Seq dataset profiling antibody staining and gene 
expression simultaneously in single cells derived from cord blood [46]. Here, clustering by 
antibody profile was lost by single-cell gene expression but was completely recovered by VIPER 
analysis. Moreover, the cell-matched coefficient of variation within each cluster was 
significantly lower for VIPER-inferred protein activity as compared to gene expression 
(p=0.0004) and compared favorably with antibody-based measurements (p=0.0083). As above, 
VIPER-measured protein activity correlated more closely with antibody staining than did gene 
expression. Taken together, these results show that protein activity-based analyses can 
recapitulate cell-type identification based on protein-level data derived by flow cytometry even 
from a relatively restricted set of marker proteins, suggesting that such analyses effectively 
mitigate the gene dropout inherent in scRNASeq. 
 
Protein Activity in CD45- Cells Distinguishes Tumor cells from Adjacent Normal Epithelium: 
We next compared expression and activity-based clustering of non-hematopoietic (CD45-) 
ccRCC TME cells. Expression-based clustering of CD45- cells from all patients (including 
tumor and adjacent normal) revealed four predominant cell types: epithelial cells, endothelial 
cells, fibroblasts, and M2 macrophages (Figures 18A). These populations showed differential 
representation in tumor vs. adjacent normal, with M2 macrophages predominant in adjacent 
normal (pM2 = 0.007), and fibroblasts and epithelial cells over-represented in tumor tissue 
(pFB = 0.009, pEpi = 0.0005).  The epithelial cluster, mostly comprised of tumor cells, showed 
tumor compartment specificity as compared to adjacent normal. As expected, it was more highly 
represented in patients with pT3a compared to pT1a disease (pEpi|pT3-pT1 = 0.011) (Figure 18E).  
The 5 most upregulated genes for each cluster are shown in in Figure 18C.  Of note, epithelial 
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cells overexpressed SERPINA1, a protease inhibitor upregulated in multiple cancer types, as 
well as CD24, recently described as a macrophage immune checkpoint protein [67], whose 
expression is associated with worse prognosis in ccRCC [68]. Additionally, the epithelial cluster 
showed upregulation of keratin 16 (KRT16) and 8 (KRT8), which have also been associated with 
poor prognosis in ccRCC [69].  
VIPER was equally successful in identifying fibroblast, endothelial, and M2 macrophage 
clusters, while revealing a deeper level of heterogeneity. Specifically, epithelial cells stratified 
into four distinct clusters (Figure 18B). While clusters E1, E3, and E4 were more represented in 
the tumor as compared to adjacent non-tumor (pE1 = 0.001, pE3 = 0.056, pE4 = 0.028), cluster E2 
was more represented in adjacent normal (pE2 = 0.312) (Figure 18E). This population represents 
normal epithelial cells, whose gene expression was not sufficiently distinct from tumor cells to 
be effectively stratified without VIPER. For visualization purposes, we show the 5 most 
differentially active proteins for each cluster (Figure 18D).  
Further analyses showed that Cluster E1—the most prevalent among the four epithelial 
clusters—was significantly over-represented in stage 3 tumors as compared to stage 1 tumors 
(pE1|S3:S1 = 0.018), while lower-frequency populations E2, E3, and E4 were represented in both 
stage 1 and stage 3 patients. This analysis suggests that differential frequency of a dominant 
epithelial cell population whose transcriptional state is virtually identical across patients 
effectively stratifies Stage 1 vs. Stage 3 tumors (Figures 18E and 18F). These data are relevant 
because transcriptionally distinct tumor cell subpopulations may have differential drug 
sensitivity and because protein activity-based analysis but not gene expression allowed distinct 





Figure 18: Deep Profiling of CD45- Cells by Gene Expression and Protein Activity 







A) UMAP of single-cell gene expression pooled across all CD45- samples, clusters labelled by 
cell type. Bottom plot is split by Tumor vs Adjacent Normal label B) UMAP of VIPER-inferred 
protein activity pooled across all CD45- samples, clusters labelled by cell type. Bottom plot is 
split by Tumor vs Adjacent Normal. C) Heatmap of top5 differentially upregulated genes for 
each cluster by expression; each row represents a gene and each column represents a cell. 
Legend shows cluster identity with cell type inferred by SingleR and Tumor (red) or Adjacent 
Normal (blue). D) Heatmap of top5 differentially upregulated proteins for each cluster by 
VIPER-inferred activity. Legend as in C. E) Bar plots of patient-by-patient cluster frequency in 
Tumor minus frequency in Adjacent Normal for each Gene Expression cluster, grouped by stage; 
values < 0 (blue) indicate higher frequency in Adjacent Normal, values greater < 0 (red) indicate 
higher frequency in Tumor. F) Bar plots of patient-by-patient cluster frequency in Tumor minus 
frequency in Adjacent Normal for each VIPER cluster, grouped by stage, as in E. 
 
Inferred Tumor-Cell Copy Number Alterations are Characteristic of Clear Cell Renal 
Carcinoma: To further understand the epithelial cell clusters, we assessed VIPER-inferred 
activity of PAX8, PAX2, and CAIX, proteins expressed in renal epithelium; these are 
upregulated in malignancy and commonly used as markers for ccRCC [70]. This analysis 
confirmed increased activity of these markers in epithelial clusters E1, E3, and E4 (Figure 19A).  
To more precisely determine which epithelial clusters represent tumor cells, we performed Copy 
Number Alteration (CNA) inference clustered by expression-based (Figure 19B) or activity-
based (Figure 19C) analysis. We inferred CNAs for each CD45 negative cell, using CD45 
positive cells as normal ploidy controls. The results (Figure 19C) showed that aberrant CNA 
regions are present in epithelial clusters E1, E3, and E4 but not E2, including recurrent 3p 
chromosomal deletions not detected in any other cell type. Of note, chromosome 3p deletions 
occur in >96% of all ccRCC patients, as that region contains the VHL tumor suppressor locus 
[71]. The epithelial cluster inferred by expression-based analysis included cells lacking gross 
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copy number alterations (highlighted in Figure 19B), corresponding exactly to activity-based 
cluster E2 (Figure 19C).  
 








A) ViolinPlots of VIPER-Inferred Activity for ccRCC tumor markers PAX2, PAX8, and CA9. 
Plots grouped by CD45- cluster label revealing increased expression in epithelial cells. B) CNA 
Inference for all CD45- populations, using CD45+ cells as reference. Columns represent 
chromosomal regions and rows represent cells, grouped by Gene Expression cluster, with a 
subset of copy-number-normal epithelial cells highlighted in green. C) CNA Inference re-
grouped by VIPER cluster. Epithelial cell clusters 1, 3 and 4 contain consistent chromosome 3p 
deletions characteristic of ccRCC, while Epithelial cluster 2, highlighted in green, is grossly 
Copy-Number normal. D) Table of known receptor-ligand interaction pairs in which ligand is 
significantly upregulated by Gene Expression in one cluster and receptor is significantly 
upregulated by VIPER in another. Subset to interactions inferred between Tumor cells and T-
cells, or between APOE+/TREM2+/C1Q+ Tumor Macrophages and Tumor cells. E) 
Visualization of receptor-ligand interaction pairs shown in D. 
 
Dissecting Receptor-Ligand Interactions in ccRCC: A critical challenge that may benefit from 
VIPER-based protein activity measurements is the elucidation of cross-compartment interactions 
that may modulate tumor homeostasis. The extensive scRNAseq dataset generated by these 
studies, which included data from both hematopoietic and non-hematopoietic cells, supported in 
silico interrogation of putative receptor/ligand interactions between cell types. To that end, we 
identified overexpressed genes encoding for secreted ligands and differential VIPER activity of 
their cognate binding receptors between all possible subpopulation pairs and across patients. 
Referencing a curated public database of 2,557 known receptor-ligand interaction pairs [72], we 
identified interactions supported by significant overexpression of the ligand in any cell 
population and concomitant activation of the cognate receptor by VIPER in any patient-matched 
subpopulation. A total of 276 candidate receptor-ligand pairs were identified. Of these, several 
had been previously established in ccRCC. For example, we identified receptor/ligand pair 
KDR/VEGFA in tumor cells and endothelial cells, respectively. Figure 19D shows a curated 
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subset of predicted receptor/ligand interactions between tumor cells and tumor-enriched immune 
populations (T cells and Macrophages).  Of these, the potential interaction between CD70 and its 
cognate receptor CD27, in tumor and CD8 T cells respectively, is of interest, given ongoing 
investigation of CD70 as a therapeutic target [73]. The majority of interactions thus identified 
were not previously reported, providing a systematic resource for future studies.  
 
A Tumor-Specific Macrophage Signature is Associated with Disease Recurrence: As above, 
protein activity analysis identified a novel, tumor-specific sub-population of macrophages and 
their top differentially active proteins (i.e., LILRB5, APOE, and TREM2) and differentially 
expressed genes (i.e., C1QA-C, APOE, and TREM2). To assess the clinical significance of this 
population, we leveraged single-cell ARACNe networks to transform bulk RNA Sequencing data 
from two independent cohorts (n=8 and n=157) using VIPER. Here, gene expression of each 
cohort was scaled by the mean and standard deviation of each gene and VIPER was applied. We 
defined a set of statistically upregulated proteins (p<0.05) in the Tumor-Specific Macrophage 
population and computed Normalized Enrichment Score (NES) of this gene set in the ranked 
differential protein activity signature of patients with post-surgical disease recurrence compared 
to those without recurrence. This analysis was first performed in a small (n=8), well clinically-
annotated cohort of bulk RNASeq samples from untreated ccRCC surgical resections; here we 
found a significant enrichment of tumor macrophage signature in 4 patients with recurrence 
compared to 4 age- and stage-matched controls (Figure 20A) (Normalized Enrichment Score 
NES = 4.08, p = 4.5×10-5). We found that the leading-edge proteins included marker proteins 
APOE and TREM2, as well as other macrophage-associated proteins of potential clinical 
interest, such as LILRB5, MERTK, and IGF1 (Figure 20C). Sample-by-sample NES of the 
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Tumor Macrophage Gene Set was computed directly on the ranked VIPER activity of proteins in 
each bulk RNA-Seq sample, and was consistent with the group-wise analysis in Figure 6A, such 
that all non-recurrent patients had significant depletion of tumor macrophage markers and 
recurrent patients had strong enrichment, with the sole exception of a single patient who recurred 
late (82 months post initial surgery) (Figure 20D). To further explore this clinical association, 
we performed Univariate Cox regression of normalized enrichment scores (NES) versus time to 
recurrence (TTR) on a patient-by-patient basis (p=0.057). Binary log-rank test of macrophage 
enrichment, with NES > 0 = “high” and NES ≤ 0 = “low”, showed a strong statistically 
significant association between signature enrichment and shorter time-to-recurrence (p = 6.7x10-
3) despite a relatively small sample size, suggesting a strong effect (Figure 20B). To validate the 
association of markers representative of this rare population with recurrence, we next measured 
their enrichment in a larger cohort of bulk RNA-Seq samples from 157 treatment-naïve ccRCC 
surgical resections, annotated with time to post-surgical recurrence. This validation cohort 
showed a consistent up-regulation of tumor macrophage markers in patients with post-surgical 
recurrence (Figure 20E) (NES = 4.33, p = 1.5x10-5), with a significant cox regression p-value of 




Figure 20: Enrichment of Tumor-Specific Macrophage Markers Defined from Single-








A) Gene Set Enrichment Analysis (GSEA) of tumor-specific macrophage marker proteins in 
VIPER-transformed bulkRNASeq data from 4 patients with post-surgical recurrence vs 4 
without.  Proteins ranked by fold-change in recurrence versus no recurrence, p-value computed 
by GSEA vs gene shuffling null model with 1000 permutations. Note enrichment in patients with 
recurrence (NES=4.08, p=4.5*10-5). B) Kaplan-Meier curve of sample-by-sample tumor-specific 
macrophage GSEA associated with time to recurrence, yellow line indicates patients with low 
enrichment, blue line indicates patients with high enrichment. Log-rank p-value = 0.0067. C) 
Heatmap of leading-edge protein set from A. D) Sample-by-sample tumor macrophage GSEA, 
annotated with each sample’s recurrence status and time to recurrence or total observation time. 
Proteins ranked by inferred activity. E) Macrophage signature GSEA in recurrence vs. no 
recurrence in validation cohort (N=157). F) Kaplan-Meier curve of sample-by-sample GSEA in 
association with time to recurrence in the validation cohort, log-rank p-value = 0.0029. 
 
C1Q/TREM2 Expressing Macrophages are Tumor-Restricted and Associated with Post-
Surgical Recurrence: We next queried whether markers of the macrophage population 
associated with poor outcome were co-expressed in cells by Immuno-fluorescence staining and 
analyzed their spatial localization to determine if these markers were tumor, T cell or 
macrophage-related. We specifically interrogated C1Q, APOE, and TREM2, as the latter two 
were identified as protein activity markers strongly associated with clinical outcome (Figure 
20C) and C1Q was highly overexpressed but could only be identified following VIPER 
clustering of the single-cell data. For these studies, we developed a fluorescence-based panel that 
included the three markers, as well as subpopulation specific markers CA9 (tumor cells), CD3 (T 
cells), and CD69/CD163 (pan-macrophage) (Figure 21A). Using this panel, we stained each of 
the 11 samples interrogated by scRNASeq and quantified expression in multiple segments of 
tumor and adjacent non-tumor tissue.  Both C1Q and TREM2 were strongly enriched in 
macrophages across all samples (Figure 21B).   
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To determine which macrophage populations were comparatively tumor-restricted, we 
tested the representation of cells co-staining for C1Q, TREM2, and CD68/CD163 within tumor 
stroma vs. adjacent normal. In contrast to total CD68/CD163 macrophages, and as predicted by 
VIPER analysis, C1Q+ and TREM2+ macrophages were significantly tumor restricted, whilst 
the double positive population (C1Q+, TREM2+) appeared to be almost completely exclusive to 
tumor tissue (Figure 21C). Furthermore, these C1Q+/TREM2+/APOE+ macrophages were 
localized more closely to tumor cells than control macrophages (C1Q-TREM2-APOE-) with a 
relative distance to the nearest CA9+ cell of 15.25 um vs 23.28 um, p = 1.7x10-14, respectively. 
The strong tumor restriction of this population did not appear to correlate with tumor stage 
(Figure 21D).  To further assess for association with disease recurrence, we stained the samples 
from the same dataset we had used for initial bulk RNAseq studies (Figure 20A-D). These 
samples showed that both TREM2 and C1Q were significantly enriched in the tumor stroma of 
patients with disease recurrence as compared to patients without recurrence (Figure 21E) (pC1Q 
= 0.047, pTREM2 =0.038, pC1Q/TREM2 = 0.009). C1Q+ macrophages, in particular, were 
significantly associated with disease recurrence (p = 0.028).  These data suggest that assessment 
of intra-tumoral C1Q+ macrophage density by IF (Figure S5) may provide a useful prognostic 
biomarker for recurrence. We explored this hypothesis by first calculating a cutoff for C1Q 
macrophage frequency that maximized the log-rank statistic, and next performing log-rank 
regression (Figure 21F). A C1Q+ macrophage frequency threshold of 0.01 significantly 
separated patients with post-surgical recurrence from those without recurrence, with a log-rank 
p-value of 6.7x10-3 and Area under the Curve (AUC) of 0.9375. These data recapitulated the 
disease recurrence Kaplan-Meier curve defined by GSEA analysis (Figure 20B), and 
independently support the association of tumor-infiltrating macrophage density with post-
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surgical recurrence, highlighting a strong consistency between IF staining and scRNASeq 
analysis.  
 
Figure 21: A Novel Population of C1Q/TREM2+ Macrophages are Tumor-Specific and 








A) Representative IHC images for each marker in tumor stroma vs adjacent normal. Note high 
C1Q/TREM2/APOE staining within CA9+ tumor as compared to tumor-adjacent (CA9-) 
regions. B) Odds ratios (OR) across samples of tumor-specific macrophage markers C1Q, 
TREM2, and APOE co-staining with CD68/CD163+ macrophage cells vs CD68/CD163- non-
macrophage cells, note association of C1Q and TREM2 with macrophage markers. Dotted red 
line represents OR=1. Individual OR for C1Q and TREM2 co-staining with CD68/CD163 is 
statistically significant by Fisher’s exact test (p<0.01). C) Frequency by IHC of C1Q+ or 
TREM2+ macrophages in tumor stroma vs adjacent normal across the 11 patient samples 
profiled by scRNASeq. Enrichment in tumor compared to adjacent normal assessed by paired 
Wilcox test, *<0.05, **<0.01. D) Frequency of C1Q+TREM2+CD68/CD163+ macrophages in 
tumor vs adjacent normal, plotted by stage (pT1a vs pT3b). No C1Q+TREM2+CD68/CD163+ 
cells were present in adjacent normal. E) Frequency of C1Q+ or TREM2+ macrophages in tumor 
stroma of patients with or without post-surgical recurrence, from the cohort profiled by 
bulkRNASeq in Figure 20A-20D. Higher frequency in patients with recurrence assessed by 
unpaired Wilcox test, *<0.05. F) Kaplan-Meier plot of C1Q+CD68/CD163+ frequency in 
association with time to recurrence. Log-rank p-value = 0.0067, with sample-by-sample 
frequency binarized by log-rank maximization to >0.01 = “high” and <0.01 = “low.” 
 
2.4 Discussion 
We report a systematic single-cell analysis of the cell populations that comprise the immune and 
non-immune compartments of clear cell renal cell carcinoma (ccRCC), from >200,000 cells 
representing tumor and adjacent normal tissue from 11 patients, with either stage 1 or stage 3 
disease. By incorporating both transcriptomic and VIPER-based proteomic data, our analysis 
characterizes sub-populations, key regulatory proteins, and candidate ligand/receptor-mediated 
interactions, providing a previously unavailable window into the microenvironment of ccRCC. 
 
These studies provide insight that could only be gleaned using our comprehensive VIPER-based 
scRNASeq protein activity analysis pipeline. In particular, key tumor-specific populations, 
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comprising both immune and non-immune cells, and their established lineage markers were 
missed by expression-based cluster analysis and by flow cytometry, due to significant gene 
dropout effects, a limited set of antibodies, and measurement reproducibility. By contrast, 
activity-based analyses provided high-resolution sub-structure and revealed a novel tumor-
specific macrophage population prognostic for recurrence.  
 
To confirm that activity-based analysis tracked protein expression (quantified using flow 
cytometry and IF), we performed a comprehensive validation of VIPER results using high-
parameter spectral flow cytometry. Our results show that VIPER-based analyses may potentially 
outperform antibody-based measurements in terms of both detection and reproducibility, while 
providing quantitative activity assessment for >6,000 proteins in a single experiment. By 
contrast, gene expression-based analyses of scRNASeq data could not recapitulate flow 
cytometry results, due to significant gene dropout effects. Thus, a key novel finding of this study 
is feasibility, accuracy, and reproducibility of network-based protein activity inference from 
single cell gene expression profile data.  
 
Importantly, activity-based analyses identified several known immune checkpoint and master 
regulatory proteins missed by gene expression analysis alone. In exhausted CD8 T-cells, for 
instance, these included LAG-3, PD-1, and CTLA-4, while in Tregs, they included FOXP3 and 
CTLA-4. Thus, the full set of differentially active regulatory proteins reported represents a 
previously unavailable resource for the study of these cell types. Analysis of both hematopoietic 
and non-hematopoietic cells allowed us to study the interaction between tumor-related cells and 
immune subpopulations in the TME, especially with respect to tumor-infiltrating macrophages. 
79 
 
Inference of interactions among established receptor-ligand pairs [72] identified >200 
ligand/receptor-mediated cell-cell interactions, which were consistently yet independently 
detected across all patients. Among multiple potentially significant interactions identified, we 
highlight CD70, localized to the surface of tumor cells, interacting with its cognate ligand, 
CD27, on tumor-infiltrating T cells. CD70 is expressed in many solid tumors, including RCC 
[74], and may facilitate tumor cell escape by inducing tumor cell proliferation and survival [73] - 
these data establish it as a potential therapeutic target in ccRCC. 
 
In terms of potential clinical relevance, activity-based analysis identified a tumor-specific 
macrophage subpopulation characterized by upregulation of C1Q, APOE, and TREM2 and high 
activity of the LILRB5 protein (Figure 13, Figure 14). This subpopulation was consistently 
detected in all tumors, and GSEA analysis of its single-cell RNASeq protein signature in 
independent bulk RNASeq profiles revealed its significant association with shorter time to post-
surgical recurrence.  These findings were confirmed in a validation cohort of 157 patients 
(Figure 20). Of note, the VIPER based test to measure activity of these proteins in patients, 
based on their tumor’s mRNA profile (OncoTarget) [44], recently received CLIA-certification by 
the NY and CA departments of health. 
 
Protein-level qmIF confirmed the clinical significance of C1Q+ tumor-specific macrophages and 
recapitulated association with shorter time to post-surgical recurrence identified at the 
transcriptional level (Figure 21F). Though the functional role of these tumor-specific 
macrophages is currently unknown, a recent study in primary renal tumors also found that high 
density of C1Q-expressing cells correlates with poor prognosis [75] although that study did not 
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characterize these findings at the single-cell level or report their tumor-specificity and interaction 
with tumor cells. Functionally, complement-deficient mice developed high densities of C1Q 
expressing macrophages with concurrent upregulation of immune checkpoints PD-1, LAG-3, and 
PD-L1.  These orthogonal data are consistent with our observations in human single-cell data, as 
we documented a C1Q-expressing tumor-specific macrophage population and a high frequency 
of likely exhausted LAG-3+ PD-1+ T cells in the ccRCC TME.  
 
Our studies also highlighted APOE and TREM2 - a member of the immunoglobulin superfamily 
that plays an important immunomodulatory role in the regulation of inflammatory processes  
[76] [77] and enhances tumor proliferation [78] [79]. The role of the TREM2-ApoE pathway in 
RCC tumor biology has not been fully explored. A recent study profiling a murine ccRCC model 
using scRNASeq in conjunction with intracellular proteomic staining identified a population of 
TREM2+ tumor-infiltrating macrophages which appears to be phenotypically similar to the 
population we discovered in patients [80]. Functional studies showed that co-culture of CD8 T-
cells with these macrophages significantly impeded T-cell proliferation, and that TREM2 
knockdown led to favorable pre-clinical outcomes. 
 
In conclusion, we report the development and application of a novel and broadly generalizable 
scRNASeq analytic pipeline which complements gene expression with inferred protein activity 
to comprehensively dissect the repertoire of subpopulations in the TME. While our analysis 
focused on treatment-naïve clear cell renal carcinoma, our validation with proteins concurrently 
profiled by flow cytometry suggests that this approach could be effectively applied to any tumor 
of interest, and potentially to other tissue-based studies. Our scRNASeq data are limited by the 
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relatively small number of cases, but it should be noted that we cumulatively profiled >200,000 
cells with high data quality and that the populations identified were remarkably consistent across 
patients (Figure 12), suggesting that additional patients would not dramatically affect the 
conclusions of the study. Enrichment of single-cell signatures in bulk data and qmIF studies 
showed strong and statistically significant association between tumor infiltration by a C1Q-
expressing macrophage subpopulation and disease recurrence. One implication of these findings 
is that ccRCC patients with an increased density of C1Q-expressing macrophages in the tumor 
stroma at baseline might be at increased risk of post-surgical disease recurrence, and thus may be 
suitable candidates for adjuvant therapy or more aggressive neoadjuvant approaches in the 
context of clinical trials. A more intriguing possibility is that these cells could be causal of 
(rather than associated with) recurrence; hence targeting their top master regulators and/or 
proteomic markers could be of clinical value in ccRCC.  
 
Limitations of the Study: 
Consistent with prior results, we found that recovery rates for protein activity inference using 
this analysis pipeline were in the 70-80% range, i.e., 20-30% of differentially active proteins may 
be missed. Although this compares favorably with gene expression, where >80%-90% of genes 
may be undetected, we expect that future studies aimed at improving the population-specific 
reporter assays used to infer protein activity by VIPER will address these limitations.  
 
2.5 Methods 
Data and Code Availability: 
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Data files and specific code used to perform all analyses in this manuscript are available at 
https://github.com/Aleksobrad/single-cell-rcc-pipeline. General pipeline for VIPER analysis of 
scRNASeq data is available as an actively maintained and updated R package at 
https://github.com/califano-lab/PISCES. Source data for all analysis in this study will also be 
publicly hosted on Mendeley at http://dx.doi.org/10.17632/nc9bc8dn4m.1  
 
Experimental Model and Subject Details: 
Fresh Surgical Tumor Tissue and Matched Adjacent Normal Tissue were obtained from 11 adult 
patients with clear cell renal carcinoma undergoing nephrectomy to treat primary, non-metastatic 
disease, ranging from grade 1 to grade 4 and including 6 patients with stage pT1a disease and 5 
patients with pT3a disease. These were dissociated immediately for Single-cell RNASeq and 
flow Cytometry analysis. Formalin-Fixed Paraffin-Embedded (FFPE) Pathology samples of the 
same patient tumors were obtained for follow-up Immunohistochemistry analysis. A separate 
cohort of FFPE tissue from primary tumor of 11 adult patients also treated for clear cell renal 
carcinoma by surgical nephrectomy was curated retrospectively to identify patients who recurred 
after surgery and match them by age and tumor stage to those who didn’t. This cohort was 
tracked over a period of 5-113 months, during which time 6 patients experienced disease 
recurrence (between 5-82 months after surgery) and 5 patients had no recurrence (between 35-
113 months after surgery). We used this cohort for validation of Immunohistochemical analysis, 
as well as for exploratory profiling by bulk RNA sequencing and association of markers 
identified from single-cell profiling with time-to-recurrence. A larger validation cohort was 
curated from the Vanderbilt tissue bank, identifying 157 treatment-naïve patients with varying 
follow-up time and annotation of post-surgical disease recurrence and profling them by bulk 
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RNA sequencing. The studies were conducted in accordance with the guidelines approved by the 
Institutional Review Board (IRB) protocols, AAAO5706 and AAAA9967, respectively. 
 
Tissue Dissociation: 
Fresh Tumor or Adjacent Normal tissue were minced to 2-4 mm sized pieces in separate 6-cm 
dishes and digested to single cell suspension using Multi Tissue Human Tumor Dissociation Kit 
1 (Miltenyi Biotec) and a gentleMACS OctoDissociator (Miltenyi Biotec) according to the 
manufacturer’s instructions. Dissociated cells from both Tumor and Adjacent Normal tissue were 
aliquoted for Flow Cytometry Analysis and single-cell sequencing, with 2-3x106 cells allocated 
for flow cytometry and the remainder used for single-cell sequencing. Cells aliquoted for 
sequencing were stained for Live/Dead (eBioscience, cat#50-112-9035) and CD45 (BioLegend, 
cat#368524) and then fluorescence-activated cell sorted (FACS) using BD InfluxTM cell sorter 
into a Live CD45 positive population and a Live CD45 negative population, each of which were 
separately loaded for single-cell RNA sequencing. Boundaries between positive and negative cell 
fractions were drawn based on single-color stain. An example gating strategy is shown in Figure 
S1. For the first set of three patients processed (Patients A-C), only the sorted CD45-positive 
population was further processed for single-cell RNASequencing, and for a second set of eight 
patients (patients 1-8), both CD45-positive and CD45-negative cells were processed for single-
cell RNASequencing.  
 
Single-Cell RNA Sequencing: 
Sorted CD45-positive and CD45-negative samples were processed for single-cell gene 
expression capture (scRNASeq) using the 10X Chromium 3’ Library and Gel Bead Kit (10x 
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Genomics), following the manufacturer’s user guide at the Columbia University Human Immune 
Monitoring Core (HIMC). After GelBead in-Emulsion reverse transcription (GEM-RT) reaction, 
12-15 cycles of polymerase chain reaction (PCR) amplification were performed to obtain cDNAs 
used for RNAseq library generation. Libraries were prepared following the manufacturer’s user 
guide and sequenced on Illumina NovaSeq 6000 Sequencing System. Single-cell RNASeq data 
were processed with Cell Ranger software at the Columbia University Single Cell Analysis Core. 
Illumina base call files were converted to FASTQ files with the command “cellranger mkfastq.” 
Expression data were processed with “cellranger count” on the pre-built human reference set of 
30,727 genes. Cell Ranger performed default filtering for quality control, and produced for each 
sample a barcodes.tsv, genes.tsv, and matrix.mts file containing counts of transcripts for each 
sample, such that expression of each gene is in terms of the number of unique molecular 
identifiers (UMIs) tagged to cDNA molecules corresponding to that gene. These data were 
loaded into the R version 3.6.1 programming environment, where the publicly available Seurat 
package was used to further quality-control filter cells to those with fewer than 10% 
mitochondrial RNA content, more than 1,500 unique UMI counts, and fewer than 15,000 unique 
UMI counts. Pooled distribution across all samples of UMI counts, unique gene counts, and 
percentage of mitochondrial DNA after QC-filtering is shown in Figure S1, with total post-
filtering cell counts and median UMIs/cell shown for each individual sample in Table S1.  
 
Single-cell RNA-Seq Gene Expression Processing: 
Gene Expression UMI count matrices for each sample were processed in R using the Seurat 
SCTransform command to perform a regularized negative binomial regression based on the 3000 
most variable genes. Each sample was then individually clustered by the Resolution-Optimized 
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Louvain Clustering Algorithm described below, and within each cluster metaCells were 
computed for downstream regulatory network inference by summing SCTransform-corrected 
template counts for the 10 nearest neighbors of each cell by Pearson correlation distance. 
Normalized datasets for both Tumor and Adjacent Normal tissue across all patients were 
combined separately for CD45-positive and CD45-negative samples using the 
FindIntegrationAnchors and IntegrateData functions in Seurat, with the default parameters. The 
resulting datasets of 102,509 CD45-positive cells from 11 patients and 61,423 CD45-negative 
cells from 8 patients were projected into their first 50 principal components using the RunPCA 
function in Seurat, and further reduced into a 2-dimensional visualization space using the 
RunUMAP function with method umap-learn and Pearson correlation as the distance metric 
between cells. Differential Gene Expression between clusters was computed by the MAST 
hurdle model for single-cell gene expression modeling, as implemented in the Seurat 
FindAllMarkers command, with log fold change threshold of 0.5 and minimum fractional 
expression threshold of 0.25, indicating that the resulting gene markers for each cluster are 
restricted to those with log fold change greater than 0 and non-zero expression in at least 25% of 
the cells in the cluster.  
 
Resolution-Optimized Louvain Clustering Algorithm: 
For each clustering step in the analysis, clustering was performed in two steps. The Louvain 
algorithm as implemented in Seurat uses the FindNeighbors and FindClusters functions, such 
that the FindClusters function includes a resolution parameter that allows selection of a 
progressively higher number of clusters as the parameter is increased, which does not control for 
over-clustering or allow for objective evaluation of cluster purity. Therefore, clustering was 
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performed with resolution values ranging from 0.01 to 1.0 at intervals of 0.01, and cluster quality 
was evaluated at each resolution value to select an optimum in this range. For each resolution 
value, the clustered cells were subsampled to 1000, and silhouette score was computed for these 
1000 cells and their cluster labels. For gene expression data, Pearson correlation was used as the 
distance metric in computation of silhouette score, and for VIPER-inferred protein activity data 
ViperSimilarity as implemented in the VIPER package was used as the distance metric. This 
procedure was repeated for 100 random samples of 1000 cells to compute a mean and standard 
deviation of average silhouette score at each resolution value. The highest resolution value that 
maximizes mean silhouette score was selected as the optimal resolution at which to cluster the 
data without over-clustering.   
 
Semi-Supervised Cell Type Calling: 
For each single cell gene expression sample, cell-by-cell identification of cell types was 
performed using the SingleR package and the preloaded Blueprint-ENCODE reference, which 
includes normalized expression values for 259 bulk RNASeq samples generated by Blueprint 
and ENCODE from 43 distinct cell types representing pure populations of stroma and immune 
cells [49] [50]. The SingleR algorithm computer correlation between each individual cell and 
each of the 259 reference samples, and then assigns both a label of the cell type with highest 
average correlation to the individual cell and a p-value computed by wilcox test of correlation to 
that cell type compared to all other cell types. Projection of cell-by-cell SingleR labels with 
p<0.05 onto the Gene Expression UMAP space is shown in Obradovic et al. (Supplemental 
Figure S3), such that localization of SingleR labels is highly concordant with the unsupervised 
clustering. Unsupervised Clusters determined by the resolution-optimized Louvain algorithm are 
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labelled as a particular cell type based on the most-represented SingleR cell type label within that 
cluster.  
 
Regulatory Network Inference: 
From each sample, metaCells were computed within each gene expression cluster by summing 
SCTransform-corrected template counts for the 10 nearest neighbors of each cell by Pearson 
correlation distance. 200 metaCells per cluster were sampled to compute a regulatory network 
from each cluster in each patient. All regulatory networks were reverse engineered by the 
ARACNe algorithm. ARACNe was run with 100 bootstrap iterations using 1785 transcription 
factors (genes annotated in gene ontology molecular function database as GO:0003700, 
“transcription factor activity”, or as GO:0003677, “DNA binding” and GO:0030528, 
“transcription regulator activity”, or as GO:0003677 and GO:0045449, “regulation of 
transcription”), 668 transcriptional cofactors (a manually curated list, not overlapping with the 
transcription factor list, built upon genes annotated as GO:0003712, “transcription cofactor 
activity”, or GO:0030528 or GO:0045449), 3455 signaling pathway related genes (annotated in 
GO biological process database as GO:0007165, “signal transduction” and in GO cellular 
component database as GO:0005622, “intracellular” or GO:0005886, “plasma membrane”), and 
3620 surface markers (annotated as GO:0005886 or as GO:0009986, “cell surface”). ARACNe is 
only run on these gene sets so as to limit protein activity inference to proteins with biologically 
meaningful downstream regulatory targets, and we do not apply ARACNe to infer regulatory 
networks for proteins with no known signaling or transcriptional activity for which protein 
activity may be difficult to biologically interpret. Parameters were set to zero DPI (Data 
Processing Inequality) tolerance and MI (Mutual Information) p-value threshold of 10-8, 
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computed by permuting the original dataset as a null model. Each gene list used to run ARACNe 
is available on github, along with the generated patient-by-patient ARACNe tables organized 
into CD45-positive and CD45-negative clusters. 
 
Protein Activity Inference: 
Protein activity was inferred for CD45-positive cells from each patient by running the 
metaVIPER algorithm with all CD45-positive ARACNe networks across all patients on the 
SCTransform-scaled and Anchor-Integrated gene expression signature of single cells from each 
patient. Because the SCTransform-scaled gene expression signature is already normalized, 
VIPER normalization parameter was set to “none.” The resulting patient-by-patient VIPER 
matrices were combined by sub-setting to the VIPER proteins for which activity was inferred in 
each patient sample, resulting in 2,562 proteins with successfully inferred activity across all 
CD45-positive patient samples. For CD45-negative single cells, protein activity was inferred by 
running the metaVIPER algorithm with all CD45-negative ARACNe networks across all patients 
in the same way, and then taking the intersection of 2,667 proteins with successfully inferred 
activity across all CD45-negative patient samples. VIPER-Inferred Protein Activity matrices 
were loaded into a Seurat Object with CreateSeuratObject, then projected into their first 50 
principal components using the RunPCA function in Seurat, and further reduced into a 2-
dimensional visualization space using the RunUMAP function with method umap-learn and 
Pearson correlation as the distance metric between cells. Differential Gene Expression between 
clusters identified by resolution-optimized Louvain was computed using bootstrapped t-test, run 




Copy Number Inference: 
Copy Number Alteration (CNA) across CD45-negative cells was inferred from gene expression 
counts at the single cell level using the InferCNA package. Cells were clustered according to 
their unsupervised clustering label by either gene expression or VIPER. The entire set of CD45-
positive cells was taken as a reference set to infer CNAs shown for each of the CD45-negative 
populations.  
 
Flow Cytometry Data Acquisition: 
From each of the 8 patient samples profiled by single-cell sequencing of both the CD45-positive 
and CD45-negative cells, an aliquot of roughly 2x106 cells was taken for staining and high-
throughput flow cytometry on CyTEK Aurora flow cytometer. Cells were stained for 10 minutes 
with Zombie NIR dye (1:1000 concentration), then stained with surface antibodies for 30 
minutes on ice protected from light. After washing, cells stained with myeloid panel antibodies 
were run fresh on the cytometer. Cells stained with the lymphoid panel were fixed with the 
FoxP3 Fix/Perm kit (ThermoFisher) for at least 30 minutes, then stained with intracellular 
markers for 30 minutes on ice protected from light. All antibodies used can be found in 
Supplementary Table X. For both panels, single stain reference controls were created using 
UltraComp eBeads (ThermoFisher). Due to poor staining quality in Patient 8, samples from this 
patient were excluded in downstream analysis of flow cytometry data. Data was evaluated by 
multi-dimensional analysis in R, and follow-up manual gating was performed as shown in Figure 
2 using FlowJo v10.5.3. 
 
Multi-Dimensional Analysis of Flow Cytometry Data: 
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Flow cytometry samples from all samples were combined and gated on Live CD45-positive, then 
the gated .fcs files for both lymphoid and myeloid antibody panel were separately exported from 
FlowJo software and analyzed in R with the flowCore and ggcyto packages. For each panel, raw 
fluorescence data were normalized with the estimateLogicle and transform functions, and in 
order to reduce computational burden of downstream analysis a sampled set of normalized 
fluorescence data from 250,000 cells were then loaded into a Seurat object with 
CreateSeuratObject. Two-dimensional representation of these data was computed by RunUMAP 
and resolution-optimized Louvain clustering was performed. Fluorescence of all markers was 
visualized in a heatmap, with cells grouped by cluster. For single-cell sequencing data, the 
CD45-positive gene expression matrix and VIPER-inferred protein activity matrix were each 
subset to genes corresponding to the proteins profiled by flow cytometry, and re-clustered by the 
resolution-optimized Louvain algorithm. Side by side comparison of the clustering and heatmaps 
for flow cytometry protein expression, gene expression, and inferred protein activity are shown 
in Figure 17.  
 
Receptor-Ligand Interaction Inference: 
A curated database of 2,557 known receptor-ligand interaction pairs was downloaded from the 
RIKEN FANTOM5 database. This list of receptor-ligand pairs was subset to pairs for which the 
ligand is significantly upregulated by gene expression in at least one VIPER cluster across 
patients and the receptor is significantly upregulated by protein activity in at least one VIPER 
cluster across patients. This reduced the total set of receptor-ligand pairs detected in our dataset 
to 276. For each pair we annotate a ligand cell type with highest median gene expression and a 
receptor cell type with highest median protein activity. Filtering to interactions involving the 
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Tumor macrophage cluster and any T cell cluster returns 5 interaction pairs, filtering to 
interactions involving any Tumor cell clusters and any T cell cluster returns 5 interaction pairs, 
and filtering to interactions involving any Tumor cell and the Tumor macrophage cluster returns 
13 interaction pairs.  
 
Staining for Multiplex Immunohistochemistry: 
After consulting with a pathologist, patient FFPE tissue blocks with at least 50% tumor were 
chosen for sectioning on to SuperfrostTM slides. Representative full section 4 µm slides of tissue 
specimens were stained for H&E and viewed by the pathologist to determine areas of tumor, 
stroma, regression, and immune infiltrates. Each patient's tissue specimen was then stained using 
OpalTM 7-color multiplex IHC kit, according to the manufacturer’s protocol (Akoya Biosciences) 
with minor modifications. Briefly, the slides were baked at 60°C for approximately 2 hrs before 
de-paraffinization and retrieval of antigen at pH 9. The slides were then blocked using 3% 
hydrogen peroxide (in 1X Tris Buffer with 0.05%Tween20), followed by an additional block 
using the antibody diluent, before staining with the primary antibodies, which include (in the 
order of staining) TREM2 (clone-D8I4C, Cell Signaling, cat# 91068S, 1:400, AR9), C1q (clone-
C1QA/2956, AbCam, cat#ab268120, 1:100, AR6), CD3 (clone-LN10, Leica, cat#NCL-L-CD3-
565,1:100, AR6), ApoE (clone – D17N, Cell Signaling, cat#13366S, 1:300, AR6), CA9 
(polyclonal, AbCam, cat#ab15086, 1:1000, AR9) and CD68 (clone – KP1, BioGeneX, 
cat#AM416-5M, RTU, AR6) along with CD163(clone – 10D6, AbCam, cat#ab74604, ready-to-
use (RTU), AR6). For each staining cycle, the slides were first incubated with primary antibody, 
followed by the secondary HRP-polymerization, and signal amplification using Tyramide 
conjugated to an Opal fluorophore and microwave treated in the AR6 or AR9 buffer as required 
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by the next round of primary antibody staining. Single color controls for each fluorochrome and 




For each patient specimen, slides were scanned using Vectra 3 (PerkinElmer), with nine 
representative areas chosen for multispectral imaging – (i) areas with 50% tumor and 50% 
stroma, (ii) areas with >90% tumor, and (iii) one area with >90% adjacent normal, wherever 
possible. These images were factored equally for each patient during analysis using InFormTM 
software (PerkinElmer). Single stained slides and unstained slides were used for building the 




Using the spectral library, the nine representative regions for each patient were spectrally 
unmixed before manual tissue segmentation using inForm software (Version 2.6, PerkinElmer). 
Tissue segmentation included highlighting examples of CA9+ renal tumor tissue, classifying the 
CA9- highly cellular regions as stroma; and the spatially distant CA9- tubular regions as adjacent 
normal. This trained the InForm algorithm to characterize each of the three tissue types and 
segment all the corresponding regions for each patient sample. Cellular components were then 
identified for each cell using the DAPI nuclear counter stain to define the nucleus; and CD3 and 
C1q stains to detect the associated membrane and cytoplasm, respectively. Using DAPI, we 
adjusted the nuclear splitting intensity to prevent incorrect identification and quantification of 
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cells due to clumping. Individual cells were then phenotyped manually on the basis of their 
staining as Tumor cells (CA9+, yellow), macrophages (CD68+ or CD163+, orange), T cells 
(CD3+, white), ApoE+ (aqua), TREM2+ (magenta) and C1q+ (green). A training set was defined 
for the InForm algorithm of around 30 cells for each phenotype, from which we were able to 
distinguish between the cell densities across all tissue types within the nine fields for each 
patient. The cells were then scored for the staining intensities of each individual marker, 
including co-expression across the three tissue types – tumor, stroma and adjacent normal, and 
threshold fluorescence value of positive staining vs background was computed for each marker 
by the InForm software. The data from each field was compiled to summarize the position, 
phenotype and density of cells for each patient. Data were further analyzed in R version 3.6.1 
using the phenoptr package, such that all fields for each patient sample were combined into a 
single data frame with cell-by-cell annotation of classified tissue context (tumor, tumor stroma, 
or adjacent normal), and fluorescence intensity of all markers.  
 
Co-staining of C1Q, TREM2, and APOE with known macrophage markers was determined by 
generating contingency tables of C1Q, TREM2, or APOE positive cells with CD68/CD163 
positive cells, and testing for statistical over-representation of C1Q/TREM2/APOE on 
macrophages by Fisher’s Exact Test. Odds ratios of co-staining with CD68/CD163+ vs 
CD68/CD163- cells were computed across all 11 patients in the cohort profiled by single-cell 
RNASeq, shown as a boxplot in Figure 21B. Cell counts were computed and normalized in the 
tumor stromal and adjacent normal tissue contexts for each combination of 
C1Q+/TREM2+/APOE+ Macrophages, defined by positive staining for DAPI and CD68/CD163 
and negative staining for CD3 and CA9. Frequencies of each cell population in tumor stroma vs 
94 
 
adjacent normal tissue were compared by paired Wilcox test for the 7 patients in which regions 
of both tumor stroma and adjacent normal tissue were identified on the same stained tissue slices 
(Figure 21C, 21D).  
 
In the separate validation cohort of 8 patients for which 4 experienced early post-surgical 
recurrence and 4 did not, frequency of each combination of C1Q+/TREM2+/APOE+ 
Macrophage cells was computed in the same way as described above, and frequencies of each 
population in tumor stroma of recurrent vs non-recurrent patients were compared by unpaired 
Wilcox test (Figure 21E). Since C1Q+ cells and C1Q+CD68/CD163+ cells were significantly 
enriched in tumor stroma of patients with early recurrence, fraction of cells staining for these 
markers was tested for association with time-to-recurrence. Threshold for defining high vs low 
fraction of cells positive for these markers was determined by maximization of the log-rank 
statistic, such that frequency of C1Q+ cells > 0.02 was determined to be high C1Q+ and 
frequency of C1Q+CD68/CD163+ cells >0.01 was determined to be high C1Q+CD68/CD163+. 
Kaplan-Meier curve was plotted for each population, with statistical significance assessed by 
log-rank test.  
 
Association of Tumor Macrophage Signature with Clinical Recurrence: 
A protein signature for the Tumor-Specific Macrophage cluster was defined based on proteins 
differentially upregulated in the VIPER macrophage cluster (see Supplemental Table S2 in 
Obradovic et al. for gene and protein marker lists defining each VIPER cluster). In the dataset of 
FFPE samples profiled by bulkRNASeq that had been followed for time-to-recurrence after 
nephrectomy, outlier samples with low total read-counts were filtered out, and signature of 
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remaining patients with recurrence (time-to-recurrence 8 months, 12 months, 12 months, and 82 
months) vs patients without recurrence (observation period 35 months, 86 months, 110 months, 
and 113 months), was computed by z-score scaling of log10(TPM) normalized counts. Protein 
activity was computed from gene signature by VIPER using the CD45+ ARACNe networks 
inferred from single-cell data. Enrichment of the Tumor-Specific Macrophage protein marker set 
in the VIPER-transformed signature of recurrence vs no recurrence from bulkRNASeq was 
computed by Gene Set Enrichment Analysis (GSEA), with normalized enrichment score and p-
value determined by 1000 random permutations of gene labels. Activity of proteins in the 
leading edge of the enrichment was plotted sample-by-sample in a gene expression heatmap. 
Sample-by-Sample Normalized Enrichment Scores were also computed by ranking proteins in 
each sample according to decreasing activity. Cox regression of the raw normalized enrichment 
scores against time to disease recurrence was performed. Normalized enrichment scores for each 
sample were then binarized to less than zero (low) or greater than zero (high), and Kaplan-Meier 
curve showing association with time to recurrence was plotted along with the binarized log-rank 
p-value.  
 
Results were further validated by repeating the sample-by-sample gene set enrichment of VIPER 
macrophage markers in a larger cohort of 157 patients profiled by bulk-RNASeq, where 
enrichment of macrophage signature was associated with shorter time to post-surgical disease 
recurrence with log-rank p-value of 0.0029. This analysis was performed using the ggsurvplot 
and survminer packages in R and is shown in Figure 20. Validation of tumor-specific 
macrophage association with time-to-recurrence was also performed by immunohistochemical 
staining of FFPE tissue from the same 8 patients analyzed by RNA sequencing. 
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Immunohistochemical staining and fluorescence thresholding was performed as described above, 
and proportion of C1Q, TREM2, APOE, and CD68/CD163 positive cells in the tumor stroma 
was compared in recurrent vs non-recurrent patient samples, along with the proportions of cell 
co-staining for every combination of those markers. Significance of the difference in frequency 
between recurrence and non-recurrence samples was assessed by unpaired Wilcox test. Cell 
populations with significant difference in staining between the two groups were further assessed 
by log-rank regression against time-to-recurrence. Frequency threshold for high vs low level of 
staining was determined by maximizing the log-rank statistic, and Kaplan-Meier curve 
associating IHC staining with time-to-recurrence was generated, shown in Figure 21F.  
Quantification and Statistical Analysis:  
All quantitative and statistical analyses were performed using the R computational environment 
and packages described above. Differential gene expression was assessed at the single-cell level 
by the MAST single-cell statistical framework as implemented in Seurat v3 [32], and differential 
VIPER activity was assessed by t-test, each with Benjamini-Hochberg multiple-testing 
correction. Comparisons of cell frequencies were performed by non-parametric Wilcox rank-sum 
test, and survival analyses were performed by log-rank test. In all cases, statistical significance 
was defined as an adjusted p-value less than 0.05. Details of all statistical tests used can be found 




Chapter 3: Single-Cell Protein Activity Enables Personalized Drug 
Sensitivity Inference Targeting Individual Tumor Cells 
3.1 Summary 
Cholangiocarcinoma is an aggressive tumor type with extremely limited treatment options. 
Furthermore, since cholangiocarcinoma is a heterogeneous tumor with significant stromal 
involvement, it is difficult to isolate the tumor cell transcriptional profile for personalized 
treatment by traditional RNA-Sequencing approaches. Here, we present the first comprehensive 
single-cell RNA-Sequencing profile of a cholangiocarcinoma patient from which we have 
developed and applied a novel framework for single-cell drug sensitivity prediction, building on 
CLIA-approved OncoTreat and OncoTarget algorithms. We have found the tumor micro-
environment to be heavily infiltrated by immune cells, with T-cells comprising nearly half of all 
cells and tumor cells representing fewer than 10%. However, isolation of tumor cells reveals 
three distinct sub-populations, with a set of five candidate drugs predicted to target them all to 
varying extents. Validation in a patient-derived xenograft model identified Plicamycin and 
Dacinostat as drugs able to effectively control tumor growth rate in vivo. This work identifies 
Plicamycin and Dacinostat as promising candidates for follow-up trials in cholangiocarcinoma, 
alone or in combination with anti-PD1 immunotherapy and current standard-of-care 
chemotherapies. Furthermore, we present a flexible pipeline for prediction of drug sensitivities at 
single-cell-resolution, with potential application in precision medicine across a broad range of 





Cholangiocarcinoma (CCA) is an aggressive biliary adenocarcinoma with both intrahepatic 
(iCCA) and extrahepatic subtypes, and the extrahepatic subtype is further characterized as either 
perihilar (pCCA) or distal (dCCA). Collectively, they account for up to 20% of newly diagnosed 
primary hepatic tumors each year, making CCA the second most common hepatic malignancy 
after hepatocellular carcinoma (HCC) [81]. 
 
A diagnosis of CCA carries with it a very poor prognosis, with a median survival of only 12-37.4 
months [82]. The American Cancer Society reports that even localized disease is associated with 
high mortality, given 5-year survival rates of 15% and 24% for extra- and intrahepatic CCA, 
respectively, and metastatic CCA offers only a 2% 5-year survival rate [83]. 
 
For patients with non-resectable disease, management differs depending on anatomic subtype, 
though no treatment option is considered curative. Localized, unresectable iCCA is sometimes 
treated with locoregional therapies, such as trans-arterial chemoembolization (TACE), yet 
median overall survival of these patients is still only 12-15 months. Certain patients diagnosed 
with pCCA may receive liver transplantation following neoadjuvant chemotherapy, with 5-year 
disease-free survival rates reportedly as high as 65%, though very few patients meet the criteria 
for transplantation. However, for the majority of patients with non-resectable or advanced 
cholangiocarcinoma, cytotoxic chemotherapy with gemcitabine-cisplatin is first-line, and 




Despite rising incidence and lack of effective therapies, studies of the cholangiocarcinoma 
micro-environment and intratumoral heterogeneity have been limited to immunohistochemical 
characterization of individual components of the stroma, especially fibroblasts, which produce an 
extracellular matrix so prominent that it outweighs the tumor component [84]. The extent of 
infiltration by diverse stromal cells further presents an obstacle to transcriptional profiling of 
patient tumors, which are likely to be heavily influenced by the extent of infiltration by various 
stromal components rather than reflective of the transcriptional state of the tumor itself.   
 
High-throughput droplet-based single-cell RNA Sequencing (scRNASeq) has recently emerged 
as a valuable tool to characterize the diverse cellular subpopulations that comprise the tumor 
microenvironment, with the ability to identify representative gene expression signatures from 
thousands of individual cells in a single sample [32] [16]. In contrast to traditional bulk 
RNASequencing, scRNASeq can provide a rough characterization of the transcriptional state of 
individual cell types contributing to emergence of specific tumor phenotypes, thus potentially 
highlighting the role of rare populations, whose gene expression signature would be diluted 
below the limits of detection in bulk samples [20]. Furthermore, single-cell RNASequencing 
enables the characterization of transcriptional heterogeneity among tumor cells themselves, 
whereas bulk sequencing even on purified tumor cells captures only the average gene expression 
of the entire tumor. In contrast to antibody-staining approaches, scRNASeq generates a 
transcriptome-wide profile of each individual cell, without manual selection of predefined 
proteomic markers. The value of scRNASeq has been demonstrated in recent studies of 
melanoma [18] [17] and breast cancer [34]. However, no single-cell RNA Sequencing studies 




One significant limitation of scRNASeq is that the physical limits of RNA capture efficiency and 
total RNA molecules per cell dramatically reduce the number of unique genes detected in any 
single cell, especially from patient-derived tumor tissue. As a result, single-cell gene expression 
matrices are extremely sparse, with ~80% - 90% of genes undetected by even one read, on 
average. We have successfully addressed this issue by applying an algorithm (VIPER), which 
leverages highly-multiplexed, fully tissue-specific gene-reporter assays to accurately measure the 
activity of up to ~6,500 regulatory proteins, including transcription factors (TFs), co-factors (co-
TFs), signaling proteins (SPs), and surface markers (SMs), based on the expression of their 
downstream regulatory targets (regulon) [21]. Tissue specific regulons are inferred directly from 
analysis of single-cell populations, using ARACNe [23], an information theoretic algorithm that 
has been experimentally validated in dozens of tissue contexts, with a >70% accuracy in target 
identification [40]. By integrating the expression of ~100 downstream targets per regulon, on 
average, VIPER can effectively measure even the activity of proteins whose encoding gene is 
undetected in scRNASeq data, thus virtually eliminating gene dropouts [26]. The VIPER 
approach to single-cell data analysis has been shown in clear cell renal carcinoma (ccRCC) to 
improve resolution of both tumor and immune cell phenotypes with dramatic improvement in 
signal-to-noise for individual regulatory genes of interest [35]. 
 
Successful application of VIPER to single-cell data also allows the adaptation of two algorithms 
previously developed for application on bulk RNA-Sequencing data, OncoTarget and OncoTreat, 
to single-cell RNA-Sequencing [24]. OncoTarget infers druggable proteins with increased 
VIPER activity relative to a standardized external reference, and OncoTreat leverages a database 
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of large-scale drug perturbation RNA Sequencing assays on tumor cell lines to infer drugs that 
invert overall VIPER activity profile of an individual patient tumor relative to external reference. 
These are both CLIA-certified algorithms for personalized drug prediction, now adapted for the 
first time to the level of individual tumor cells. The value of extending these algorithms to the 
single-cell level is that single-cell RNA-Seq allows the purification of tumor cells among 
immune and stromal cell infiltrate, significantly reducing transcriptional noise, and enabling 
identification of tumor cell heterogeneity and prediction of drugs targeting the largest number of 
patient-specific tumor cell sub-populations comprising a tumor mass.  
 
Here we present a case study of the first comprehensive profiling of cholangiocarcinoma tumor 
micro-environment at the resolution of single-cell RNA-Sequencing, and the first application of 
a unique OncoTarget and OncoTreat approach to assess potentially actionable drug targets at the 
single-cell level. This has significant implications for the application of single-cell RNA-
Sequencing in precision medicine for personalized treatment of cholangiocarcinoma and other 
highly treatment-resistant malignancies, as well as for improving the understanding of treatment 




The patient first presented to the Emergency Department with signs and symptoms of obstructive 
jaundice and a 6.8cm lesion in the gall bladder fossa. Fine-needle aspiration was positive for 
adenocarcinoma and PET CT showed one PET avid lesion in the hilum and non-avid sub-
centimeter lung nodules. Two months after initial presentation, the patient underwent a central 
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hepatectomy with cholecystectomy and excision of bile duct tumor, which was collected for 
dissociation and single-cell RNA Sequencing. Pathology at that time revealed  
adenocarcinoma, biliary type, moderately to poorly differentiated (grades 2-3), with contiguous 
involvement of multiple segments of the biliary tree, including common bile duct, gall bladder, 
cystic duct, left and right hepatic bile ducts, liver, and perihilar soft tissue. There was also 
extensive lymphovascular and perineural invasion. Tumor staging was pT3N1M1, given 2/5 
regional lymph nodes were positive for adenocarcinoma, and there were distant metastases noted 
on the falciform ligament. Immunohistochemistry was negative for HER2 overexpression, and 
PD-L1 combined positive score was 10. Next-generation sequencing of 467 cancer-associated 
genes showed a TP53 mutation as well as multiple variants of uncertain significance (EPHA5, 
STAT3, FAT1), with an intermediate tumor mutational burden (3.15 mutations/Mb). The tumor 
was microsatellite stable, and CA19-9 tumor marker levels were regularly measured to track 
tumor progression. The patient was initiated on combination gemcitabine, cisplatin, and 
paclitaxel, which were continued for seven 21-day cycles.  
 
Cholangiocarcinoma microenvironment is highly immune-infiltrated: 
Single-cell RNA-Sequencing revealed significant tumor heterogeneity at the gene expression 





Figure 22: Data Quality and Cell Types Represented in Cholangiocarcinoma Tumor 
Micro-Environment by Gene Expression 
(A) Violin plots showing the distributions of the number of genes detected in each cell, the 
number of UMIs per cell and the percentage of UMIs in MT genes. These are the QC metrics 
used to filter out low quality cells from the dataset. (B) UMAP projection showing the results of 
the unsupervised clustering analysis performed at gene expression level (Louvain algorithm). 
Cell types are inferred for each cluster by SingleR. (C) Heatmap containing top-5 differentially 
upregulated genes in each cluster. The markers of each cluster are identified comparing the 
average expression of all the genes in one cluster versus the average expression of the same 
genes in the rest of the cells (MAST test). 
 
Differentially upregulated genes in each cluster are shown in Figure 22C, with cell type inferred 
by SingleR, which correlates cell-by-cell expression with a sorted bulkRNA-Seq reference 
database. Most strikingly, the largest cluster by cell counts consisted of Tumor-Infiltrating T-
cells, representing over half of all cells profiled by single-cell RNASeq. By VIPER, we are able 
to further sub-cluster these T-cells, identifying cytotoxic CD8 T-cells with high inferred activity 
of GZMB as the predominant population, as well as a cluster of CD4 T-cells with high activity of 
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CCR7, consistent with a central memory phenotype, as well as VIM, a marker of tissue 
residency. Finally, there is a population of activated CD4 T-cells with high STAT4 signaling 
(Figure 23A-B).  
Figure 23: Cell Types Represented in Cholangiocarcinoma Tumor Micro-Environment 
by Protein Activity 
(A) Results of unsupervised clustering analysis performed on the VIPER-inferred protein activity 
signatures of the single-cells (Louvain algorithm). UMAP projections are used to plot the cells. 
(B) Heatmap showing the top-10 differentially activated proteins of each cluster identified with a 
t-Test comparing the average activity of each VIPER-inferred regulator in one cluster versus the 
activity of the same regulators in all the other clusters. 
 
Other populations highly represented in the Tumor micro-environment included Fibroblasts, 
myeloid cells, mast cells, endothelial cells, B-cells, and neutrophils. Of these, several have 
previously been associated with immunosuppression and tumor immune evasion, including 
neutrophil myeloid-derived suppressor cells [85] and fibroblasts [86]. A relatively small 
population of 140 cells were identified as epithelial in origin, and expressed KRT19, a marker of 
105 
 
cholangiocarcinoma [78], as the top most up-regulated gene. These cells were further validated 
as tumor cells by copy-number variation inference (Figure 24A).  
 
Figure 24: Cholangiocarcinoma Tumor Cell Sub-Clustering and Phenotyping 
(A) InferCNV analysis was performed to confirm that the cluster of epithelial cells contains 
tumor cells, as they show substantially more copy number alterations across most of the 
chromosomes. T-Cells were chosen as a copy-number normal reference to infer copy number 
variations.  (B) UMAP projection of the 3 clusters identified from the sub-clustering analysis of 
tumor cells. (C-D) Heatmap of the top MRs for each one of the tumor sub-clusters and the 
corresponding most statistically significant enriched pathways from Hallmarks of Cancer. 
 
Tumor cells are heterogeneous by inferred protein activity: 
From application of VIPER to infer protein activity of tumor cells within the 
cholangiocarcinoma sample, three strikingly distinct sub-populations could be identified (Figure 
24B). These sub-populations were only revealed following VIPER analysis as the initial gene 
expression data are too noisy to further sub-cluster and suffer from gene dropout. In contrast, 
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VIPER profiling was able to reliably recover activity of 1602 regulatory proteins in each 
individual tumor cell and demonstrated high within-cluster consistency of protein activity 
profiles. Top differentially active proteins within each cluster are shown in Figure 24C, with the 
predominant cluster defined by upregulation of KRAS signaling and estrogen response pathway, 
a second cluster defined by upregulation of TNFa signaling via NF-kB and epithelial-
mesenchymal transition, and the smallest cluster defined by upregulation of Myc targets and 
oxidative phosphorylation pathway (Figure 24D).  
 
Cluster-specific druggable protein targets are inferred by single-cell OncoTarget  
We applied VIPER using TCGA [87] as an external reference to perform single-cell OncoTarget 
and OncoTreat analysis, enabling both inference of druggable proteins with aberrant activity and 
drug candidates with transcriptional effects complementary to the overall protein activity profile 
of each tumor cell (Figure 25).  
 
 




OncoTarget: Druggable proteins are first selected from the VIPER-inferred protein activity 
matrix using the DrugBank database and are then ranked according to the integrated p-Value 
across all the cells. OncoTreat: VIPER analysis using multiple ARACNe networks reconstructed 
from different TCGA cohorts and multiple tumor cell lines was performed to identify the best 
model to recapitulate the Master Regulators of tumor cells. Best-matched networks/cell lines 
were used to prioritize a list of drugs based on their ability to invert the activity of master 
regulator proteins cell-by-cell. 
 
Applying single-cell OncoTarget to infer only druggable protein proteins identified significant 
differences between tumor cell sub-clusters in predicted drug sensitivity, with very high 
consistency within-clusters, and between single-cell resolution and OncoTarget inference on 





Figure 26: Results of OncoTreat and OncoTarget drug predictions.  
(A) Negative log10 pValues of the top-drugs predicted by OncoTreat from the single-cells 
protein activity profiles of the three tumor sub-clusters. (B) Negative log10 pValues of the most 
statistically significant activated proteins in the DrugBank database, i.e. OncoTarget predictions. 
(C) OncoTreat drug predictions performed on synthetic bulk samples generated from the three 
tumor sub-clusters and on the bulk protein activity profile of the PDX model. (D) Top-activated 
proteins predicted by OncoTarget from synthetic bulk samples generated from the three tumor 
sub-clusters and from the bulk of the PDX. 
 
Despite the extremely noisy nature of single-cell gene expression profiles, with >90% of genes 
undetected in any given cell, VIPER activity and drug predictions were dramatically conserved 
across single cells, confirming that the transcriptional states of the single cell populations that 
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comprise a tumor mass are remarkably stable. Twenty-two druggable targets were inferred by 
OncoTarget, including several HDAC proteins and other proteins of biological interest druggable 
by known FDA-approved or investigational compounds.  
 
Drug predictions are consistent by single-cell OncoTreat and OncoTarget: 
Drug predictions by single-cell OncoTreat are shown in Figure 26A-C, and are highly consistent 
with drug target predictions by single-cell OncoTarget, with six drugs in the top-25 predicted by 
OncoTreat known to target proteins predicted by OncoTarget. These included Dacinostat and 
Belinostat (which target HDAC5, HDAC9, and HDAC6), Rocilinostat (which targets HDAC6), 
flavopiridol (which targets CDK7), Sotrastaurin (which targets PTK2B), and Bardoxolne methyl 
(which targets NFE2L2 and NFKB2). The top five drugs predicted to target the greatest number 
of tumor cells were: Glasdegib, Plicamycin, Flavopiridol, Dacinostat, and AT9283.  
 
Patient-Derived Xenograft Model Recapitulates Tumor Cell Population Signatures and 
Demonstrates Sensitivity to OncoTreat- Predicted Drugs:   
We successfully engrafted and propagated a patient-derived xenograft model from resected 
tumor tissue at time of biopsy. Bulk RNA-Sequencing of the engrafted model demonstrates 
significant enrichment for Master Regulator Proteins of all three single-cell tumor populations 
observed in the initial biopsy (Figure 27A), with greatest enrichment for the two largest clusters. 
OncoTarget predictions on the PDX model include only proteins also observed in OncoTarget 
for at least one of the single-cell tumor clusters (Figure 26D), and OncoTreat predictions overlap 
entirely between PDX and the two largest clusters, with partial overlap in the third cluster of 
tumor cells (Figure 26C). In this analysis, Glasdegib, Plicamycin, Flavopiridol, AT9283, and 
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Dacinostat, which were ranked as the top 5 drugs with best overall tumor cell coverage in single-
cell OncoTreat (Figure 26A), were also identified at the level of artificial bulk for each cluster 
and for the PDX (Figure 26C). Therefore, we administered these five drug candidates as well as 
vehicle control to a cohort of 8 mice per treatment arm, in order to evaluate their effectiveness in 
vivo for control of tumor growth rate and extension of time-to-disease-control. Dacinostat and 
Plicamycin were found to significantly reduce tumor growth rate (p=0.007 and p=0.03, 
respectively), with Dacinostat demonstrating stable tumor size over 28 days of treatment (Figure 
27B). Both of these drugs were also found to significantly survival time by Kaplan-Meier 
regression (Dacinostat p=0.001 with median survival time exceeding 28 days vs 14 days by 
vehicle alone, Plicamycin p=0.03, with median survival time 22.5 days vs 14 days by vehicle 
alone) (Figure 27C).  
 
Figure 27: Dacinostat and Plicamycin Significantly Inhibit Growth Rate of 
Cholangiocarcinoma Patient-Derived Xenograft Model 
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(A) Gene Set Enrichment Analysis of the top and bottom MRs of each tumor sub-cluster in the 
protein activity signature of the PDX model. (B) Tumor growth curves comparing the volume of 
the tumor in PDX models treated with the 5 selected drugs vs Vehicle control. Each drug was 
tested in N=8 mice, except for Dacinostat for which we have N=6.  (C) Kaplan-Meier curve 




We present in this case study the first single-cell RNA-Sequencing profile of a 
cholangiocarcinoma patient, to our knowledge. This profiling has clarified the composition of the 
cholangiocarcinoma microenvironment in this patient, with significant therapeutic implications 
for other patients. Cholangiocarcinoma has been previously described as having a significant 
stromal component, particularly with respect to fibroblasts producing a dense extracellular 
matrix [84]. However, in addition to a significant fibroblast infiltrate, here we observe T-cells 
comprising nearly half of the patient’s tumor. This extent of lymphocytic infiltration suggests 
checkpoint immunotherapies as a potentially valuable adjunct to traditional standard-of-care 
treatments. Additional immune populations of interest include sizeable clusters of mast cells, 
myeloid cells, B-cells, and a cluster of neutrophils actively expressing IL8, which has been 
observed in studies of melanoma [88] and prostate cancer [89] to correlate with poor clinical 
outcomes via accumulation of myeloid-derived suppressor cells, and for which several inhibitor 
compounds are currently in clinical trials [90].  
 
Furthermore, the low overall representation of tumor cells (<10% of total cell count) 
demonstrates the critical value of single-cell sequencing, as their transcriptional profile in bulk 
RNASeq would be overwhelmed by noise from the transcriptional profiles of the more highly 
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represented non-tumor cell types. This level of resolution combined with our protein activity 
inference tools has enabled us to profile the phenotypes of individual tumor cells in this patient, 
identifying three distinct subpopulations characterized by upregulation of KRAS signaling, 
TNFa signaling via NF-kB with epithelial-mesenchymal transition, and Myc signaling, 
respectively. This level of phenotypic heterogeneity of tumor cells has never previously been 
described in cholangiocarcinoma studies, and represents an important characteristic of the 
disease, as effective treatment must target all three of the populations identified in this patient. It 
remains to be determined in future work which of these phenotypes may generalize across 
patients, but it is reasonable to expect some degree of intratumoral heterogeneity requiring a 
precision medicine approach in this highly treatment-resistant disease.  
 
We have extended our OncoTreat and OncoTarget personalized drug prediction algorithms to the 
single-cell level for the first time in analysis of this patient’s tumor, identifying five candidate 
drugs with predicted activity against all of the observed tumor cell states. Indeed, our drug 
sensitivity and drug target predictions at the single-cell level precisely matched the predictions 
from synthetic bulk of each tumor cell cluster. Because we were able to establish a patient-
derived xenograft model and confirm that it represents a good match for the tumor cell states 
observed in the patient both by overall gene set enrichment and OncoTreat/OncoTarget profile, 
we were able to validate our drug predictions in vivo. Of the predicted drugs, Dacinostat and 
Plicamycin were found to significantly decrease tumor growth rate and improve disease control 
rate vs vehicle control in a cohort of 8 mice per treatment arm. Plicamycin, which was predicted 
to strongly inhibit the first two tumor cell clusters but weakly inhibit the third, Myc-pathway-
expressing, cluster, resulted in a slowed but continued tumor growth rate, with only one out of 
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eight mice still demonstrating disease control at 28 days. Dacinostat, however, was predicted to 
target all three cell clusters with similar effectiveness by OncoTreat and demonstrated stable 
tumor size with no significant growth from baseline for the majority of treated mice by 28 days.  
 
In a prior study by Li et al. of in vitro manual drug screening on 27 organoids derived from 3 
cholangiocarcinoma and 2 hepatocellular carcinoma patients, Plicamycin was found to be pan-
effective across a broad range of organoids [91]. Out of 129 drugs screened in vitro, the authors 
found 9 drugs with at least 90% killing across all organoids, belonging to 5 classes of 
antineoplastic agents (histone deacetylase [HDAC] inhibitors, proteasome inhibitors, DNA 
topoisomerase II inhibitors, protein translation inhibitors, and RNA synthesis inhibitors). The 
authors found Plicamycin to be effective across organoids in vitro, consistent with our observed 
effectiveness of Plicamycin in slowing tumor growth rate in vivo. This prior in vitro evidence 
across a large number of organoids points toward the potential for generalized utility of 
Plicamycin across cholangiocarcinoma patients, with important implications for future clinical 
trials. In contrast to [91] Pant, K, we have identified Plicamycin here as a candidate adjunct to 
treatment for cholangiocarcinoma from a personalized drug prediction pipeline which narrowed 
down the space of all cancer drugs in a systematic way from several hundred to only five 
candidates, two of which were successfully validated in vivo. This is a much-improved success 
rate when compared to 9 out of 129 drugs identified as potentially effective by manual screening 
and allows for rapid and feasible validation of personalized drug predictions in vivo.  
 
Dacinostat, which we identify to be even more effective than Plicamycin, was not included in the 
drug panel assessed by [91], and represents a novel candidate for cholangiocarcinoma therapy. 
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CG200745, an HDAC inhibitor, was previously found to induce anti-tumor effects in 
cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway [92]. HDACs are also 
known to have a role in cholangiocarcinoma carcinogenesis and are being actively explored as 
therapeutic candidates, but each HDAC inhibitor has highly variable binding affinities for the 
different HDAC proteins [93], with potential for very different therapeutic efficacy based on 
broad downstream transcriptional effects, which we directly assess by OncoTreat. To our 
knowledge, we are the first to identify Dacinostat as an HDAC inhibitor effective in treatment of 
cholangiocarcinoma. These findings are limited to the patient assessed in the case study due to 
difficulty of cholangiocarcinoma PDX-engraftment, but may generalize across patients similarly 
to Plicamycin, meriting further clinical follow-up alone or in combination with current 
treatments, particularly given the dismal treatment outcomes and lack of response to current 
standard-of-care therapy.  
 
In addition to translating the findings from this study to trials in combination of immunotherapy, 
Dacinostat, and Plicamycin with traditional approaches for cholangiocarcinoma treatment, we 
hope in the future to extend our single-cell OncoTreat/OncoTarget approach to personalized drug 
prediction for additional cholangiocarcinoma patients and for a broad range of aggressive tumor 
types with limited treatment options. This would enable rapid reporting of plausible drug 
candidates for inhibition of tumor cells even in highly heterogeneous or stromally-infiltrated 






Human Research Participation and Clinical Course of Treatment 
Fresh surgical tissue was obtained with patient’s consent from central hepatectomy performed at 
tumor stage pT3N1M1. Tissue was dissociated immediately for Single-cell RNA Sequencing. 
Following data analysis, tumor composition and OncoTreat/OncoTarget drug predictions were 
communicated to the medical team. Treatment with combination gemcitabine, cisplatin, and 
paclitaxel was initiated on a 21-day schedule one month after surgery, with dosing at day1 and 
day8, and CA19-9 tumor marker levels were drawn to monitor progression. With the patient’s 
consent a trial of nivolumab was initiated following non-response to triple-combination 
chemotherapy and discovery of significant tumor T-cell infiltration by single-cell RNA 
Sequencing. Following interval improvement in CA19-9, patient was enrolled in an ongoing trial 
of TP-1287 (NCT03604783). Research was conducted in accordance with the Declaration of 
Helsinki.   
 
Tissue Dissociation 
Fresh tumor tissue was minced to 2-4 mm sized pieces in a 6-cm dish and subsequently digested 
to single cell suspension using Multi Tissue Human Tumor Dissociation Kit 1 (Miltenyi Biotec) 
and a gentleMACS OctoDissociator (Miltenyi Biotec) according to the manufacturer’s 
instructions. Dissociated cells were aliquoted for single-cell sequencing.  
 
Single-Cell RNA-Sequencing 
Dissociated sample was processed for single-cell gene expression capture (scRNASeq) using the 
10X Chromium 3’ Library and Gel Bead Kit (10x Genomics), following the manufacturer’s user 
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guide at the Columbia University Genome Center. After GelBead in-Emulsion reverse 
transcription (GEM-RT) reaction, 12-15 cycles of polymerase chain reaction (PCR) 
amplification were performed to obtain cDNAs used for RNAseq library generation. Libraries 
were prepared following the manufacturer’s user guide and sequenced on Illumina NovaSeq 
6000 Sequencing System. Single-cell RNASeq data were processed with Cell Ranger software at 
the Columbia University Single Cell Analysis Core. Illumina base call files were converted to 
FASTQ files with the command “cellranger mkfastq.” Expression data were processed with 
“cellranger count” on pre-built human reference set of 30,727 genes. Cell Ranger performed 
default filtering for quality control, and produced a barcodes.tsv, genes.tsv, and matrix.mts file 
containing transcript counts for each cell, such that expression of each gene is in terms of the 
number of unique molecular identifiers (UMIs) tagged to cDNA molecules corresponding to that 
gene. These data were loaded into the R version 3.6.1 programming environment, where the 
publicly available Seurat package was used to further quality-control filter cells to those with 
fewer than 25% mitochondrial RNA content, more than 1,000 unique UMI counts, and fewer 
than 25,000 unique UMI counts. Pooled distribution of UMI counts, unique gene counts, and 
percentage of mitochondrial DNA after QC-filtering is shown in Figure 22A.  
 
Single-cell RNASeq Gene Expression Processing 
Gene Expression UMI count matrix was processed in R using the Seurat SCTransform command 
to perform a regularized negative binomial regression based on the 3000 most variable genes. 
The sample was then clustered on gene expression by a Resolution-Optimized Louvain 
Algorithm leveraging mean silhouette score of sub-sampled data to select optimal resolution 
without over-clustering [35]. Within each cluster metaCells were computed for downstream 
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regulatory network inference by summing SCTransform-corrected template counts for the 10 
nearest neighbors of each cell by Pearson correlation distance. The resulting dataset of 2738 cells 
was projected into its first 50 principal components using the RunPCA function in Seurat, and 
further reduced into a 2-dimensional visualization space using the RunUMAP function with 
method umap-learn and Pearson correlation as the distance metric between cells. Differential 
Gene Expression between clusters was computed by the MAST hurdle model for single-cell gene 
expression, as implemented in the Seurat FindAllMarkers command, with log fold change 
threshold of 0.5 and minimum fractional expression threshold of 0.25, indicating that the 
resulting gene markers for each cluster are restricted to those with log fold change greater than 0 
and non-zero expression in at least 25% of the cells in the cluster.  
 
Semi-Supervised Cell Type Calling  
Unbiased inference of cell types was performed using the SingleR package and the preloaded 
Blueprint-ENCODE reference, which includes normalized expression values for 259 bulk RNA-
seq samples generated by Blueprint and ENCODE from 43 distinct cell types representing pure 
populations of stromal and immune cells [49]. The SingleR algorithm computes correlation 
between each individual cell and each of the 259 reference samples, and then assigns a label of 
the cell type with highest average correlation to the individual cell and a p-value computed by 
wilcox test of correlation to that cell type compared to all other cell types. Unsupervised Clusters 
determined by the resolution-optimized Louvain algorithm are labelled as a particular cell type 
based on the most highly represented SingleR cell type label within that cluster among labels 




Copy Number Inference 
Copy Number Variation (CNV) was inferred from gene expression counts at the single cell level 
using the InferCNV package. Cells were clustered according to their unsupervised clustering 
label by gene expression, and the large T-cell cluster was used as a Copy-Number-Normal 
reference set. The cluster labelled by SingleR as epithelial cells was confirmed to exhibit 
significant copy-number alteration across the entire genome relative to other cell types, 
confirming this 140-cell cluster as Tumor cells.  
 
Regulatory Network Inference 
Within each gene expression cluster, metaCells were computed by summing SCTransform-
corrected template counts for the 10 nearest neighbors of each cell by Pearson correlation 
distance. For clusters exceeding 200 cells, metaCells were sub-sampled to 200, and for each 
cluster a transcriptional regulatory network was inferred. All regulatory networks were reverse 
engineered by the ARACNe algorithm. ARACNe was run with 200 bootstrap iterations using 
1785 transcription factors (genes annotated in gene ontology molecular function database as 
GO:0003700, “transcription factor activity”, or as GO:0003677, “DNA binding” and 
GO:0030528, “transcription regulator activity”, or as GO:0003677 and GO:0045449, “regulation 
of transcription”), 668 transcriptional cofactors (a manually curated list, not overlapping with the 
transcription factor list, built upon genes annotated as GO:0003712, “transcription cofactor 
activity”, or GO:0030528 or GO:0045449), 3455 signaling pathway related genes (annotated in 
GO biological process database as GO:0007165, “signal transduction” and in GO cellular 
component database as GO:0005622, “intracellular” or GO:0005886, “plasma membrane”), and 
3620 surface markers (annotated as GO:0005886 or as GO:0009986, “cell surface”). Parameters 
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were set to zero DPI (Data Processing Inequality) tolerance and MI (Mutual Information) p-
value threshold of 10-8, computed by permuting the original dataset as a null model. Each gene 
list used to run ARACNe is available on github, along with the generated ARACNe tables.  
 
Protein Activity Inference 
Protein activity was first inferred for all cells by running the metaVIPER algorithm with all 
ARACNe networks on the SCTransform-scaled single-cell gene expression signature. Because 
the SCTransform-scaled gene expression signature is already normalized, VIPER normalization 
option was set to “none.” The resulting VIPER matrix included 1602 proteins with successfully 
inferred activity across all 2738 cells. Subsetting to tumor cells only, this protein activity matrix 
was loaded into a Seurat Object with CreateSeuratObject, then projected into its first 50 principal 
components using the RunPCA function in Seurat, and further reduced into a 2-dimensional 
visualization space using the RunUMAP function with method umap-learn and Pearson 
correlation as the distance metric between cells. Differential Protein Activity between clusters 
identified by resolution-optimized Louvain was computed using bootstrapped t-test, run with 100 
bootstraps, and top proteins for each cluster were ranked by p-value. This analysis identified 
three phenotypically distinct clusters of tumor cells by VIPER which were not previously 
identifiable by raw gene expression.  
 
Single-cell OncoTarget 
In order to highlight potentially druggable proteins with aberrant activity in the three tumor cell 
sub-clusters identified in this patient, we generated single-cells differential gene expression 
signatures by scaling the log-Normalized Counts-Per-Million (CPM) single-cells data 
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(log10[CPM-UMI count +1]) to the log-Normalized Transcripts-Per-Million (TPM) data 
(log10[TPM+1]) of the entire publicly available TCGA, as an external reference to enable 
identification of any proteins concurrently upregulated in all tumor cells in addition to proteins 
differentially upregulated across tumor cell sub-clusters. We ran VIPER on this gene expression 
signature using the single-cell tumor cluster ARACNe network. Resulting matrix was sub-set to 
proteins targeted by known FDA-approved or investigational drug compounds in DrugBank. 
Enrichment scores for each protein in each cell were then converted to Bonferroni-corrected p-
values and subset to proteins with median p-value < 10-5 in any tumor cell sub-cluster. To assess 
robustness of OncoTarget predictions, the same analysis was performed on artificial bulk of each 
tumor cell sub-cluster, increasing sample depth at the cost of single-cell resolution by summing 
UMI counts across all cells in each cluster. Notably, this resulted in the exact same druggable 
protein predictions as predicted at the single-cell level (Figure 26D).     
 
Single-cell OncoTreat 
In order to incorporate off-target and downstream drug effects on the entire transcriptional 
profile to improve drug prediction, we further leveraged a database of drug perturbation RNA 
Sequencing on multiple tumor cell lines generated in Califano Lab (BT20, HCC1143, GISTT1, 
GIST430, HSTS, KRJ1, IOMM, U87, HF2597, H1793, ASPC1, PANC1, LNCAP, DU145, 
TCCSUP, EFO21, ASPC1, PANC1). Analogously to OncoTarget analysis, we computed single-
cell differential gene expression signatures with respect to TCGA. In order to identify the top-
matched cell lines able to recapitulate the Master Regulators of the tumor sub-clusters and the 
best regulatory model, we first applied VIPER using ARACNe networks derived from distinct 
TCGA tumor cohorts. The Normalized Enrichment Scores produced by VIPER were converted 
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into bonferroni-corrected p-values and for each single-cell we measured the ratio between the 
AUC of the cumulative distribution of the regulators with a p-value less than 0.01 and the AUC 
of the null model. The pancreatic adenocarcinoma ARACNe network showed the highest median 
score among the tumor types for which we had drug perturbational data (Figure 28A).  
 
 
Figure 28: Selection of Best-Matched Cell Line From Drug Perturbational Database 
(A) Results of the ARACNe network-matching procedure applied to determine the best 
regulatory model for the OncoTreat analysis of tumor cells. The top-matched network for which 
we have perturbational data is the Pancreatic Adenocarcinoma Interactome (second one in the 
overall ranking) (B) Results of the Gene Set Enrichment Analysis of the top/bottom 50 MRs of 
each single-cells in the protein activity signature of the two pancreatic cell lines ASPC1 and 
PANC1. 
 
Consequently, we tested the enrichment of the top/bottom 50 MRs of each single cell in the 
protein activity signature of the two available pancreatic cell lines in the Califano Lab database, 
ASPC1 and PANC1 (Figure 28B).  We subsequently applied OncoTreat using the perturbational 
data of ASPC1, since all of the tumor cells have a strong statistically significant enrichment for 
the signature of this cell line. From the drug perturbation data on ASPC1, we matched each 
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individual cell to the drug that best inverted the protein activity profile of that cell, using the 
standard CLIA-certified OncoTreat algorithm to estimate p-value for each drug’s ability to invert 
the tumor cell profile. Drug prioritization was weighted by p-values of each drug in each cell by 
fisher integration of p-values, such that drugs predicted to invert the profile of a larger number of 
cells were higher-ranked. In Figure 26A we show p-values across all tumor cells for the top-25 
drugs predicted from ASPC1 drug perturbation data. As we did for OncoTarget, in order to 
assess the robustness of the top predicted drugs from single cells, the same analysis was 
performed on artificial bulk of each tumor cell sub-cluster computed by summing the UMI 
counts by gene. 
 
OncoTarget/OncoTreat analysis of PDX bulk RNA-Seq data 
Bulk RNA-Seq data of the PDX model was analyzed using the same pipeline conceived for 
single-cells and artificial bulk samples. Consequently, a differential gene expression signature 
was computed scaling the log-transformed TPM data to the average of TCGA and then processed 
through the VIPER algorithm. The enrichment of the MRs of the three tumor sub-clusters in the 
protein activity signature of the PDX was computed with Gene Set Enrichment Analysis 
(GSEA). Results in Figure 6A show that the PDX is able to recapitulate the MRs of the tumor 
cell sub-clusters, with particular enrichment of genes marking the two largest cluster defined by 
upregulation of KRAS and Nf-kb/EMT signaling. Finally, the OncoTarget/OncoTreat analysis 
was performed as described in the previous sections, using the same regulatory models and cell 
lines used for single-cells and synthetic bulk samples.  
 
Patient-Derived Xenograft Model & Treatment 
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All mice were maintained under barrier conditions and experiments were conducted using 
protocols and conditions approved by the Memorial Sloan Kettering Cancer Center (MSKCC) 
Institutional Animal Care and Use Committee (IACUC) under protocol 16-08-011. Patient 
derived tumor tissue to generate PDX models were obtained under the MSKCC Institutional 
Review Board (IRB)-approved protocols #17-387 and #06-107. PDX mouse models were 
established by implanting tumor cells subcutaneously into non-obese diabetic/severe combined 
immunodeficiency interleukin-2R gamma null, HPRT null (NSGH) mice (Jackson Labs, IMSR 
Cat# JAX:012480, RRID: IMSR_JAX:012480). Mice were treated with vehicle or one of five 
treatment groups for four weeks: (1) Vehicle control, (2) Glasdegib 100mg/kg PO daily, (3) 
Plicamycin 0.2mg/kg IP 3 times/week, (4) AT9283 15mg/kg daily, IP 4 days on 3 days off, (5) 
Flavopiridol 15mg/kg PO daily, 5 days on 2 days off, (6) Dacinostat 25mg/kg IP daily. Fifty-four 
mice were implanted in total. Once the tumor reached a volume of 80-120 mm3, mice were 
assigned to treatment groups using block randomization with eight animals per group. Tumors 
were measured by caliper measurement twice weekly and tumor volume (TV) was calculated as 
follows: TV = width2 X ½ length. Treatment failure was defined as >100% increase in tumor 
volume relative to baseline in each respective mouse. For in vivo statistical analysis, the Mann-
Whitney-Wilcoxon method was used to evaluate differences in distribution of tumor volume 
between treatment groups. Vardi’s test was used to evaluate difference in area under the curve 
(AUC) between treatment groups. Event-free survival (EFS) was defined as the percentage of 
mice that survived at any given time point without treatment failure. Kaplan-Meier survival 
curves were compared using the log-rank test. Statistical analysis was performed using R 
software (v3.5.0). Waterfall plots and tumor volume curves for in vivo analysis were generated 
with GraphPad Prism (v8.4.1). Statistical significance was defined as p values < 0.05.  
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Chapter 4: Cancer-Associated Fibroblast Sub-Populations Mediate 
Clinical Immunotherapy Response in Head and Neck Squamous 
Cell Carcinoma 
4.1 Summary 
The heterogeneity of cancer associated fibroblasts (CAF) has precluded rigorous understanding 
of their function in the tumor microenvironment. Using an inferred protein network-based 
methodology to generate CAF atlas from single-cell transcriptomic profiles of human head and 
neck carcinoma, pre and post nivolumab treatment, we resolved 5 unique CAF subtypes. The 
head and neck CAF (HNCAF) protein activity profiles, derived from a nested cohort of paired 
single-cell RNA sequencing profiles, were then used to perform protein activity enrichment 
analysis on the 36-patient parental cohort of clinically annotated bulk transcriptomic profiles. 
Among these subtypes, HNCAF-0/3 emerged as predictive of nivolumab response, while 
HNCAF-1 was associated with immunosuppression. Functionally, HNCAF-0/3 were found to 
reduce TGFβ dependent PD-1+TIM-3+ exhaustion of T cells and increase CD103+NKG2A+ 
resident memory phenotype to enhance the overall cytolytic profile of T cells. Our findings 
implicate distinct HNCAF subsets as clinically actionable modulators of human TIL repertoire.  
Significance: Our utilization of systems biology-based master regulator analysis of single-cell 
transcriptomic profiles unveiled unique CAF subtypes that can predict clinical responses to aPD-
1 blocking antibodies to warrant biomarker validation studies. Furthermore, our CAF atlas will 





Anti-PD-1 immune checkpoint inhibitors (ICI) are currently the first line therapy for 
recurrent/metastatic head and neck squamous cell carcinoma [94] [95]. Yet, overall response 
rates can be as low as 20%, with increased responses in tumors with elevated PD-L1 expression 
and tumor infiltrating T cells [94] [96] [97]. While this is partly a T cell dependent mechanism, 
there may be additional cellular subpopulations in the tumor microenvironment (TME) 
responsible for mediating response to ICI (5). Recent studies have suggested that cancer 
associated fibroblasts (CAF) are associated with this resistance, but their role in T cell 
immunomodulation is still unclear in the human TME [98] [99] [100].  
 
In human breast cancer, four CAF subtypes (CAF-S1 to S4), were identified based on the 
expression of six fibroblast markers — fibroblast activation protein (FAP), integrin β1 (CD29), 
⍺-smooth muscle actin (⍺-SMA), fibroblast-specific protein-1 (FSP-1), platelet-derived growth 
factor receptor β (PDGFRβ), and caveolin-1 (CAV1) [101]. In their follow-up study, single-cell 
RNA sequencing further divided CAF-S1 into eight subtypes with the majority of these subtypes 
linked to immunosuppression and resistance to immunotherapy [100]. In contrast, only three 
molecularly and phenotypically distinct CAF subpopulations were identified in pancreatic 
cancer, based on spatial location and imputed function, as defined by cytokine and surface 
marker expression. These include inflammatory CAF (iCAF), myofibroblastic CAF (myCAF) 
and antigen-presenting CAF (apCAF) [33] [102]. In head and neck, three CAF types were 
previously identified by single-cell RNA sequencing corresponding to myCAF and two 
undefined CAF subtypes (CAF1 and CAF2), but the functionality of these subtypes and their 
association with immunotherapy response remains unknown [103]. In general, these various 
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orthogonal approaches to cancer specific CAF characterizations have not provided a concordant 
classification of this important stromal host cell type.   
 
To assess whether CAF-related or other TME subpopulations can regulate clinical responses to 
nivolumab, we leveraged single-cell RNA-sequencing (scRNA-Seq) to longitudinally profile pre 
and post treatment human head and neck squamous cell carcinoma to generate a dynamic atlas of 
the human HNSCC TME. Our novel bioinformatic approach uses the VIPER algorithm [21] [26] 
to address limitations imposed by high noise and significant gene dropout rates in most scRNA-
Seq analysis platforms. Specifically, VIPER leverages knowledge of regulatory networks to 
allow full quantitative characterization of protein activity by assessing the enrichment of their 
transcriptional targets in differentially expressed genes. On average, the resulting protein activity 
profiles outperform antibody-based measurements and dramatically outperform gene expression-
based analyses in terms of identifying and characterizing molecularly distinct TME 
subpopulations [35], thus enabling mechanistic dissection of the HNSCC microenvironment at 
hitherto unattained resolution. We present the results of these protein activity-based analyses on 
clinical biospecimens to generate a high-resolution atlas of the human HNSCC immune and 




Proteomic Master Regulatory Network Analysis of Longitudinal Single-Cell 




Longitudinal scRNA-Seq of patient tumors, pre- and post-treatment with nivolumab, and gene 
expression clustering with Seurat revealed 12 broadly distinct cellular populations, consistently 
expressed across all the tumors sequenced (Fig. 29A-B).  
 
Figure 29: Single-Cell RNA-Sequencing and VIPER Inference Shows Increased T-
cell Activity Induced by Nivolumab  
A) 2-dimensional UMAP projection of single-cell RNA-Seq gene expression data before VIPER 
is applied, colored by unsupervised cluster grouping. B) 2-dimensional UMAP projection of 
gene expression data from A, colored by cell type inferred from SingleR, as in Figure 1D. C) 




αPD-1 treatment with bulk RNAseq data. D) Interferon Gamma VIPER-inferred protein activity 
among T-cell populations pre vs post immunotherapy. E) Plot of inferred receptor-ligand 
interactions between cell types, such that receptor-ligand pairs with known interaction have 
significant upregulation of ligand gene expression among fibroblasts, and significant 
upregulation of corresponding receptor protein activity by VIPER in another cell type. Width of 
lines is weighted by the number of inferred interactions between fibroblasts (in the middle), and 
each other cell type. F) Heatmap of differentially expressed CAF1/CAF2 genes defined by 
Puram et al. for each gene expression-based CAF cluster identified in A (Clusters 3 and 6). 
 
To achieve higher resolution of cellular subpopulation characterization, we used scRNA-Seq 
profiles from each cluster to infer subpopulation-specific gene regulatory networks with the 
ARACNe algorithm [40], followed by protein activity analysis using the Virtual Inference of 
Protein-activity by Enriched Regulon (VIPER). Protein activity-based re-clustering identified 
two additional, previously undetected clusters for a total of 14 distinct cellular populations which 
were also consistently expressed across all four patients (Fig. 30A). To visualize key differences 
between these cellular populations, we generated a heatmap showing the activity of the five 
proteins most differentially activated in each cluster (Fig. 30B). We first assessed the ability of 
these VIPER generated populations to accurately respond to expected treatment-induced 
changes. As expected, both gene expression and protein activity analyses revealed increased T 
cells and interferon-gamma protein activity following nivolumab treatment (Fig. 30C (cluster 8), 
Fig. 29C-29D). When we interrogated changes in the abundance of other cell populations, 
VIPER clustering revealed heterogeneity among fibroblast cells not discoverable from gene 
expression clustering alone, with two clusters (clusters 4 and 9) presenting highly statistically 
significant post-treatment cellular fraction increase (Fig. 30C). Cell lineage inference, using 
SingleR [48], identified both clusters as fibroblasts, suggesting that PD-1 targeted 
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immunotherapy in head and neck cancer was associated with CAF upregulation (Fig. 30D). 
Accordingly, imputed receptor-ligand interactions between cell types [35] suggested strong 
interplay between CAF and CD8 T cells (Fig. 29E). Furthermore, two additional clusters 
(clusters 6 and 7), also characterized as fibroblasts by SingleR (Fig. 30D), did not show 
significant fractional representation differences following immunotherapy (Fig. 30C), thus 




Figure 30: VIPER analysis of longitudinal single-cell transcriptomic profiles of 




A) 2-dimensional UMAP projection of cells across all samples, processed by VIPER and 
clustered by resolution-optimized Louvain. Cells are colored by unsupervised cluster number, 
with fibroblast clusters (4,6,7,9) further labelled by cell type. B) Heatmap of top 5 most 
differentially upregulated proteins per cluster for each cell population in A. C) Boxplot of 
population frequency at baseline and following ⍺PD-1 immunotherapy for each cell type cluster 
in A. CAF subtypes increasing in response to immunotherapy (p<0.01) are circled in blue. D) 
SingleR cell type inference projected on UMAP plot. Each cluster is assigned a lineage cell type 
based on its majority SingleR-inferred label. 
 
VIPER Fibroblast Clustering Identifies Unique Sub-Populations Associated with Response 
and Resistance to Immunotherapy 
To further evaluate functional differences between the distinct CAF sub-populations in the 
HNSCC TME, we performed protein activity-based sub-clustering focusing only on fibroblast 
cells using ARACNe and VIPER. The analysis identified five molecularly-distinct CAF clusters, 
preliminarily termed HNCAF-0 – HNCAF-4 (Fig. 31A). Importantly, gene expression-based 
sub-clustering of fibroblasts only identified two distinct CAF populations corresponding to the 
two fibroblast populations seen in Fig. 29A (Clusters 3 and 6). As expected, these two clusters 
phenotypically match the two CAF populations previously identified in HNSCC such that 
Cluster 3 corresponds to CAF1 and Cluster 6 corresponds to CAF2 (Fig. 29F) [103]. Among the 
five HNCAF populations identified by protein activity-based clustering, cell fractional 
representation increased for HNCAF-0 and HNCAF-3, decreased for HNCAF-1 and HNCAF-2, 
and was unaffected for HNCAF-4 (Fig. 31B). The top ten most differentially active proteins, 
presented as a ranked list of differentially active transcription factors and signaling molecules, in 
each of the five clusters highlight their potential functional properties (Fig. 31C) to help define 
the molecular biology of each HNCAF phenotype. To assess the associations of each HNCAF 
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subpopulation with clinical response to ⍺PD-1 immunotherapy, we used the HNCAF molecular 
signatures to analyze the bulk RNA sequencing profiles from the 36-patient parental cohort 
annotated with clinical response to nivolumab. For this purpose, we first used VIPER to generate 
protein activity profiles from each bulk profile, using fibroblast specific regulatory networks 
generated at the single-cell level, and then evaluated the enrichment of the most differentially 
active proteins in each HNCAF subpopulation (marker protein sets) among proteins 
differentially active in responders vs non-responders. The analysis revealed statistically 
significant enrichment of HNCAF-0 and HNCAF-3 marker genes in pre-treatment samples of 
patients who subsequently responded to ⍺PD-1 immunotherapy (Fig. 31D). This result indicates 
that the HNCAF-0 and HNCAF-3 populations, which also expand following nivolumab 
treatment, may be predictive of clinical response in human HNSCC patients. By contrast, 
HNCAF-1, HNCAF-2, and HNCAF-4 cells did not expand following therapy and their markers 




Figure 31: Fibroblast sub-clustering reveals distinct populations associated with 




A) 2-dimensional UMAP projection of CAF across all samples, re-clustered by resolution-
optimized Louvain and colored by cluster identity. B) Boxplot of cluster frequencies pre vs post 
nivolumab therapy, such that HNCAF-0 and HNCAF-3 show statistically significant increase in 
frequency (p<0.01) while HNCAF-1 and HNCAF-2 show significant decrease (p<0.01). C) 
Heatmap of top 10 most differentially upregulated proteins per cluster for each CAF population. 
D) Protein Activity Profile Enrichment plots of single-cell protein population markers for each 
HNCAF cluster (Supplemental Table 1) in bulk-RNASeq signature of immunotherapy 
responders (18 patients) vs non-responders (18 patients), profiled pre-treatment. HNCAF-0 and 
HNCAF-3 profiles are significantly enriched in treatment responders (p=3.2 x 10-7 and p=1.7 x 
10-6, respectively). 
 
Fibroblast Subtype Analysis Reveals Novel Classification Paradigm in HNSCC 
Due to scant literature on CAF in human HNSCC, we next quantified the extent of CAF 
infiltration from surgical HNSCC specimens using flow cytometry. CAF abundance — as 
defined by CD45- EpCAM- CD31-— ranged between 12% and 58% of the total live cells (Fig. 
33A). Having confirmed significant abundance of CAF in human HNSCC, we proceeded to 
assess the presence of novel HNCAF subpopulations predicted by the VIPER analysis. Distinct 
CAF subpopulations termed CAF-S1, CAF-S2, CAF-S3, and CAF-S4 have been previously 
identified in breast cancer based on the expression of CD29 and fibroblast activation protein 
(FAP) by flow cytometry [101]. Kieffer et al. showed that CAF-S1 can be found in HNSCC but 
the presence of other CAF-S populations in HNSCC remains unknown [100]. Hence this protein-
based framework was initially used to assess how the VIPER imputed HNCAF align with breast 
cancer CAF scheme. Following the same gating strategy employed by Costa et al. (Fig. 32), we 
confirmed the presence of all four breast cancer CAF-S populations in HNSCC (Fig. 33B). 
Interestingly, CAF-S1 and CAF-S2 were most abundant, while CAF-S3 and CAF-S4 abundance 
was quite minimal (Fig. 33C). We then sorted CAF-S1 – S4 cells from HNSCC tumors (Fig. 32) 
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and performed bulk RNA sequencing of each subpopulation to assign these sorted cells to the 
VIPER generated HNCAF populations. Pairwise gene set enrichment analysis of the HNCAF 
protein activity signatures in the bulk transcriptome indicated that the gene sets representative of 
HNCAF-0, HNCAF-1, and HNCAF-3 were all enriched in the same breast subtype (CAF-S1), 
while HNCAF-2 and HNCAF-4 were both enriched in CAF-S4 with HNCAF-4 also enriched in 
CAF-S3 (Fig. 34A). CAF-S2—primarily defined as double-negative for FAP and CD29—did 
not significantly align with any HNCAF. These analyses importantly showed that VIPER-
clustered HNCAF provide much greater resolution of functionally distinct CAF phenotypes 
compared to the flow-based CAF-S1/S2/S3/S4 framework. Specifically, the CAF-S1 subtype 
matched three distinct HNCAF subtypes, which have opposing association with clinical 
responses to immunotherapy. Additionally, the HNCAF subtypes did not clearly correlate with 
any of the CAF-S1 subclusters later identified by gene expression in breast cancer apart from 
ecm-myCAF (Fig. 34B). HNCAF-0,1,2 and 3 were all significantly enriched for the ecm-
myCAF signature, with HNCAF-0 and HNCAF-3 being more enriched than HNCAF-1 and 
HNCAF-2. However, ecm-myCAF are associated with immunosuppression and resistance to 
immunotherapy leading us to believe that HNCAF-0 and HNCAF-3 differ from ecm-myCAF in 
terms of functionality [100]. 
 
We also tested for concordance of our classification schema with previously defined gene set 
markers of inflammatory CAF (iCAF) and myofibroblastic CAF (myCAF), as first described in 
pancreatic cancer [33]. Cell-by-cell enrichment of iCAF and myCAF gene signatures revealed an 
enrichment for the iCAF signature in HNCAF-1 cells and for myCAF in HNCAF-2 cells (Fig. 
34C-D). Correlations between our HNCAF populations and the breast or pancreatic CAF 
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phenotypes is summarized in the classification scheme shown in Fig. 33D. While presenting 
some similarity to CAF-S1 cells, we conclude that HNCAF-0 and HNCAF-3 represent novel, 
molecularly distinct fibroblast subpopulations, potentially unique to head and neck cancer and 
predictive of patient outcome (Fig. 31D), which do not completely match the iCAF/myCAF 
classification. Furthermore, in contrast to the HNCAF-0 and HNCAF-3 subtypes, iCAF/myCAF 
and CAF-S1/S2/S3/S4 are not significantly enriched in responder cohorts, suggesting that these 
classification schemes do not accurately depict CAF function in HNSCC (Fig. 35). 
Cumulatively, these data underscore the greater resolution of HNCAF from our VIPER analysis 
compared to previous efforts, and more critically, the HNCAF populations identified through 






Figure 32: Flow cytometry gating strategy for sorting of CAF-S1 through CAF-S4 
populations.  






Figure 33: Prognostically associated HNCAF sub-populations as defined by scRNA-
Seq provide greater resolution than CAF phenotypes previously characterized.  
A) Relative frequencies across 5 HNSCC patients of stromal (CD45-Epcam-CD31-), 
epithelial/endothelial (CD45-Epcam+/CD31+) and immune (CD45+) cells components 
quantified by flow cytometry. B) Flow cytometry gating strategy to isolate CAF phenotypes 
previously described in the literature, implemented as described in [101]. C) Relative frequency 
for each patient of CAF subtypes from B among total CAF quantified by flow cytometry. D) 
Phenotype-matching between unsupervised clusters from single-cell RNA-Seq and bulk-
RNASeq of sorted populations CAF-S1 to CAF-S4, as well as iCAF and myCAF, from [33]. 
Each single-cell population is labelled as the sorted population with highest gene set enrichment, 
as shown in Figure S3. The data in A and C were analyzed using one-way ANOVA and * 









A) Pairwise Protein Activity Gene Set Enrichment of single-cell HNCAF gene sets (rows) 
among bulk RNA-Seq of sorted CAF populations, CAF-S1, CAF-S2, CAF-S3, and CAF-S4, as 
defined by [101]. Best match by enrichment for each HNCAF cluster is outlined in red. B) Cell-
by-Cell enrichment of published CAF-S1 subcluster gene sets [100] in our single-cell HNCAF 
dataset, grouped by cluster. C-D) Cell-by-Cell enrichment of published iCAF and myCAF 
protein activity gene sets (Elyada at. al, 2019) in our single-cell HNCAF dataset, grouped by 
cluster, such that HNCAF-1 is enriched for iCAF gene set, and HNCAF-2 is enriched for 
myCAF gene set. 
 
 
Figure 35: iCAF/myCAF and CAF-S1/S2/S3/S4 Population Markers are Not 
Significantly Enriched in Immunotherapy Responders vs Non-Responders Pre-Treatment.  
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A) Gene Set Enrichment plot of iCAF protein activity markers [33] in bulkRNA-Seq signature of 
immunotherapy responders vs non-responders, profiled pre-treatment. B) Gene Set Enrichment 
plot of myCAF protein activity markers [33] in bulkRNA-Seq signature of immunotherapy 
responders vs non-responders, profiled pre-treatment. C) Gene Set Enrichment of Top50 most-
upregulated proteins from bulk-RNA-Seq of CAF-S1 vs CAF-S1/S2/S3/S4 in bulk-RNA-Seq 
signature of immunotherapy responders vs non-responders, profiled pre-treatment. D) Gene Set 
Enrichment of Top50 most-upregulated proteins from bulk-RNA-Seq of CAF-S2 vs CAF-
S1/S2/S3/S4 in bulk-RNA-Seq signature of immunotherapy responders vs non-responders, 
profiled pre-treatment. E) Gene Set Enrichment of Top50 most-upregulated proteins from bulk-
RNA-Seq of CAF-S3 vs CAF-S1/S2/S3/S4 in bulk-RNA-Seq signature of immunotherapy 
responders vs non-responders, profiled pre-treatment. F) Gene Set Enrichment of Top50 most-
upregulated proteins from bulk-RNA-Seq of CAF-S4 vs CAF-S1/S2/S3/S4 in bulk-RNA-Seq 
signature of immunotherapy responders vs non-responders, profiled pre-treatment. 
 
HNCAF-0 Predicts Favorable Disease Course in TCGA, in Contrast to HNCAF-1. 
To evaluate the prognostic relevance of the CAF populations identified in a setting free from 
external immunotherapeutic pressures, we quantified the enrichment of HNCAF protein activity 
signatures in The Cancer Genome Atlas (TCGA) HNSCC cohort (Fig. 36, Fig. 37). Gene set 
enrichment (GSEA) analysis [104], on a patient-by-patient basis, revealed significant enrichment 
of the HNCAF-0 signature in patients with better overall survival in TCGA (Fig. 36A), 
suggesting that these cells may not only be important regulators of immunotherapy response but 
may also play a key role in mounting clinically relevant, endogenous immune responses against 
HNSCC. In contrast, the HNCAF-1 protein activity signature was associated with early worse 
overall survival when there were sufficient number of patients (Fig. 36B). Prognosis in HNSCC 
has been associated with higher TIL level in the TCGA cohort [105], and these results were 
consistent with the differential immunomodulatory functional roles of distinct VIPER derived 





Figure 36: HNCAF-0 and HNCAF-1 have contrasting prognostic associations.  
A) Kaplan-Meier plot of HNCAF-0 Protein Activity Gene Set Enrichment among TCGA dataset 
of head and neck squamous cell carcinoma patients in association with overall survival time. 
Enrichment scores were binarized by log-rank maximization to “high HNCAF-0” and “low 
HNCAF-0” and showed significant association with improved survival (p=0.014, median 
survival time = 602 days vs 1671 days). B) Kaplan-Meier plot of HNCAF-1 Protein Activity 
Gene Set Enrichment among TCGA head and neck squamous cell carcinoma patients in 
association with overall survival time, as in A. HNCAF-1 enrichment shows significant 
association with worse survival (p=0.011, median survival time = 1718 days vs 773 days). The 






Figure 37: HNCAF-2, HNCAF-3, and HNCAF-4 are not associated with overall 
survival in TCGA.  
Kaplan-Meier plot of HNCAF-2 (A), HNCAF-3 (B), and HNCAF-4 (C) Protein Activity Gene 
Set Enrichment among TCGA head and neck squamous cell carcinoma patients in association 
with overall survival time. Enrichment scores were binarized by log-rank maximization to “high 




HNCAF-0/3 cells inhibit TGFβ dependent T-cell exhaustion in functional co-culture 
experiments. 
Prompted by these intriguing clinical findings (Fig. 31D), we studied the potential interactions of 
HNCAF-0 and HNCAF-3 cells with other TME subpopulations. Interactome analysis showed 
that HNCAF have more receptor-ligand interactions with CD8 T cells than with any other cell 
subtype in the TME (see methods) (Fig. 29E). Therefore, we next interrogated the relationship 
between HNCAF-0 and human CD8 T cells in situ and in vitro. Digital spatial profiling (DSP, 
NanoString) of immune-related transcripts and protein markers was performed on HNSCC tissue 
from patients prior to nivolumab treatment. We first analyzed global CAF infiltration pattern in 
HNSCC tissue using aSMA, aCD8, and acytokeratin antibodies. These multiplexed 
immunofluorescent images exhibited colocalization of CAF with CD8+ T cells in the stromal 
compartment (Fig. 38A, white arrow). Reliable validated antibodies for each of the VIPER 
derived HNCAF subpopulations are currently unavailable to prevent histological analysis of each 
HNCAF population at this time.   
 
To test whether HNCAF-0 cells can directly affect the biology of the CD8 T cells, we performed 
in vitro co-culture assays with HNCAF harvested from surgical resection mixed with either naïve 
T cells or tumor-infiltrating T cells. Primary fibroblasts enriched for HNCAF-0/3 were isolated 
from human HNSCC samples and their transcriptional identity was verified by RNA-Sequencing 
and protein activity analysis (Fig. 39). Due to the phenotypic similarity between HNCAF-0 and 
HNCAF-3, we were unable to enrich solely for HNCAF-0 and proceeded with a heterogeneous 
population enriched for both HNCAF-0 and HNCAF-3. When co-cultured with T cells isolated 
from peripheral blood mononuclear cells of healthy donors, HNCAF-0/3 cells reduced the PD-
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1+TIM-3+ exhaustion phenotype among exogenously activated CD8 T cells and increased the 
CD103+NKG2A+ tissue resident memory phenotype, as well as their cytolytic function, based 
on Perforin and Granzyme B expression (Fig. 38B). It is important to note that reduced 
exhaustion and increased tissue resident memory phenotypes caused by HNCAF-0/3 was not due 
to PD-1:PD-L1 signaling (Fig. 40A-40B). Transwell co-culture assays revealed that HNCAF-
0/3-mediated T cell activation increase and induction of tissue resident memory phenotypes—but 
not T cell exhaustion phenotype mitigation—depends on cell-to-cell contact (Fig. 38C). 
Additionally, coculture of HNCAF-0/3 cells with tumor-infiltrating T cells isolated directly from 
human HNSCC specimens resulted in an equivalent increase in tissue resident memory 
phenotype and cytotoxicity among CD8 T cells. HNCAF-0/3 cells could not rescue the 
exhaustion phenotype of terminally exhausted tumor-infiltrating T cells (Fig. 38D). Regardless, 
HNCAF-0/3 cells strongly promoted production of the activation markers, Perforin, Granzyme 
B, and IFNɣ, in tumor-infiltrating T cells (Fig. 38D-E), suggesting that HNCAF-0/3 may prevent 
terminal exhaustion in early activated T cells, while not be able to reverse the phenotype of 
already exhausted T cells from the TME. Notably, we found that HNCAF-0/3 completely 
rescued TGFβ-mediated PD-1/TIM-3 induction in culture, without inhibiting total TGFβ 
signaling, as defined by CD103 induction (Fig. 38F).  
 
To evaluate CAF influences on T cell exhaustion in situ without a validated antibody for each 
HNCAF populations, we leveraged the digital spatial profiling data to evaluate colocalization of 
HNCAF-0 and HNCAF-1 protein activity signatures in regions enriched for the T-cell functional 
exhaustion signature. Indeed, the HNCAF-1 signature enrichment significantly correlated with 
increased T cell exhaustion signature enrichment (r = 0.94, p = 0.0014). In sharp contrast, the 
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HNCAF-0 signature was not significantly associated with the T-cell exhaustion signature in the 
TME region of interest (Fig. 38G-H). Given the association of HNCAF-1 cells with an 
immunosuppressive environment, we aimed to evaluate the direct impacts of isolated HNCAF-1 
cells on T cell phenotypes in co-culture, as performed for HNCAF-0/3 cells. However, despite 
repeated experiments, T cells co-cultured with HNCAF-1 rapidly died, leaving an insufficient 
number of viable cells for further analyses (Fig. 38I, Fig. 40C-E). T cell death induction was not 
observed when T cells were cultured in isolation or with HNCAF-0/3 cells, suggesting HNCAF-





Figure 38: HNCAF spatially co-localizes with CD8 T-cells and HNCAF-0/3 
functionally decrease TGFb dependent T-cell exhaustion in vitro.  
A) Pre-treatment DSP immunofluorescence imaging from representative patient treated with 
⍺PD-1 immunotherapy, such that tumor cell localization is indicated by panCK staining (green), 
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CD8 T-cell localization, CD8 staining (4), fibroblast localization, ⍺SMA staining (yellow), and 
nucleated cells, DAPI staining (blue). Arrows indicate interactions between ⍺SMA+ fibroblasts 
and CD8+ T cells. B) Co-culture experiment of naïve T cells derived from peripheral blood 
mononuclear cells (PBMC) with CD3/CD28 stimulation and isolated HNCAF-0/3 cells, showing 
reduced T cell exhaustion (%PD-1+ TIM-3+ cells), increased tissue residency markers 
(%CD103+ NKG2A+ cells), and increased cytotoxicity (%Perforin+ GzmB+ cells). C) Co-
culture experiment of T cells with HNCAF-0/3 cells as in B in contact-isolating transwell 
culture, showing reduced T cell exhaustion, but no significant difference in tissue residency 
markers or cytotoxicity. D) Co-culture experiment of Tumor-Infiltrating Lymphocytes (TIL) 
with CD3/CD28 stimulation and isolated HNCAF-0/3 cells, showing increased tissue residency 
markers and increased cytotoxicity. E) Interferon gamma levels in co-culture of naïve T cells 
derived from PBMC and TIL with HNCAF-0/3 cells determined by ELISA, showing significant 
increase in co-culture with TIL but not naïve T cells. F) Rescue experiment of T cells with 
CD3/CD28 stimulation and TGFβ with or without HNCAF-0/3. T-cell exhaustion markers on the 
left plot (%PD-1+ TIM-3+ cells) are rescued by HNCAF-0/3, and tissue localization markers on 
the right plot (%CD103+ cells) increase with TGFβ but are unaffected by addition of HNCAF-
0/3. G) Spatial enrichment of HNCAF-0/3 gene set vs enrichment of T-cell exhaustion signature 
in Nanostring DSP of tissue slices across patients. No statistically significant association in 
spatial co-enrichment. H) Spatial enrichment of HNCAF-1 gene set vs enrichment of T-cell 
exhaustion signature in Nanostring DSP of tissue slices across patients. Signatures are positively 
correlated with respect to spatial co-localization (correlation coefficient = 0.94, p = 0.0014). I) 
Quantitation of live cells out of total CD8 T cells determined by flow cytometry from co-culture 
with HNCAF-0/3 or HNCAF-1. B-D, F) Percentages were quantified by flow cytometry. Results 
are shown as mean ± SD and are representative of at least three independent experiments. The 
data were analyzed using one-way ANOVA (B-D, F, I) or the Student t test (E) and * indicates 






Figure 39: Isolated CAF in co-culture experiments are strongly enriched for 
HNCAF-0 and HNCAF-3.  
A) Gene Set Enrichment plots of single-cell protein activity population markers for each 
HNCAF cluster (Supplemental Table 1) in bulk-RNASeq of isolated CAF used for co-culture 
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experiments. HNCAF-0 and HNCAF-3 gene sets are significantly enriched in cultured CAF 
(p=4.2 x 10-2 and p=2.1 x 10-2, respectively), and no other HNCAF signatures show statistically 
significant gene set enrichment. B) CIBERSORTx inference of cell type abundances in bulk-
RNASeq of sorted CAF used for co-culture experiments, across three technical replicates, such 
that HNCAF-0 and HNCAF-3 constitute the majority of inferred cell frequency. For reference, in 
single-cell RNASeq (Figure 2) HNCAF-0 represents 43% of overall CAF frequency, HNCAF-1 




Figure 40: PD-L1 blockade does not affect HNCAF-0/3-induced T cell phenotypes 
and HNCAF-1 fibroblasts induce T cell death in co-culture experiments.  
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A-B) Co-culture experiment of Peripheral Blood Mononuclear Cells (PBMCs) with isolated 
HNCAF-0/3 cells with or without PD-L1 blocking antibody, showing reduced PD-1/TIM-3 (A) 
and increased CD103/NKG2A (B). *** indicates p<0.001 and **** indicates p<0.0001. C-E) 
Representative flow plots of T cells co-cultured without CAF (C) with HNCAF-0/3 (D) or with 
HNCAF-1 (E) for 5 days, gated on CD8+ T cells. 
 
HNCAF-0 can predict clinical outcome to aPD-1 blocking antibodies. 
To test for the potential generalizability of these HNCAF subpopulations, we next performed 
enrichment of HNCAF protein activity signatures across TCGA, by tumor type, focusing on 
tumors with high stromal cell content. Enrichment analyses revealed that HNCAF-0 enrichment 
is relatively specific to HNSCC while HNCAF-1 enrichment is more broadly observed (Fig. 
41A-B). Intriguingly, HNCAF-1 enrichment is highest in pancreatic adenocarcinoma, which is 
known to be unresponsive to PD-1 based immunotherapy (Fig. 41B). HNCAF-1 phenotypically 
matches the previously defined iCAF population from pancreatic cancer (Fig. 34D). To 
externally validate our HNCAF-0/3’s potential for clinical response prediction, we tested for 
enrichment of protein activity signatures in another cohort of HNSCC patients treated with αPD-
1 immunotherapy, pembrolizumab [106]. The analysis revealed statistically significant 
enrichment of HNCAF-0 and HNCAF-3 marker genes in pre-treatment samples of patients who 
subsequently responded to pembrolizumab, validating the association of HNCAF-0/3 with 
immunotherapy response in an independent cohort (Fig. 42). Although not as enriched as 
HNCAF-0 and HNCAF-3, analysis of this cohort also revealed a significant enrichment of 





Figure 41: HNCAF-0 enrichment is highly specific to Head and Neck Squamous Cell 
Carcinoma.  
A) Boxplot of HNCAF-0 protein activity gene set enrichment among TCGA tumor types with 
high stromal involvement. B) Boxplot of HNCAF-1 protein activity gene set enrichment among 
TCGA tumor types with high stromal involvement. LIHC: Liver Hepatocellular Carcinoma, 
CHOL: Cholangiocarcinoma, BRCA: Breast Cancer, UCS: Uterine Carcinosarcoma, SARC: 







Figure 42: HNCAF-0 and HNCAF-3 are also predictive of favorable responses to 
pembrolizumab.  
Protein Activity Profile Enrichment plots of single-cell protein population markers for each 
HNCAF cluster in bulk-RNASeq signature of pembrolizumab immunotherapy responders (5 
patients) vs non-responders (15 patients), profiled pre-treatment from (Uppaluri et al, 2020). 
HNCAF-0, HNCAF-2, and HNCAF-3 profiles are significantly enriched in treatment responders 
(p=8.0 x 10-4, p=1.8 x 10-3, and p=3.4 x 10-7, respectively). 
 
4.4 Discussion 
In this study, we used protein activity profiles, as measured by the VIPER algorithm analysis of a 
longitudinal single-cell transcriptomics HNSCC dataset, to identify five molecularly distinct 
CAF subtypes. We took advantage of the longitudinally harvested biospecimens from a 
neoadjuvant clinical trial to show that two subtypes, HNCAF-0 and HNCAF-3, are predictive of 
favorable clinical responses to PD-1 checkpoint blockade therapy. Moreover, we discovered 
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HNCAF-0/3 cells have an immunostimulatory effect on CD8 T cells while HNCAF-1 cells are 
associated with immunosuppression. From a functional perspective, we have shown that 
HNCAF-0/3 fibroblasts prevent induction of an exhausted T cell phenotype and are associated 
with increased CD8 T cell cytotoxicity. HNCAF-1 fibroblasts, in contrast, correlate with 
increased T cell exhaustion in situ and T cell apoptosis in vitro, suggesting contrasting roles for 
these CAF subtypes. Functional significance of HNCAF-2 and HNCAF-4 subtypes have yet to 
be defined. 
 
Protein activity-based clustering with VIPER has previously been shown to outperform gene 
expression-based clustering and we have corroborated this with the identification of five HNCAF 
subtypes compared to two with gene expression-based clustering [35]. Although we are not the 
first to identify CAF in HNSCC by single-cell sequencing, we were able to achieve greater 
resolution with VIPER allowing for a more granular picture of the CAF composition in HNSCC 
[100] [103]. We were also able to integrate the major subclasses of CAF identified in breast 
cancer and pancreatic cancer into our HNSCC CAF data. We showed through GSEA that CAF-
S1, identified in breast cancer and in our HNSCC samples as CD29+FAP+ fibroblasts, correspond 
to three of the HNCAF groups we identified, HNCAF-0, HNCAF-1 and HNCAF-3 [101]. 
Kieffer et al. further dissected CAF-S1 in breast cancer and identified 8 subgroups but only 
focused on the 5 most abundant groups [100]. We performed GSEA of these 5 subgroups but 
were only able to identify one with significant enrichment in our HNCAF subpopulations - ecm-
myCAF. We did find that the ecm-myCAF signature was significantly enriched on 4 of our 5 
HNCAF groups. The discrepancies between our sub-clustering of CAF-S1 and Kieffer et al. may 
be due to tumor specific differences in the CAF heterogeneity between breast and HNSCC as 
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well as the use of a protein activity-based algorithm in contrast to gene expression. Additionally, 
we have found a CAF population (HNCAF-0) that is relatively specific to HNSCC amidst the 
other CAF types seen across different cancers. At this time, we hypothesize that tumor intrinsic 
factors may be influencing the differentiation of tumor specific CAF subpopulations (HNCAF-0) 
while nonspecific CAF subpopulations like HNCAF-1 could be derived from mesenchymal stem 
cells [107] [108] [109] [110] [111]. 
 
Despite the incomplete biological understanding of the HNCAF, our work introduces a novel 
clinically actionable biomarker for HNSCC. Immune checkpoint inhibitors (ICI) have 
revolutionized the field of cancer immunotherapy with monoclonal antibodies targeted against 
CTLA-4, PD-1, and PD-L1 being recently approved for use as frontline therapies for HNSCC 
and other cancer types [94] [96] [112]. The factors driving resistance to ICI remain largely 
unknown, making it difficult to select those who will respond and who will not. Accordingly, 
there remains an unmet need for reliable biomarkers predictive of response to guide patient 
selection and optimization of ICI treatment. In recent studies, CAF have been implicated to 
influence resistance to checkpoint immunotherapy. A preclinical model of pancreatic ductal 
adenocarcinoma showed that depletion of CAF expressing high levels of FAP improves response 
to ⍺PD-L1 blockade [98]. Similarly, single-cell RNA sequencing revealed a LRRC15+ CAF 
population associated with worse response to ⍺PD-L1 immunotherapy in a clinical trial for 
bladder cancer [99].  
 
Furthermore, distinct CAF populations identified in breast cancer were also shown to be 
associated with poor ⍺PD-1 immunotherapy response in melanoma and lung cancer [100]. All 
156 
 
these studies have implicated CAF primarily as contributors to resistance; however, the precise 
nature of molecularly distinct CAF subtypes and their role in mediating the effect of 
immunotherapy remains poorly investigated. With our ability to provide a higher resolution CAF 
repertoire, we show that the presence of two unique HNSCC-specific CAF subtypes is predictive 
of clinical response to immunotherapy in HNSCC. In particular, our functional findings suggest 
that HNCAF-0/3 fibroblasts are active participants in the immune response elicited by PD-1 
directed immunotherapy through T cell modulation. For HNSCC, we are currently evaluating 
whether these CAF subtypes behave differently in virally associated HPV+ HNSCC vs. HPV- 
tumors. 
 
Previous studies have typically shown CAF as promoters of immunosuppression. CAF have been 
shown to prevent T cell infiltration and to kill T cells in an antigen-dependent manner, via PD-
L2 and FasL [98] [113]. CAF have also been shown to suppress T cells through upregulation of 
PD-L1 and PD-L2 and through recruitment of regulatory T cells [101] [114]. While confirming 
the immunosuppressive role of some HNCAF subtypes, our work has also established a novel 
pro-inflammatory role for distinct CAF subtypes, which act as a promoter of T cell activation 
and cytotoxicity. In light of this immunostimulatory function, we have termed the HNCAF-0/3 
phenotype as T cell-stimulating CAF (tsCAF). Based on previous studies identifying TGFβ1 
signaling through SMAD3 as a regulator of PD-1 expression, we hypothesize that tsCAF may 
repress SMAD3 to transcriptionally inhibit PD-1/TIM-3 expression [115]. Although our data 
strongly suggests that HNCAF-0/3 are immunostimulatory, the inability to sort these cells to 
obtain pure populations is a major limitation of this study as the CAF cells used in our functional 
studies do not encompass a pure population at this point. Proteomic based approach to select and 
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sort CD29+FAP+ CAF into tsCAF and HNCAF-1 is an active area of investigation. Recently, 
tumor restrictive CD105- CAF have been demonstrated in murine models of PDAC which are 
mediated by the adaptive immune system [116]. CD105- CAF highly overlap with the myCAF 
gene signature, which has also previously been demonstrated to be tumor constraining [117]. 
Since the tsCAF we describe here are distinct from the myCAF population both molecularly and 
by surface marker expression, we believe they represent a distinct CAF population from CD105- 
CAF.  
 
Interestingly, we found that co-culture of HNCAF-0/3 with CD8 T cells induced a tissue-resident 
memory (Trm) phenotype that co-expressed NKG2A. NKG2A is an inhibitory receptor that we 
and others found to be highly enriched in tumor-infiltrating Trm+ CD8 T cells in HNSCC [118] 
[119]. NKG2A ligation with its ligand HLA-E reduces cytotoxicity and effector function and is 
therefore a novel immunotherapy target [120]. Clinical trials combining NKG2A blockade 
(monalizumab) and other checkpoint inhibitors have shown promising results in HNSCC [118]. 
While it is not clear why NKG2A is upregulated on tumor-infiltrating CD8 T cells, our findings 
suggest HNCAF characterization may also inform clinical development of NKG2A inhibition 
along with other immune checkpoint inhibitors.  We found that upregulation of NKG2A required 
contact between the HNCAF-0/3 and activated CD8 T cells, which suggests that induction is 
mediated by either a surface ligand on HNCAF-0/3 or a component in the extracellular matrix 
produced by the CAF. To our knowledge, NKG2A expression on CD8 T cells has never been 
associated with fibroblasts and our finding here provides a clear link between intra-tumoral 
NKG2A expression on CD8 T cells and the tumor stroma. Future studies will need to be 
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performed on HNSCC specimens to determine if NKG2A expression on CD8 T cells is localized 
to stromal regions or associated with increased HNCAF-0/3 cells.  
 
Plasticity of CAF subtypes have also been well demonstrated [102] [121], and our CAF atlas 
provides an excellent framework to develop strategies to force CAF differentiation towards the 
pro-inflammatory tsCAF phenotype rather than the immunosuppressive HNCAF-1 phenotype, to 
be combined with immunotherapy. Our characterization of each CAF subpopulation 
characterization through their master regulatory network lends itself towards this strategy. 
Further investigation of the signals that induce tsCAF formation and activation, possibly by 
targeting master regulators of the two subtypes, either genetically [66] [65] or 
pharmacologically, via the OncoTreat algorithm [24] is currently underway. Critically, this study 
highlights a much greater molecular heterogeneity of CAF subtypes than previously appreciated 
and demonstrates the critical need to functionally characterize their pleiotropic effects in terms of 
cancer progression, outcome, and response to immunotherapy and other cancer treatments.  
 
4.5 Methods 
Clinical Design and Tissue Collection 
Biospecimens were harvested from a window of opportunity trial of locally advanced HNSCC 
patients (oral cavity, oropharynx, larynx, hypopharynx) who were candidates for primary 
surgical intervention with curative intent (NCT03238365). All enrolled patients were treated 
with 1 month of 240mg nivolumab every 2 weeks for 2 doses prior to definitive surgery (N=50). 
Half of the patients received tadalafil, and no differences were noted in response rates between 
the two cohorts [122]. Consented patients were required to have fresh pre-nivolumab biopsy as 
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well pre and post imaging. Meta-clinical annotation using pathological criteria was used to 
delineate paired subject specimens as responders vs. non-responders. For both pre and post 
treatment timepoints, fresh specimens were collected for frozen fixation, paraffin embedded 
fixation, and processed for both bulk and single-cell transcriptomic sequencing. Due to 
insufficient RNA quality, only 36 of the 50 patients were used for bulk and single-cell RNA 
sequencing.   
 
Clinical Design and Tissue Collection 
Fresh head and neck squamous cell carcinoma tumor specimens were collected in DMEM 
supplemented with streptomycin (200 mg/ml), penicillin (200 U/ml), and amphotericin B (250 
mg/mL). Tumor specimens were minced to 2-4 mm sized pieces in separate 6-cm dishes and 
digested to single cell suspension using the Miltenyi Biotec human tumor dissociation kit 
(Miltenyi Biotec #130-095-929) on the Miltenyi gentleMACS Octo dissociator (Miltenyi Biotec 
#130-096-427) following manufacturer’s instructions. Dissociated cells were aliquoted for 
single-cell sequencing, flow cytometry analysis, or CAF culture.  
 
Single-Cell RNA-Sequencing 
Samples were processed to generate single-cell gene expression profiles (scRNA-Seq) using the 
10X Chromium 3’ Library and Gel Bead Kit (10X Genomics), following the manufacturer’s user 
guide. After GelBead in-Emulsion reverse transcription (GEM-RT) reaction, 12-15 cycles of 
polymerase chain reaction (PCR) amplification were performed to obtain cDNAs used for 
RNAseq library generation. Libraries were prepared following the manufacturer’s user guide and 
sequenced on the Illumina NovaSeq 6000 Sequencing System. Gene expression data were 
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processed with “cellranger count” on the pre-built human reference set of 30,727 genes to 
generate counts matrices. Cell Ranger performed default filtering for quality control, and 
produced for each sample a barcodes.tsv, genes.tsv, and matrix.mts file containing counts of 
transcripts for each sample, such that the expression of each gene is in terms of the number of 
unique molecular identifiers (UMIs) tagged to cDNA molecules corresponding to that gene. 
These data were loaded into the R version 3.6.1 programming environment, where the publicly 
available Seurat package v3.0 was used to further quality-control filter cells to those with fewer 
than 10% mitochondrial RNA content, more than 1,500 unique UMI counts, and fewer than 
15,000 unique UMI counts.   
 
Single-Cell Data Processing 
Gene Expression UMI count matrices for each sample were normalized and scaled in R using the 
Seurat SCTransform command to perform a regularized negative binomial regression based on 
the 3000 most variable genes. Scaled data from each patient were batch-corrected by Seurat 
using the functions FindIntegrationAnchors and IntegrateData, with default parameters. The 
resulting dataset included 22906 high-quality cells (mean UMI count 4802) across four patients, 
including both pre-treatment and post-treatment time points for each patient (Patient1: 5857 pre-
treatment, 7360 post-treatment, Patient2: 4938 pre-treatment, 1550 post-treatment, Patient3: 487 
pre-treatment, 1741 post-treatment, Patient4: 401 pre-treatment, 572 post-treatment). The batch-
corrected dataset was projected into its first 50 principal components using the RunPCA function 
in Seurat, and further reduced into a 2-dimensional visualization space using the RunUMAP 
function with method umap-learn and Pearson correlation as the distance metric between cells. 
The data were clustered by the Louvain algorithm with silhouette score resolution-optimization 
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selecting the resolution with maximum bootstrapped silhouette score in the range of resolution 
from 0.01 to 1.0 incremented by 0.01 [35]. This resulted in an initial coarse clustering on gene 
expression (Fig. 29A). Within each cluster metaCells were computed for downstream regulatory 
network inference by summing SCTransform-corrected template counts for the 10 nearest 
neighbors of each cell by Pearson correlation distance.  
 
For each single cell, inference of cell type was performed using the SingleR package and the 
preloaded Blueprint-ENCODE reference, which includes normalized gene expression values for 
259 bulk RNASeq samples generated by Blueprint and ENCODE from 43 distinct cell types 
representing pure populations of stroma and immune cells [49] [50]. The SingleR algorithm 
computes correlation between each individual cell and each of the 259 reference samples, and 
then assigns both a label of the cell type with highest average correlation to the individual cell 
and a p-value computed by wilcox test of correlation to that cell type compared to all other cell 
types. Highest-Frequency SingleR labels within each cluster among labels with p<0.05 are 
projected into the Gene Expression UMAP space in Fig. 29B, such that localization of SingleR 
labels is highly concordant with the unsupervised clustering. Unsupervised Clusters determined 
by the resolution-optimized Louvain algorithm are therefore labelled as a particular cell type 
based on the most-represented SingleR cell type label within that cluster.  
 
Differential gene expression analysis between single cell clusters throughout the manuscript is 
computed by the MAST hurdle model, as implemented in the Seurat FindAllMarkers command, 
with a log-fold change threshold of 0.5 and minimum fractional expression threshold of 0.25, 
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indicating that the resulting gene markers for each cluster are restricted to those with log fold 
change greater than 0 and non-zero expression in at least 25% of the cells in the cluster.   
 
Regulatory Network Inference 
From the integrated dataset, metaCells were computed within each gene expression-inferred 
cluster by summing SCTransform-corrected template counts for the 10 nearest neighbors of each 
cell by Pearson correlation distance. 200 metaCells per cluster were sampled to compute a 
regulatory network from each cluster. All regulatory networks were reverse engineered by the 
ARACNe algorithm. ARACNe was run with 100 bootstrap iterations using 1785 transcription 
factors (genes annotated in gene ontology molecular function database as GO:0003700, 
“transcription factor activity”, or as GO:0003677, “DNA binding” and GO:0030528, 
“transcription regulator activity”, or as GO:0003677 and GO:0045449, “regulation of 
transcription”), 668 transcriptional cofactors (a manually curated list, not overlapping with the 
transcription factor list, built upon genes annotated as GO:0003712, “transcription cofactor 
activity”, or GO:0030528 or GO:0045449), 3455 signaling pathway related genes (annotated in 
GO biological process database as GO:0007165, “signal transduction” and in GO cellular 
component database as GO:0005622, “intracellular” or GO:0005886, “plasma membrane”), and 
3620 surface markers (annotated as GO:0005886 or as GO:0009986, “cell surface”). ARACNe is 
only run on these gene sets so as to limit protein activity inference to proteins with biologically 
meaningful downstream regulatory targets, and we do not apply ARACNe to infer regulatory 
networks for proteins with no known signaling or transcriptional activity for which protein 
activity may be difficult to biologically interpret. Parameters were set to zero DPI (Data 
Processing Inequality) tolerance and MI (Mutual Information) p-value threshold of 10-8, 
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computed by permuting the original dataset as a null model. Each gene list used to run ARACNe 
is available on github [35].  
 
Protein Activity Inference 
Protein activity was inferred for all cells by running the metaVIPER algorithm, using all cluster-
specific ARACNe networks, on the SCTransform-scaled and Anchor-Integrated gene expression 
signature of single cells from each patient. Because the SCTransform Anchor-Integrated scaled 
gene expression signature is already normalized as an internal signature comparing all cells to 
the mean expression in the dataset, VIPER normalization parameter was set to “none.” The 
resulting VIPER matrix included 1239 proteins with activity successfully inferred from 
ARACNe gene regulatory networks. VIPER-Inferred Protein Activity matrix was loaded into a 
Seurat Object with CreateSeuratObject, then projected into its first 50 principal components 
using the RunPCA function in Seurat, and further reduced into a 2-dimensional visualization 
space using the RunUMAP function with method umap-learn and Pearson correlation as the 
distance metric between cells. Clustering was performed by resolution-optimized Louvain 
algorithm, as for gene expression (Fig.30A, Fig. 29A), and SingleR-inferred cell type labels were 
carried over to identify cluster-by-cluster cell type labels (Fig. 30D). Differential Protein Activity 
between clusters identified by resolution-optimized Louvain was computed using bootstrapped t-
test, run with 100 bootstraps, and top proteins for each cluster were ranked by p-value (Fig. 
30B). The entire pipeline is implemented as in (15). Cluster cell counts were normalized to a 
fraction of the total sample separately for each patient and separately for pre-treatment and post-
treatment samples, with differences in pre-treatment vs post-treatment frequency distribution 




Association of HNCAF Signatures with Response to Immunotherapy 
Fibroblast clusters including 5,414 cells from overall VIPER clustering of all cells were further 
isolated and sub-clustered (Fig. 31A), with differential protein activity and frequency pre-
treatment vs post-treatment compared as in the analysis of initial clustering for all cells. A 
proteomic gene set for each head and neck cancer-associated fibroblast (HNCAF) cluster was 
defined based on proteins differentially upregulated in each cluster.  In the dataset of clinical trial 
patients profiled by bulkRNASeq that had been annotated with subsequent response (n=9) or 
non-response (n=19) to ⍺PD-1 immunotherapy (39), we applied VIPER transformation using the 
single-cell ARACNe networks on z-score scaled log10(TPM) counts from pretreatment bulk-
RNA-Seq data, and computed a differential protein activity signature ranking proteins by most 
upregulated in responders to most downregulated in responders. Enrichment of each HNCAF 
cluster marker set in the VIPER-transformed signature of responders vs nonresponders from 
bulkRNASeq was computed by Gene Set Enrichment Analysis (GSEA), with normalized 
enrichment score and p-value determined by 1000 random permutations of gene labels (Fig. 
31D). Insufficient number of HPV+ samples prevented CAF enrichment analysis in HPV+ vs 
HPV- groups. 
 
Clinical association of HNCAF cluster 0 and cluster 1 signatures with outcome was further tested 
in TCGA head and neck cancer cohort processed by ARACNe and VIPER as above. Sample-by-
Sample Normalized Enrichment Scores were computed ranking VIPER-inferred protein activity 
in each patient sample from highest to lowest activity and then applying GSEA. Normalized 
Enrichment scores for HNCAF cluster signatures were binarized to less than zero (low) or 
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greater than zero (high), and Kaplan-Meier curve showing association with Overall Survival time 
was plotted along with the log-rank p-value (Fig. 36, Fig. 37), such that HNCAF-0 enrichment is 
associated with improved overall survival (p=0.014, median survival time = 602 days vs 1671 
days) and HNCAF-1 enrichment is associated with worse overall survival (p=0.011, median 
survival time = 1718 days vs 773 days). We further plotted the sample-by-sample enrichment of 
these HNCAF populations among different TCGA tumor types with high stromal involvement 
(HNSC, PAAD, SARC, UCS, BRCA, CHOL, LIHC) and plotted the distribution of these 
enrichment scores by tumor type to assess relative tumor-type specificity of the identified 
HNCAF signatures (Fig. 41). 
 
Digital Spatial Profiling 
NanoString GeoMX Digital Spatial profiling was further applied, profiling IO360 immune gene 
panel expression among three regions of interest (ROIs) from one patient and four ROIs from 
another. Anti-CD8, anti-⍺SMA, anti-PanCK, and DAPI stains were used for morphology 
identification and ROIs were selected based on high abundance of tumor (PanCK), cytolytic T 
cells (CD8), and fibroblasts (⍺SMA). ROIs were split into PanCK-positive and PanCK-negative 
components, with gene expression evaluated separately in each. In order to further assess spatial 
co-localization of HNCAF subtypes with functionally exhausted T-cells, we applied segment-by-
segment gene set enrichment of HNCAF-0 and HNCAF-1 markers as well as enrichment of a 
published T-cell exhaustion signature [123], and correlate normalized enrichment scores for 





In order to assess phenotypic concordance between prior fibroblast categorizations, including 
CAF-S1/S2/S3/S4 subtypes described in the setting of breast cancer [101] and iCAF/myCAF 
subtypes described in the setting of pancreatic cancer [33], we have performed pairwise gene set 
enrichment of fibroblast phenotype marker gene sets among our HNCAF clusters identified by 
scRNA-Seq. Published iCAF/myCAF VIPER-inferred marker gene sets [33] were directly tested 
by GSEA for enrichment in each single-cell, with resulting enrichment scores plotted by HNCAF 
cell cluster in Fig. 34C-D, such that cells in HNCAF-1 are enriched for iCAF signature and cells 
in HNCAF-2 are enriched for myCAF signature. For CAF-S1/S2/S3/S4 phenotype-matching, we 
sorted S1/S2/S3/S4 cells by FACS using the gating strategy described by [101] (Fig. 32), and 
subsequently performed bulk-RNA Sequencing of each sorted population, applied VIPER using 
single-cell derived ARACNe networks, and computed differential protein activity of each 
population against the mean to define population-specific signatures, with genes ranked from 
most differentially-upregulated protein activity to most differentially-downregulated protein 
activity in CAF-S1/S2/S3/S4. We then performed pairwise Gene Set Enrichment Analysis of 
HNCAF cluster marker gene sets (by VIPER protein activity) among CAF-S1/S2/S3/S4 gene 
signatures (Fig. 34A). We highlight the findings that CAF-S1 gene signature was significantly 
enriched for the gene sets of HNCAF-0 (NES=7.43, p=1.1 x 10-13), HNCAF-1 (NES=6.54, p=6 x 
10-11), and HNCAF-3 (NES=6.24, p=4.4 x 10-10), CAF-S2 gene signature was not significantly 
enriched for any HNCAF population, CAF-S3 signature was significantly enriched for HNCAF-
4 gene set (NES=3.09, p=2 x 10-3), and CAF-S4 signature was significantly enriched for 
HNCAF-2 gene set (NES=6.7, p=2.2 x 10-11). This phenotypic classification scheme is shown on 
Fig. 33D and highlights the distinction between our HNCAF categorization observed from 





Receptor-Ligand Interactions were inferred between coarse-grained cell types using 2,557 high-
quality receptor-ligand interactions reported in the RIKEN FANTOM5 database [124]. This list 
of receptor-ligand pairs was filtered to identify pairs where the ligand was significantly 
upregulated, at the gene expression level, in at least one subpopulation, across patients, and the 
corresponding receptor was significantly activated in another subtype, based on VIPER protein 
activity analysis, as proposed in [35]. We further filtered these interactions to those detected in 
cancer-associated fibroblasts and plotted the number of unique receptor-ligand interaction pairs 
inferred between fibroblasts and each other detected subpopulation (Fig. 29E).    
 
CAF isolation and culture 
Fresh head and neck squamous cell carcinoma tumor specimens were processed to single cell 
suspension as described above. For HNCAF-0/3, tumor single cell suspension was cultured in 
DMEM supplemented with 10% FBS, streptomycin (100 µg/ml), and penicillin (100 U/ml) for 
2-3 weeks at 37°C until fibroblasts grew out. For HNCAF-1, tumor single cell suspension was 
cultured in pericyte medium (ScienCell #1201) supplemented with 2% FBS, streptomycin (100 
µg/ml), and penicillin (100 U/ml) for 2-3 weeks at 37°C until fibroblasts grew out. To verify 
CAF identity, RNA was isolated from CAF lysates using TRIzol (Invitrogen #10296010) and 
sent for bulk RNA sequencing. Gene set enrichment analyses for the HNCAF subtype protein 
activity signatures were then performed on the bulk sequencing data, along with inference of cell 
type proportions by CIBERSORTx. Fibroblasts were passaged when cultures reached ~80% 




T cell isolation 
CD3+ T lymphocytes were isolated from the peripheral blood of healthy human donors. 
Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque Plus, following 
manufacturer’s instructions. CD3+ T cells were isolated from PBMCs using magnetic bead sort 
with the MojoSort Human CD3 T Cell Isolation Kit (Biolegend #480022) according to 
manufacturer’s instructions. For isolation of CD3+ tumor-infiltrating lymphocytes (TILs), fresh 
head and neck squamous cell carcinoma tumor specimens were processed to single cell 
suspension as described above. CD3+ tumor-infiltrating lymphocytes were isolated from the 
tumor single cell suspension using magnetic bead sort with the MojoSort Human CD3 T Cell 
Isolation Kit.  
 
T cell and CAF Coculture Assays 
25,000 primary CAF were plated in DMEM supplemented with 10% FBS in 96 well plates. 
After CAF had attached to the plate, 50,000 CD3+ T cells were added to the CAF with or 
without CD3/CD28 activation beads (Gibco # 11131D) and cocultured at 37°C for 5-7 days with 
or without 20 ng/mL TGFβ. Media was renewed on days 3 and 5. Cocultures with tumor-
infiltrating lymphocytes were only cultured for 3 days to preserve TIL viability. Following 
incubation, T cells were harvested and stained with Live/Dead Aqua (1:1600) for 15 minutes in 
PBS. Cells were then washed and stained for 15 minutes with an antibody cocktail containing 
anti-CD4-APC/Fire 810 (1:1000, SK3), anti-CD8-BB515 (1:200, RPA-T8), anti-PD-1-BV421 
(1:100, EH12.2H7), anti-TIM-3-BV786 (1:100, F38-2E2), anti-NKG2A-PE (1:200, S19004C), 
and anti-CD103 (1:400, Ber-ACT8). Cells were then washed, fixed, permeabilized and stained 
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with an intracellular antibody cocktail containing anti-Perforin-PerCP/Cy5.5 (1:100, B-D48) and 
anti-Granzyme B-Alex Fluor 700 (1:100, QA16A02). Cells were subsequently analyzed by flow 
cytometry using the Cytek Aurora.   
 
Transwell T cell and CAF Coculture Assays 
100,000 primary CAF were plated in DMEM supplemented with 10% FBS in the lower chamber 
of the transwell (0.4 µm pore size, Corning Polycarbonate Membrane Transwells #3401). 
200,000 CD3+ T cells were plated in DMEM supplemented with 10% FBS in the upper chamber 
of the transwell. Cells were incubated at 37°C for 7 days. Media was renewed on days 3 and 5. 
Following incubation, T cells were stained and analyzed by flow cytometry using the Cytek 
Aurora as described above.  
 
ELISA 
The level of IFNɣ in cell culture supernatants was measured using an ELISA MAX Deluxe kit 
(Biolegend #430104) following manufacturer’s instructions. Supernatants were collected from 
CAF-T cell cocultures as described above.  
 
Statistical Analysis 
All quantitative and statistical analyses were performed using the R computational environment 
and packages described above with the exception of CAF composition and co-culture 
experiments. Statistical analyses of these assays were performed using Prism 9 software 
(GraphPad). Differential gene expression was assessed at the single-cell level by the MAST 
single-cell statistical framework as implemented in Seurat v3 [32], and differential VIPER 
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activity was assessed by t-test, each with Benjamini-Hochberg multiple-testing correction. 
Comparisons of cell frequencies were performed by non-parametric Wilcox rank-sum test, and 
survival analyses were performed by log-rank test. In all cases, statistical significance was 
defined as an adjusted p-value less than 0.05. Details of all statistical tests used can be found in 














Chapter 5: Single-Cell-Derived Proteomic Signatures Strongly 
Predict anti-PD1 Response in CTLA-4 Naive and CTLA-4 Pre-
Treated Melanoma 
5.1 Summary 
Anti-PD1 Checkpoint immunotherapy has been transformative in the treatment of melanoma, 
and is now considered first-line therapy, with response rates of 40-45% in patients with 
melanoma given pembrolizumab or nivolumab in the first line [2]. To date, PD-L1 expression in 
tumor tissue has been the most-utilized biomarker for anti-PD1 response, yet this has been 
poorly predictive, with negative predictive value as low as 58% for anti-PD1 (nivolumab) and 
45% for combination with anti-CTLA4 immunotherapy (ipilimumab) [2]. Here, we leverage 
published single-cell RNA-Seq datasets profiling melanoma patients who did or did not respond 
to anti-PD1 checkpoint blockage [17] [18] in combination with a protein activity inference 
pipeline [35] and random forest feature selection, in order to identify a single-cell signature of 
inferred protein activity which is strongly predictive of anti-PD1 immunotherapy response across 
bulk-RNA-Seq datasets [7] [125]. Crucially, distinct predictive signatures were identified for 
treatment-naïve patients receiving anti-PD1 (nivolumab or pembrolizumab) as first-line therapy 
and for patients previously treated with anti-CTLA4 (ipilimumab). Optimal predictive power was 
achieved using immune cell population marker proteins, with out-of-bag training AUC in Riaz et al. 
for the treatment-naïve signature of 0.972 (95% CI 0.908 – 1.0), and out-of-bag training AUC in Riaz 
et al. for the CTLA4-experienced signature of 0.909 (95% CI 0.731 – 1.0). We independently 
validated these predictive models in the Liu et al. cohort, achieving an test AUC for treatment-naïve 
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signature of 0.839 (95% CI 0.733 -0.944), and a test AUC for CTLA4-experienced signature of 
0.893 (95% CI 0.771 – 1.0).  
 
5.2 Results 
We have identified two significant single-cell RNA-Sequencing datasets which profile melanoma 
patients who did or did not respond to anti-PD1 checkpoint immunotherapy. The first dataset 
includes 16,292 cells across 48 nivolumab-treated patients, including 31 non-responders and 17 
responders, defined by RECIST criteria [17]. The manuscript primarily focuses on characterization 
of changes induced in the melanoma micro-environment by treatment in responders versus non-
responders, but it also includes pre-treatment profiles from 8 subsequent responders and 10 
subsequent non-responders. Each sample includes only sorted CD45-positive immune cells. We have 
analyzed this subset of pre-treatment cells from subsequent responders vs non-responders by both 
gene expression clustering using the standard Seurat v3 pipeline, as well as by protein activity 
inference, as described previously in [35]. For clusters identifed by each method, we report their 
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frequency in responders vs non-responders and predictive value by random forest model with out-of-
bag AUC (Figure 43).  
 
 
Figure 43: Single-Cell Profiling of Melanoma Immune Infiltrate and Predictive Power 
with Respect to Anti-PD1 Response.  
A) UMAP Plot of Gene Expression based clusters from Pre-Treatment samples in Sade-Feldman et 
al, B) UMAP plot of VIPER Protein-Activity based re-clustering of data from A. C) Gene 
Expression heatmap of top5 differentially upregulated genes from clusters shown in A. D) Boxplot of 
frequencies for each immune population from A at baseline in subsequent responders vs non-
responders to immunotherapy. E) Boxplot of frequencies for each immune population from B at 
baseline in subsequent responders vs non-responders to immunotherapy. F) Out-of-bag AUC from 
random forest classifier of response vs non-response using frequencies of each cluster in A as 
features. 95% Confidence Interval is shown. G) Out-of-bag AUC from random forest classifier of 
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response vs non-response using frequencies of each cluster in B as features. 95% Confidence Interval 
is shown. 
 
In addition to these data, we have also identified a separate single-cell RNA-sequencing cohort which 
profiles 16 melanoma patients, including 15 non-responders and 1 responder [18]. This dataset did 
not pre-sort for CD45-positive immune cells and therefore included primarily tumor cells, which 
were identified in the original study for each patient, with significant batch effect across patients. The 
dataset includes 1,193 pre-treatment tumor cells. Therefore, we supplement the data from Sade-
Feldman et al. with the gene expression and inferred protein-activity profiles of these tumor cells. 
Notably, although gene expression based clustering of tumor cells showed strong batch effect 
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between patients, VIPER protein activity based clustering resolved batch effect into a smaller 
number of tumor cell phenotypes shared across patients (Figure 44).  
 
 
Figure 44: Single-Cell Profiling of Melanoma Tumor Cells Prior to Anti-PD1 
Checkpoint Immunotherapy.  
A) UMAP Plot of Gene Expression based clusters from Pre-Treatment tumor cells in Jerby-Arnon et 
al. B) Gene Expression heatmap of top5 differentially upregulated genes from clusters shown in A. 
C) UMAP Plot of VIPER Protein Activity based clusters from Pre-Treatment tumor cells in Jerby-
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Arnon et al. D) Gene Expression heatmap of top5 differentially upregulated genes from clusters 
shown in C. 
 
From single-cell RNA-Sequencing data, we first perform coarse clustering on gene expression, and 
generate clsuter-specific gene regulatory networks by ARACNe. With these, we run VIPER to infer 
cell-by-cell regulatory protein activity, and re-cluster [35]. We then generate for each cluster a 
signature of all regulatory proteins significantly up-regulated compared to the centroid of all clusters. 
We define this as the candidate Master Regulator feature set, generated separately for immune cells 
[17] and tumor cells [18].  
 
We transfer this single-cell information into the context of two larger bulk-RNA Sequencing cohorts 
by normalizing all bulk cohort gene expression to TCGA as an external reference, and inferring 
protein activity by VIPER using the single-cell-derived gene regulatory networks. To date, we have 
identified two major public datasets profiling both bulkRNASeq and Tumor Mutational Burden in 
melanoma patients treated with anti-PD1 immunotherapy, which allows direct comparison of our 
novel predictor to Tumor Mutational Burden as an independent predictor of immunotherapy 
response. These datasets are [7], and [125]. Both datasets contain treatment-naïve patients (N=23 and 
N=64, respectively) and patients previously treated with anti-CTLA4 checkpoint immunotherapy 
(N=26 and N=39, respectively), and report response to anti-PD1 checkpoint immunotherapy by 
RECIST criteria. We construct and report discovery of distinct predictive signatures for pre-treated 
and treatment-naïve patients, separately.  
 
Taking the full regulatory protein activity feature set identified from single-cell population markers, 
we first perform Boruta Random Forest Feature Selection to construct a machine-learning predictor 
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of treatment response in the Riaz et al. cohort, converging to a minimum set of proteins most strongly 
predictive of response to anti-PD1 immunotherapy. For treatment-naïve patients, this protein set 
consists of the following: (immune cell cluster markers: ASF1B, CD1E, CENPK, SPAG5, GMCL1, 
MED23,SLC19A1, TBC1D31,NEK4,ZGPAT, APAF1, PLAGL2, RBBP8, IFNAR1, STOML1, 
PLAA, MCMBP, MCM3, AKAP8, PEAK1, CDCA7L, RAB14, GOT2; tumor cell cluster markers: 
UHRF1, ASF1B, CENPK, IQGAP3, SPAG5, GMNN, DEPDC1, CDCA7L, TYMS, SLC19A1, 
FANCI, OXTR, ARHGAP25). For anti-CTLA4 pre-treated patients, the protein set consists of 
(immune cell cluster markers: KLRD1,CBLB, ZNF324B, TSHZ3, SLC1A5, PLCD1, RBBP8, 
SLC38A5, MCM6, PRDX4, CDK2, RAB18, NSFL1C, RRP8, ZNF747, EDARADD, CNIH1, 
CENPI, ZC3H12D, NCOA3, TAF4B, CERKL, CD84, ZNF292; tumor cell cluster markers: CD84, 
CXCL10, CD27, IPCEF1, LBH, SLC38A1, CCDC88C, FGFRL1, SHANK2, SHOX2, MCF2L, 
DAPK2, ZNF396, ICOSLG, MAP3K5). We evaluate the predictive power of each protein set in the 
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Riaz et al. cohort by out-of-bag AUC and validate independently in the Liu et al. cohort. The entire 
analysis pipeline is described in Figure 45.  
 
 
Figure 45: Analysis Pipeline For Selection of Treatment Response Predictive Signature in 
Bulk-RNA-Seq Data From Single-Cell RNA-Seq Immune and Non-Immune Master Regulator 




The protein activity of all immune and non-immune single-cell markers in responders vs non-
responders to anti-PD1 immunotherapy are visualized among the Riaz et al. cohort in Figure 46.  
 
 
Figure 46: Protein Activity of Top Predictive Immune and Non-Immune Feature Sets in 
Subsequent Responders vs Non-Responders to anti-PD1 Immunotherapy 
A) VIPER protein activity heatmap of tumor cell derived features most predictive of anti-PD1 
treatment response in CTLA4-naïve patients. B) VIPER protein activity heatmap of immune cell 
derived features most predictive of anti-PD1 treatment response in CTLA4-naïve patients. C) VIPER 
protein activity heatmap of tumor cell derived features most predictive of anti-PD1 treatment 
response in CTLA4 pre-treated patients. D) VIPER protein activity heatmap of immune cell derived 
features most predictive of anti-PD1 treatment response in CTLA4 pre-treated patients. 
 
Optimal predictive power is achieved with immune cell population marker proteins, with out-of-bag 
training AUC for treatment-naïve signature of 0.972 (95% CI 0.908 – 1.0), and out-of-bag training 
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AUC for CTLA4-experienced signature of 0.909 (95% CI 0.731 – 1.0). We independently validate 
these predictive models in the Liu et al. cohort, achieving an test AUC for treatment-naïve signature 
of 0.839 (95% CI 0.733 -0.944), and a test AUC for CTLA4-experienced signature of 0.893 (95% CI 
0.771 – 1.0). Predictive power for all feature sets alone and in combination is shown in Figure 47. In 
all cases this drastically improved over tumor mutational burden as a predictor of response to 
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immunotherapy, which never achieved statistically significant predictive power (maximum test AUC 




Figure 47: Predictive Power of Single-Cell-Derived Protein Activity Feature Sets For 
Classifying Response vs Non-Response to anti-PD1 Immunotherapy.  
A) For CTLA4-Naïve patients, ROC curves for (left-to-right) immune cell derived features, tumor 
cell derived features, and combination of both, showing AUC with 95% confidence intervals for out-
of-bag training data (top) and validation cohort (bottom).  B) For CTLA4 Pre-Treated patients, ROC 
curves for (left-to-right) immune cell derived features, tumor cell derived features, and combination 
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of both, showing AUC with 95% confidence intervals for out-of-bag training data (top) and 
validation cohort (bottom).   
 
5.3 Discussion 
Solid tumors consist of a heterogeneous micro-environment of tumor cells and immune cells, 
including various cytotoxic and immunosuppressive populations. Mechanisms of immune tolerance 
in tumors are common, most notably the activity of immune checkpoints that inhibit cytotoxic T-cell 
activity. In particular, the interaction between PD-1 and PD-L1 has been successfully targeted in the 
clinic by the anti-PD1 antibodies pembrolizumab and nivolumab. However, many patients evade 
response by engaging additional immunosuppressive factors, including recruitment of 
immunosuppressive cell populations. These mechanisms are incompletely understood, and there is 
currently a lack of clinically relevant predictors for treatment response.  
 
Existing predictors based on PD-L1 staining have shown poor predictive value of only and predictors 
based on mutational load and T-cell infiltration have been similarly limited [2], such that none to date 
are part of routine clinical care in prioritization of treatment options. The increasing use of 
immunotherapy in the first and second line across a range of tumor types means that identifying 
patients likely to respond to it could lead to dramatic improvement in clinical outcomes. More 
importantly, identifying patients unlikely to respond to immunotherapy could lead to prioritization of 
alternative therapies and rapid enrollment in combination therapy trials to overcome immunotherapy 
resistance.  
 
Our approach represents a novel pipeline for discovery of immunotherapy response predictors which 
also serves to identify potentially mechanistic regulators of response vs non-response, which may 
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directly suggest combination-therapy candidates to overcome resistance among patients predicted not 
to respond. Our approach presents specific advantages relative to previously reported biomarker 
approaches. Specifically, immuno-histochemical profiling is very limited in the number of markers 
which can be concurrently profiled by fluorescent-tagged antibodies, such that biomarker discovery 
is limited to cell markers already suspected to associate with clinical outcome a priori. This severely 
limits potential for novel biological insights. On the other hand, traditional bulk RNA-Sequencing is 
limited by its high background noise and inability to distinguish transcriptional contribution of 
different cell types, and single-cell RNA-Sequencing without our VIPER analytic approach suffers 
from substantial data dropout, with loss of up to 95% of genes in any given cell. Our approach 
enables cell-by-cell master regulatory protein discovery across all cells without dropout, profiling up 
to 6000 signaling and transcriptional regulatory proteins simultaneously, then selecting the most 
strongly predictive proteins by a random forest machine learning algorithm. This approach in itself is 
novel, and furthermore none of the proteins in the identified predictive signatures have been 
previously reported, highlighting their novelty and need for follow-up mechanistic studies. 
 
The chief advantage of the invention over existing approaches for predictive biomarker discovery is 
that we have shown a higher predictive area-under-the-curve than reported in any prior approach 
(genomic, transcriptomic, or immuno-histochemical). Furthermore, the fact that all proteins 
discovered to predict response to therapy with this approach are regulatory proteins active in 
modulating cell state opens up opportunity for a mechanistic rather than simply predictive 
understanding of response to therapy. In addition to providing an improved biomarker of response to 
anti-PD1 immunotherapy, the mechanistic nature of the discovered master regulators also represents 
a potential avenue for therapeutic intervention, both by direct targeting of discovered proteins 
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differentially activated among immunotherapy-resistant patients, and through drug screening for off-
target transcriptional effects predicted to invert the observed anti-PD1 resistance signature.  
 
Furthermore, although our current discovery has been made in the context of melanoma, as 
additional single-cell and bulk RNA-Sequencing data accrue across tumor types in the setting of 
immunotherapy-treatment, the predictive discovery approach we have developed may readily be 
extended to other tumor types and to broader development of treatment response biomarkers for 
other therapeutic regimens from master regulators of cell populations in the tumor immune micro-
environment. We are therefore working to continue these analyses in novel clinical datasets and 
planning to extend to datasets profiling response to immunotherapy in additional tumor types (e.g. 
renal cell carcinoma). We are also planning functional experiments knocking down the identified 
Master Regulators in the predictive response signatures to assess their therapeutic potential in an 
immune-competent mouse model. Ultimately, resistance-associated proteins in this predictive 
signature may be inhibited by a variety of pharmaceutical or gene therapy approaches, and we 
anticipate future utility of combining such treatments with anti-PD1 immunotherapy, with or without 






Chapter 6: Prostate Cancer Hormonal Therapy Induces a Complex 
Immune Infiltrate Counteracted by Influx of Tumor-Infiltrating 
Regulatory T-cells  
The following is adapted from:  
 
Obradovic, A. Z.*, Dallos, M. C.*, Zahurak, M. L., Partin, A. W., Schaeffer, E. M., Ross, A. E., 
Allaf, M. E., Nirschl, T. R., Liu, D., Chapman, C. G., O'Neal, T., Cao, H., Durham, J. N., 
Guner, G., Baena-Del Valle, J. A., Ertunc, O., De Marzo, A. M., Antonarakis, E. S., & 
Drake, C. G. (2020). T-cell infiltration and adaptive treg resistance in response to androgen 
deprivation with or without vaccination in localized prostate cancer. Clinical Cancer 
Research, 26(13), 3182–3192. https://doi.org/10.1158/1078-0432.ccr-19-3372 
  *These authors contributed equally 
 
6.1 Summary 
Statement of Translational Relevance: In preclinical models of prostate cancer, androgen 
deprivation therapy (ADT) promotes immunogenic cell death, transiently mitigates T cell 
tolerance to tumors and augments vaccine-induced antigen-specific CD8+ T cell responses. 
However, there are limited data on the immunologic effects of ADT on the tumor 
microenvironment (TME) in patients.  In a neoadjuvant trial, we treated men with high-risk 
localized prostate cancer with either ADT or ADT plus low-dose cyclophosphamide and a cell-
based vaccine (Cy/GVAX), prior to radical prostatectomy. ADT induced a complex immune cell 
infiltrate and increased intratumoral cytolytic CD8+ T cells.  However, this CD8+ T cell increase 
was accompanied by a proportional increase in FoxP3+ regulatory T cells (Tregs), proving strong 
evidence for adaptive Treg resistance. When given prior to surgery, Cy/GVAX modestly 
augmented the immunologic effects of ADT and decreased disease recurrence compared to ADT 
alone. These data support the observation that ADT has pro-inflammatory effects. However, these 





Purpose: Previous studies suggest that androgen deprivation therapy (ADT) promotes antitumor 
immunity in prostate cancer. Whether a vaccine-based approach can augment this effect remains 
unknown. 
 
Experimental Design: Therefore, we conducted a neoadjuvant, randomized study to quantify the 
immunologic effects of a granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting 
allogeneic cellular vaccine in combination with low-dose cyclophosphamide (Cy/GVAX) 
followed by degarelix versus degarelix alone in patients with high-risk localized prostate 
adenocarcinoma who were planned for radical prostatectomy. 
 
Results: Both Cy/GVAX plus degarelix and degarelix alone led to significant increases in 
intratumoral CD8+ T cell infiltration and PD-L1 expression as compared to a cohort of untreated, 
matched controls. However, the CD8+ T cell infiltrate was accompanied by a proportional increase 
in regulatory T cells (Treg), suggesting that adaptive Treg resistance may dampen the 
immunogenicity of ADT. Although Cy/GVAX followed by degarelix was associated with a 
modest improvement in time-to-PSA progression and time-to-next treatment as well as an increase 
in PD-L1, there was no difference in the CD8 T-cell infiltrate as compared to degarelix alone. 
Gene expression profiling demonstrated that CHIT1, a macrophage marker, was differentially 
upregulated with Cy/GVAX plus degarelix compared to degarelix alone. 
 
Conclusions: Our results highlight that ADT with or without Cy/GVAX induces a complex 
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immune response within the prostate tumor microenvironment. These data have important 
implications for combining ADT with immunotherapy. In particular, our finding that ADT 
increases both CD8+ T cells and Tregs, supports the development of regimens combining ADT 
with Treg-depleting agents in the treatment of prostate cancer.  
 
6.2 Introduction 
Prostate cancer remains the second most common cause of cancer-related mortality in men and 
definitive local therapy represents the only treatment modality with the potential for cure [126]. 
Despite advances in surgical approaches, patients with high-risk localized prostate cancer continue 
to have a high likelihood of disease recurrence following definitive local therapy [127] [128]. To 
date, no neoadjuvant therapy preceding prostatectomy has demonstrated sufficient efficacy to 
warrant FDA approval.  
 
In contrast to traditional therapies which decrease tumor bulk prior to surgery, immunotherapy has 
the potential to re-engage systemic anti-tumor immune responses, thereby eradicating distant 
micro-metastases. Although the development of sipuleucel-T for castration-resistant prostate 
cancer (CRPC) demonstrated the potential for immunotherapy in prostate cancer, immune 
checkpoint inhibitors have not yielded significant responses, except perhaps when used in 
combination [129] [130] [131] [132] [133] [134] [135]. One significant challenge to inducing anti-
tumor immunity in prostate cancer is the non-inflamed tumor microenvironment (TME) [136]. 
Prostate tumors also generally have a low mutational burden and low PD-L1 expression; these 
factors predict response to immunotherapy in other tumor types [37] [137]. In addition, prostate 
tumors demonstrate multiple mechanisms of immune escape including defective antigen 
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processing, decreased MHC class I expression, and infiltration with regulatory T cells (Tregs), 
myeloid-derived suppressor cells, and M2 macrophages [138] [139] [140] [141].  
 
Prostate GVAX is an allogeneic cell-based prostate cancer vaccine composed of two irradiated 
cell lines (PC3 and LNCaP) that have been genetically modified to secrete granulocyte-
macrophage colony-stimulating factor (GM-CSF) [138]. The release of GM-CSF by these 
modified tumor cells promotes the recruitment of dendritic cells and subsequent presentation of 
tumor antigens to T-cells with associated activation of anti-tumor immune responses. Prior 
randomized controlled trials of GVAX as monotherapy or in combination with docetaxel in 
mCRPC failed to show a survival benefit over chemotherapy, suggesting that allogeneic cell-based 
immunotherapy may be insufficient on its own to generate a robust T cell response against prostate 
cancer [138]. This may be particularly relevant in advanced metastatic CRPC, wherein a more 
immunosuppressive TME predominates [139]. However, preclinical studies demonstrate that 
administering low-dose cyclophosphamide prior to a cell-based GM-CSF-secreting vaccine can 
increase CD8+ T cell infiltration in the prostate, and transiently deplete regulatory T cells (Tregs) 
[140] [141]. These preclinical data are supported by clinical trials combining GVAX with low-
dose cyclophosphamide in breast cancer, colorectal cancer and pancreatic cancer [4] [142].   
 
In addition, prior studies in murine models show that castration results in de novo presentation of 
prostate-restricted antigens in tumor-draining lymph nodes, with transient mitigation of T cell 
tolerance [4]. ADT can also induce a pro-inflammatory immune cell infiltrate, supporting the 
hypothesis that androgen ablation may augment vaccine-induced effector T cell responses, 
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particularly during the peri-castration period [4]. Whether similar immune modulation occurs in 
patients remains poorly understood.  
 
To address these questions, we conducted a randomized neoadjuvant study to test the hypothesis 
that the combination of low-dose cyclophosphamide plus GVAX (Cy/GVAX) could augment the 
ADT-induced immune response in men with localized high-risk prostate cancer. The LHRH 
antagonist degarelix acetate was selected as ADT for this study based on its rapid onset-of-action 
allowing shorter time-to-surgery, lack of transient increase in testosterone reducing risk of tumor 
flare, and the observation that degarelix leads to a robust immune cell infiltrate in pre-clinical 
models, peaking around 2 weeks after administration [4].  A secondary endpoint of the study was 
to test whether ADT plus Cy/GVAX prolongs time to PSA recurrence as compared to ADT alone. 
We also sought to more deeply profile the immunological changes in the prostate TME mediated 
by ADT with or without Cy/GVAX.  
 
6.3 Results 
Thiry-two patients were recruited to the study with 16 randomized to each arm. 1 patient 
randomized to degarelix alone and 2 patients randomized to degarelix plus Cy/GVAX withdrew 





Figure 48: Clinical trial design and patient disposition diagram. 
Patients with high-risk localized prostate cancer (T1c–3b N0 M0, Gleason 7–10) were 
randomized 1:1 to degarelix (240 mg SQ) vs. Cyclophosphamide (200 mg/m2 IV) / GVAX 
(2.5×108 PC3 cells, 1.6×108 LNCaP cells) given 2 weeks before degarelix. All patients then 
underwent radical prostatectomy 2 weeks after degarelix. Abbreviations: Eastern Cooperative 
Oncology Group (ECOG); subcutaneously (SQ); intravenously (IV). 
 
 
15 patients received degarelix alone and 14 received degarelix plus Cy/GVAX (one patient in this 
group withdrew following cerebrovascular ischemia and was subsequently lost to follow-up). 
Clinical characteristics of the two treatment groups were similar with respect to age, risk status, 
Gleason sum, tumor stage, regional nodal involvement, and surgical margins (Figure 49). 64% of 
patients had Gleason ≥8 disease, 56% had pathological stage T3b, and 18% were found to have 






Figure 49: Patient baseline demographics and disease characteristics.  
Clinical variables for patients treated with degarelix alone versus degarelix plus Cy/GVAX. 
*Gleason sums for the histologic pattern of carcinoma range from 7-10 with higher scores 
indicating a higher-grade tumor. 
 
Safety 
Both degarelix alone and degarelix plus Cy/GVAX were well-tolerated. A single grade 3 ALT 
elevation was reported in the degarelix plus Cy/GVAX group, with no other treatment-related 
grade 3 or 4 adverse events reported (Figure 50). All enrolled patients successfully underwent 
radical prostatectomy, with no significant unexpected surgical complications or toxicities reported. 
Significant surgical complications were defined as blood loss in excess of 2500mL, operative time 
in excess of 3.5 hours, hospital stay in excess of 4 days or systemic symptoms including fever, 






Figure 50: Adverse events reported by treatment group. 
Adverse events for patients treated with degarelix alone versus degarelix plus Cy/GVAX were 
reported for all patients in the study, including one patient in the degarelix plus Cy/GVAX group 
that subsequently went off-study following cerebrovascular ischemia. 
 
Degarelix (ADT) Induces CD8 T Cell Infiltration with a Proportional Increase in Tregs  
Prostatectomy samples from both treatment arms, degarelix and degarelix + Cy/GVAX, showed 
significantly increased intratumoral CD8+ T cell density by IHC as compared to untreated 
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matched controls (Figure 51C). However, this CD8 infiltration was balanced by a proportionally 
increased infiltration with Tregs, such that the CD8/Treg ratio remained consistent across all 
treatment groups (Figure 51D, 51E). While there was a significant increase in both CD8+ T cell 
and Treg infiltrate with degarelix versus controls and degarelix + Cy/GVAX versus controls, 
there was no statistically significant difference between the degarelix and degarelix + Cy/GVAX 
treatment groups (Figure 51), suggesting that the GVAX vaccine did not induce additional CD8 





Figure 51: Degarelix and degarelix + GVAX increase CD8+ and FOXP3+ T cell 
infitration in prostate tumors. 
A) Representatitive H&E and immunohistochemistry (IHC) for CD8+ T cells, visualized at 4x 
and 20x magnification B) Representative H&E and IHC for FOXP3+ T cells, visualized at 4x 









represented in A. D) Boxplots of Log2(FOXP3+ T cell density), quantified from IHC as 
represented in B. E) Boxplots of the CD8+/FOXP3+ T cell ratio, quantified from IHC as 
represented in A and B. F) Table of mean CD8+ T cell density (cells/mm2), mean Treg density 
(cells/mm2), and CD8/Treg ratio for each treatment group and untreated controls, with 95% 
confidence intervals and p-values by Gleason-stratification-adjusted ANOVA reported for each 
comparison of groups; * = p<0.05, ** = p<0.01, and *** = p<0.005 
 
Since FOXP3 can potentially be expressed in other T-cell populations, we also analyzed our 
transcriptomic data to identify whether treatment led to increased expression of other Treg 
markers including GITR (TNFRSF18), CTLA-4 and CD25 (IL2RA). We observed increased 
expression of GITR, CTLA-4 and CD25 with both degarelix alone and degarelix plus Cy/GVAX 
compared to untreated controls (Figure 52). However, there was no difference in expression of 





Figure 52: Expression of Cytotoxicity and Treg related genes by treatment group. 
Violin-plots of log-scaled post-normalization Nanostring gene counts for specific genes of 
interest in each treatment group and untreated controls. GZMB (granzyme) and IFNG (interferon 
gamma) correspond to cytotoxicity-related genes, and show no statistically significant expression 
difference across groups. IL2RA (CD25), TNFRSF18 (GITR), and CTLA4, correspond to Treg-
related genes, such that expression of each gene is significantly up-regulated in both treatment 
groups relative to untreated control, but significantly different between treatment arms. Raw 
Wilcox test p-values are shown as * = p<0.05, ** = p<0.01, and *** = p<0.005. 
 
Increased PD-L1 Expression after GVAX Vaccination  
Consistent with prior reports, tumor cell PD-L1 expression was minimal in untreated patients 
(Figure 53). Degarelix alone appeared to modestly increase PD-L1 expression, consistent with the 
notion that cytokine secretion from infiltrating CD8+ T cells may drive up-regulation of immune 
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checkpoints.  Tumor samples from patients treated with degarelix + Cy/GVAX were found to have 
increased PD-L1 staining compared to patients treated with degarelix alone, with a higher 
proportion of samples exceeding 5% PD-L1 positivity (Figure 53); this trend was not statistically 
significant. Although there appeared to be some areas of PD-L1 staining in inflammatory cells in 
the stroma, the majority of cells staining positive for PD-L1 were tumor cells. Taken together, 
these data suggest that while the GVAX vaccine does not significantly increase CD8+ T cell 
density, the infiltrating immune cells induced by GVAX may be capable of promoting PD-L1 up-
regulation.  
 





A) Representative IHC for PD-L1, visualized at 4x and 20x magnification B) Stacked barplot of 
%PD-L1 positive cells, showing relative proportion of samples with 0% PD-L1 staining, <1% 
PD-L1 staining, <5% PD-L1 staining, and >5% PD-L1 staining in tumor cells in each treatment 
group and a cohort of untreated matched controls.  Distributions of %PD-L1 categories may be 
visually compared between groups, such that the degarelix + Cy/GVAX group has the highest 
proportion of samples with PD-L1 > 5%. Proportions of samples with %PD-L1 > 0 were also 
compared between groups by Fisher’s exact test, with p-values shown above the plot for each 
comparison, where * = p<0.05, ** = p<0.01, and *** = p<0.005. 
 
Degarelix and Degarelix plus Cy/GVAX Induce Complex Changes in Immune Gene Expression 
Pairwise differential gene expression was performed on normalized Nanostring data from 
prostatectomy samples, comparing untreated control patients, degarelix-treated patients, and 
degarelix + Cy/GVAX treated patients. This analysis identified 98 genes up-regulated in both 
degarelix and degarelix + Cy/GVAX vs control (Figure 54A). CHIT1, a macrophage activation 
marker, was the only gene significantly up-regulated in degarelix + Cy/GVAX vs degarelix (Figure 
54B) [143]. The CIBERSORT algorithm was used to de-convolute and infer the abundance of 
immune cell subtypes in each sample from Nanostring gene expression. Fractional contributions 
of immune cell populations were then compared between treatment groups (Figure 54C). These 
data show that a complex immune infiltrate was present in these prostatectomy samples at time of 
surgery, with significant populations of B cells, CD4 T cells, M1 macrophages, M2 macrophages, 
and mast cells. Summing the inferred abundance of each cell type yielded a total immune infiltrate 
estimate from gene expression data. Those data showed that that total immune infiltrate was 
significantly increased in both degarelix and degarelix + Cy/GVAX compared to control, but not 
in degarelix + Cy/GVAX as compared to degarelix alone (Figure 54D). CIBERSORT analysis 
also revealed an increased infiltrate of CD8+ T cells, M2 macrophages, and gamma-delta T-cells 
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in both treatment groups as compared to untreated controls, with a raw p-value < 0.05.  Although 
the CD8+ T cell increase is consistent with the IHC data (Figure 48), these differences based on 
gene-expression analysis were not statistically significant after adjustment for multiple testing 
(Figure 54E). To further assess whether treatment could increase T-cell activation, we evaluated 
interferon-γ and granzyme B expression levels and demonstrated no significant difference in 





Figure 54: Degarelix and degarelix + Cy/GVAX induce complex changes in immune gene 
signatures in primary prostate tumors. 






primary prostate tumors after degarelix, degarelix + Cy/GVAX, and untreated matched controls. 
Euler plots showing number of genes with Benjamini-Hochberg corrected t-test p-value < 0.01 
for each pairwise comparison of groups, such that “up-regulated genes” refers to genes that have 
higher mean frequency in the degarelix + Cy/GVAX group than in the degarelix group (cyan), 
higher mean frequency in the degarelix group than the untreated control group (purple), and 
higher mean frequency in the degarelix + Cy/GVAX group than the untreated control group 
(orange), and “down-regulated genes” refers to genes that have lower mean frequency in 
degarelix + Cy/GVAX vs degarelix (cyan), degarelix vs controls (purple), and degarelix + 
Cy/GVAX vs controls (orange), respectively.  B) Violin-plot of log-scaled post-normalization 
Nanostring gene counts for CHIT1 in each treatment group and untreated controls. In A, CHIT1 
is the sole gene significantly upregulated in each comparison. C) Boxplot of immune cell type 
absolute abundances as inferred by CIBERSORT, colored by treatment group and reported for 
all samples with CIBERSORT p-value<0.05. D) Violin-plot of total immune cell infiltrate for 
each sample by treatment group, such that total immune cell infiltrate represents the sum of 
CIBERSORT immune cell abundances as shown in C. E) Boxplot of immune cell populations 
for which t-test comparing abundance between groups showed an uncorrected p-value<0.05. P-
values were obtained by unpaired t-test with Benjamini-Hochberg multiple-testing correction and 
shown on B and D with * = p<0.05, ** = p<0.01, and *** = p<0.005. 
 
Degarelix plus Cy/GVAX is Associated with Clinical Outcome  
At 24 months post-prostatectomy, 69% of patients were free of PSA recurrence in the Cy/GVAX 
plus degarelix treatment group as compared to 40% in the degarelix-only group (Figure 49). Initial 
univariate cox regression of treatment group against time-to-PSA recurrence stratified by Gleason 
sum 7 versus Gleason sum greater than 7 yielded a hazard ratio of 0.44 (95% Confidence Interval 
0.13-1.43, p = 0.17), with time-to-next-treatment yielding a hazard ratio of 0.41 (95% Confidence 
Interval 0.13-1.36, p = 0.15). After determining informative clinical variables for prediction of 
time-to-PSA recurrence using backwards feature selection by the Akaike Information Criterion, 
multiple Cox regression was performed accounting for interactions between patient age, tumor 
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stage, Gleason sum, and treatment group. Using this regression analysis, treatment with Cy/GVAX 
plus degarelix showed an increased time to PSA recurrence as compared to that observed in 
patients treated with degarelix alone, with a hazard ratio of 0.29 (95% Confidence Interval 0.08-
1.00, p = 0.05) (Fig. 55A, 55B). Backward feature selection converged to the same set of clinical 
variables for prediction of time-to-next treatment, where there was a statistically significant 
treatment effect for degarelix plus Cy/GVAX compared to degarelix alone, with a hazard ratio of 
0.26 (95% Confidence Interval 0.071-0.97, p = 0.046) (Fig. 55C, 55D).  
 
Figure 55: Combination of Cy/GVAX with degarelix improves time-to-PSA recurrence and 
increases time-to-next treatment.  
A) Kaplan-Meier curves comparing time-to-PSA recurrence of patients treated with degarelix + 
Cy/GVAX vs degarelix alone. Informative clinical variables for multivariate analysis were 
selected by backward feature selection using the Akaike Information Criterion. B) Forest plot 
showing time-to-PSA recurrence hazard ratios with 95% confidence interval for multiple cox 







Gleason score. P-values for each variable are reported, as is the overall log-rank p-value, Akaike 
Information Criterion value, and concordance index for the regression C) Kaplan-Meier curves 
comparing time to next treatment for patients treated with degarelix + Cy/GVAX vs degarelix 
alone, with log-rank p-value reported from multiple cox regression of time-to-next-treatment 
against Cy/GVAX status, patient age, tumor stage, and Gleason score. Informative clinical 
variables were selected as in A D) Forest plot showing time-to-next-treatment hazard ratios with 
95% confidence interval for multiple cox regression of time-to-next-treatment against Cy/GVAX 
status, patient age, tumor stage, and gleason score. P-values for each variable are reported, as is 
the overall log-rank p-value, Akaike Information Criterion value, and concordance index for the 
regression. 
 
There was no significant difference observed between the two treatment groups in prediction of 
time-to-metastasis, where backward feature selection converged to a null model, and univariate 
cox regression with treatment group yielded a p-value of 0.46 (Figure 56). This may be due to the 
overall low rate of metastases in this patient population, with only 5 cases of metastasis observed 
across the two treatment groups (Figure 49). There was also no significant difference in time-to-
testosterone recovery between the two treatment groups (Figure 56), suggesting that the improved 
time to PSA recurrence cannot be accounted for by differences in the duration of a castrate level 
of testosterone. Correlation with recurrence is shown in Figure 57 for each variable considered in 
the first step of the backward feature selection model, such that CD8+ and FOXP3+ density as 
well as PD-L1 level were each negatively correlated with recurrence, but were not individually 
predictive of time-to-recurrence and were not additionally informative after accounting for 




Figure 56: No evidence for effect of Cy/GVAX on metastasis or time-to-testosterone 
recovery.  
A) Kaplan-Meier curves comparing time to metastasis for patients treated with degarelix + 
Cy/GVAX vs degarelix alone. When selecting for informative clinical variables by backwards 
feature selection as in Figure 55, Akaike Information Criterion converged on a null model with 
no informative variables, indicating that no set of clinical variables provided predictive value. 
Therefore, a univariate cox regression was performed of time to metastasis against treatment 
group, and the log-rank p-value for that regression is reported here.  B) Kaplan-Meier curves 
comparing time-to-testosterone recovery for patients treated with degarelix + Cy/GVAX vs 
degarelix alone. As in A, backwards feature selection of clinical variables converged to a null 
model with no informative features. Therefore, a univariate cox regression was performed of 








Figure 57: Correlation plot of clinical, genetic, and immunohistochemical features.  
Pairwise Pearson correlations between disease recurrence, clinical variables (treatment group, 
patient age, stage, gleason sum, very-high-risk status), CD8+ T cell and FOXP3 density as 
determined by IHC in Figure 51, CHIT1 gene expression (normalized Nanostring counts), total 
CIBERSORT immune infiltrate, and CIBERSORT M2 macrophage abundance, CD8 abundance, 
and Treg abundance, as determined from Nanostring profiling in Figure 53. 
 
6.4 Discussion 
This study demonstrates that neoadjuvant ADT (degarelix acetate) with or without the addition of 
GVAX immunotherapy and low-dose cyclophosphamide promotes a complex immune response 
within the prostate TME. Treatment was well-tolerated and did not lead to unexpected surgical 
complications, providing proof-of-concept for an immunotherapy-based neoadjuvant approach to 
prostate cancer treatment. Importantly, we found that ADT significantly increases the intra-
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tumoral CD8+ T cell infiltrate in prostate cancer. However, our comprehensive analyses of the 
immune TME showed that ADT induces other important immunologic changes, with both pro-
inflammatory and immunosuppressive effects. Perhaps most strikingly, we observed that the 
CD8+ T cell infiltrate was accompanied by a proportional increase in Tregs, a key 
immunosuppressive cell population that mediates immune resistance in multiple tumor types 
[144]. The addition of cyclophosphamide, which has previously been shown to transiently deplete 
Tregs, did not appear to significantly deplete Tregs in this setting.  The addition of Cy/GVAX to 
ADT did lead to a modest increase in PD-L1 expression as well as a statistically significant 
increase in the macrophage marker CHIT1, perhaps suggesting increased immunologic activity for 
the combination therapy. When accounting for patient age, tumor stage and Gleason sum in a 
multiple regression model selected by unbiased AIC backward feature selection [145] [146] [147], 
there were significant improvements in time-to-PSA recurrence and time-to-next therapy in 
patients treated with Cy/GVAX plus degarelix compared to degarelix alone, suggesting the 
possibility that the combination regimen has some clinical activity.    
 
Prior pre-clinical and clinical studies showed that androgen deprivation can re-model the immune 
TME in prostate tumors towards a pro-inflammatory state. Our group previously demonstrated in 
the MycCaP murine model that ADT initially leads to a pro-inflammatory immune cell infiltrate 
in prostate tumors with increases in CD8+ T cells, Tregs, macrophages and NK cells [4]. However, 
this infiltrate is transient and appears to dissipate with the emergence of castration-resistance. 
Other groups have also shown that androgen ablation can increase B-cell infiltration, which may 
promote progression to castration-resistance through B-cell-derived lymphotoxin production 
[148]. In patients, the androgen-receptor blocker flutamide was shown to induce T cell infiltration 
207 
 
and increase expression of pro-inflammatory immune-related genes (interferon-ɣ, TNF-⍺, 
Granzyme A) in prostate cancers when given prior to prostatectomy [143] [149]. Several prior 
studies have also investigated the use of neo-adjuvant vaccine-based immunotherapy approaches 
to enhance anti-tumor immune responses. For example, the autologous cellular vaccine, 
sipuleucel-T, was shown to promote lymphocyte recruitment and enhance TH1 responses when 
given in the neoadjuvant setting [150] [151].  
 
The findings reported here are largely consistent with these prior observations and suggest that 
ADT may prime prostate-specific T cell responses. We observed that ADT led to a robust increase 
in CD8+ T cells, which was not further enhanced by Cy/GVAX. One possible reason for the lack 
of further CD8+ infiltration with Cy/GVAX could be the allogeneic nature of the GVAX vaccine 
relative to the patients’ tumors. The vaccine cell line PC3 was originally derived from a skull 
metastasis, and LNCAP is originally derived from a lymph node metastasis, and it is possible that 
neither consistently shared tissue-specific antigens with the primary prostate tumors in the treated 
patients. It may also be the case that GM-CSF was insufficiently able to activate dendritic cells, as 
it has been found that modified versions of GVAX expressing dendritic cell activating molecules 
such as STING were far more effective in preclinical models [152]. It should also be noted that the 
prostate cancer microenvironment is particularly immunosuppressive, such that CD8 T-cells 
isolated from the prostate remain refractory to stimulation even in ex vivo experiments [153], 
indicating that improved depletion of Tregs may also improve response to GVAX. Of note, there 
was also increased PD-L1 expression with ADT, which did appear to be augmented by the addition 
of Cy/GVAX. The significance of this upregulation of PD-L1 is unclear but could reflect an 
adaptive response to interferon-ɣ produced by activated T-lymphocytes. Future mechanistic work 
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is required to better understand this observation. Furthermore, and consistent with the hypothesis 
that counter-regulatory mechanisms can function to maintain immune evasion, we observed an 
increase in Treg infiltration with ADT. This process of adaptive Treg resistance has not previously 
been described in the setting of neo-adjuvant ADT, although increases in Treg density have been 
observed in response to a range of therapies across a number of tumor types, highlighting the 
notion that adaptive Treg resistance may be a broad-based mechanism that can attenuate maximal 
responses to immunotherapy in patients with diverse malignancies.   
 
Interestingly, in both treatment groups, differential gene expression analysis showed that degarelix 
treatment upregulated CHIT1, a marker of macrophage activation shown to regulate many 
inflammatory processes through stimulation of inflammatory mediators such as IL8, MMP9, 
CCL2, CCL5, and CCL11, and correlated with levels of IL-1b and TNFa [154]. Given that 
macrophages are key antigen-presenting cells, this finding corroborates the notion that ADT 
enhances prostate-antigen presentation and thereby promotes prostate-specific T-cell responses. 
CHIT1 expression appeared to be further upregulated by the addition of Cy/GVAX to ADT.  
     
Limitations of this study include the relatively small number of patients in each treatment arm and 
our inability to capture serial immunologic changes within the prostate TME over time. We 
hypothesized that 2 weeks of ADT would be optimal to elicit robust immunologic responses, since 
pre-clinical data suggest that the immunologic effects of ADT are transient, with the initial immune 
infiltrate evolving over time into a more suppressive one, dominated by Tregs [4]. The optimal 
duration of ADT prior to radical prostatectomy remains unknown and it is possible that the single 
dose of degarelix acetate used in this study was insufficient to sustain a clinically significant 
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immune response. Our study used cyclophosphamide in combination with GVAX based on the 
hypothesis that low-dose cyclophosphamide would be capable of depleting Tregs and therefore 
augmenting an anti-tumor immune response. This approach was supported by preclinical studies 
which showed significant augmentation of anti-tumor immunity upon administration of 
cyclophosphamide approximately 24 hours prior to vaccination with GVAX [155] [156]. The 
dosage of cyclophosphamide used here reflects the dosage in a breast cancer study that also showed 
augmentation of anti-tumor immunity with administration of cyclophosphamide prior to a GM-
CSF secreting vaccine [157]. However, we observed no difference in Treg density with the addition 
of Cy/GVAX to degarelix. One possibility is that the dosing regimen of cyclophosphamide used 
in this study was not optimal for Treg depletion. Since the completion of our study, emerging data 
showed that oral cyclophosphamide may be more effective for Treg depletion [158] [159]. Given 
these limitations, future studies may be required to fully characterize the evolution of the immune 
TME over time and to optimize neoadjuvant immunotherapy in patients with prostate cancer. 
 
However, these results do provide important insights into the immunologic effects of ADT, either 
alone or in combination with an allogeneic cell-based vaccine. Importantly, the complexity of the 
immune response to ADT suggests that selectively targeting immunosuppressive cell populations 
may be essential for maximizing the immunogenicity of neoadjuvant ADT. The observation that 
ADT can induce adaptive Treg resistance provides a strong rationale for novel strategies aimed at 
depleting Tregs within the prostate TME. Finally, future mechanistic studies aimed at 
comprehensively understanding how androgen deprivation regulates anti-tumor immunity in 






Men with intermediate to high-risk localized prostate adenocarcinoma, defined as clinical stage 
T1c-T3b, N0, M0 and a Gleason sum ≥ 4+3 (grade group ≥3) in at least two cores were considered 
eligible if they were planning to undergo prostatectomy. All patients were required to have an 
Eastern Cooperative Oncology Group performance status of 0 or 1; and normal kidney, liver, and 
marrow function. Patients with nodal (N1) or distant (M1) metastases were excluded. Key 
additional exclusion criteria included prior immunotherapy or vaccine therapy for prostate cancer, 
prior radiation, hormonal, or chemotherapy, autoimmune disease requiring corticosteroids, or 
known allergy to cyclophosphamide or G-CSF/GM-CSF. Written informed consent was obtained 
from all patients, and studies were conducted in accordance with the U.S. Revised Common Rule 
and approved by Institutional Review Board.  
 
Study Design and Treatment 
Patients were randomized 1:1 to degarelix alone (240 mg subcutaneously) versus 
cyclophosphamide (200 mg/m2 intravenously) and GVAX (2.5×108 PC3 cells, 1.6×108 LNCaP 
cells) given 2 weeks before degarelix.  Randomization was stratified by Gleason sum: ≤7 vs 8-10. 
All patients underwent radical prostatectomy 2 weeks after degarelix (Figure 48). Prostatectomy 
specimens were assessed for Gleason grade, nodal involvement, and pathological stage using 
standard methods. Following pathological review of prostatectomy specimens, a tumor block was 
selected from the highest-grade tumor located in the prostate and microtome sections were 
prepared for biological analysis of the TME, including immunohistochemical staining for CD8, 
FOXP3, and PD-L1, with additional sections for expression profiling (Nanostring). In addition, a 
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contemporaneous cohort of matched-controls (Cohort C) who did not receive any neoadjuvant 
therapy provided untreated radical prostatectomy tumor samples, which were compared to post-
treatment prostatectomy samples from study Cohort A (degarelix alone) and Cohort B (Cy/GVAX 
plus degarelix) in genetic and immunohistochemical analysis. Patients were subsequently followed 
for biochemical (PSA) and metastatic disease progression.  
 
Outcomes:  
The co-primary endpoints of the trial were safety and CD8+ T cell density (CD8+ cells/mm2) in 
the prostate tumor tissue following neoadjuvant therapy. Safety was assessed using NCI Common 
Toxicity Criteria version 4.03. Secondary endpoints included feasibility, Treg density (FoxP3+ 
cells/mm2) in the prostate gland, CD8 to Treg ratio, time-to-PSA recurrence, time-to-next anti-
cancer therapy, and time-to-metastatic progression. Time-to-PSA recurrence was defined as the 
interval from time of prostatectomy to the time when the PSA was ≥0.2ng/mL for the first of at 
least two serial rises in PSA (≥2 weeks apart). 
 
Immunohistochemistry 
CD8 staining was performed by steaming slides for 45 minutes in Dako Target Retrieval Solution 
(Agilent Technologies, Inc, Wilmington, DE), followed by incubation with a mouse anti-human 
monoclonal anti-CD8 antibody for 45 minutes at room temperature (Agilent Technologies, Inc, 
Wilmington, DE). For FoxP3 staining, slides were steamed for 45 minutes in Dako Target 
Retrieval Solution (Agilent Technologies, Inc, Wilmington, DE) and then incubated with a mouse 
monoclonal anti-FoxP3 antibody overnight at 4C (eBioscience, San Diego, CA, 1:250 dilution). 
For CD8, the secondary antibody used was the UltraVision Quanto Detection System HRP DAB 
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(ThermoFisher, Waltham, MA). For Foxp3, the secondary antibody was the PowerVision+ kit 
(Leica Biosystems, Buffalo Grove, IL). Staining was visualized using 3,3’-Diaminobenzidine 
(DAB) (Sigma, Saint Louis, MO, FAST 3,3’-Diaminobenzidine Tablets) and slides were 
counterstained with hematoxylin. For CD8 and Foxp3, IHC stained slides were scanned using an 
Aperio ScanScope CS. Sections for tumor for image analysis were performed using ImageScope 
by selecting regions of invasive carcinoma and carefully excluding regions in which inflammatory 
infiltrates involved benign glands. CD8 and Foxp3 cell data were obtained using positive IHC cell 
counting algorithms implemented in Aperio Spectrum software by applying Hue, Saturation and 
Brightness (HSB) color space. Cell numbers were normalized to the overall areas/region of interest 
and annotated a trained pathologist to provide cell density, which was assessed for each patient 
and compared across study arms. PD-L1 IHC staining and scoring was performed as previously 
described [137]. Although some PD-L1 expression has previously been reported on immune cells 
in prostate cancer, such cells are morphologically identified as primarily macrophages; here we 
analyzed and report tumor-cell PD-L1 expression.  
 
Expression Profiling 
Immune gene expression in the prostate TME was profiled using the Nanostring IO360 Immune 
Panel [142]. Sufficient tissue for analysis was available from 13 patients from arm A (degarelix) 
and 12 patients from arm B (degarelix + Cy/GVAX) as well as 18 untreated matched-control 
patients. Nanostring count data were normalized by first thresholding to exceed mean + 1 standard 
deviation of negative controls, then scaling each sample by a positive control normalization factor 
to correct for total counts, and additionally, scaling with a set of pre-defined housekeeping genes, 
as described in the Nanostring documentation [144]. Three housekeeping genes (FCF1, POLR2A, 
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and TUBB) were excluded from the normalization process due to high cross-sample variance, and 
two additional genes (CC2D1B and GUSB) were excluded due to poor correlation with other 
housekeeping genes. This scaling corrected for background noise and differences in total gene 
count across samples, allowing for differential gene expression between groups to be calculated 
by unpaired t-test. For each pairwise comparison, we performed Benjamini-Hochberg multiple-
testing correction and reported the number of differentially expressed genes with p-value<0.05.  
 
Nanostring data were used to computationally infer an absolute abundance of immune cell types 
in each sample in order to compare the two study arms with each other and with the untreated 
group. These analyses were performed using the CIBERSORT algorithm, which de-convolutes 
gene expression matrices to a mixture of known immune cell types by fitting to a validated 
reference matrix of 22 immune cell subtypes, where each cell subtype has a defined set of 
differentially expressed genes [148]. This approach was limited by the fact that Nanostring profiles 
a limited set of targeted genes rather than the whole-transcriptome, so not all differentially 
expressed genes in the CIBERSORT reference matrix were captured. However, Nanostring 
specifically targets immune-related genes, and there are a significant number of differentially 
expressed genes captured for each immune cell subtype by the Nanostring panel.  CIBERSORT 
was able to de-convolute immune cell composition from these genes with a p-value of <0.05 for 
13 treatment arm A samples, 10 treatment arm B samples, and 12 untreated control samples.  
 
Statistical Analysis 
Our primary hypothesis was that men receiving Cy/GVAX followed by ADT would have a 2-fold 
(100%) increase in CD8+ T cell infiltration as compared to men receiving ADT alone. With 16 
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patients per arm, and assuming an 86% coefficient of variation for the average CD8+ T cell density, 
a one-sided 0.05 α-level t-test of the logarithms of these ratios would provide 82% power to detect 
a 2-fold (100%) increase in CD8+ T cell density between treatment groups. Thus, the trial was 
powered to recruit 32 patients, with a total of 29 patients ultimately recruited. The primary 
statistical endpoint of this study was CD8+ T cell density quantified by the number of nuclei of 
staining positive for CD8 per mm2. Following a log transformation, the mean CD8+ T cell 
densities were compared between treatment arms using a two-way analysis of variance (ANOVA) 
with the stratification variable, Gleason score, treated as a block factor. Event time distributions 
for PSA recurrence, time to metastasis, and time to next cancer treatment were estimated with the 
method of Kaplan and Meier and compared using a stratified Cox proportional hazards model. For 
all comparisons of differential gene expression, t-tests were applied to the normalized Nanostring 
counts matrix, and p-values corrected for multiple testing by the Benjamini-Hochberg method. 
Similarly, t-tests with Benjamini-Hochberg correction were applied to the inferred CIBERSORT 
immune cell abundance matrices, and to the IHC density values for CD8 and FOXP3. In a 
secondary analysis, hypothesis testing for unbiased association of clinical variables with time-to-
PSA recurrence and time-to-next treatment was performed using multiple Cox regression with 
backward feature selection using the Akaike Information Criterion [145] [146] [147], and 
visualized using hazard ratio forest plots and Kaplan-Meier survival curves. The same multiple 
Cox regression with backward feature selection was performed to test for association of clinical 
variables with metastasis and time to testosterone recovery (Figure 56). Pearson correlation was 
also calculated between all clinical, gene expression, and IHC variables as well as correlation of 
each variable with disease recurrence, visualized in Figure 57. Statistical analyses were performed 
using R version 3.5.3 and SAS version 9.2. 
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Chapter 7: Combination of Hormonal Therapy with 
Immunotherapy Induces T-cell Expansion in Metastatic and 




We and others have shown that the tumor microenvironment (TME) in primary prostate and 
castration-resistant prostate cancer (CRPC) are relatively void of immune cells. Treatment with 
Androgen Deprivation Therapy (ADT) is known to induce a complex immune infiltrate in 
localized prostate cancer, in both animal models and humans. The baseline features of the TME 
and tumor cells in metastatic tumor sites and the effect of ADT alone or in combination with 
checkpoint blockade in metastatic, hormone-sensitive prostate cancer (mHSPC) have not been 
well-described. Here, we present single-cell RNA-sequencing data of longitudinal metastatic 
tumor biopsies at baseline and on-treatment from patients enrolled on our phase 2 clinical trial 
(NCT03951831), which aims to test the hypothesis that ADT-induced immune infiltrate can be 
further augmented with anti-PD-1 inhibition in men with mHSPC. Using protein activity 
inference, we comprehensively describe the baseline TME and tumor sub-clusters, highlight 
significant changes induced with treatment, and features of both the immune micro-environment 
and tumor cells themselves associated with differences in clinical response. We describe a 
treatment-resistant tumor sub-cluster phenotype that increases in frequency at time of metastatic 
progression, markers for which are enriched across several bulk-RNA-Seq cohorts in patients 
with worse clinical outcomes. Our study outlines several potential druggable targets in this tumor 
216 
 
population and in resistance-associated immune populations which may advance treatment and 
improve outcomes for men with mHSPC.   
 
7.2 Introduction 
Localized prostate cancer (PC) is an immunologically ‘cold’ tumor microenvironment (TME) 
with a relative dearth of immune cells compared to other tumor types [160] [161]. Preclinical 
studies and analyses of human primary PC samples show that the immune cell infiltration that 
does exist is likely immune tolerant and suppressive given the presence of terminally 
differentiated cytotoxic T cells and T regulatory cells [153] [162] [163]. Several studies show 
that androgen deprivation therapy (ADT), the backbone of therapy for advanced prostate cancer, 
induces immunogenic changes in the TME of hormone-sensitive prostate cancer. This is due to 
several mechanisms including: thymic regeneration and increased production of naïve T cells; 
decreased tolerance and clonal expansion of effector T cells; stimulation of an antigen-specific 
adaptive immune response; and by driving a robust and functional immune infiltrate into primary 
prostate tumors with chemokine and cytokine secretion [164] [12] [149] [165] [166] [4] [167] 
[168] [169] [170] [171]. However, these favorable effects on the immune system are not durable, 
and they are often counter balanced by a concomitant increase in immunosuppressive cell 
compartments or interference with T cell priming [4] [172] [173] [174]. Therefore, combination 
therapy with ADT and immunotherapies that leverage the positive immune effects and mitigate 
the immunosuppressive compartments induced by ADT makes rational sense. Investigating the 
optimal timing and sequencing of specific combination therapies for men with prostate cancer is 




Most preclinical and translational studies evaluating the immunogenic effects of ADT to date 
have focused on primary prostate cancer. The TME of metastatic hormone-sensitive prostate 
tumors has not been well characterized, nor have the effects of ADT pressure on the TME of 
metastatic tumors. This is likely due to the challenges associated with tissue acquisition from 
metastatic tumor biopsies. It is not known whether metastatic hormone-sensitive tumors have 
immunologically ‘cold’ TMEs like primary prostate cancer. Studies using digital spatial imaging 
and single-cell sequencing show that there is a paucity of immune cells in the more advanced 
castrate-resistant setting, like primary PC [175] [176]. Data comparing PD-L1 protein expression 
between primary and metastatic castrate-resistant prostate cancer (mCRPC) show that there were 
notable differences between the two disease stages (7.7% of cases had detectable PD-L1 
expression in primary PC and 31.6% of mCRPC cases had detectable expression) [137]. Whether 
the TME differs by metastatic niches, or the changes induced by ADT pressure are similar across 
all metastatic niches is also not well described. 
 
In this study, we comprehensively characterized the TME and tumor cells of metastatic 
hormone-sensitive prostate cancer across several metastatic niches (bone, lymph node, liver, and 
lung) using high-throughput droplet-based single-cell RNA sequencing (scRNASeq) and our 
previously developed pipeline for Virtual Inference of Protein Activity by Enriched Regulons 
(VIPER) [26] [21] [35]. This has enabled deep sub-clustering of immune cell subpopulations and 
tumor cells as well as amplification of biological signal-to-noise to eliminate data dropout for 
key regulatory and signaling proteins. We apply this method to a series of paired metastatic 
tumor biopsies (baseline and on-treatment) from eight patients enrolled in a phase 2 clinical trial 
that is testing the activity of ADT and an anti-PD-1 antibody (cemiplimab-rwlc) with docetaxel 
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in men diagnosed with metastatic hormone-sensitive prostate cancer (NCT03951831). In 
addition to characterizing the differences in TME composition across baseline samples by 
metastatic site, we also investigated TME and tumor cell transcriptional perturbation and 
phenotypic changes with treatment, either with ADT alone or ADT plus anti-PD-1 therapy. We 
next highlight associations between early PSA responses and characteristics of the baseline TME 
composition and tumor cells. Finally, we apply the CLIA-certified OncoTarget algorithm for 
inference of druggable proteins active in tumor cell sub-clusters at the single-cell level to reveal 
candidate drugs for upfront treatment of tumor cells associated with treatment resistance, and we 
performed gene set enrichment analysis (GSEA) testing association of distinct tumor cell sub-
cluster gene sets with recurrence-free survival outcomes in external, publicly available datasets.  
 
7.3 Results 
Gene expression and protein activity clustering reveal a robust immune infiltrate in 
metastatic hormone-sensitive prostate cancer. Given that primary prostate cancer (PC) is a 
relative immune desert with low proportions of immune cell subpopulations [160] [161], we 
sought to determine if the tumor microenvironment (TME) in patients with metastatic hormone-
sensitive prostate cancer was similarly immunologically ‘cold’. We collected baseline, pre-
treatment metastatic needle-core biopsies from 10 patients (Figure 58) across 4 different 
metastatic niches (bone, lymph nodes, liver, and lung), isolated and analyzed all live cells using 






Patient Biopsy Location Baseline (no. cells) ADT only (no. cells) ADT + aPD-1 (no. cells) Recurrence (no. cells) 
1 Bone 2360 0 686 0 
3 Bone 1027 995 0 764 
5 Lymph Node 4090 5153 0 0 
6 Liver 0 0 2475 0 
7 Lung 699 0 1956 0 
8 Bone 606 1784 0 0 
10 Bone 521 0 97 0 
12 Bone 0 913 0 0 
13 Lymph Node 1212 0 0 0 
14 Liver 2161 0 0 0 
Figure 58: Tissue site and cellular yield per biopsy sample. 
 
We performed both gene expression-based clustering and protein activity-based clustering, using 
VIPER [35]. We correlated these scRNASeq data to a preexisting dataset of lineage-sorted bulk 
RNA sequencing with SingleR, commonly used to phenotype single-cell subpopulations [48]. 
Gene expression-based clustering revealed 15 overall clusters across all metastatic sites, 
including 12 distinct immune cell clusters, as well as fibroblasts, endothelial, and epithelial 





Figure 59: Gene Expression Clustering 
A) UMAP plot showing clustering of all cells in tumor micro-environment across all patients, 
clustered on gene expression instead of VIPER-inferred protein activity. Cell types are inferred 





Clustering was performed using the Seurat Louvain algorithm with resolution optimized in the 
range of 0 to 1 at increments of 0.01 by sub-sampled silhouette score [35]. Clusters were 
visualized using 2D UMAP dimensionality reduction. Inspection of the top five most 
differentially upregulated transcripts by cluster (Figure 60) further confirmed the ascribed 
cellular identity of clusters assigned by SingleR.  
 
 
Figure 60: Top Gene Expression Cluster Markers 
Heatmap of top 5 most differentially upregulated genes for each cell type cluster from aggregate 
single-cell RNA-Sequencing data across all patient samples, with clusters corresponding to 
Figure 59. Each row represents a protein, grouped by cluster in which they are the most active, 





For example, granzyme M (GZMM) and natural killer granule 7 (NKG7) were differentially 
upregulated in CD8 T cells, and CD37 in B cells. The sorted bulk RNA seq reference used by 
SingleR does not contain tumor cells, therefore tumor cells with epithelial origin such as prostate 
cancer cells are labelled by SingleR as ‘epithelial cells.’ These can then be confirmed as tumor 
cells by expression of tumor marker genes such as KLK3 and presence of inferred Copy Number 
Variations (Figure 61).  
 




A) log10 normalized expression of prostate cancer tumor marker protein KLK3 in each cell 
cluster identified by VIPER, such that expression is non-zero only in Epithelial cell clusters. B) 
InferCNV plot of cell-by-cell copy number variations, where all immune-lineage cells are taken 
as a copy-number-normal reference for inference of variations in copy number in Epithelial cell 
clusters and Endothelial cell cluster as a control. Each epithelial cell cluster is notable copy 
number aberrant across multiple chromosomes, while endothelial cells are grossly copy number 
normal. 
 
Due to high levels of data dropout, single-cell RNA-Seq is inherently noisy, and we therefore 
employed a previously published analysis pipeline which uses the VIPER algorithm for inference 
of protein activity from single-cell gene expression data to mitigate dropout and amplify 
detection of transcriptional regulatory proteins and signaling molecules through their effect on 
downstream transcriptional state [35]. We re-clustered on inferred protein activity to increase 
resolution of the immune and stromal cell subpopulations. This analysis revealed 24 distinct 
protein activity-based clusters, primarily immune cells but also including erythrocytes, 




Figure 62: Baseline Composition of Micro-Environment by Tissue Site. 
A) Uniform Manifold Projection (UMAP) plot constructed from VIPER-inferred protein activity 
of all cells in aggregate across baseline pre-treatment patient samples. Cells are clustered by 
resolution-optimized Louvain algorithm with cell type inferred by SingleR B) Stacked barplot of 
the frequency of each major cell lineage within each baseline patient sample, with each column 
representing a unique patient and patients grouped by metastatic site. Cell clusters from A are 
aggregated by shared cell type. C) Stacked barplot of immune vs non-immune cell frequencies, 
from B. D) Boxplot showing distribution of frequencies for each cell cluster in A at baseline, 
comparing tissue sites. 
 
VIPER increased granularity with respect to the number of myeloid, lymphoid, and epithelial 
clusters compared to gene expression clustering. While gene expression clustering yielded only 
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one large homogeneous monocyte / macrophage combined cluster, VIPER-based protein activity 
inference showed three distinct monocyte cellular subpopulations, one each of macrophage and 
neutrophil clusters. Additionally, there was further refinement of the T cell clusters specifically 
with additional clusters of T-regulatory (Treg) and CD8 T cell clusters using protein activity-
based analysis compared to gene expression. Furthermore, five B cell clusters and one plasma 
cell cluster were identified with VIPER as compared with one and two clusters, respectively, 
with gene expression. Overall, the mean proportion of immune cells across all metastatic sites 
was 87% (range: 30.9% [lung] – 94.6% [lymph node]) and exceeds the sparse immune 
infiltration typically seen in primary prostate cancer [163] [177].  
 
Protein activity reveals distinct differences in immune cell subpopulations in different 
metastatic sites. The proportional composition of immune cell subpopulations in the TME can 
vary depending on the tissue type [178] [179]. To compare cellular composition across different 
metastatic sites, we collapsed the initial 24 VIPER clusters into eight lineage-specific meta-
clusters (e.g., B cells, CD4 non-Treg, CD8, endothelial, erythrocyte, myeloid, Treg, and tumor) 
and visualized frequencies across the four different metastatic sites prior to treatment with ADT 
or anti-PD-1 therapy (Figure 62B, 62C). Overall, bone, liver, and lymph node were more 
immune infiltrated, with mean proportion of immune cells of 90.5% and 77.9%, and 94.6% 
respectively, compared to 30.9% in lung. We next compared the frequency of the 24 different 
cellular subpopulations identified across the four different metastatic sites (bone, lymph node, 






Figure 63: Top Protein Activity Cell Cluster Markers 
Heatmap of top 5 most differentially activated proteins for each cell type cluster from aggregate 
single-cell RNA-Sequencing data across all patient samples. Each row represents a protein, 
grouped by cluster in which they are the most active, with cluster labels on the x and y-axes. 
Each column represents a single cell. Above the x-axis cluster label there is also a treatment label 
indicating timepoint at which a given cell was profiled. 
 
In the bone samples, as expected, more plasma cells were seen relative to other sites. 
Additionally, there was an increased frequency of monocytes (monocytes 1 and 2) relative to 
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other metastatic sites, with increased protein activity of transcriptional repressors (BATF3), 
transcriptional activators (SH3BP2), protein members in G-protein signaling (RGS18), and 
serine proteases (PRTN3). We also saw a large population of erythrocytes in the bone metastases 
with high protein activity of epithelial cell transforming 2 (ECT2), Rho GTPase Activating 
Protein 11A (ARHGAP11A), and Kinesis Family Member 14 (KIF14), proteins that are involved 
in mitosis, cell-cycle arrest, and microtubule motor proteins respectively. These likely represent 
dividing erythroid progenitor cells in the bone marrow captured incidentally by the process of 
bone marrow biopsy. In lymph node samples, a robust B cell population was seen (B cell 2). 
There was also a higher proportion of T regulatory cells (Treg 3), with elevated activity of 
TNFSRF18 (GITR), in the lymph nodes compared to other metastatic sites. Of interest, this 
specific T regulatory population had high activity levels of ETS Variant Transcription Factor 1 
(ETV1) which is a gene known to be overexpressed in prostate cancer [180] [181]. To our 
knowledge, this has not been previously described in T regulatory cells of prostate cancer tumor 
metastases and supports recent findings that immune cells can express tumor marker genes [182]. 
The liver metastases had immune infiltrations similar in both overall proportion and in 
subpopulation frequencies to bone metastases. Notably across all tissues there was a large 
proportion of CD8 T cells (CD8 T cell 1 and 2) and CD4 non-Treg T cells (CD4 T cell 1). The 
CD8 T cell 2 cluster was chiefly defined by increased protein activity of lymphocyte activation 
gene 3 protein (LAG3), an inhibitory immune receptor [183]. Finally, the single lung metastasis 
profiled was notably the most immune depleted at baseline, with only 30.9% immune cells 
overall.  
 
Treatment with combination ADT and anti-PD-1 results in a dramatic expansion of CD8 T 
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cells across several metastatic sites. To compare the immunologic effects of ADT alone and 
ADT plus anti-PD-1 (cemiplimab-rwlc) in the TME of the four different metastatic sites, we 
compared cluster frequencies and visualized changes in the microenvironment by UMAP plots 











Figure 64: Treatment with ADT+aPD1 Induces Dramatic Changes in the Tumor 
Micro-Environment 
A) UMAP plot of all cells from patients with metastatic Bone lesions, split by treatment time-
point (Baseline, ADT-only, ADT+aPD1, and post-treatment Recurrence) and labelled by cell 
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cluster. B) Stacked barplot showing the relative frequency of each major cell lineage by 
treatment time-point for patients with metastatic Bone lesions, with each column representing 
aggregate of all samples profiled at a specific treatment time-point. C) UMAP plot, as in A, for 
patients with metastatic Lymph Node lesions. D) Stacked barplot, as in B, for patients with 
metastatic Lymph Node lesions. E) UMAP plot, as in A, for patients with metastatic Liver 
lesions. F) Stacked barplot, as in B, for patients with metastatic Liver lesions. G) UMAP plot, as 
in A, for patients with metastatic Lung lesions. H) Stacked barplot, as in B, for patients with 
metastatic Lung Lesions. I) Boxplot showing distribution of frequencies for each cell cluster, 
comparing frequencies across treatment time-points including Baseline, ADT-only, and 
ADT+aPD1. 
 
All patients on the clinical trial were required to have a baseline metastatic biopsy as well as an 
on-treatment biopsy. Patients were randomized to one of two time points for the on-treatment 
biopsy, either four weeks after beginning ADT (degarelix) initiation or after ADT plus two 
cycles of anti-PD-1 antibody. Tumor biopsies at the time of disease progression were optional. In 
each patient, the same site of disease was sampled for both the baseline and on-treatment 
biopsies to compare changes in the TME within the same tissue type. Overall, enough patients 
with bone and lymph node metastases were enrolled to enable collection of biopsy samples at 
baseline and both on-treatment time points. Critically, we were also able to obtain a tumor 
progression biopsy from a patient with subsequent tumor recurrence in the bone after 11 months 
on treatment. Liver and lung biopsy samples were collected at baseline and after ADT with two 
cycles of anti-PD-1. No patients with lung and liver metastases were randomized to have their 
on-treatment biopsy after ADT alone.  
 
Treatment pressure can induce complex changes in the TME. We thus used our single-cell data 
to interrogate the dynamic shifts in cellular composition with ADT and ADT plus anti-PD-1 as 
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compared to baseline samples. Collapsing sub-clusters into B-cells, CD4 non-Tregs, Tregs, CD8 
T-cells, Myeloid cells, Endothelial cells, Erythrocytes, and Tumor cells, we have characterized 
changes induced in the tumor micro-environment by treatment in each metastatic tissue site. In 
the bone, treatment with ADT resulted in an increased proportion of myeloid cells with a relative 
decrease in CD4 non-T reg cells and tumor cells (Figure 64A-B). However, myeloid cell 
abundance decreased with a concomitant dramatic increase in CD8 T cells after treatment with 
the combination of ADT and anti-PD-1. In the single bone tumor progression biopsy, the relative 
frequencies of each cell type returned to a distribution resembling the baseline samples, albeit 
with a greater proportion of tumor cells. In the lymph node samples, treatment with ADT 
resulted in a mild expansion of CD4 non-Treg cells (Figure 64C-D). Unlike the bone samples, 
myeloid cells were not expanded in the lymph node with ADT alone. These findings confirmed 
our suspicion that treatment-induced immunologic changes vary based on the metastatic niche 
and that different strategies to alter tumor immunology may be warranted depending on the site 
of disease. Few cells were recovered in lymph nodes after the combination of ADT and anti-PD-
1. However, of the cells recovered, there was a greater proportion of Treg cells and myeloid 
cells, with virtually no CD8 T-cells or B cells present. Surprisingly, in both the bone and lymph 
nodes, there was a relative increase in tumor cells after the combination of ADT and anti-PD-1 
compared to baseline and ADT only samples. This is in contrast to observations from the viscera 
(liver and lungs), where combination ADT and anti-PD-1 demonstrated a substantial reduction 
in the overall proportion of tumor cells (Figure 64E-H). Additionally, the expansion of the 
myeloid compartment seen in bone samples after ADT alone and in the lymph nodes with 
combination therapy was not observed in the viscera (liver and lungs). However, similar to the 
bone samples, there was a dramatic increase in the CD8 T cells with combination of ADT and 
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anti-PD-1 therapies in the liver and lung samples, which was not seen in either case with ADT 
alone.  
 
In fact, the only tissue site in which dramatic expansion of CD8 T-cells with combination 
therapy was not observed was lymph node, which was also severely limited in sample size in 
terms of the number of cells profiled from the treatment time-point following combination ADT 
and anti-PD1. Taken together, these data demonstrate that anti-PD-1 immunotherapy increased 
CD8 T cell infiltration into metastatic sites in combination with ADT to an extent that was not 
observed with ADT alone. Further interrogating the relative expansion or depletion of each cell 
sub-cluster in response to treatment reveals a few specific phenotypes most responsive to therapy 
(Figure 64I). Overall, after ADT alone, the median level of CD8 T cells cluster 2 decreased 
relative to baseline (p=0.034), while there was a concordant increase in monocytes (p=0.036). 
Notably after treatment with ADT and anti-PD-1 we observed a dramatic expansion in CD4 T 
cells cluster 1 (characterized by high protein activity of TNF; Figure 63), CD8 T cells cluster 2 
(characterized by high protein activity of LAG3; Figure 63), and Treg cells cluster 3 
(characterized by high protein activity of TNFRSF18; Figure 63), with p-value = 0.033, 0.026, 
and 0.008, respectively. These three populations represent the bulk of tumor-infiltrating immune 
cells induced by anti-PD1 therapy.  
 
Association of immune subpopulations at baseline with subsequent PSA response.  
We sought to compare baseline cellular subpopulation frequencies by treatment response to 
determine if the presence of any subpopulations at baseline was associated with PSA response to 
therapy as a potential biomarker or mechanistic target for depletion in therapy-resistant patients. 
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We first categorized patients into three treatment response groups (early PSA response, stable 
disease, or late progressors) based on PSA log10 fold-change (Figure 65A), such that early 
responders represent patients with excellent rapid decrease in PSA to below 1% of initial value, 
indicating excellent response to therapy, and late progressors represent patients who initially 
respond to therapy with a decrease in PSA level but begin a rapid increase in PSA by week 28. 
We then compared the frequencies of each cell cluster between patients categorized as ‘early 
responders’ versus ‘late progressors’  
 
 
Figure 65: Differences in Baseline Immune Composition Associate with Differences 
in Treatment Response 
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A) Spider-plot of log10(Fold-Change) from Baseline in Prostate-Specific Antigen (PSA) over 
time with treatment, for each patient, such that three patients, labelled in blue, exhibited rapid 
and dramatic decrease to below 1% of initial PSA and were identified as Early Responders to 
treatment, and two patients, labelled in orange, initially responded to treatment with a rapid 
increase in PSA observed after on-treatment week 28. These were considered Late Progressors 
on-treatment. The remaining patients, in grey, generally trended toward a decreasing PSA, 
though not as rapidly as the Early Responders. B) Boxplot showing distribution of frequencies at 
Baseline for each cell cluster, comparing frequencies in Early Responders vs Late Progressors, 
such that clusters with significant difference at baseline (p<0.05 by Student’s T-test) included 
CD4 T-cell 1, CD8 T-cell 2, Treg 3, and Epithelial 2. 
 
Overall, higher levels of CD8 T cells cluster 2 at baseline were significantly associated with an 
early PSA response (p = 0.007). Interestingly, this is the same population of LAG3+ CD8 T-cells 
expanded by anti-PD1 immunotherapy. Additionally, we found that the specific subpopulation of 
TNFRSF18+ T regulatory cells (Treg cluster 3) was also associated with an early PSA response, 
though not with statistical significance (p = 0.14). Conversely, CD4 T cells cluster 1 was 
significantly associated with late PSA progression (p = 0.026). One of the most differentially 
active proteins by VIPER in CD4 T cell 1 cluster was tumor necrosis family (TNF), a 
multifunction proinflammatory cytokine implicated in tumor progression [184] [185] [186]. 
These data may suggest modulation of TNF as a potentiating adjunct to the administered 
combination ADT plus anti-PD1 therapy.  
 
Tumor cell clustering revealed a phenotypic shift in tumor cells across metastatic sites and 
with treatment. Initial analysis of tumor cells by protein activity-based clustering resulted in 
three ‘epithelial’ clusters (epithelial 1, epithelial 2, and epithelial 3). As discussed, we performed 
copy number alteration (CNA) inference and profiling of KLK3 prostate tumor marker 
235 
 
expression to confirm that the three epithelial clusters indeed represented tumor cells (Figure 61). 
Tumor cells were identified in all baseline samples across metastatic sites and all three epithelial 
/ tumor clusters were observed in bone, lymph node, and lung samples. In order to provide more 
granularity of the transcriptomic program in all tumor cells across different metastatic sites, we 
pursued additional sub-clustering of the tumor cells after excluding all other cell types. This 
analysis yielded eight tumor sub-clusters (Figure 66A).  
 
Figure 66: Sub-Clustering Reveals Heterogeneity of Tumor Cells by Tissue Site 
A) UMAP plot showing sub-clustering by resolution-optimized Louvain algorithm of only tumor 
cells (Epithelial 2 and Epithelial 3 from Figure 62A). Plot shows aggregate of all 2,550 tumor 
cells across all patients at all time-points. B) Stacked barplot of tumor cluster frequency by 
treatment time-point in patients with metastatic Bone tumors. C) Stacked barplot of tumor cluster 
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frequency by treatment time-point in patients with metastatic Lymph Node tumors. D) Stacked 
barplot of tumor cluster frequency by treatment time-point in patients with metastatic Liver 
tumors. E) Stacked barplot of tumor cluster frequency by treatment time-point in patients with 
metastatic Lung tumors. F) Boxplot showing distribution of frequencies at Baseline for each 
tumor sub-cluster, comparing frequencies in Early Responders vs Late Progressors, such that the 
only cluster with significant difference at baseline (p<0.05 by Student’s T-test) was cluster 1, 
with higher baseline frequency in Late Progressors. 
 
These were assessed for enrichment in hallmarks of cancer pathways among differentially 
activated proteins (Figure 67), such that cluster 0 is most defined by enrichment of androgen 
response, clusters 1 and 2 are defined by upregulation of E2F targets, Myc targets, and G2M 
checkpoint, clusters 3 and 4 are defined by upregulation of TNFa signalling and interferon 
response, cluster 5 is defined by heme metabolism, cluster 6 by unfolded protein response and 




Figure 67: Hallmarks of Cancer Enriched Pathways in Tumor Cell Sub-Clusters 
For each tumor cell sub-cluster identified in Figure 66, plots of the top10 enriched pathways 
from Hallmarks of Cancer. Pathway enrichment is computed on genes differentially expressed in 
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each tumor sub-cluster relative to other tumor sub-clusters. -Log10(p-values) are plotted on the 
x-axes, such that statistically significant enriched pathways are shaded in blue. 
 
Top differentially upregulated proteins in each cluster are reported in Figure 68.  
 
Figure 68: Top Protein Activity Tumor Sub-Cluster Markers 
Heatmap of top 10 most differentially activated proteins for each tumor sub-cluster in Figure 66 
from aggregate single-cell RNA-Sequencing data across all patient samples. Each row represents 
a protein, grouped by cluster in which they are the most active, with cluster labels on the x and y-
axes. Each column represents a single cell. Above the x-axis cluster label there is also a 
treatment label indicating timepoint at which a given cell was profiled. 
 
Stacked frequency bar plots (Figure 66B-E) show changes in the relative proportions of each 
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tumor subcluster across different metastatic sites at baseline, after ADT only, after combination 
ADT and anti-PD-1, and at recurrence in available biopsy samples. At baseline, there was wide 
variability in the composition of tumor subclusters across the different metastatic sites. The bone 
and lymph node samples were more heterogenous, with nearly all tumor sub-clusters identified 
within these samples. In contrast, the liver and lung samples had fewer tumor cell sub-clusters 
represented. Notably, lung was comprised almost entirely of tumor sub-cluster 0 and 1. After 
treatment, the proportions of tumor subclusters differentially changed between different 
metastatic sites. In bone samples, there was a relative increase in cluster 5 after administration of 
ADT. With the addition of anti-PD-1 to ADT cluster 5 nearly disappeared and subcluster 4 
comprised nearly 65% of the tumor cells. However, in the recurrent bone sample, subcluster 5 
returned and comprised nearly 75% of all tumor cells, while sub-cluster 4 represented only 1% of 
all tumor cells at recurrence (Figure 66B). In the lymph node baseline samples, sub-cluster 0 
accounted for nearly 50% of tumor cells. After ADT, the relative proportion of subcluster 0 
increased to ~65% of all tumor cells present. Similar to bone samples, after ADT only the 
proportions of tumor sub-clusters in the lymph nodes changed slightly but overall remained 
heterogeneous. However, with the addition of anti-PD-1 therapy, a predominant sub-cluster (sub-
cluster 1) emerged in the lymph node samples. The liver and lung samples each maintained 
heterogeneity without emergence of a predominant subcluster after treatment with combination 
ADT and anti-PD-1. There were no patients with liver and lung metastases randomized to the 
ADT only timepoint.  
 
Tumor subclusters present at baseline differ by subsequent treatment response and 
druggable protein profile. We next and most critically compared the frequency of tumor 
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subclusters at baseline by subsequent PSA treatment response in order to assess if there were 
significant differences in tumor phenotypes associated with ‘early responders’ versus ‘late 
progressors’. Sub-cluster 0, which had the highest upregulation of androgen response, was 
significantly higher at baseline in ‘early responders’ (p = 0.05) compared to ‘late progressors.’ 
Conversely, sub-clusters 1 and 2 were higher at baseline in ‘late progressors’, who were 
ultimately non-responsive to treatment (p = 0.0008, p = 0.08, respectively). Interestingly, two 
proteins (TMPRSS2 and NKX3-1) among the top differentially active proteins in subcluster 0 
are mediated by the androgen receptor (AR). There were no other AR-mediated proteins 
observed in the top differential protein list for the other tumor subclusters. This may indicate that 
a higher proportion of AR-mediated proteins within tumor cells is predictive of treatment 
response and may be a novel predictive biomarker in future studies. More interestingly, clusters 
1 and 2 share high differential protein activity of KIF14 as the most-upregulated protein, which 
has previously been described as a candidate oncogene correlating with poor prognosis in 
prostate cancer [187]. This suggests that targeting these populations may represent an attractive 
prospect to overcome any treatment resistance mediated by these tumor cells.  
 
To this end, we have utilized the OncoTarget algorithm [24] to identify potential druggable 
proteins active in each tumor cell subcluster according to compounds listed in DrugBank [188] 




Figure 69: OncoTarget Druggable Proteins in Each Tumor Cell Sub-Cluster 
Single-Cell heatmap of all druggable proteins from DrugBank, active with median -log10(p-
value) > 5 in any tumor cell sub-cluster, as inferred by OncoTarget. Clusters 1 and 2 are the most 
phenotypically distinct with respect to druggable protein activity, as they do not have high 
activity of AR and are characterized instead by high activity of TOP2A. Cluster 5, which was 
specifically enriched in post-treatment recurrence for the Late Progressor sample with post-
recurrence single-cell RNA-Seq, is also phenotypically distinct, with activity of PRKACB, 
MMP14, and HIF1A. 
 
Amazingly, clusters 1 and 2, which associated at baseline with subsequent tumor progression on 
treatment, lacked activity of druggable proteins shared by other tumor cell clusters, most notably 
activity of the androgen receptor protein (AR). AR activity was highest in cluster 0, which was 
most enriched in subsequent early responders. Other druggable proteins with high activity in this 
cluster as well as clusters 3, 4, 6, and 7 included EGFR, FOLH1, PTK2, TACSTD2, ERBB3, 
ERBB3, STEAP1, and HDAC11 (Figure 69). Clusters 1 and 2, while they lack these druggable 
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targets, share elevated activity of druggable protein topoisomerase 2-alpha (TOP2A), for which 
36 FDA-approved and investigational compounds exist as drugs annotated in DrugBank, 
including Doxorubicin and Etoposide. Cluster 2 also has uniquely elevated activity of CD33, 
druggable by investigational compounds Gemtuzumab ozogamicin and AVE9633. Finally, 
cluster 5, which was dramatically expanded in the bone metastasis patient profiled at time of 
recurrence (5B), also had a unique druggable protein profile lacking activity of AR and the other 
druggable proteins identified in clusters 0, 3, 4, 6, and 7. Instead, cluster 5 exhibited high activity 
of PRKACB, MMP14, and HIF1A. This represents a unique profile of druggable proteins for 
which subsequent patients may be assessed and which may represent a rare and more aggressive 
prostate tumor cell phenotype, but which did not associate with differences in subsequent 
response to treatment at baseline across patients (Figure 66F), instead being represented 
primarily in a single outlier patient.  
 
Association of Tumor Cell Cluster Signatures with Clinical Outcome is Validated in 
External Bulk-RNA-Seq Cohort In order to assess the generalizability of our findings with 
respect to tumor cell sub-cluster association with treatment response, we have defined each set of 
differentially active proteins in each sub-cluster as a unique protein activity signature for that 
cluster (Figure 68). With these signatures and our protein activity inference algorithm, we can 
test for the enrichment of each cluster within larger cohorts of bulk-RNA-Sequencing data. 
While there are no previously published cohorts of metastatic prostate cancer patients treated 
with combination ADT plus anti-PD1 immunotherapy, we can assess the general prognostic 
significance of each tumor cell population across treatments in the TCGA. By Cox regression on 
patient-by-patient normalized enrichment scores (Figure 70A), enrichment of tumor cell sub-
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cluster 1 is significantly associated with shorter recurrence-free-survival (hazard ratio 1.37, p = 
0.002). The leading-edge genes in the cluster 1 protein activity signature most enriched in 
patients with recurrence vs non-recurrence are reported in Figure 70B and include KIF14 as well 
as TOP2A, both previously noted as biologically significant markers of clusters 1 and 2.  
 
Figure 70: Tumor Single-Cell Sub-Cluster Signatures Associate with Differential 
Outcomes in TCGA. 
A) Forest plot of Cox regression hazard ratios testing association in TCGA of patient-by-patient 
Normalized Enrichment Score for each tumor sub-cluster gene set with Recurrence-Free 
survival. Cluster 1 gene set enrichment is significantly associated with worse survival outcomes 
(p = 0.002). B) Heatmap of Leading-Edge Gene Set from Cluster 1 comparing all Recurrent vs 
Non-Recurrent patients in TCGA. C) Kaplan-Meier curve testing association of binarized cluster 
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1 gene set enrichment (greater than 0 = high, less than 0 = low) with recurrence-free survival in 
TCGA, such that cluster 1 enrichment significantly associates with worse recurrence-free 
survival. D) Kaplan-Meier curve testing association of binarized cluster 2 gene set enrichment 
(greater than 0 = high, less than 0 = low) with recurrence-free survival in TCGA, such that 
cluster 2 enrichment significantly associates with worse recurrence-free survival. E) Kaplan-
Meier curve testing association of binarized cluster 0 gene set enrichment (greater than 0 = high, 
less than 0 = low) with recurrence-free survival in TCGA, such that cluster 0 enrichment 
significantly associates with improved recurrence-free survival. F) Kaplan-Meier curve testing 
association of binarized cluster 6 gene set enrichment (greater than 0 = high, less than 0 = low) 
with recurrence-free survival in TCGA, such that cluster 6 enrichment significantly associates 
with improved recurrence-free survival, up to 2800 days. Kaplan-Meier curves are not shown for 
the remaining clusters as log-rank p-values for these were not statistically significant (p>0.05). 
 
Furthermore, log-rank tests on enrichment scores binarized to “high” vs “low” show significant 
association of both cluster 1 (p = 0.0087) and cluster 2 (p = 0.022) with shorter recurrence-free 
survival (Figure 70C-D), and significant association of cluster 0 (p = 0.0062) and cluster 6 (p = 
0.042) with improved recurrence-free survival (Figure 70E-F). No other cluster signature was 
associated with survival at statistical significance of p<0.05. In two smaller datasets specifically 
profiling metastatic prostate tumors (East Coast Stand Up to Cancer, West Coast Stand Up to 
Cancer) [189] [190], trends were observed toward association of clusters 1 or 2 with worse 
overall survival (Figure 71, Figure 72), such that cluster 2 was significantly associated with 
worse overall survival in East Coast SU2C (Figure 72B), though cluster 1 did not reach statistical 
significance. However, neither of these datasets included recurrence-free survival or PSA 





Figure 71: Tumor Single-Cell Sub-Cluster Signatures and Outcome in West Coast 
SU2C 
A) Forest plot of Cox regression hazard ratios testing association in West Coast Stand Up to 
Cancer (SU2C) dataset of patient-by-patient Normalized Enrichment Score for each tumor sub-
cluster gene set with overall survival. B) Kaplan-Meier curve testing association of binarized 
cluster 6 gene set enrichment (greater than 0 = high, less than 0 = low) with survival, such that 
cluster 6 enrichment significantly associates with improved survival. Kaplan-Meier curves are 






Figure 72: Tumor Single-Cell Sub-Cluster Signatures and Outcome in West Coast 
SU2C 
A) Forest plot of Cox regression hazard ratios testing association in East Coast Stand Up to 
Cancer (SU2C) dataset of patient-by-patient Normalized Enrichment Score for each tumor sub-
cluster gene set with overall survival. B) Kaplan-Meier curve testing association of binarized 
cluster 2 gene set enrichment (greater than 0 = high, less than 0 = low) with survival, such that 
cluster 2 enrichment significantly associates with worse survival. C) Kaplan-Meier curve testing 
association of binarized cluster 6 gene set enrichment (greater than 0 = high, less than 0 = low) 
with survival, such that cluster 6 enrichment significantly associates with improved survival. D) 
Kaplan-Meier curve testing association of binarized cluster 7 gene set enrichment (greater than 0 
= high, less than 0 = low) with survival, such that cluster 6 enrichment significantly associates 
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with improved survival. Kaplan-Meier curves are not shown for the remaining clusters as log-
rank p-values for these were not statistically significant (p>0.05). 
 
Taken together, these results are highly concordant with the finding in our own data that cluster 0 
enrichment at baseline associates with better treatment response while clusters 1 and 2 associate 
with worse treatment response. This suggests that while we are able to dramatically increase 
intra-tumoral CD8 T-cell infiltration by combination of anti-PD1 with ADT in metastatic 
prostate cancer, patients may further benefit from targeting an independent treatment resistance 
mechanism mediated by the TOP2A+ tumor cell sub-clusters we have identified.  
 
7.4 Discussion 
Evaluation of primary prostate cancer and metastatic, castration-resistant disease using high-
throughput, transcriptomic sequencing [176] [182] [191] [192] [193], has shown that the TME is 
relatively immune-depleted. We used scRNAseq to comprehensively characterize the TME of 
metastatic, hormone-sensitive prostate cancer (mHSPC), across a variety of tissue types. Using 
longitudinal samples from 10 patients over a treatment course with ADT and anti-PD-1 antibody, 
we describe the baseline TME and tumor cells, the specific changes induced with treatment, and 
associated baseline features with PSA response. We leveraged our expertise in inferred protein-
activity computational methods to increase resolution of the immune and tumor cell 
subpopulations as compared to conventional gene-expression and transcriptomic methods.  
 
Profiling transcriptomes from a cumulative 40,270 single-cells, our study uncovered a previously 
unknown rich immune infiltrate in untreated metastatic, hormone-sensitive tumors. In our 
analyses the baseline bone, lymph node, and liver samples were similarly immune infiltrated 
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while the lung metastasis was relatively immune-depleted (Figure 62B-C) and distinctly 
different, this with the caveat of a small sample size. These data add to the notion that 
pulmonary-tropic and non-pulmonary metastatic mHSPC may be biologically and/or 
immunologically fundamentally different [194]. Regarding prostate tumor cells, our data adds to 
the body of literature demonstrating intra- and inter-patient tumor cell heterogeneity [195] and 
expands this knowledge by highlighting the different frequencies of the eight tumor-cell sub 
clusters (Figure 66A), using protein-based activity, between tissue types (Figure 66B-E). 
Furthermore, we show phenotypic changes in tumor cell types induced by treatment, associate 
baseline tumor cell phenotypes with clinical response, and define pathways enriched 
longitudinally and upon recurrent, progressive disease.  
 
Our study is limited regarding the total number of patient samples per tissue type and analysis of 
a single metastatic site per patient. However, the longitudinal analysis of prostate cancer tumor 
metastases using single-cell sequencing over a course of treatment, to our knowledge, has never 
been reported. Our analyses are potentially biased towards more aggressive biology given that 
only patients with evaluable disease at the time of on-treatment biopsy were able to safely 
undergo metastatic biopsy. As such, we are unable to comment regarding the on-treatment 
changes in the TME and tumor cell profiles of participants who were rapidly responding to 
therapy. The time points for on-treatment biopsies are fixed due to the nature of a clinical trial 
and are not based on tumor kinetics although may be an option in future studies. Here we 
comment on cell types that were represented across all tissue types to avoid analyzing 
subpopulations that may be less relevant to tumor-immune crosstalk given their expected 
presence in a specific metastatic niche, i.e. common progenitor cells in the bone marrow and B 
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cells in the lymph nodes. This approach highlights broad changes in transcriptional program 
across tissue types in lieu of a deep dive on tissue specific idiosyncrasies.  
 
The observation that treatment induces changes in both the TME cellular composition and 
transcriptional program of tumor cells, so called lineage plasticity, is consistent with other 
studies in prostate cancer [196] [197] [198].  However, the TME changes we observed with 
administration of ADT in mHSPC are opposite of those described in primary prostate cancer. In 
primary prostate cancer, an immune infiltrate rich in T cells invades the TME after ADT 
administration [199] [4]. In mHSPC biopsy samples we observed a decrease in CD4 and CD8 T 
cells after ADT, whereas the combination of ADT and anti-PD-1 immunotherapy was effective 
at recruiting CD8 effector T cells. It is possible that these observed differences between primary 
and metastatic HSPC are due to the baseline TME composition, i.e. an ‘immune desert’ vs. 
‘immune replete’ respectively, and immunomodulatory factors already present in the milieu.  
 
Importantly, in our study, we observed significant increases in TNF+ CD4 non-T reg T cells 
(CD4 1), LAG3+ CD8 T cells (CD8 2), and GITR+ T regs (Treg 3) after combination therapy. 
This highlights the notion that combination therapy with ADT and anti-PD-1 therapy in men 
with mHSPC is an immunologically active combination, even in bone metastasis. Lymphocyte 
activation gene-3 (LAG3, CD223), a CD4 homologue that binds to MHC class II [183], is 
upregulated on CD8 T cells after antigen experience and represents an ‘exhausted’ state, which 
negatively regulates their activation and homeostasis [200] [201]. Dual-inhibition of PD-1 and 
LAG-3 was recently shown to improve outcomes in patients with melanoma in a large phase 3 
clinical trial [202]. In prostate cancer models that are resistant to single-agent PD-1, dual 
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blockade of PD-1 and LAG3 improved vaccine efficacy providing evidence that combination 
immune checkpoint therapy may be key to improving clinical response outcomes [203]. Taken 
together, these data suggest that LAG3 may be a potential adjunct to combination immune 
checkpoint therapy in prostate cancer. Glucocorticoid-induced TNFR-Related (GITR) protein, an 
immune checkpoint receptor, belongs to Tumor Necrosis Factor Receptor Superfamily 
(TNFRSF). GITR is preferentially expressed on CD8 and T reg cells and agonistic antibodies are 
shown to potentiate the former and reduce functionality of the latter [204] [205] [206]. Although 
several preclinical and early phase studies have shown that anti-GITR agonist antibodies are 
safe, clinical results have been modest thus far [207] [208]. Trials of dual immune checkpoint 
blockade targeting GITR and PD-1 have shown slight advantage over single-agent anti-GITR 
agonists antibodies [209] [210], although data in mHSPC is limited. Tumor Necrosis Factor 
(TNF), a major inflammatory cytokine with signaling potential both as a membrane-bound 
protein and as a soluble ligand, was initially implicated as an anti-tumor cytokine but has since 
been implicated, in complete contraindication to its name, in tumor progression [184] [185] 
[211]. Given the ever-increasing number of patients treated with combination immune 
checkpoint therapy, more patients are developing immune-related adverse events (irAEs) that 
frequently require treatment with immunosuppressive therapies like anti-TNFa inhibitors. As 
such, much has been learned about the effects of anti-TNFa inhibitors in patients with cancer 
[185]. In several studies aimed to abrogate irAEs upfront using concomitant TNFa inhibitors 
with combination immune checkpoint blockade, also showed improvements in anti-tumour 
efficacy [186] suggesting a role for TNFa blockade as an anti-tumor agent. Our group has shown 
that elevated TNFa levels are indeed associated with PSA progression in men with biochemically 
recurrent prostate cancer [212]. Indeed, in Myc-CaP androgen-sensitive murine models, TNFa 
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signaling signatures were observed to be upregulated following ADT. Additionally, intratumoral 
TNFa was upregulated in microdissected human mCRPC lesions [89], and furthermore 
associated with failure to respond to enzalutamide. Taken together, these data in the context of 
increased protein activity of TNFa in CD4 T cells after ADT and anti-PD-1 therapy shown here 
(Figure 63, 67), suggest that inhibiting TNFa, concurrently or sequentially, with ADT and 
immune checkpoint therapy in hormone-sensitive prostate cancer may be an effective treatment 
combination.  
 
Due to the tropism of metastatic prostate cancer to bone, tissue-specific changes occurring in the 
TME of bone samples were of particular interest. Notably, following ADT alone, we observed a 
relative increase of myeloid cells (Figure 64A-B) and a noticeable decrease in CD4 non-T reg T 
cells as well as tumor cells. As discussed earlier, the observed expansion of CD8 T cells was 
most pronounced in the bone TME after combination therapy compared to other tissue types 
(Figure 64B). This highlights the notion that moving away from a ‘one-therapy-treats-all’ 
treatment paradigm and towards more precision-based, targeted, and tissue-based algorithms is 
likely on the horizon.   
 
Given that our transcriptomic data comes from a prospective clinical trial with close monitoring 
of clinical response, associations between baseline biopsy features and PSA response was 
possible. Thus far, the primary endpoint of our phase 2 trial, the rate of undetectable PSA (< 0.02 
ng/dL) at 37 weeks after combination therapy, is 42%. This compared to 32% in the ADT plus 
docetaxel arm of the phase 3 CHAARTED trial (E3805) [213]. Although the proportional 
difference in the rates of undetectable PSA between our small phase 2 study and CHAARTED 
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are not statistically significant, due to current statistical power and enrollment, we remain 
encouraged. It is, however, somewhat perplexing that the rate of undetectable PSA is not 
overwhelmingly lower given the robust influx of CD8 effector T cells we observed with 
combination therapy.  
 
New observations from our data sheds light on issues using classically defined immune markers 
as predictive biomarkers. As previously noted, the association of baseline immune sub-clusters 
with PSA response showed that TNFa+ CD4 T cells (CD4 1) were statistically significantly 
associated with late PSA progression, and also that LAG3+ CD8 T cells (CD8 2) and GITR+ T 
reg cells (Treg 3) were both statistically significantly associated with early PSA response. In the 
case of Tregs this is somewhat paradoxical. T regulatory cells are classically considered to be an 
immune suppressive subpopulation of T cells. However, a recent analysis of Tregs using high-
dimensional flow cytometry from an NPK-C1 transplantable prostate tumor model revealed 
significant phenotypic diversity within Tregs, including a Treg subpopulation enriched in 
regressing tumors [214]. Thus, our data supports this preclinical observation that ‘favorable’ 
Tregs may be present in the TME at various states of treatment pressure. Further, taken together, 
these data demonstrate the capacity of single-cell and high-dimensional data to provide more 
granularity on immune subpopulations and may even challenge the definitions of classical 
‘immunosuppressive’ or ‘immune effector cells.’ 
 
We observed both expected and unexpected findings upon association of baseline tumor 
subclusters with PSA response. Subcluster 0, which has high protein activity levels of two 
androgen receptor (AR) regulated proteins (TMPRSS2 and NKX3-2), was, not surprisingly, 
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associated with early PSA response (Figure 66F). Using the ‘hallmarks of cancer’ pathway 
enrichment analysis37, we confirmed that subcluster 0 was indeed enriched with androgen 
response genes (Figure 67). We confirmed this positive association between this gene set and 
clinical outcomes in the TCGA dataset using GSEA (Figure 70E). In contrast, subclusters 1 and 
2, defined by upregulation of E2F targets, Myc targets, and G2M checkpoint (Figure 67), were 
associated with late PSA progression (Figure 66F). These associations were validated in a similar 
manner (Figures 70C-D, 72). Interestingly, we did not observe tumor subcluster 3, the subcluster 
enriched with TNFa signaling genes (Figure 67), to be associated with worse outcomes (Figure 
66F). This association is opposite to what we observed in the TNFa+ CD4 T cells (CD4 1), 
which was associated with decreased clinical outcomes. Taken together, these observations 
highlight the notion that the specific cell of protein activity and/or expression (CD4 T cells vs. 
tumor cells) indeed matters and is a reflection of the underlying immunologic processes at play.  
 
Because certain tumor subclusters were associated with PSA progression or prominent on 
disease progression, we used OncoTarget (see methods) to examine potential druggable proteins 
active in the tumor subclusters. Subclusters 1 and 2 showed high activity of TOP2A and low AR 
activity suggesting these subclusters may be upfront resistant to AR-targeted therapies (Figure 
69). Although subclusters 1 and 2 were associated with PSA progression in our dataset (Figure 
66F), and validated as such in external datasets, they were not the dominant tumor subclusters 
seen in the tumor progression biopsy (Figure 66B). More metastatic biopsies at the time of tumor 
recurrence would be helpful to delineate if there is a role for targeting tumor subclusters 1 and 2 
with topoisomerase inhibition in mHSPC. Targeting these tumor cell populations upfront to 
eradicate them prior to combination ADT, anti-PD-1 therapy may be one approach for future 
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clinical trials. Of interest particular interest was tumor subcluster 5, the dominant cluster seen in 
the bone progression biopsy. Figure 69 shows that potential druggable proteins in subcluster 5 
include PRKACB (cAMP-dependent protein kinase catalytic subunit beta), MMP14 (matrix 
metallopeptidase 14), and HIF1a (Hypoxia Inducible Factor 1 Subunit Alpha). Taken together, 
our combined dataset and analyses highlight several potential targets for worthy of further 
investigation in mHSPC.  
 
Building on this rich longitudinal transcriptomic dataset, we propose that the “holy grail” 
treatment for men with mHSPC will require a multi-pronged and adaptive combination regimen 
to elicit complete and durable responses. We propose a term ‘Highly Active Anti-Tumor 
Therapy’ (or HAATT), that includes a treatment regimen with the following properties: 1) strong 
upfront tumor cell killing perhaps directed at known resistant tumor cell clones, 2) activation of 
CD8 effector T cell function via combination immune checkpoint therapy (anti-PD-1 with anti-
LAG3, anti-GITR agonist antibodies, or novel agents targeting costimulatory agonists like 4-
1BB or B7-H3), 3) depletion or blocking of T regulatory cells, and 4) targeting 
immunosuppressive or tumor-permissive molecules in the TME (i.e. cytokines, chemokine 
receptors, metabolomic pathways, or transcription factors). As demonstrated, it is imperative to 
review the underlying tumor immunology and biology continuously and critically with advanced 
techniques when conceiving of the next biologically plausible clinical trials.  
 
7.5 Methods 
Study design and participants 
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The PRIME-CUT (modulating the Prostate cancer Immune Microenvironment with 
Chemoimmunotherapy for metastatic prostate cancer) study is an open-label, single-arm, phase 2 
study (NCT03951831) conducted at Columbia University Irving Medical Center (New York, 
NY) that tests the clinical activity of phased administration of ADT, anti-PD-1 therapy, and 
docetaxel in men with newly diagnosed metastatic, hormone-sensitive prostate cancer. The study 
was approved by the institutional review board and all participants provided written consent. Key 
eligibility criteria included diagnosis of metastatic, hormone-sensitive prostate cancer with a 
robust testosterone level (>150ng/dL). Prior ADT was allowed but not if within preceding six 
months. Recruitment was restricted to patients with metastatic lesions amenable to biopsy. 
Patients with bone metastases were allowed. Treatment consisted of ADT (degarelix 240mg SC 
one dose, followed by leuprolide 22.5mg SC every 12 weeks) followed by anti-PD-1 antibody 
(cemipliamb-rwlc 350mg IV every 3 weeks) beginning four weeks after ADT initiation. To 
prime the immune system, a two-cycle lead-in of anti-PD-1 therapy is administered prior to 
docetaxel (75mg/m2 every 3 weeks for six cycles). Participants receive ADT and anti-PD-1 
antibody until study completion (52 weeks) or until lack of clinical benefit or intolerable side 
effects. The primary endpoint is the rate of undetectable prostate specific antigen (PSA) at 6 
months after chemotherapy initiation (37 weeks on-study) and will be compared to the historical 
control (i.e., CHAARTED) [213]. Secondary endpoints include time to progression to CRPC and 
rate of radiographic response upon study completion. To ensure patient safety within the 
limitations of a small phase 2 study, toxicity is monitored using a Bayesian method which 
provides continuous monitoring boundaries for termination of the trial if the toxicity rate is 




Sample collection  
Twelve patients were enrolled on the phase 2 trial from May 2019 through December 2020. At 
enrollment all patients were scheduled for an interventional radiology-guided baseline biopsy of 
the most accessible metastasis. Subjects were randomized to one of two time points, either week 
4 or week 10 on-study, for an on-treatment biopsy as well. Subsequent biopsies at the time of 
disease progression were optional. In all cases, patients had their on-treatment biopsy at the same 
location as their baseline biopsy. Patients randomized to the week 4 time point have been treated 
with four weeks of ADT (degarelix) alone. Patients randomized to the week 10 time point have 
been treated with 10 weeks of ADT (4 weeks of degarelix and 6 weeks of leuprolide) as well as 
two cycles (6 weeks) of anti-PD-1-therapy. We subsequently refer to these time points as ‘ADT 
only’ and ‘ADT+aPD1,’ respectively. Given the phased administration of ADT and anti-PD-1 
therapy and the differing time points for on-treatment biopsies, these data present a unique 
opportunity to comprehensively define and compare the specific treatment effects of ADT only 
and ADT+aPD1 on the transcriptional program of immune cell subpopulations and tumor cells in 
the TME across a variety of tissue types. 
 
Of the twelve patients enrolled, two patients’ samples baseline and on-treatment samples were 
excluded from these analyses due to either an insufficient number of viable cells for loading onto 
the 10X Genomics instrument or a lack of tumor cells identified in the biopsy sample using copy 
number inference (see methods below). Here, we report on 10 patients’ samples from bone, 
lymph node, liver, and lung metastases. We recovered an adequate number of cells in both 
baseline and on-treatment biopsy samples from six patients (four patients with bone metastases, 
one patient with lymph node metastases, and one patient with lung metastases). In four patients, 
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only one of the two samples yielded adequate cells for sequencing and analysis (one baseline 
lymph node sample, one baseline liver sample, and one on-treatment bone sample [ADT only], 
and one on-treatment [ADT+aPD1] liver sample (Figure 59). 
 
Tissue Dissociation  
Fresh tumor was minced to 2-4 mm sized pieces with micro-scissors. For bone metastases, 
minced tissue was resuspended and examined under microscope. If already found to be 
dissociated to a single-cell suspension, the entire sample was passed through a 70-um filter for 
downstream processing. For bone metastases not found to be dissociated and for all other tissue 
sites, tissue was digested with 2.5mL of in-house digestion medium (collagenase IV 800 U/ml, 
DNase 0.1 mg/ml in L-15 medium with 1g/L glucose, 5% FBS, 15 mM HEPES) in glass bottle 
with stir bar in 37C water bath for 30min. Digested tissue was passed through a 70-um filter. If 
pink, single-cell suspensions were incubated with ACK red cell lysis buffer and washed. All 
spins were performed at 300g, for 5min, at 4 degrees Celsius. Dissociated cells were aliquoted 
for single-cell sequencing, loading 10,000-20,000 cells per sample.  
 
Single-cell RNA sequencing and data processing 
Samples were processed for single-cell gene expression capture (scRNASeq) using the 10X 
Chromium 3’ Library and Gel Bead Kit (10x Genomics), following the manufacturer’s user 
guide at the Columbia University Human Immune Monitoring Core (HIMC). After GelBead in-
Emulsion reverse transcription (GEM-RT) reaction, 12-15 cycles of polymerase chain reaction 
(PCR) amplification were performed to obtain cDNAs used for RNAseq library generation. 
Libraries were prepared following the manufacturer’s user guide and sequenced on Illumina 
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NovaSeq 6000 Sequencing System. Single-cell RNASeq data were processed with Cell Ranger 
software at the Columbia University Single Cell Analysis Core. Illumina base call files were 
converted to FASTQ files with the command “cellranger mkfastq.” Expression data were 
processed with “cellranger count” on the pre-built human reference set of 30,727 genes. These 
data were loaded into the R version 3.6.1 programming environment, where the publicly 
available Seurat package was used to further quality-control filter cells to those with fewer than 
10% mitochondrial RNA content, more than 1,500 unique UMI counts, and fewer than 15,000 
unique UMI counts. Gene Expression count matrices for each sample were processed in R using 
the Seurat SCTransform command to perform a regularized negative binomial regression based 
on the 3000 most variable genes. Samples were then combined by the Seurat Anchor Integration 
algorithm. The resulting matrix was clustered by the Louvain Algorithm, with resolution selected 
automatically to maximize clustering silhouette score, as previously described [35]. Gene 
Expression data were projected into their first 50 principal components using the RunPCA 
function in Seurat, and further reduced into a 2-dimensional visualization space using the 
RunUMAP function with method umap-learn and Pearson correlation as the distance metric 
between cells. Differential Gene Expression between clusters was computed by the MAST 
hurdle model for single-cell gene expression modeling, as implemented in the Seurat 
FindAllMarkers command, with log fold change threshold of 0.5 and minimum fractional 
expression threshold of 0.25, indicating that the resulting gene markers for each cluster are 
restricted to those with log fold change greater than 0 and non-zero expression in at least 25% of 
the cells in the cluster. 
 
Semi-Supervised Cell Type Calling  
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For each single cell gene expression sample, cell-by-cell identification of cell types was 
performed using the SingleR package [48] and the preloaded Blueprint-ENCODE reference, 
which includes normalized expression values for 259 bulk RNASeq samples generated by 
Blueprint and ENCODE from 43 distinct cell types representing pure populations of stroma and 
immune cells [49] [50]. The SingleR algorithm computes correlation between each individual 
cell and each of the 259 reference samples, and then assigns both a label of the cell type with 
highest average correlation to the individual cell and a p-value computed by Wilcox test of 
correlation to that cell type compared to all other cell types. Cell-by-cell SingleR labels were 
restricted to those with p<0.05, and unsupervised clusters are labelled as a particular cell type 
based on the most-represented SingleR cell type label within that cluster. Since tumor cells are 
not represented within the Blueprint-ENCODE reference, tumor cells are typically assigned as 
epithelial, since prostate cancer is epithelial in origin. The tumor cell identity of these cells was 
further confirmed by expression of KLK3, a prostate cancer marker gene, as well as by inference 
of copy number variations using the InferCNV algorithm with all lymphoid and myeloid cell 
clusters specified as a copy-number-normal reference.  
 
Regulatory network and protein activity inference 
Protein activity was inferred from gene expression at the single-cell level according to the 
pipeline described [216] and previously used for analysis of single cell ccRCC samples [35]. 
From the combined dataset, metaCells were computed within each gene expression cluster by 
summing SCTransform-corrected template counts for the 10 nearest neighbors of each cell by 
Pearson correlation distance. 200 metaCells per cluster were sampled to compute a regulatory 
network from each cluster. All regulatory networks were reverse engineered by the ARACNe 
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algorithm. ARACNe was run with 100 bootstrap iterations using 1785 transcription factors 
(genes annotated in gene ontology molecular function database as GO:0003700, “transcription 
factor activity”, or as GO:0003677, “DNA binding” and GO:0030528, “transcription regulator 
activity”, or as GO:0003677 and GO:0045449, “regulation of transcription”), 668 transcriptional 
cofactors (a manually curated list, not overlapping with the transcription factor list, built upon 
genes annotated as GO:0003712, “transcription cofactor activity”, or GO:0030528 or 
GO:0045449), 3455 signaling pathway related genes (annotated in GO biological process 
database as GO:0007165, “signal transduction” and in GO cellular component database as 
GO:0005622, “intracellular” or GO:0005886, “plasma membrane”), and 3620 surface markers 
(annotated as GO:0005886 or as GO:0009986, “cell surface”). ARACNe is only run on these 
gene sets so as to limit protein activity inference to proteins with biologically meaningful 
downstream regulatory targets, and we do not apply ARACNe to infer regulatory networks for 
proteins with no known signaling or transcriptional activity for which protein activity may be 
difficult to biologically interpret. Parameters were set to zero DPI (Data Processing Inequality) 
tolerance and MI (Mutual Information) p-value threshold of 10-8, computed by permuting the 
original dataset as a null model. Protein activity was inferred by running the VIPER algorithm 
with all ARACNe networks on the combined SCTransform-scaled and Anchor-Integrated gene 
expression signature of all single cells from each patient. The resulting protein activity matrix 
was loaded into a Seurat Object with CreateSeuratObject, then projected into its first 50 principal 
components using the RunPCA function, and further reduced into a 2-dimensional visualization 
space using RunUMAP function with method umap-learn and Pearson correlation as the distance 
metric between cells. Differential protein activity between clusters identified by resolution-
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optimized Louvain was computed using Student’s t-test, and top proteins for each cluster were 
ranked by p-value. 
 
Association of cell clusters with tissue site and PSA response 
Cell counts per cluster were normalized within each individual sample to cluster frequencies, and 
subsequent comparisons were made between cluster frequencies in different tissue sites, 
treatment time-points, and at baseline between patients who responded or did not respond to 
treatment, as assessed by change in PSA over time (Figure 65). This was done for clusters 
identified by the Louvain algorithm in combined dataset of all cells, representing the entire 
tumor micro-environment. Separately, tumor cell clusters were isolated as a new Seurat object on 
which principal components and UMAP projection were re-computed from the VIPER-inferred 
protein activity matrix. These were subsequently sub-clustered by resolution-optimized Louvain 
algorithm [35]. Differential protein activity was computed for tumor cell sub-clusters by 
Student’s t-test, with results shown in Figure 68, and pathway enrichment within each cluster 
was assessed by the Enrichr browser tool [217] (Figure 67). Tumor cell counts within each sub-
cluster were normalized to the total count of all tumor cells to compare relative frequencies of 
each tumor cell population at baseline in patients with early response to treatment (defined by 
reduction to less than 1% of initial PSA within 10 weeks of treatment) vs patients with initial 
response followed by progression of PSA on-treatment (late progressors). The same was done to 
compare frequencies of each population by tissue site and by treatment time-point.  
 




Druggable protein activity within tumor-cell sub-clusters was evaluated by the OncoTarget 
algorithm, in which the log(UMI/million) gene expression of each tumor cell was scaled by z-
score against the log(TPM) gene expression of the entire TCGA database as a reference, and 
VIPER was applied using the set of single-cell ARACNe networks. From the resulting protein 
activity matrix, a subset of proteins was selected for which a known drug targeting that protein 
exists in the DrugBank online database [188]. Cell-by-cell protein activity scores for these 
proteins were transformed into p-values by fitting to the analytical normal distribution and 
corrected for multiple hypothesis testing within each cell by Bonferonni’s method. Corrected p-
values were converted to -log10(p-value) for ease of visualization, and the matrix was 
subsequently subset to proteins with mean -log10(p-value) of at least 5 in any of the identified 
tumor cell sub-clusters. The resulting druggable protein activity matrix is shown in Figure 69. 
Further, a protein signature for each tumor cell sub-cluster was defined based on the set of all 
proteins differentially upregulated in that cluster. Then for each of three independent external 
prostate cancer bulk-RNA-Seq datasets, (TCGA, East Coast SU2C, West Coast SU2C) [218] 
[189] [190], enrichment of these protein signatures was assessed as follows. First, the bulk-RNA-
Seq dataset was internally scaled by z-score, then VIPER protein activity inference was 
performed using the single-cell ARACNe networks, and finally enrichment of each tumor sub-
cluster signature was determined in each bulk-RNA-Seq sample by Gene Set Enrichment 
Analysis (GSEA) [104], where genes were ranked by highest to lowest protein activity. The 
resulting normalized enrichment scores were tested against recurrence-free-survival time in 
TCGA or overall survival time in SU2C by Cox regression (Figure 69A). Since enrichment of 
tumor cell cluster 1 was found to be significantly associated with shorter recurrence-free-survival 
in TCGA, the leading-edge genes within the protein signature responsible for this association 
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were further identified by GSEA on the set of all proteins ranked by differential activity in 
TCGA samples with vs without recurrence. Activity of these proteins for all TCGA samples is 
shown in Figure 69B. Finally, patient-by-patient enrichment scores were binarized to less than 
zero = “low” and greater than zero = “high” and assessed for effect on survival by log-rank test 
and Kaplan-Meier curve, with all statistically significant results shown in Figure 69C-F.  
 
Quantification and Statistical Analysis:  
All quantitative and statistical analyses were performed using the R computational environment 
and packages described above. Differential gene expression was assessed at the single-cell level 
by the MAST single-cell statistical framework as implemented in Seurat v3, and differential 
VIPER activity was assessed by t-test, each with Benjamini-Hochberg multiple-testing 
correction. Comparisons of cell frequencies were performed by non-parametric Wilcox rank-sum 
test, and survival analyses were performed by log-rank test and cox regression. In all cases, 
statistical significance was defined as an adjusted p-value less than 0.05. Details of all statistical 
tests used can be found in the corresponding figure legends.   
 
 
7.6 Preliminary Data from Primary Prostate Cancer  
In addition to the above clinical trial profiling response to combination androgen deprivation 
therapy (ADT) plus checkpoint immunotherapy in metastatic prostate cancer, we are also 
collecting single-cell RNA-Sequencing data from a separate clinical trial of combination ADT 
plus anti-CTLA4 checkpoint immunotherapy in high-risk primary prostate cancer. This trial 
(NEO-RED-P) consists of two separate arms, each aiming to enroll 10 patients, such that 
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treatment arm A will consist of ADT alone, and treatment arm B will combine ADT with an anti-
CTLA4 checkpoint inhibitor immunotherapy (BMS-986218). Patients in both arms will undergo 
radical prostatectomy for subsequent single-cell RNA-Seq analysis, along with a comparator set 
of 10 treatment-naïve prostatectomy specimens. Clinical trial design is outline in Figure 73.  
 
Figure 73: NEO-RED-P Primary Prostate Cancer Clinical Trial Design 
 
The trial opened in 2021 and has currently enrolled and sequenced 4 untreated controls, 6 
patients on combination ADT plus aCTLA4, and 2 ADT-only patients, with an aggregate Quality 
Control filtered cell count of 5,357 cells from untreated controls, 1,397 cells from ADT-only, 
and 14,684 cells from combination therapy. Results from preliminary comparison of these 
patients by single-cell protein activity inference analysis are presented below, and the trial is 
rapidly continuing enrollment, aiming to reach full enrollment over the next year. Ultimately, 
patients will have prostate-specific antigen (PSA) checked every 3 months for the first year of 
Neoadjuvant randomized trial of degarelix or degarelix in combination with non-fucosylated anti-CTLA-4 therapy (BMS-
986218) in men with high risk localized prostate cancer
Key Eligibility Criteria
Histologically confirmed adenocarcinoma of the prostate
Men ≥18 years
Gleason ≥4+3=7 localized prostate cancer
Physically fit for radical prostatectomy
Criteria for Evaluation
• Feasibility
• Toxicity (CTCAE v5.0)
• Difference in T-reg density
• Difference in CD8 T cell density and CD8/Treg ratio
• Pathological complete response (pCR) rate 
• Undetectable PSA 12 months after radical
prostatectomy (PSA < 0.1ng/mL)
• PSA response rate (>50% decrease in PSA)
• Time to PSA recurrence (PSA ≥0.2 ng/mL)
Primary Outcomes Secondary Outcomes
Radical Prostatectomy (day 15)
*During follow up patients will be assessed with PSA and testosterone level every 3 months (year 1), every 6 months (year 2) or until disease progression. 
Degarelix acetate 240mg SQ (day 1)
SAFETY LEAD-IN: BMS-986218 20mg IV (day 1 and day 15), degarelix acetate 2240mg SQ (day 8)
BMS-986218 20mg IV (day 1 and day 15), degarelix acetate 
2240mg SQ (day 8)







follow up or until relapse of disease. For year 2 of follow-up patients will have PSA measured 
every six months until disease relapse, and tumor micro-environment between responders vs 
non-responders to therapy will be compared separately in each treatment arm.  
 
Clustering on VIPER-inferred protein activity of cells aggregated across patients reveals a 
significant immune heterogeneity, with thirty-two distinct clusters of cells identified, and their 
cell lineage and respective frequencies in untreated vs ADT alone vs combination therapy 
characterized in Figure 74.  
 
Figure 74: Clustering of all Cells Across Patients on VIPER-Inferred Protein Activity 
A) UMAP Projection of unsupervised clustering performed on all cells aggregated across 
patients. Tumor cells (as defined by Copy Number Variation Inference and expression of tumor 






that major cell types represented include Epithelial (Tumor) cells, Myeloid cells 
(Macrophage/Monocyte), T-cells (CD4, CD8, and Treg), Endothelial cells, Fibroblasts, and B-
cells. C) Boxplot of cluster frequencies from A, split by treatment group, comparing untreated 
patients, patients treated with ADT alone, and patients treated with combination ADT + 
aCTLA4. 
 
Consistent with our prior work [199], we see few immune cells in primary prostate cancer at 
baseline, particularly few cytotoxic CD8 T-cells, with diverse subsequent influx of immune cells 
after ADT. Indeed, we see influx of CD8 T-cells into the prostate tumor micro-environment 
counterbalanced by influx of immunosuppressive regulatory T-cells (Treg), such that the Treg to 
CD8 ratio actually increases with ADT versus treatment-naïve baseline (Figure 75). With the 
addition of aCTLA4 combination therapy, we actually see less overall immune infiltration than 
with ADT alone. However, we crucially see an inversion of the Treg to CD8 ratio, with increase 
in CD8 infiltrate relative to baseline and decrease in Treg infiltrate (Figure 75). It remains to be 
seen on clinical follow-up whether this corresponds to generation of a more active anti-tumor 
immune response, but the changes observed in the micro-environment from this initial patient 





Figure 75: Prostate Tumor Infiltration by Activated CD8 T-cells and 
Immunosuppressive Regulatory T-cells with ADT versus Combination ADT + aCTLA4.  
A) Boxplot showing distribution of Treg frequencies as a percentage of all cells in tumor micro-
environment among treatment-naïve patients (red), patients treated with ADT only (green), and 
patients treated with combination ADT + aCTLA4 (blue). B) Boxplot showing distribution of 
Treg frequencies as a percentage of total CD4+ T-cells by treatment group. C) Boxplot showing 
distribution of cytotoxic CD8 T-cell frequencies by treatment group. D) Boxplot showing 
distribution of Treg/CD8 ratio by treatment group.  
 
Moreover, five distinct sub-clusters of tumor cell phenotypes are observed across patients, with 
differing representation in different patients (Figure 76A). Although it is too early to correlate 





each treatment arm, we are able to infer significant diversity in activity of druggable proteins 
among these clusters by OncoTarget (Figure 76B), as well as differences in relative enrichment 



















Figure 76: Sub-Clustering of Tumor Cells Reveals Phenotypic Diversity, with Distinct 






A) Heatmap of VIPER-inferred protein activity for the top 5 most differentially up-regulated 
proteins in the five tumor cell sub-clusters observed across patients. B) Heatmap of -
log10(Bonferroni-corrected p-values) cell by cell for all druggable protein targets inferred by 
OncoTarget in any tumor cell cluster with mean -log10(p-value) exceeding 2. C) For each tumor 
cell cluster in A, plots of the top10 most-enriched pathways among differentially active proteins, 
from MSigDB Hallmarks of Cancer.  
 
Nevertheless, if we take the single-cell-derived marker proteins of each tumor cell cluster and 
test for their enrichment patient-by-patient in TCGA by Gene Set Enrichment Analysis (GSEA), 
we find by Cox regression and by Kaplan-Meier analysis that Tumor cell cluster 2 is enriched 
among patients with worse clinical outcome, and Tumor cell cluster 4 is enriched among patients 
with better clinical outcome (Figure 77). The relative favorability of unfavorability of these 
tumor cell phenotypes with respect to immunotherapy response will be borne out by further 















Figure 77: Single-Cell Tumor Sub-Cluster Marker Enrichment Associates with 
Clinical Outcome in TCGA 
A) Cox regression forest plot showing proportional hazards with 95% confidence intervals and 
p-values for association of each tumor cluster gene set with Recurrence-Free Survival Time in 
TCGA. Enrichment of Tumor Cell Cluster 2 markers (GSEA2) was found to associate with 
worse clinical outcome (p=0.003), and enrichment of Tumor Cell Cluster 4 markers (GSEA4) 
was found to associate with better clinical outcome (p=0.002). B) Kaplan-Meier curve showing 
association of binarized Tumor Cell Cluster 2 marker enrichment (>0 = “high”, <0 = “low”) with 
Recurrence-Free Survival Time in TCGA. Enrichment for Cluster 2 associates with shorter 
Recurrence-Free Survival Time with log-rank p-value = 0.046. C) Kaplan-Meier curve showing 
association of binarized Tumor Cell Cluster 4 marker enrichment (>0 = “high”, <0 = “low”) with 
Recurrence-Free Survival Time in TCGA. Enrichment for Cluster 4 associates with longer 




Chapter 8: Elucidating and Targeting Proteomic Master Regulators 
of Tumor-Infiltrating Regulatory T-cells as a Novel 
Immunotherapeutic Approach  
8.1 Summary 
Tumor infiltrating regulatory T cells (TI-Tregs) suppress natural and therapeutically stimulated 
antitumor immunity. While TI-Tregs are highly attractive therapeutic targets across cancers, the 
main challenge in designing TI-Treg inhibitors is the need to preserve peripheral Treg (P-Treg) 
function, which is critically required to suppress autoimmunity. To address this problem, we 
have identified and validated novel regulators of the human TI-Treg phenotype, leveraging a 
large collection of transcriptional profiles of multiple T cell populations sorted from tumor and 
blood of patients with several distinct tumor types. We performed VIPER (Virtual Inference of 
Protein Activity) analysis on this dataset to systematically identify 17 Master Regulator (MR) 
proteins predicted to determine the TI-Treg phenotype. To identify actionable therapeutics that 
modulate the TI-Treg MR program, we first performed a systematic ex vivo drug screen against 
human P-Tregs and TI-Tregs, generating perturbational RNA-Seq profiles for an unbiased set of 
drugs from a panel of 1,554 total compounds which exhibited greatest inhibition of Treg growth 
ex vivo. We then applied the OncoTreat algorithm to identify three candidate drugs that invert 
the TI-Treg MR activity signature and exhibit preferential cytotoxic activity on TI-Tregs relative 
to P-Tregs. We validated the top target, Gemcitabine (Gem), in vivo using the MC38 model and 
found that at low doses Gem inhibits tumor growth in immune-competent but not immune-
incompetent mice. Further, Gem synergizes with anti-PD-1 checkpoint blockade and 
preferentially inhibits a subset of TI-Tregs with high activity of TI-Treg MRs, assessed by 
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single-cell RNA-Seq. Additionally, we validated the functional relevance of TI-Treg MRs in a 
pooled in vivo CRISPR screen using the CHIME CRISPRko hematopoietic stem cell transplant 
model1. We validated 7 candidate MRs for which knockout inhibits TI-Treg recruitment and/or 
retention in the TME without perturbing P-Tregs. The top candidate, TRPS1 (Transcriptional 
Repressor GATA Binding 1), was also confirmed to inhibit TI-Treg tumor infiltration with 
respect to infiltration by CD4nonTregs. To further validate the biological effect of TRPS1, we 
generated single gene knockout CHIME chimeras and found that tumor growth was strongly 
inhibited in mice bearing knockout of this gene in hematopoietic cells. Together, these studies 
identified a collection of novel TI-Treg MRs with potentially transformative clinical utility as 
therapeutic targets for the specific inhibition of TI-Tregs, and additionally discovered related 
small molecule compounds with preferential activity against TI-Tregs. These compounds, 
particularly low-dose Gemcitabine, are attractive candidates to use in combinatorial strategies to 
sensitize tumors to checkpoint inhibitors, with potential to improve treatment outcomes across a 
broad range of tumor types.  
 
8.2 Introduction 
To manifest as clinically relevant disease, cancer must evade a complex host-protective immune 
response, the outcome of which is largely determined by the balance of inflammatory (anti-
tumor) and tolerogenic (pro-tumor) immune cell function in the tumor microenvironment (TME). 
The regulatory T cell (Treg) lineage, characterized by expression of the transcription factor 
FoxP3, promotes tumor growth and immunotherapy resistance by establishing a tolerogenic 
TME (Figure 78A). As such, increased Treg infiltration in the tumor is generally correlated with 
poor prognosis across most human malignancies and increased resistance to checkpoint targeting 
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immunotherapy [135] [199]. While this makes Tregs attractive therapeutic targets, several 
factors have prevented clinical translation. First, any Treg-directed therapy must target only 
tumor infiltrating Tregs (TI-Tregs), while sparing peripheral Tregs (P-Tregs), to avoid 
catastrophic autoimmunity [219]. Second, from a molecular perspective, Tregs express genes 
that broadly recapitulate those in activated T cells, thus complicating design of targeting 
strategies that would spare anti-tumor cytotoxic CD8+ and inflammatory CD4+ T cell function 
[220]. Unfortunately, the Treg-targeting agents that satisfy these criteria, although effective in 
murine models, have not been effective in human patients [214] [221] [222], thus highlighting 
the need for more specific actionable vulnerabilities of TI-Tregs. 
 
Our work improves upon several recent studies that have assembled transcriptional profiles of 
Tregs from independent cancer patients. De Simone et al. profiled Tregs from up to ten non-
small cell lung cancer (NSCLC) or colorectal cancer (CRC) [223] patients; Plitas et al. 
sequenced Tregs from tumor, blood, and normal ductal epithelial tissue from a breast cancer 
cohort [224]; Zheng et al. performed single cell RNA sequencing (scRNA-Seq) on T cells from 6 
patients with hepatocellular carcinoma (HCC) [225]; finally, Magnuson et al. profiled 
cryopreserved Tregs from 12 CRC patients [226]. Each team sequenced Tregs flow sorted from 
tumor versus peripheral blood and most groups included FoxP3- CD4+ conventional T cells 
(Tconv), as additional controls.  
 
One limitation of all of these studies was a failure to include canonically activated Tconv cells as 
an additional control, as Tregs commonly overexpress markers of T cell activation [220]. We 
overcame this limitation by sequencing αCD3/αCD28-stimulated CD4 T cells from 8 patients, 
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thus more rigorously filtering shared markers. The samples profiled here were also patient-
matched, thus reducing inter-patient variability. Patients were selected across four tumor types 
that were not represented in the existing datasets, including: prostate adenocarcinoma, bladder 
cancer, clear cell renal carcinoma, and glioblastoma. Thus, Treg transcriptional profiles were 
acquired from both immunotherapy-sensitive and immunotherapy-resistant tumors and across 




Figure 78: Graphical Abstract and Experimental Design 
A) Illustrates immunosuppressive function of Tregs. B) Clinical data collected profiling Tumor 
vs Peripheral Tregs with additional control populations and outline of downstream analyses and 






Given the challenge of elucidating complex mechanisms from scRNA-Seq analysis, due to 
massive gene dropout effects which result in less than 4,000 genes being sequenced, we first de-
noised the scRNA-Seq data and then transformed it into highly reproducible and fully 
quantitative protein activity profiles, using VIPER (Virtual Inference of Protein-activity by 
Enriched Regulon analysis) [214]. Since VIPER infers protein activity based on the differential 
expression of a protein’s regulatory targets, akin to a highly multiplexed gene reporter assay, the 
most differentially active proteins represent candidate MR proteins that are most likely to 
mechanistically control the transcriptional state of these cells. This approach has never been 
previously applied to address this question.  
 
To validate candidate MR proteins, we further leveraged an optimized CHIME (chimeric 
immune editing) platform designed to support in vivo CRISPR-Cas9 perturbations in immune 
competent animals, without requiring artificial adoptive transfer [227]. Finally, we identified and 
experimentally validated drugs capable of rescuing the signature of P-Tregs in TI-Tregs, thus 
abrogating the tumor infiltrating phenotype, using the CLIA-certified OncoTreat algorithm.  
 
8.3 Results 
Discovery of Treg Tumor-infiltration Master Regulators from Human RNA-Sequencing 
Data using VIPER: Tumor and matched peripheral blood were collected from 32 patients, 
including 8 glioblastoma, 8 bladder adenocarcinoma, 8 clear cell renal carcinoma, and 12 
prostate adenocarcinoma patients. The following T cell lineages were freshly sorted from each 
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patient by FACS: TI-Tregs, P-Tregs, peripheral blood CD4 T cells, tumor-infiltrating CD8 T 
cells, and peripheral blood CD8 T cells. As additional controls for T cell activation, aliquots of 
peripheral blood CD4 and CD8 T cells were stimulated for 24-hours with anti-CD3/anti-CD28 
beads. RNA from each population was isolated and sequenced; in total we have generated a 236-
sample transcriptional dataset. Gene expression clustering of these data was extremely noisy 
(Figure 79A), with only weak separation based on T-cell subtype. By contrast, clustering based 
on VIPER-inferred protein activity showed clear separation of naïve and activated cells in a 
reduced principal component space, with tumor-infiltrating cells in-between (Figure 79B). 
Neither gene expression nor protein activity-based clustering stratified the data according to 
tumor type, suggesting a rather homogeneous molecular state for Tregs across different tumors. 
To define MRs with differential activity in TI-Tregs as compared to P-Tregs, naïve CD4, and 
activated CD4 T cells, we applied a Random Forest algorithm for selection of top discriminative 
features. This was done by splitting the dataset into 75% training and 25% testing, with test-
AUC for a given number of top differentially active proteins compared against test-AUC for a 
randomly sampled set of control proteins with differential activity p-value = 1.0, converging on a 
number of features which maximizes AUC while maintaining statistically significant difference 
compared to AUC from an equivalent number of randomly sampled control proteins (Figure 
79C, 79D). This analysis yielded 15 proteins significantly up-regulated in TI- vs. P-Tregs with 
VIPER activity computed on gene signature normalized against CD4non-Tregs (Figure 79F), 
with predictive test AUC = 0.982 (Figure 79D). A further 7 proteins were found to be 
differentially active in in TI-Tregs as compared to all controls, with VIPER activity computed on 
gene signature normalized against Tumor CD8+ T-cells (Figure 79E), with predictive test AUC 
= 0.988 (Figure 79C). These gene lists significantly overlap, and the union of the gene sets 
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comprises 17 putative MRs of Treg Tumor-Infiltration in total, including: EGR1, NR3C1, PBX4, 
MAFB, ID2, STAT4, NR4A3, NR4A1, TRPS1, EGR3, BANP, ZEB2, KLF4, GLI1, CSRNP2, 
KDM2B, and FOSL2.  
 




A) Principal Component Analysis (PCA) plot of Gene Expression colored by T-cell subtype 
where black indicates activated CD4nonTregs, green indicates activated CD8 T-cells, red 
indicates naïve CD4nonTregs, cyan indicated naïve CD8 T-cells, yellow indicates Tumor CD8 
T-cells, purple indicates Peripheral Tregs, and grey indicates Tumor Tregs. B) PCA plot of 
VIPER-inferred protein activity, colored as in A, showing spatial separation of T-cell sub-types 
not seen in A. C) Random Forest Feature Selection of VIPER Master Regulators Up-Regulated 
in Tumor Tregs vs Peripheral Tregs, Naïve CD4nonTregs, and Activated CD4nonTregs, 
normalized against Naïve CD8 T-cells. Boxplot shows distribution of test-AUCs for randomly 
sampled number of genes corresponding to x-axis, with red line indicating actual AUC of 
selected Master Regulator gene set. AUC of master regulator gene set for selected number of 
AUCs is shown in inset to the right. D) Random Forest Feature Selection of VIPER Master 
Regulators Upregulated in Tumor Tregs vs Peripheral Tregs, normalized against Naïve 
CD4nonTregs. Boxplot shows distribution of test-AUCs for randomly sampled number of genes 
corresponding to x-axis, with red line indicating actual AUC of selected Master Regulator gene 
set. AUC of master regulator gene set for selected number of AUCs is shown in inset to the right.  
E) Heatmap of VIPER Protein Activity for Master Regulators Selected in C. F) Heatmap of 
VIPER Protein Activity for Master Regulators Selected in D. 
 
Drug Screening in Human Tregs Identifies Tumor-Treg Directed Therapeutic Candidates: 
We next performed drug screening on human tumor Tregs to compile a resource of the 
transcriptional effect of FDA-approved and investigational oncology compounds on TI-Tregs, in 
an unbiased manner. For these studies, we first performed a single-dose viability screen on flow 
sorted and ex vivo expanded peripheral human Tregs using a library of 1,554 FDA-approved and 
investigational compounds plated in 96-well format (Figure 80A). From these, we selected 195 
compounds that inhibited Treg viability by 60% or more, then performed a secondary dose-
response titration with these compounds in order to identify IC20 doses at which 80% of plated 
peripheral Tregs remain viable at 24 hours of incubation. We next performed a high-throughput 
PLATE-Seq screen using the top 86 growth-inhibiting compounds at their IC20 concentrations 
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on Tregs flow sorted from a fresh clear cell renal carcinoma tumor and expanded ex vivo. The 
screen was run in duplicate and allowed for measurement of TI-Treg viability in addition to 
generating transcriptional profiles of Tregs exposed to each compound. (Figure 80A). This 
screen identified seven compounds with significantly greater growth inhibition on tumor derived 
Tregs than peripheral Tregs. Notably, each drug was found to significantly inhibit the protein 





Figure 80: High-Throughput Drug Screening Platform Identifies Potential Drug 
Candidates with Tumor-Treg Directed Toxicity 
A) Experimental design of High-Throughput Treg-Directed Drug Toxicity Screen, such that an 
initial set of 1,554 FDA-approved and investigational Oncology compounds are screened at 
single-dose for peripheral Treg growth inhibition, then 195 compounds with >60% inhibition at 
5uM are dose-titrated to define IC20 dose, and subsequently assessed for growth inhibition on 
sorted Tumor Tregs at peripheral-Treg IC20 dose, and effect on transcriptional state by PLATE-
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Seq. Table of all seven drugs found to have significantly higher toxicity in tumor Tregs relative 
to peripheral Tregs, and their respective in vitro doses. B) Heatmap of VIPER protein activity for 
Tumor vs Peripheral Treg MRs defined in 79E, 79F comparing transcriptional effect of drugs in 
A vs untreated control, with downregulation of nearly all identified Master Regulators by these 
drugs. 
 
In a parallel analysis, we utilized the CLIA-certified OncoTreat algorithm to rank each drug for 
its ability to invert the TI-Treg signature in our original human Treg transcriptional dataset, in a 




Figure 81: Tumor-Treg OncoTreat Drug Predictions, Expanded List of All 
Statistically Significant Compounds. 
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A) Patient-by-Patient Drug predictions according to inversion of patient-specific Tumor Treg vs 
Peripheral Treg protein activity signature by drug-treatment protein activity signature. Each drug 
predicted to invert Tumor Treg signature with -log10(Bonferroni-Corrected p-value) < 0.01 in a 
particular patient is colored red. Patients are grouped by tumor type. B) Table of all drugs 
significantly down-regulating Tumor-Treg MRs identified in Figure 79E, 79F, ordered by p-
value. Drugs also identified by growth screen to have differentially higher toxicity in Tumor 
Tregs vs Peripheral Tregs are highlighted in yellow. All seven of these are identified as 
statistically significant hits down-regulating Tumor-Treg MRs. 
 
By this approach we identified three of the seven above drugs that consistently inverted the TI-
Treg signature across nearly all patients (representing four tested tumor types): gemcitabine, 
triapine, and floxuridine (Figure 82A). As additional analytical validation, we ranked compounds 
by their overall ability to invert the 17-gene TI-Treg MR signature across all patients in 
aggregate. We found all seven drugs with differentially greater inhibition of TI-Tregs ex vivo 
were identified as statistically significant, with gemcitabine, floxuridine, and triapine in the top 5 





Figure 82: Transcriptional Profiling Identifies Drugs Acting on Functionally 
Validated Tumor Treg Master Regulator Proteins. 
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A) Patient-by-Patient Drug predictions according to inversion of patient Tumor Treg vs 
Peripheral Treg protein activity signature by drug-treatment protein activity signature. Each drug 
predicted to invert Tumor Treg signature with -log10(Bonferroni-Corrected p-value) < 0.01 in a 
particular patient is colored red. Patients are grouped by tumor type. Subset to drugs identified 
by tumor Treg growth screen in 80A, 80B, with columns colored by tumor type and clustered by 
unsupervised hierarchical clustering. B) Forest-plot showing the result of multiple cox regression 
assessing treatment effect on time-to-death for each of the treatments Gemcitabine, Floxuridine, 
Triapine, anti-PD1, anti-PD1+Gemcitabine, anti-PD1+Floxuridine and anti-PD1+Triapine, 
versus untreated control. Hazard ratios are shown with 95% confidence interval and p-value, 
such that anti-PD1+Gemcitabine most improves survival, followed by Gemcitabine 
monotherapy. C) Kaplan-Meier survival curves for treatments shown in B. 
 
Low-Dose Gemcitabine Alone and in Combination with anti-PD1 Inhibits tumor growth in 
immune-competent mice by differential depletion of Tumor-Specific Tregs.  
We first tested whether gemcitabine, floxuridine, or triapine are efficacious in vivo at doses 
approximating the IC20 values of the above PLATE-Seq assay, where differential activity 
against TI-Tregs is observed. We implanted C57BL/6J mice with subcutaneous MC38 
carcinomas, and initiated therapy 12 days later when MC38 tumors are largely resistant to anti-
PD-1 immunotherapy. Gemcitabine was administered IP on days 12, 15, and 18 at 12 mg/kg, or 
1/10th of the lowest conventional clinical-equivalent dose in mice (120 mg/kg). Floxuridine and 
triapine were IP daily from day 12-18, also at 1/10th the standard murine dose. Additional cohorts 
of mice received combination therapy with anti-PD-1 administered IP on days 12, 15, and 18. 
We found only low-dose Gem exhibited single-agent efficacy against established MC38 (Figure 
82B-C), and the combination of anti-PD-1 and low-dose Gem were synergistic, curing 50% of 
mice versus 0% individually (Fisher’s Exact Test p-value = 0.07). To test whether low-dose Gem 
functions via immune-dependent versus immune-independent mechanisms, we performed 
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parallel dose titrations of Gem in immune-competent C57BL/6J mice and immune-deficient 
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (Figure 83A-C). The standard clinical dose of 
120mg/kg inhibits tumor growth in both C57BL/6J and NSG mice, with cox regression p-values 
<0.001 (Figure 83D), but with no difference in efficacy between C57BL/6J and NSG (p = 0.19, 
Figure 83E). However, at 12mg/kg, efficacy was rapidly lost in NSG mice but not in C57BL/6J 
(p = 0.012, Figure 83E), such that 12mg/kg Gem dose achieved cure in 40% of C57BL/6J as 
monotherapy (equivalent to the observed cure rate at 120mg/kg in C57BL/6J mice) and 60% 
cure in combination with anti-PD1 checkpoint immunotherapy. At 1.2mg/kg there remains a 
trend toward improved outcomes in C57BL/6J vs NSG mice, but it is no longer statistically 









A) Tumor growth curves with varying doses of gemcitabine (0.12mg/kg, 1.2mg/k, 12mg/kg, 
120mg/kg) in NSG immune-incompetent mouse model, such that 120mg/kg represents the lowr 
end of clinically administered gemcitabine dosing. B) Tumor growth curves with varying doses 
of gemcitabine (0.12mg/kg, 1.2mg/k, 12mg/kg, 120mg/kg) in BL6 immune-competent mouse 
model.  C) Tumor growth curves with varying doses of gemcitabine (0.12mg/kg, 1.2mg/k, 
6mg/kg, 12mg/kg, 120mg/kg) in combination with anti-PD1 checkpoint immunotherapy in BL6 
immune-competent mouse model. D) Forest-plot showing the result of multiple cox regression 
assessing treatment effect on time-to-death for each of the treatments in A, B, and C as well as 
untreated controls. Hazard ratios are shown with 95% confidence interval and p-value. E) 
Kaplan-Meier survival curves for 1.2mg/kg, 12mg/kg, and 120mg/kg gemcitabine dosing (left-
to-right) comparing treatment efficacy in each mouse model, such that 1.2mg/kg shows non-
significant trend toward improved survival in BL6 mice (p = 0.09) but no cures, 120mg/kg 
shows no significant difference in efficacy between BL6 vs NSG mouse (p = 0.19), and 12mg/kg 
shows significant improvement in outcome for immune-competent BL6 mice, with 40% of mice 
cured in BL6 by gemcitabine monotherapy and 60% of mice cured by gemcitabine + anti-PD1. 
 
To test the hypothesis that low-dose Gem modulates TI-Tregs, we performed single cell RNA 
sequencing of MC38 tumor- and spleen-derived Tregs 24 hours after exposure to a single dose of 
12 mg/kg Gem as well as 24 hours after vehicle control. For this study, we implanted FoxP3Yfp-
Cre mice with MC38 to facilitate flow-sorting of TCR-b+ CD4+ FoxP3+ Tregs from tumor and 
spleen specifically by the YFP marker. We identified five unique clusters of Tregs by VIPER 
analysis of the single cell data (Fig 84A), of which cluster 3 was highly enriched for human TI-
Treg MRs (Fig 84B-C). In Vehicle-treated control, cluster 3 represented 7.8% of splenic Tregs, 
compared to 30.1% of TI-Tregs (p = 1.78e-84), while Gemcitabine-treatment reduced this cluster 
by roughly 50% to only 14.9% of TI-Tregs, while no change was observed in the spleen (Fig 
84D). Furthermore, this resulted in a proportional increase in Tregs from cluster 1, which exhibit 
signs of interferon exposure (high IFI16 activity). These data suggest low-dose Gem has 
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antagonistic effects on tumor Tregs expressing the TI-Treg signature in vivo, and that pro-
inflammatory effects of low-dose Gem can be uncoupled from direct tumor cytolysis in the 
context of anti-PD-1 checkpoint blockade. 
 
Figure 84: Single-Cell RNA-Sequencing Confirms Depletion by Low-Dose 




A) UMAP plot and unsupervised clustering by VIPER-inferred protein activity of Tregs from 
Untreated and Gemcitabine-treated Tumor and Spleen B) Distribution of Tumor-Treg MR 
signature (Figure 79E, 79F) normalized enrichment score by Gene Set Enrichment Analysis 
(GSEA), grouped by cluster, such that cluster3 is most enriched for the Tumor Treg signature. C) 
Heatmap of cell-by-cell protein activity for each Tumor-Treg MR identified by single-cell 
RNASeq, grouped by cluster. D) Barplot of Cluster Frequency in each sample, such that cluster3 
has a baseline frequency of 7.8% in spleen of vehicle-control sample and 30.1% in tumor (p = 
1.78e-84, OR = 0.198 [95% CI: 0.169-0.231]), with Frequency of only 14.9% in tumor of 






Figure 85: Single-Cell RNA-Seq Characterization of Tumor-Infiltrating and 
Peripheral Tregs With or Without Low-Dose Gemcitabine Treatment 
A) Number of Tregs per sample post-quality control filtering. Violinplot of data quality showing 
distribution of nFeature_RNA (number of unique genes profiled), nCount_RNA (number of 
unique molecular identifiers profiled), and percent.mt (percentage of mitochondrial transcripts) 
per cell. B) Clustering of Tregs by Gene Expression (top-left) and VIPER protein activity 
inference (bottom-right), showing noisiness of clustering by gene expression due to cross-sample 





Pooled CRISPRko-screen in Mouse Hematopoietic Stem Cell Model Validates Functional 
Role of Tumor Treg Master Regulators: To functionally validate individual candidate MRs for 
their ability to regulate TI-Treg recruitment and/or retention with the tumor microenvironment, 
we performed a pooled, in vivo CRISPR knockdown screen using the established CHIME 
(CHimeric IMmune Editing) system1. In brief, we sorted Lin-Sca-1+c-Kit- hematopoietic stem 
cells from mice constitutively expressing Cas9, and lentivirally transduced them with a sgRNA 
library targeting 34 genes—including 17 MRs, 13 randomly selected negative control genes with 
differential protein activity p-value = 1.0 between TI-Tregs and P-Tregs, and 4 positive controls 
known to be toxic to Tregs (Fig 86A). In this model, we transduced hematopoietic stem cells 
sorted from Cas9+ mice using a library of 102 sgRNAs (34 genes, 3 guides / gene) cloned in 
pXPR_053-vector, which also encodes a Vex fluorophore, then implanted them into recipients 
irradiated at two doses of 600 rads, allowing the immune system to reconstitute over 10 weeks. 
During this time, all Vex+ immune lineage cells, including Tregs, harbored CRISPR mediated 
knockouts. This system allowed us to implant syngeneic MC38 tumors, allow two weeks for 
tumor growth, then flow-sort Vex+ Tregs as well as CD4nonTregs from tumors and spleen to 
compare guide frequencies in Tumor Tregs vs peripheral Tregs. Upon engraftment and 
reconstitution of the hematopoietic system, roughly 25-40% of immune cells harbored CRISPR 
gene knockdown. We implanted two cohorts of CHIME chimeras with syngeneic MC38 tumors 
(the second cohort implanted with Vex+ Lin-Sca-1+c-Kit- hematopoietic stem cells harvested 
from the bone marrow of the first), allowed 18 days for tumor growth, then flow sorted 
CD4+CD25+ Tregs and CD4+CD25- Tconv cells from tumors and spleen (Figure 86B) and 




Figure 86: Chimeric Immune Editing Mouse Model Enables Validation of Treg 
Tumor-Infiltration Master Regulators 
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A) Experimental design for CRISPRko Validation of Tumor vs Peripheral Treg Master 
Regulators MR targets, randomly sampled negative control genes, and Treg-toxic positive 
control genes are listed in the Figure. B) Representative flow cytometry gating for Vex+ 
CRISPR-transduced Tregs, CD4nonTregs, and CD8 T-cells in Spleen (top) and Tumor (bottom). 
 
Across both mouse cohorts, we noted strong correlation between replicates of sorted spleen and 
tumor Tregs (Figure 87A,87B), such that the predicted Master Regulators Trps1, Mafb, Banp, 
Fosl2, Egr3, Gli1, Nr3c1, and Zeb2 were significantly depleted in TI-Tregs relative to P-Tregs 
(Figure 87C, 87E), indicating a significant degree of dependence on activity of these proteins for 
successful Treg tumor infiltration and/or retention. Importantly, Trps1, Mafb, Fosl2, Egr3, Gli1, 
and Zeb2 were also significantly depleted in TI-Tregs relative to tumor CD4 Tconv, (Figure 87D, 
87E) supporting Treg-specificity in the function of these genes, such that knocking them down 





Figure 87: CRISPRko of Master Regulators Reproducibly Inhibits Treg Tumor-
Infiltration and Tumor Growth 
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A) Correlation of sgDNA frequency distribution between replicates of Spleen and Tumor Tregs 
in experimental cohort 1. B)  Correlation of sgDNA frequency distribution between replicates of 
Spleen and Tumor Tregs in experimental cohort 2. C) Table of log2(Fold Change) and 
Bonferroni-corrected p-values Stouffer-integrated across experimental cohorts for genes with 
consistent and statistically significant depletion of targeting gDNAs in Tumor Tregs vs Spleen 
Tregs. D)  Table of log2(Fold Change) and Bonferroni-corrected p-values Stouffer-integrated 
across experimental cohorts for genes with consistent and statistically significant depletion of 
targeting sgDNAs in Tumor Tregs vs Tumor CD4-nonTregs. E) Barplot of -log10(P-values) 
from C and D (inset). F) Tumor growth curves and Kaplan-Meier plot for CRISPRko validation 
using sgRNAs targeting TRPS1 vs or non-targeting scramble-control, showing significant 
difference in tumor growth (p<0.05). 
 
These findings were consistent across both CRISPR screen cohorts (Figure 88). Notably, 
knockdown of the positive control Foxp3 is expected to be differentially more lethal to Tregs 
than CD4nonTregs and is also differentially depleted in this comparison. The most statistically 
significant hit both in terms of relative depletion in TI-Tregs vs P-Tregs (p=2.21*10-175) and 
relative depletion in TI-Tregs vs Tumor CD4 Tconv (p=1.72e-76) was Trps1, a gene with 




Figure 88: Cohort-Specific CRISPR Validation Results 
A) Barplot of -log10(Bonferroni-Corrected P-values) for genes with statistically significant 
depletion of targeting gDNAs in Tumor Tregs vs Peripheral Tregs, separately for experimental 
cohort 1 (left) and experimental cohort 2 (right). B) Barplot of -log10(Bonferroni-Corrected P-
values) for genes with statistically significant depletion of targeting gDNAs in Tumor Tregs vs 
Tumor CD4nonTregs, separately for experimental cohort 1 (left) and experimental cohort 2 
(right). 
 
Loss of Trps11 in Hematopoietic Cells Significantly Inhibits Tumor Growth  
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Due to the discovery from high-throughput CRISPRko screen that Trps1 knockout has the 
strongest effect on inhibiting Treg tumor-infiltration and the greatest differential effect on Tumor 
Tregs vs Tumor CD4-non-Tregs, we performed a follow-up single-gene knockdown of Trps1 in 
the hematopoietic lineage in a cohort of 6 bone marrow transplant chimeras. For comparison, we 
also performed transduction of hematopoietic stem cells with a non-targeting scramble guide as a 
control and transplanted into a comparator cohort of 5 mice (Figure 87F). Upon simultaneous 
implantation of both cohorts with MCA205, an immune-resistant fibrosarcoma tumor model, 
there was a significantly slower tumor growth among mice where Trps1 was targeted by 
CRISPRko  (p<0.05), with dramatic biological effect, such that three of the six mice in this 
cohort spontaneously rejected the tumor and were cured, and three of the remaining four had 
dramatically slowed rate of tumor growth relative to mice with scramble control guide (Figure 
87F). This indicates that inhibition of TRPS1 represents a potent immune-stimulatory pathway, 
which has never previously been described.  
 
8.4 Discussion 
Treg immunosuppression in the TME is a major barrier to antitumor immunity and undermines 
efficacy of checkpoint blockade immunotherapy, which remains effective only in a minority of 
cancer patients [219] [228]. Limitations in the prior research has led to prioritization of tumor 
Treg targeting approaches that have failed to affect this clinical reality. We have tailored our 
approach to overcome these limitations, as solving the problem of Tumor-Specific Treg 
depletion would have extremely broad clinical impact, leading to both conceptual advancements 
in the understanding of Treg biology and a selection of actionable targets with potential for rapid 
translation into clinical trials. Furthermore, by generating a resource of high-throughput drug 
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perturbations on transcriptional profile of human Tumor Tregs, we can apply the New York and 
California CLIA-certified OncoTreat algorithm [21] to rank current FDA-approved and 
investigational drug compounds according to their ability to invert the identified Tumor vs 
Peripheral Treg Master Regulator activity, which may further accelerate drug development and 
clinical trials directed at the identified Master Regulators. 
 
By applying VIPER followed by Random Forest feature selection to a unique bulk-RNA-
Sequencing database of purified Tregs, CD4nonTregs, and CD8 T-cells sorted from tumor and 
peripheral blood of 36 patients across a variety of tumor types, we have discovered a set of 17 
master regulators  (EGR1, NR3C1, PBX4, MAFB, ID2, STAT4, NR4A3, NR4A1, TRPS1, 
EGR3, BANP, ZEB2, KLF4, GLI1, CSRNP2, KDM2B, FOSL2) specifically enriched in Tumor 
Tregs relative to Tregs in the peripheral circulation and non-Treg subsets. We have found that 
the activity of these proteins is differentially upregulated in tumor-infiltrating regulatory T cells 
(Tregs) relative to peripheral blood Tregs, peripheral blood conventional CD4 T cells, and ex 
vivo activated T cell controls in samples freshly isolated from human patients, demonstrating 
relative specificity to Tumor Tregs, along with a generalized effect across tumor types (Figure 
79).   
 
Downregulating or inhibiting these proteins was found to decrease the ability of regulatory T 
cells (Treg) to infiltrate tumors and locally exert their immunosuppressive function, thus 
augmenting the immune response to cancer. Since this predominantly targets Tumor-Infiltrating 
Tregs rather than peripheral Tregs, it therefore limits adverse effects resulting from systemic 
Treg inactivation, which may otherwise lead to autoimmune diseases and chronic inflammation. 
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We have functionally validated the MRs by CRISPRko in a Chimeric Immune Editing (CHIME) 
MC38 mouse tumor model (Figure 86), such that the top-most-depleted targeted MRs in Tumor 
Tregs relative to Peripheral Tregs were found to be depleted with highly significant p-values 
both in Tumor Tregs relative to Peripheral Tregs and in Tumor Tregs relative to Tumor 
CD4nonTregs (Figure 87), and included TRPS1 as the most-strongly-depleted MR.  
 
These data show that the loss of TRPS1 dramatically impairs the ability of Tregs to infiltrate the 
tumor mass, relative to control tissue (spleen). Further, the retained presence of TRPS1 and other 
master regulator knockdown cells among circulating Tregs shows that TRPS1, MAFB, BANP, 
FOSL2, EGR3, GLI1, NR3C1, and ZEB2 are not required for survival or homeostatic regulation 
of extra-tumoral Tregs. The ability of CRISPRko perturbed HSCs to successfully engraft and 
reconstitute all subsets of T-cells further indicates that inhibition of the Master Regulators is not 
broadly toxic to immune cells. Instead, these data show that Master Regulator activity mainly 
controls Treg targeting to tumors. Finally, we observe a dramatic inhibition of tumor growth in 
mice with single-gene CRISPRko of TRPS1 in the hematopoeitic lineage, highlighting inhibition 
of TRPS1 as a novel target for Treg-directed immunotherapy, particularly exciting since the role 
of TRPS1 in T-cells has never previously been described.  
 
TRPS1 is a transcription factor that represses GATA-regulated genes and binds to a dynein light 
chain protein. As such, TRPS1 may be therapeutically inhibited by the action of drugs which are 
found to invert the expression of its downstream regulon targets. Alternatively, TRPS1 may be 
inhibited by small molecule inhibitors, antisense oligonucleotides, epigenetic modulators, protein 
mimetics, intracellular targeted antibodies, specific degraders such as proteolysis targeting 
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chimera (PROTAC) molecules, and gene therapy. Analogous approaches may be taken to target 
the other discovered Master Regulators, alone or in combination, anticipating further synergy in 
combination with conventional immunotherapy, antibody-drug conjugates, targeted therapy, 
radiation therapy, chemotherapy, and/or surgery. 
 
Furthermore, we have generated a unique drug perturbation PLATE-SEQ resource from human 
Tumor-Infiltrating Tregs, which we have used to effectively identify drugs with a transcriptional 
effect on Tumor-Treg Master Regulators and differential toxicity to Tumor vs Peripheral Tregs 
(Figure 80), specifically highlighting low-dose gemcitabine as having great potential for rapid 
translation to clinical trials. Critically, the dosages at which gemcitabine was found to be toxic to 
Tumor Tregs in vitro were orders of magnitude lower than doses which are clinically 
administered as cytotoxic tumor-cell-directed therapy. Therefore, low-dose gemcitabine 
combination with checkpoint immunotherapy is likely to exert differential depletion of Tregs 
relative to non-Treg populations and Tumor Tregs relative to non-Tumor Tregs, representing 
potential for novel drug synergy to overcome Treg-mediated treatment resistance with minimal 
drug toxicity. We have found that each of the drugs observed to have differential toxicity in TI-
Tregs vs P-Tregs also reduced activity of the CRISPR-validated Master Regulator gene set we 
have identified (Figure 80B), suggesting that a more intentional development of drugs targeting 
these master regulators as an intended rather than secondary effect may represent an even better 
synergy with immunotherapy.  
 
Critically, gemcitabine administered in vivo at a dose of 12mg/kg alone and in combination with 
anti-PD1 checkpoint immunotherapy was found to significantly inhibit tumor growth in immune-
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competent, but not NSG mouse model (40% cure rate in immune-competent mice as 
monotherapy, 60% cure rate in combination with anti-PD1, and 0% cure rate in NSG mice, p = 
0.012). This is especially significant because typical cytotoxic doses of gemcitabine administered 
as anti-tumor therapy exceed 120mg/kg, at which there is no statistically significant difference in 
survival between immune-competent and immune-incompetent mice (p = 0.19). Therefore, the 
immunogenic effects of gemcitabine are more pronounced at low doses, where we observe 
differential toxicity in TI-Tregs relative to P-Tregs, confirmed in vivo by single-cell RNA-
Sequencing (Figure 84). The Tregs depleted by gemcitabine are found to be tumor-specific and 
characterized by high activity of the Master Regulator protein signature we have discovered, 
including TRPS1, suggesting inhibition by gemcitabine of these MRs as the putative mechanism 
of its immunogenicity in the low-dose regimen.  
 
The paradigm we have presented of large-scale drug screening ex vivo followed by CRISPR 
validation of putative regulatory proteins in chimeric mouse model represents a novel approach 
to discovery of Treg-directed immunotherapy targets, and can be extended in the future to other 
immunosuppressive cell types, as well as serving as a resource for further investigation of 
potential Treg-depleting therapies. This may discover previously unknown treatment synergies 
and represents a paradigm-shift by informing development of rational pan-cancer treatment 
approaches directed at Treg-mediated treatment resistance. The utility of this approach is 
exemplified by our discoveries of low-dose gemcitabine’s differential toxicity to tumor-
infiltrating Tregs with potential for rapid clinical translation, and of TRPS1 as a mechanistic 
regulator of Treg tumor-infiltration with significant effect on tumor growth and attractive 





Clinical Sample Collection, Sorting, and RNA-Sequencing: Tissue was collected from 
treatment-naïve resected tumors across patients with four tumor types, including 8 patients with 
glioblastoma multiforme, 8 patients with clear cell renal carcinoma, 8 patients with bladder 
cancer, and 12 patients with prostate cancer (Figure 79). For each patient, 50ml of peripheral 
blood was drawn at the same time that tumor was resected. Tumors were dissociated with the 
GentleMACS OctoDissociator following manufacturer’s instruction, and subsequently Tregs and 
CD8 T-cells were flow-sorted from tumor along with Tregs, naïve CD4nonTregs, and naïve CD8 
T-cells from peripheral blood. An aliquot of naïve CD8 and CD4nonTreg were stimulated ex 
vivo with IL2 and anti-CD3/anti-CD28 beads for 24 hours to induce T-cell activation. Flow-
sorted and ex-vivo-stimulated populations were processed to prepare cDNA libraries following 
Illumina user guide and were sequenced on Illumina NovaSeq 6000 Sequencing System.  
 
Gene Expression and VIPER Analysis: Gene Expression was combined across all samples and 
scaled to log10(Transcripts Per Million + 1). Gene Expression was subsequently scaled across 
rows by z-score transformation and used as input for Principal Component Analysis (Figure 
80A) and differential gene expression. Log10(TPM+1) matrix was separately used to infer gene 
regulatory network structure by the ARACNe algorithm. ARACNe was run with 100 bootstrap 
iterations using 1785 transcription factors (genes annotated in gene ontology molecular function 
database as GO:0003700, “transcription factor activity”, or as GO:0003677, “DNA binding” and 
GO:0030528, “transcription regulator activity”, or as GO:0003677 and GO:0045449, “regulation 
of transcription”), 668 transcriptional cofactors (a manually curated list, not overlapping with the 
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transcription factor list, built upon genes annotated as GO:0003712, “transcription cofactor 
activity”, or GO:0030528 or GO:0045449), 3455 signaling pathway related genes (annotated in 
GO biological process database as GO:0007165, “signal transduction” and in GO cellular 
component database as GO:0005622, “intracellular” or GO:0005886, “plasma membrane”), and 
3620 surface markers (annotated as GO:0005886 or as GO:0009986, “cell surface”). ARACNe is 
only run on these gene sets so as to limit protein activity inference to proteins with biologically 
meaningful downstream regulatory targets, and we do not apply ARACNe to infer regulatory 
networks for proteins with no known signaling or transcriptional activity for which protein 
activity may be difficult to biologically interpret. Parameters were set to zero DPI (Data 
Processing Inequality) tolerance and MI (Mutual Information) p-value threshold of 10-8, 
computed by permuting the original dataset as a null model.  
 
Using the ARACNe gene regulatory network structure, VIPER protein activity inference was 
performed on gene expression signature. First directly on z-score-scaled gene expression 
signature for all T-cell subtypes, used for Principal Component Analysis and clustering (Figure 
80A). Then separately scaling Tumor and Peripheral Tregs against naïve CD4nonTregs by 
viperSignature command in Rstudio for comparison of Tumor Treg vs Peripheral Treg (Figure 
80D, 80F), and scaling all Tregs and CD4nonTregs against naïve CD8nonTregs by 
viperSignature for comparison of Tumor Treg vs all Treg and CD4nonTreg controls (Figure 80C, 
80E). 
 
Random Forest Feature Selection: The full dataset was randomly split into 75% training data 
and 25% testing data. On training data, a Random Forest Model was built with VIPER-inferred 
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protein activity to classify Tumor Treg vs Peripheral Treg (Figure 80D) or Tumor Treg vs all 
Controls (Figure 80C), taking the list of all differentially active proteins (t-test p-value < 0.01) as 
an initial feature set. Features were ranked by mean decrease in model accuracy and included 
one-by-one to construct random forest models with feature selection. Predictive power was 
assessed by Area-Under-ROC-Curve (AUC) in the held-out testing data, and a null model of 
AUC was constructed from random sampling of the same number of genes (from the set of genes 
with differential activity p-value =1.0) 1000 times. For each comparison, the maximum number 
of discriminative genes was selected for which AUC vs null model remained statistically 
significant (Figure 80C, 80D). These genes are shown in Figure 80E and 80F and aggregated 
into a combined list of 17 putative Tumor Treg vs Peripheral Treg Master Regulators with 
Activity specifically upregulated in Tumor Tregs.  
 
CRISPR Validation in Chimeric Immune Editing Model: Confirmatory evidence that the 
predicted proteins regulate tumor Treg infiltration  was generated in murine models in a pooled 
CRISPR screen (Figure 82); by comparing the differential representation of gene-knockout Tregs 
in tumor versus non-tumor tissue (spleen, as a control), for each candidate Master Regulator 
gene. For these studies, Hematopoetic Stem Cells (HSCs) were extracted from Cas9+ mice and 
transduced with sgRNA library targeting 34 genes with 3 guides/gene. The transduced stem cells 
were reimplanted into irradiated recipient mice, allowing reconstitution of the entire immune 
system, including Tregs, with a unique pool of CRISPR knockout genes in place. Subsequent 
implantation of a subcutaneous MC38 murine colon adenocarcinoma tumor model allowed direct 
observation of differential infiltration of tumors by Tregs receiving selected CRISPR guides, in a 
single, high-throughput experimental screen. Critically, the experiment would not have been 
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possible on a genome-wide level without initial narrowing of candidate master regulators by 
VIPER protein activity analysis, due to fundamental limitations in achieving a sufficient number 
of tumor-infiltrating Tregs harboring guide DNAs for the full set of human genes. This is 
because we typically find fewer than 10,000 tumor-infiltrating Tregs in MC38 tumor model.  
 
We designed the gDNA library with three guides per gene targeting the 17 predicted Tumor Treg 
MRs and 13 randomly sampled negative control genes (genes with p=1.0 comparing 
Tumor Treg to Peripheral Treg). We also included Treg context-specific positive controls such as 
Foxp3 and Cd4 and core-essential genes Cdk1 and Plk1 (these were not detected in any cells 
post-transduction, indicating successful gene-editing). For guide design, we used the Broad 
Institute Genetic perturbation platform (GPP) sgRNA designer-tool. Sorted Cas9+ hematopoietic 
stem cells were successfully transduced and implanted into irradiated recipient mice, A cohort of 
six replicate mice (cohort 1) and three replicate mice (cohort 2) were separately implanted and 
harvested. Vex+ gDNA-bearing Tregs and CD4nonTregs were flow-sorted from Tumor and 
spleen, separately.  
 
Pelleted Tregs/CD4s were first pooled together, with entire tumor samples pooled and spleen 
samples pooled in proportion to ratio of sorted cell counts from Tumor. gDNA was extracted 
first by adding 400ul of RIPA buffer (with added RNAseA) on top of the pelleted Tregs/CD4s, 
followed by 1h incubation at 65C. This was followed by Phenol/Chloroform/Isoamyl alcohol-
extractions and Isopropanol-precipitations. Extracted gDNA was divided into 8 replicates with 
equal volumes for cohort 1 and four replicates with equal volumes for cohort 2, each then 
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amplified by 2-step PCR and then sequenced. Correlation between replicates was assessed 
(Figure 83A, 83B).  
 
After sorting and gDNA sequencing, differential frequency of guides in Tumor Treg vs 
Peripheral Treg and Tumor Treg vs Tumor CD4nonTreg are assessed by DESeq with Bonferroni 
correction on the p-values, separately (Figure 88), and then p-values were integrated by 
Stouffer’s Method (Figure 87A-E).  
 
CRISPRko library design : For CRISPRko screening we designed the target gene list to 
include 34 genes (3 sgRNAs / gene)—including 17 MRs and 13 negative control genes (genes 
whose loss is not predicted to differentially affect Tumor Tregs compared to Peripheral Tregs i.e. 
p=1.0 comparing Tumor Treg to Peripheral Treg), and 4 positive controls (2 genes whose loss is 
known to be toxic to Tregs (FOXP3 and CD4) and 2 core-essential genes (PLK1 and CDK1)). 
Positive control sgRNAs were not detected in any cells post-transduction, indicating successful 
gene-editing. For guide design, we used the Broad Institute Genetic perturbation platform (GPP) 
sgRNA designer-tool. The pooled guide-library was ordered from Twist-bioscience.  
 
CRISPRko oligo synthesis and library cloning: Oligo libraries (102 oligos) were ordered from 








From the initial oligo pool, this TREG sub-library was amplified first with KAPA polymerase 
(KK2502) with the following PCR primers and settings:  
TREG_1F=AGCGTGGAGTGAGCC,  
TREG_1R=TCTGGTTGCTGCCGA 
DNA(oligo pool 1ng/ul) 2ul 
5xHF-buffer   5 
dNTPs    0.75ul 
Oligo_F(10uM)   0.75ul 
Oligo_R(10uM)   0.75ul 
KAPA pol    0.5ul 
H2O     to 25ul 
95C  3min 
98C  20s 
55C  15s 
72C  15s 
72C  1min 
4C  --- 
 
The PCR product from PCR1 was gel purified with GeneJet gel purification-kit. The final 2nd 
PCR prior to the Gibson cloning-step was done with the following primers and settings: 
TREG_2F: AGCGCTCACAATTATATATCTTGTGGAAAGGACGAAACACCG 
TREG_2R: CGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC 
DNA(product from 1st PCR)  3ng 
5xHF-buffer    5 
dNTPs     0.75ul 
Oligo_F(10uM)    0.75ul 
Oligo_R(10uM)    0.75ul 
KAPA pol     0.5ul 
H2O      to 25ul 
95C  3min 
98C  20s 
64C  15s 
72C  15s 
72C  1min 
4C   --- 
 
Both of these amplifications were done with qPCR and the program was stopped before the 
amplification started to plateau. After PCR the insert was gel purified (GeneJet) and Gibson 
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cloned into BsmBI-digested pXPR_053 (Addgene# 113591). Gibson cloned insert and vector 
was column purified (GeneJet) and large-scale electroporated into Lucigen Enduro competent 
cells. The bacterial colonies were scraped from 24,5cm x 24,5cm agar plates, so that the 
estimated library complexity was approximately 1000 colonies / sgRNA. 
 
Lentiviral packaging of the sgRNA library: 13 million 293T cells were seeded for each 15cm 
dish the night before transfection. The following morning, viral transfections were conducted 
with the following components:  
- 22.1ug sgRNA containing pXPR_053 (Addgene 113591). 
- 16.6ug PsPAX2 (Addgene 12260) 
- 5.5ug PMD2G (Addgene 8454).  
- 1660ul of sterile H2O. 
 
 After mixing the plasmids and H2O, 110,6ul of Fugene HD (Promega) was added to the mix. 
The transfection mixture was vortexed, then incubated for 10 minutes before adding dropwise to 
293T cells. The transfection mixture was removed the following day and virus was collected at 
48h and 72h after initial transfections. To remove cellular debris, the virus-containing 
supernatant was centrifuged 500 x g for 5min and filtered with 0.45um PES filters (Millipore), 
followed by ultracentrifugation (25,000rpm for 2h), dissolving the viral pellet into PBS, 
aliquoting the virus and storing the aliquots at -80C. Viral titer was measured with 293T cells by 
using violet-excited GFP in the pXPR_053-plasmid. 
 
Cell culture and sgRNA transductions into hematopoietic LSK cells:  
HEK293T cells: HEK293T cells used in this study were obtained from the American Type 
Culture Collection (ATCC) and cultured at 37 °C in a humidified incubator (5% CO2) with the 
following media: DMEM + 10% FBS, 1% L-Glutamine and 1% Penicillin/Streptomycin. Cell 
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line was tested for mycoplasma status before viral production. LSKs: After sorting the LSKs 
from donor mice, cells were sorted into 96-well plate (100k LSKs/well) and incubated overnight 
in SFEM media supplemented with 100 ng/mL of the following cytokines: SCF, TPO, Flt3-
Ligand, and IL-7. Pen/Strep was used in all in vitro cultures. The following day, LSK cells were 
transferred into Retronectin-coated 24-well plate and sgRNA-containing Lentiviruses were 
added to the wells with MOI 30 (based on viral tittering in 293T cells). The final volume was 
adjusted to 400ul / well by adding cytokine supplemented SFEM stem cell media. The cells were 
centrifuged at 650 x g for 1.5 hours at 37°C with an acceleration of 2 and a brake of 1. After 
centrifugation, the plate was placed into 37C incubator for 1h, before adding 500 microliters of 
prewarmed stem cell media on top of the LSKs and overnight incubation. Transduced LSKs 
were implanted into donor mice irradiated with two doses of 600rads, spaced four hours apart, by 
intravenous tail vein injection immediately following the second irradiation.  
 
Genomic DNA extraction: Since the number of Vex+ tumor Tregs was very low in any 
individual mouse and because the mice all share the same genetic background, we decided to 
pool all tumor Tregs and tumor CD4s together across mice before the gDNA extraction step in 
order to reliably purify gDNA with sufficient yield. After the gDNA extractions, the extracted 
gDNA was split evenly into 8 (for cohort 1) or 4 (for cohort 2) separate technical replicates and 
library prep PCRs and NGS were done individually to all these technical replicates. In other 
words, genomic DNA was extracted by pooling all the FACS sorted Vex+ tumor Tregs (or tumor 
CD4 cells) from all the mice within each cohort and lysing the cells with 400ul of RIPA-buffer + 
RNAseA, followed by 1h incubation in 65C. After this, 400ul of Phenol/Chloroform/Isoamyl 
alcohol was added, followed by 6 min centrifugation at room temperature. Finally, the gDNA 
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was recovered by Isopropanol precipitation. For spleen Tregs and spleen CD4 all the gDNA 
extractions were done individually for each mouse-sample (not pooled together at the lysis-stage 
as with tumor Tregs and tumor CD4s), since the number of extracted Vex+ cells was much 
higher than with tumor Tregs / CD4s. Otherwise, the protocol was identical compared to gDNA 
extractions from tumor Tregs and CD4s. 
 
Preparation of NGS libraries from the extracted gDNA: NGS libraries were prepared from 
extracted gDNAs following a 2-step PCR protocol with 2 x KAPA Mastermix (KK2612, KAPA 
Biosystems). For spleen Tregs and CD4s, individually purified gDNAs were pooled before the 
NGS library prep PCRs. This was done by pooling Spleen Tregs and CD4s in the same ratio as 
Tumor Tregs and CD4s previously pooled for gDNA extraction as measured by Vex+ FACS cell 
count. Before the 1st PCR, all pooled Treg and CD4 samples were split into 8 or 4 (first and 
second cohort) technical replicates, which were amplified separately and with different sample 
indexes. Correlation between replicates by gDNA frequency was assessed in each cohort and for 
each set of replicates following library sequencing (Figure 83A, 83B). Both 1st and the 2nd 
PCRs were stopped before amplification started to saturate in order to avoid biases in the library 




gDNA    12.5 - 25% of pooled material (depending on the cohort) 
2 x KAPA mastermix  12.5ul 
Oligo_F(10uM)  1ul 
Oligo_R(10uM)  1ul 















NNNNNNNN = sample-index 
1:50 diluted DNA template from PCR 1 8ul 
2 x KAPA mastermix    12.5ul 
Oligo_F(10uM)    1ul 
Oligo_R(10uM)    1ul 







After the 2nd PCR, samples were gel purified (GenJet), pooled and sequenced with Illumina. 
Sequencing reads were aligned to a reference of sgRNA template sequences by kallisto to 
determine a counts matrix of reads per guide for each sample. Differential frequency of guides 
targeting the same gene in Tumor Treg vs Peripheral Treg and Tumor Treg vs Tumor 
CD4nonTreg was assessed by DESeq with Bonferroni correction on the p-values, separately 
(Figure 81), and then p-values across cohorts were integrated by Stouffer’s Method (Figure 83C-
F).  
 
High-Throughput Treg-Directed Drug Screening: From an initial library of 1,554 FDA-
approved or investigational oncology compounds (SelleckChem), single-dose viability screening 
was performed in vitro on human Tregs sorted from Buffy Coat peripheral blood mononuclear 
cells (PBMCs). 195 compounds were identified which reduced peripheral Treg growth by at least 
60% relative to DMSO control at 5uM. For these, dose-response titrations were performed to 
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identify the IC20 dose at which peripheral Treg growth is inhibited by 20%, either by direct 
toxicity to Tregs or inhibition of Treg cell division. Subsequently, Tumor-Infiltrating Tregs were 
sorted from a large clear cell renal carcinoma tumor and plated with Treg-expansion beads in 
culture for 5 days, resulting in 5-million Tumor-Infiltrating Tregs. These were suspended at 
160,000cells/mL and divided among 2 replicate plates for downstream RNA-Sequencing 
(PLATE-Seq) and 1 plate for viability testing in comparison to peripheral Tregs at the peripheral 
Treg IC20 dose. Seven drugs with significantly greater toxicity to tumor Tregs vs peripheral 
Tregs were identified (Figure 84A). 
 
Wells of drug-treated Tregs were RNA-Sequenced and each normalized with viperSignature 
against the internal DMSO-control wells on the same PLATE. VIPER was run on the normalized 
gene expression using the T-cell ARACNe network inferred from sorted bulk-RNA-Sequencing 
clinical data. Drugs were ranked on their overall inversion across patients of the 17-gene Master 
Regulator signature previously identified and validated by CRISPR (Figure 81B), as well as on 
their patient-by-patient inversion of Tumor-Treg vs Peripheral-Treg protein activity signature by 
OncoTreat (Figure 86).  
 
Tumor-Growth Screens: We assessed tumor growth first in response to treatment with 
floxuridine, triapine, and gemcitabine relative to untreated control, with or without anti-PD1 
immunotherapy (Fig 82B-C). 10 C57BL/6J mice per treatment arm were implanted with 
subcutaneous MC38 tumor cells. Treatment was initiated after 12 days of initial tumor growth, at 
which point mice were monitored for tumor volume until exceeding 1000mm^3 or ulceration 
exceeding a diameter of 5mm. Gemcitabine was administered IP on days 12, 15, and 18 at 12 
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mg/kg, or 1/10th of the lowest conventional clinical-equivalent dose in mice (120 mg/kg). 
Floxuridine and triapine were IP daily from day 12-18 at 1mg/kg and 5mg/kg, respectively, also 
reflecting 1/10th the standard murine dose. Mice receiving anti-PD-1 were administered anti-PD-
1 IP on days 12, 15, and 18. Treatment response outcomes were assessed by cox proportional 
hazards model (Figure 82B), Kaplan-Meier curve (Figure 82C), and computation of mean tumor 
growth slope over time. By all criteria, gemcitabine was the only treatment found to significantly 
inhibit tumor growth, alone and in combination with anti-PD1.  
 
To further assess the doses at which gemcitabine inhibits tumor growth and the immune-
mediated effects of gemcitabine, we performed parallel dose titrations of Gem in immune-
competent C57BL/6J mice and immune-deficient NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice, 
administering doses ranging from 0.12mg/kg up to 120mg/kg as shown in Figures 83A-83C. Six 
mice were treated per treatment arm. Doses were administered IP on days 12, 15, and 18, and 
treatment response was assessed by cox proportional hazards model (Figure 83D) and Kaplan-
Meier test (Figure 83E).  
 
Finally, tumor growth was assessed in single-gene TRPS1 CRISPRko generated by the CHIME 
protocol described above, compared to transduction by CHIME with a non-targeting scramble 
control guide. These cohorts included 6 TRPS-KO mice and 5 Scramble-control mice. For these 
mice, we pooled two guides targeting TRPS1 and two non-targeting guides with approx. MOI 50 
based on 293T cell line tittering. These guide sequences were: 
TRPS1_1: AGAGGGGCAGACATCCTACG 
TRPS1_2: AGCATCGGATGTCAAACAGG 
Non-targeting guide 1: GCGAGGTATTCGGCTCCGCG 




Following immune reconstitution, mice were initially implanted with subcutaneous MC38 tumor, 
which spontaneously regressed in both arms following initial tumor growth for two weeks post-
implantation. Subsequently, these mice were implanted with subcutaneous MCA205, a more 
aggressive and immune-resistant fibrosarcoma cell line. Tumor volume was assessed every 48 
hours following day 7 post-implantation, such that tumor volumes in TRPS1 mice3 were 
determined to be significantly lower than scramble controls by day 13 (p < 0.05). Treatment 
response was assessed by cox proportional hazards model and Kaplan-Meier test.   
 
Single-Cell RNA-Seq Profiling of Gemcitabine Effect on TI-Tregs: To test the hypothesis 
that low-dose Gem modulates TI-Tregs, we performed single cell RNA sequencing of MC38 
tumor- and spleen-derived Tregs 24 hours after exposure to a single dose of 12 mg/kg Gem as 
well as 24 hours after vehicle control. For this study, we implanted FoxP3Yfp-Cre mice with MC38 
to facilitate flow-sorting of TCR-b+ CD4+ FoxP3+ Tregs from tumor and spleen specifically by 
the YFP marker. Tissue was harvested at day 14 post tumor-implantation, and fresh tissue was 
minced to 2-4 mm sized pieces in a 6-cm dish and subsequently digested to single cell 
suspension using Multi Tissue Mouse Tumor Dissociation Kit 1 (Miltenyi Biotec) and a 
gentleMACS OctoDissociator (Miltenyi Biotec) according to the manufacturer’s instructions.  
 
Dissociated cells were flow-sorted for YFP+ Tregs and processed for single-cell gene expression 
capture (scRNASeq) using the 10X Chromium 3’ Library and Gel Bead Kit (10x Genomics), 
following the manufacturer’s user guide at the Columbia University Genome Center. After 
GelBead in-Emulsion reverse transcription (GEM-RT) reaction, 12-15 cycles of polymerase 
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chain reaction (PCR) amplification were performed to obtain cDNAs used for RNAseq library 
generation. Libraries were prepared following the manufacturer’s user guide and sequenced on 
Illumina NovaSeq 6000 Sequencing System. Single-cell RNASeq data were processed with Cell 
Ranger software at the Columbia University Single Cell Analysis Core. Illumina base call files 
were converted to FASTQ files with the command “cellranger mkfastq.” Expression data were 
processed with “cellranger count” on pre-built mouse reference. Cell Ranger performed default 
filtering for quality control, and produced a barcodes.tsv, genes.tsv, and matrix.mts file 
containing transcript counts for each cell, such that expression of each gene is in terms of the 
number of unique molecular identifiers (UMIs) tagged to cDNA molecules corresponding to that 
gene.  
 
These data were loaded into the R version 3.6.1 programming environment, where the publicly 
available Seurat package was used to further quality-control filter cells to those with fewer than 
25% mitochondrial RNA content, more than 1,000 unique UMI counts, and fewer than 15,000 
unique UMI counts. Pooled distribution of UMI counts, unique gene counts, and percentage of 
mitochondrial DNA after QC-filtering is shown in Figure 85A, along with the number of sorted 
Tregs captured per sample. Gene Expression UMI count matrix was processed in R using the 
Seurat SCTransform command followed by Seurat Anchor-Integration. The sample was 
clustered on gene expression by a Resolution-Optimized Louvain Algorithm [35]. Protein 
activity was inferred for all cells by VIPER using the SCTransform gene expression signature 
and the T-cell ARACNe network derived from sorted T-cell bulk-RNA-Seq. The single-cell data 
were then re-clustered on VIPER protein activity (Figure 85B). Top 5 most differentially 
upregulated proteins per cluster were assessed by t-test (Figure 85C). Enrichment of the TI-Treg 
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MRs was assessed by Gene Set Enrichment Analysis (GSEA) on a cell-by-cell basis, with 
normalized enrichment scores shown in Figure 84B and protein activity of the individual MRs 
shown in Figure 84C. Cluster frequencies were plotted for each sample (Vehicle-Treated Tumor, 
Vehicle-Treated Spleen, Gem-Treated Tumor, Gem-Treated Spleen), with pairwise comparisons 






















In this thesis I have developed and validated a suite of novel tools leveraging protein activity 
inference in single cells to profile the micro-environment of distinct tumor types and presented a 
platform to accelerate both drug repurposing in the context of immunotherapy resistance and 
rapid validation of novel therapeutic targets. The algorithms developed and successfully applied 
to elucidate aspects of tumor immune biology include the analytical pipeline for single-cell 
protein activity inference described, comprehensively validated, and benchmarked in Chapter 1, 
as well as the novel resolution-optimized Louvain clustering approach and receptor-ligand 
interaction inference described in Chapter 2, and the single-cell OncoTreat/OncoTarget drug 
prediction algorithms first described in Chapter 3. With these tools, the micro-environment of 
various tumors and their response to immunotherapy may be profiled at greater resolution than 
previously possible, with detection of key signaling and regulatory proteins which control 
downstream cell phenotype. In aggregate, we have discovered that different tumor types have 
different populations of cells driving therapy response and resistance, with opportunity to tailor 
therapies both to particular tumor types and to individual patients, targeting both tumor cells and 
cells in their immune microenvironment. 
 
Critically, this work has demonstrated the successful application of cell sub-population markers 
derived from single-cell protein activity inference to perform Gene Set Enrichment Analysis in 
larger clinically-annotated bulk-RNA Sequencing databases such as TCGA, enabling 
independent validation of clinically significant immune and tumor sub-cluster signatures initially 
discovered in small single-cell RNA-Seq patient cohorts using much larger bulk RNA-Seq 
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cohorts. In Chapter 2, we use this approach to discover the association of our newly discovered 
tumor-specific C1Q+/TREM2+/APOE+ Macrophages in clear cell renal carcinoma with early 
post-surgical recurrence in two independent bulk-RNA-Seq cohorts, where prognostic 
significance of this population and its VIPER-discovered markers was additionally validated by 
quantitative immunofluorescence. In Chapter 4, the same approach enabled us to identify which 
sub-populations of head-and-neck cancer fibroblasts were associated with improved or worsened 
response to anti-PD1 immunotherapy, which was confirmed by flow cytometry and functional 
co-culture experiments. In Chapter 7, this approach was extended to prostate tumor sub-clusters 
to confirm that populations with distinct inferred drug sensitivity to TOP2A which were 
observed to be enriched at baseline in non-responders to immunotherapy are also enriched in 
TCGA among patients with shorter recurrence-free survival times. Finally, in Chapter 5, we take 
the single-cell derived Master Regulator enrichment approach to the pure biomarker discovery 
task of classifying responders vs. non-responders to anti-PD1 checkpoint immunotherapy in 
melanoma, where we achieve excellent classification accuracy across two independent bulk-
RNA sequencing cohorts, although the functional role of the biomarker proteins identified 
remains to be explored.  
 
In a broad systems biology approach leveraging protein activity inference, we can discover that 
different cell clusters associate with outcome in different tumor types, such that we can use these 
populations as biomarkers for treatment prioritization, but also target their active Master 
Regulator proteins and inferred drug sensitivities in combination with immunotherapy to 
potentially sensitize non-responders. This analysis pipeline represents a substantial improvement 
on previous approaches of analyzing single cell data and has yielded multiple actionable therapy 
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targets across a broad range of tumor types and cell types. In particular, we have identified the 
following: 
 
In Chapter 2, a population of recurrence-associated C1Q+/TREM2+/APOE+ Macrophages in 
clear cell renal carcinoma, but not in the other tumor types examined, indicating that intra-
tumoral frequency of this population may effectively risk-stratify patients for prioritization of 
more aggressive up-front treatment options and targeting it for depletion may provide clinical 
benefit in ccRCC.  
 
In Chapter 3, we observe a significant and diverse immune infiltrate in cholangiocarcinoma, such 
that traditional bulk RNA-Sequencing is dominated by non-tumor cells, but our approach allows 
us to isolate and infer the sensitivity of cholangiocarcinoma tumor cells themselves to 
plicamycin and dacinostat, validated in a pre-clinical Patient-Derived Xenograft model. 
Although limited to a case report, this precision medicine approach and the two drug candidates 
discovered merit clinical follow-up, since there are no effective treatment options for 
cholangiocarcinoma currently in the clinic.   
 
In Chapter 4, we find distinct fibroblast sub-clusters in head and neck squamous cell carcinoma 
(HNSCC) associated with improved response to immunotherapy which decrease T-cell 
exhaustion in co-culture but have not been described in previous studies of fibroblasts in breast 
cancer or pancreatic adenocarcinoma, and appear to be HNSCC-specific. Stimulation of these 
fibroblasts ex vivo may represent a novel paradigm for combination with checkpoint inhibitor 




In Chapter 6, we discover that androgen deprivation therapy (ADT) in prostate cancer is actually 
immunogenic, stimulating a robust infiltration by cytotoxic CD8 T-cells which is then 
neutralized by an infiltration of immunosuppressive regulatory T-cells, or Tregs, although 
modestly improved outcomes were observed in combination of ADT with a GVAX immune-
therapy. The discovery of immunogenic effect of ADT has already led to active clinical trials of 
combination ADT with immune checkpoint inhibitors, in both the primary and metastatic 
contexts, which we are profiling at the single-cell level and discuss further in Chapter 7, as well 
as motivating the inhibition of Tumor-Infiltrating Tregs, which are observed not only in prostate 
cancer but across a range of tumor types, which is further explored in Chapter 8.  
 
In Chapter 7, we discover among other things that in combination of androgen deprivation plus 
immunotherapy-treated prostate cancer, infiltration at baseline by CD4 T-cells with high activity 
of TNF inferred by VIPER is associated with worse clinical outcomes, as well as that infiltrating 
CD8 T-cells have high activity of the immune checkpoint LAG3, suggesting a rationale for 
combination of anti-PD1 checkpoint immunotherapy in prostate cancer with both TNF and 
LAG3 inhibitors, which are currently in clinical investigation across a range of other tumor 
types. Furthermore, we discover recurrence-associated tumor cell subpopulations with inferred 
sensitivity to TOP2A inhibitors, the signature for which is also enriched among patients in 
TCGA with early post-treatment recurrence. This suggests TOP2A inhibitors as an additional 




Finally, in Chapter 8 we discover Master Regulators of tumor infiltration by immunosuppressive 
regulatory T-cells from a clinical database including prostate cancer, bladder cancer, renal cell 
carcinoma, and glioblastoma. We present here an entire platform for functional validation of 
immune Master Regulators in the tumor micro-environment by CRISPR as well as a high-
throughput drug screening approach for rapid repurposing of FDA-approved and investigational 
oncology compounds with beneficial off-target effects on the Treg transcriptional profile 
resulting in reduced tumor-infiltration. By this approach, we make two clinically significant 
discoveries with potential pan-cancer implications as a novel approach for immunotherapeutic 
treatment, targeting tumor-infiltrating Tregs without significantly depleting circulating Tregs or 
tumor-infiltrating non-Treg T-cells. First, we identify very-low-dose gemcitabine as 
differentially toxic to tumor-infiltrating Tregs, with significant inhibition of tumor growth rate in 
mouse models alone and in combination with anti-PD1 checkpoint immunotherapy. In addition, 
we identify single-gene knockout of TRPS1 (the most strongly validated Tumor-Treg Master 
Regulator) in the hematopoietic lineage as having a significant effect on tumor growth, leading 
to spontaneous rejection in 50% of mice implanted with MCA205 tumor model.   
 
This final discovery in effective inhibition of Tumor-Specific Tregs based on discoveries from 
protein activity inference represents a very useful paradigm for high-throughput ex vivo drug 
screening and functional validation of putative immune micro-environment treatment targets by 
hematopoietic stem cell CRISPR. Such an approach can readily be extended beyond Tregs to 
macrophages such as those discovered in clear cell renal carcinoma, or even to fibroblasts, in 





In addition to pursuing pre-clinical and clinical trials targeting the treatment resistance associated 
elements of immune micro-environment described above, we are actively pursuing additional 
work in progress clarifying the functional role of prognostic markers of melanoma anti-PD1 
response discovered in Chapter 5, as well as extending the Treg drug screening platform 
described in Chapter 8 to other immunosuppressive cell types, including Macrophages and 
myeloid-derived suppressor cells. Work is ongoing in single-cell profiling of our clinical trial 
testing combination ADT with anti-CTLA4 immunotherapy in primary prostate cancer, awaiting 
follow-up to define treatment responders and non-responders. We are also collaborating with 
Abate-Shen lab to profile circulating tumor cells by single-cell RNA-Sequencing in a mouse 
model of prostate cancer metastasizing to the bone [221], from which we may characterize the 
transition from primary to metastatic prostate tumor phenotype with respect to both tumor cells 
and micro-environment. We are also accruing single-cell RNA-Sequencing data from a clinical 
trial of il1-beta inhibition in clear cell renal carcinoma, which has been shown in mice to 
remodel the tumor macrophage compartment and reduce tumor growth rate [229], with 
significant implications for differentiation or depletion of the C1Q/TREM2/APOE Macrophage 
phenotype we observe in treatment-naïve renal carcinoma.  
 
On the technical side, we are working to further improve the analysis pipeline described in 
Chapter 1 and have implemented a protein-activity-based cell type inference to replace SingleR 
in the workflow, as well as working to incorporate updated versions of ARACNe. As the 
pipeline has been designed with intentional modularity, any future changes to the workflow will 
be benchmarked for improvement in technical and biological robustness against the benchmarks 
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described in Chapter 1. Furthermore, since we have identified that given high-quality context 
matched ARACNe networks protein activity inferences are robust to significant data dropout, we 
are actively compiling a resource of ARACNe networks for each cell type reported in the Human 
Single Cell Type Atlas [230], to be included in the final publication of our pipeline validation 
manuscript as a resource for the community. The Single Cell Type Atlas aggregates 4,012,680 
single cells from 13 different healthy human tissues, reporting 192 individual cell type clusters 
corresponding to 12 major cell type lineages. Given the selection for high data quality in this 
resource, ARACNe networks compiled across the entire range of cell types and tissue sites 
represented in this atlas may be used by researchers with significantly lower-quality data (Mean 
UMI counts below 5000 UMIs/cell) to salvage protein activity inference using ARACNe 
networks in the same cell lineage as the cells being profiled.  
 
Finally, the principles and discoveries demonstrated in this thesis extend beyond the study of 
tumor micro-environment response to immunotherapy to include other forms of cancer 
treatment, including an active study of response to radiation therapy by protein activity inference 
on single-cell RNA-Sequencing at varying levels of radiation over time, where we have  
discovered and are further studying a resistance to radiation among myeloid cells relative to T-
cells. The analysis pipeline developed can be extended even to study of non-malignant 
pathologies, such as organ transplant rejection, autoimmune disease, etc., where the 
immunosuppressive populations we have identified may actually be of clinical benefit. In 
summary, this thesis presents a broad systems biology approach to studying drivers of single-cell 
state in association with disease and a set of discoveries in the field of cancer immunotherapy 
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identifying cell populations driving subsequent response or non-response, with significant 

























[1]  L. Galluzzi et al., "Immunological Effects of Conventional Chemotherapy and Targeted 
Anticancer Agents," Cancer Cell, vol. 28, no. 6, pp. 690-714, 2015.  
[2]  G. T. Gibney et al., "Predictive Biomarkers for Checkpoint Inhibitor-Based 
Immunotherapy," The Lancet Oncology, vol. 17, no. 12, 2016.  
[3]  G. Schepisi et al., "Inflammatory Biomarkers as Predictors of Response to 
Immunotherapy in Urological Tumors," Journal of Oncology, pp. 1-11, 2019.  
[4]  Y.-C. Shen et al., "Combining Intratumoral Treg Depletion with Androgen Deprivation 
Therapy (ADT): Preclinical Activity in the Myc-CaP Model," Prostate Cancer and 
Prostatic Diseases, vol. 21, no. 1, p. 113–125, April 2018.  
[5]  W. Hugo et al., "Genomic and Transcriptomic Features of Response to Anti-PD-1 
Therapy in Metastatic Melanoma," Cell, vol. 168, no. 3, p. 542, 2017.  
[6]  J. Kalina et al., "Immune Modulation by Androgen Deprivation and Radiation Therapy: 
Implications for Prostate Cancer Immunotherapy," Cancers, vol. 9, no. 12, p. 13, 2017.  
[7]  N. Riaz et al., "Tumor and Microenvironment Evolution during Immunotherapy with 
Nivolumab," Cell, vol. 171, no. 4, p. 934–949, November 2017.  
[8]  Z. Lopez-Bujanda and C. G. Drake, "Myeloid-Derived Cells in Prostate Cancer 
Progression: Phenotype and Prospective Therapies," Journal of Leukocyte Biology, vol. 
102, no. 2, p. 393–406, 2017.  
[9]  R. Noy and J. W. Pollard, "Tumor-Associated Macrophages: From Mechanisms to 
Therapy," Immunity, vol. 41, no. 5, p. 866, 2014.  
329 
 
[10]  S. Ostrand-Rosenberg et al., "Cross-Talk between Myeloid-Derived Suppressor Cells 
(MDSC), Macrophages, and Dendritic Cells Enhances Tumor-Induced Immune 
Suppression," Seminars in Cancer Biology, vol. 22, no. 4, p. 275–281, 2012.  
[11]  R. Saleh and E. Elkord, "Treg-Mediated Acquired Resistance to Immune Checkpoint 
Inhibitors," Cancer Letters, vol. 457, p. 168–179, 2019.  
[12]  C. G. Drake et al., "Androgen Ablation Mitigates Tolerance to a Prostate/Prostate Cancer-
Restricted Antigen," Cancer Cell, vol. 7, no. 3, p. 239–249, 2005.  
[13]  J. A. Wargo et al., "Immune Effects of Chemotherapy, Radiation, and Targeted Therapy 
and Opportunities for Combination With Immunotherapy," Seminars in Oncology, vol. 
42, no. 4, p. 601–616, 2015.  
[14]  L. A. Emens and G. Middleton, "The Interplay of Immunotherapy and Chemotherapy: 
Harnessing Potential Synergies," Cancer Immunology Research, vol. 3, no. 5, p. 436–443, 
2015.  
[15]  C. W. Wanderley et al., "Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-
Associated Macrophages to an M1- Profile in a TLR4-Dependent Manner," Cancer 
Research, 2018.  
[16]  G. Zheng et al., "Massively Parallel Digital Transcriptional Profiling of Single Cells," 
Nature Communications, 16 January 2017.  
[17]  M. Sade-Feldman et al., "Defining T Cell States Associated with Response to Checkpoint 
Immunotherapy in Melanoma," Cell, vol. 175, no. 4, p. 998–1013, November 2018.  
[18]  L. Jerby-Arnon et al., "A Cancer Cell Program Promotes T Cell Exclusion and Resistance 
to Checkpoint Blockade," Cell, vol. 175, no. 4, p. 984–997, November 2018.  
330 
 
[19]  Q. Wang et al., "Single-Cell Profiling Guided Combinatorial Immunotherapy for Fast-
Evolving CDK4/6 Inhibitor-Resistant HER2-Positive Breast Cancer," Nature 
Communications, vol. 10, no. 1, 2019.  
[20]  T. Stuart et al., "Comprehensive integration of single-cell data," Cell, vol. 177, no. 7, pp. 
1888-902, 13 June 2019.  
[21]  M. J. Alvarez et al., "Functional Characterization of Somatic Mutations in Cancer Using 
Network-Based Inference of Protein Activity," Nature Genetics, vol. 48, no. 8, p. 838–
847, 2016.  
[22]  A. Califano and M. J. Alvarez, "The Recurrent Architecture of Tumour Initiation, 
Progression and Drug Sensitivity," Nature Reviews Cancer, vol. 17, no. 2, p. 116–130, 
2016.  
[23]  A. Lachmann et al., "ARACNe-AP: Gene Network Reverse Engineering through 
Adaptive Partitioning Inference of Mutual Information," Bioinformatics, vol. 32, no. 14, 
p. 2233–2235, 2016.  
[24]  M. J. Alvarez et al., "A Precision Oncology Approach to the Pharmacological Targeting 
of Mechanistic Dependencies in Neuroendocrine Tumors," Nature Genetics, vol. 50, no. 
18, p. 979–989, June 2018.  
[25]  F. M. Giorgi et al., "Inferring Protein Modulation from Gene Expression Data Using 
Conditional Mutual Information," PLoS ONE, vol. 9, no. 10, 2014.  
[26]  H. Ding et al., "Quantitative Assessment of Protein Activity in Orphan Tissues and Single 
Cells Using the MetaVIPER Algorithm," Nature Communications, vol. 9, no. 1, 2018.  
331 
 
[27]  He P et al., "The changing mouse embryo transcriptome at whole tissue and single-cell 
resolution," Nature, vol. 583, no. 7818, pp. 760-767, July 2020.  
[28]  Qian J et al., "A pan-cancer blueprint of the heterogenous tumor microenvironment 
revealed by single-cell profiling," Cell Res, vol. 30, no. 9, pp. 745-762, September 2020.  
[29]  J. Zhao et al., "Single-cell RNA sequencing reveals the heterogeneity of liver-resident 
immune cells in human," Cell Discovery, vol. 6, no. 22, 2020.  
[30]  G. Xu et al., "The differential immune responses to COVID-19 in peripheral and lung 
revealed by single-cell RNA sequencing," Cell Discovery, vol. 6, no. 73, 20 October 
2020.  
[31]  E. Speranza et al., "Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics 
in lungs of African green monkeys," Sci Transl Med, vol. 13, no. 578, 27 Jan 2021.  
[32]  G. Finak et al., "MAST: a flexible statistical framework for assessing transcriptional 
changes and characterizing heterogeneity in single-cell RNA sequencing data," Genome 
Biology, vol. 16, no. 278, 2015.  
[33]  E. Elyada et al., "Cross-Species Single-Cell Analysis of Pancreatic Ductal 
Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts," Cancer 
discovery, vol. 9, pp. 1102-1123, 2019.  
[34]  W. Chung et al., "Single-cell RNA-seq enables comprehensive tumour and immune cell 




[35]  A. Obradovic et al., "Single-Cell Protein Activity Analysis Identified Recurrence-
Associated Renal Tumor Macrophages," Cell, vol. 184, no. 11, pp. 2988-3005, 27 May 
2021.  
[36]  A. Butler et al., "Integrating single-cell transcriptomic data across different conditions, 
technologies, and species," Nature Biotechnology, vol. 36, pp. 411-420, 2018.  
[37]  V. Thorsson et al., "The Immune Landscape of Cancer," Immunity, vol. 48, no. 4, pp. 812-
830, 17 April 2018.  
[38]  R. Kushwaha et al., "Interrogation of a context-specific transcription factor network 
identifies novel regulators of pluripotency," Stem Cells, vol. 33, no. 2, pp. 367-377, 
February 2015.  
[39]  P. Laise et al., "Pancreatic ductal adenocarcinoma comprises coexisting regulatory states 
with both common and distinct dependencies," bioRxiv, 2020.  
[40]  K. Basso et al., "Reverse engineering of regulatory networks in human B cells," Nature 
Genetics, vol. 37, no. 4, pp. 382-90, 2005.  
[41]  P. Rajbhandari et al., "Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive 
Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma," Cancer 
Discovery, vol. 8, no. 5, pp. 582-599, May 2018.  
[42]  M. Carro et al., "The transcriptional network for mesenchymal transformation of brain 
tumours," Nature, vol. 463, pp. 318-325, 2010.  
[43]  A. Aytes et al., "ETV4 promotes metastasis in response to activation of PI3-kinase and 
Ras signaling in a mouse model of advanced prostate cancer," Proceedings of the 
National Academy of Sciences, vol. 110, no. 37, pp. E3506-E3515, 2013.  
333 
 
[44]  T. Zeleke et al., "Network-based assessment of HDAC6 activity is highly predictive of 
pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat," medRxiv, 2020.  
[45]  K. Mani et al., "Systems biology and personalized medicine in cancer," Current 
Pharmacogenomics and Personalized Medicine, vol. 8, no. 1, pp. 64-72, 2010.  
[46]  M. Stoeckius et al., "Simultaneous epitope and transcriptome measurement in single 
cells," Nature Methods, vol. 14, pp. 865-868, September 2017.  
[47]  A. Teschendorff et al., "Single-cell entropy for accurate estimation of differentiation 
potency from a cell’s transcriptome," Nature Communications, vol. 8, no. 15599, 2017.  
[48]  D. Aran et al., "Reference-based analysis of lung single-cell sequencing reveals a 
transitional profibrotic macrophage," Nature Immunology, vol. 20, no. 2, pp. 163-172, 
February 2019.  
[49]  J. Martens et al., "BLUEPRINT: mapping human blood cell epigenomes," 
Haematologica, vol. 98, no. 10, pp. 1487-1489, 2013.  
[50]  The ENCODE Project Consortium et al., "An integrated encyclopedia of DNA elements 
in the human genome," Nature, vol. 489, p. 57–74, 2012.  
[51]  H. Koul et al., "Molecular aspects of renal cell carcinoma: a review," American journal of 
cancer research, vol. 1, no. 2, pp. 240-254, 2011.  
[52]  A. Sánchez-Gastaldo et al., "Systemic treatment of renal cell cancer: A comprehensive 
review," Cancer Treatment Reviews, vol. 60, pp. 77-89, 2017.  
[53]  T. Davoli et al., "Tumor aneuploidy correlates with markers of immune evasion and with 
reduced response to immunotherapy," Science, vol. 355, 2017.  
334 
 
[54]  Y. Senbabaoglu et al., "Tumor immune microenvironment characterization in clear cell 
renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger 
RNA signatures," Genome Biology, vol. 17, no. 231, 2016.  
[55]  S. Turajlic et al., "Insertion-and-deletion-derived tumour-specific neoantigens and the 
immunogenic phenotype: a pan-cancer analysis," The Lancet Oncology, vol. 18, pp. 1009-
1021, 2017.  
[56]  X. Li et al., "Prognostic value of CD44 expression in renal cell carcinoma: a systematic 
review and meta-analysis," Scientific Reports, vol. 5, no. 13157, 2015.  
[57]  S. Chevrier et al., "An Immune Atlas of Clear Cell Renal Cell Carcinoma," Cell, vol. 169, 
no. 4, pp. 736-749, 2017.  
[58]  J. Chao et al., "Unlocking the Complexities of Tumor-Associated Regulatory T Cells," 
Journal of immunology, vol. 200, pp. 415-421, 2018.  
[59]  K. Mani et al., "A systems biology approach to prediction of oncogenes and molecular 
perturbation targets in B-cell lymphomas," Molecular Systems Biology, vol. 4, no. 169, 
2008.  
[60]  F. Vargas et al., "Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T 
Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors," Immunity, 
vol. 46, no. 4, pp. 577-586, 2017.  
[61]  E. Becht et al., "Prognostic and Theranostic Impact of Molecular Subtypes and Immune 
Classifications in Renal Cell Cancer (RCC) and Colorectal Cancer (CRC)," 
OncoImmunology, vol. 4, no. 12, July 2015.  
335 
 
[62]  O. Khan et al., "TOX transcriptionally and epigenetically programs CD8+ T cell 
exhaustion," Nature, vol. 571, pp. 211-218, 2019.  
[63]  A. Scott et al., "TOX is a critical regulator of tumour-specific T cell differentiation," 
Nature, vol. 571, p. 270–274, 2019.  
[64]  A. Dutta et al., "Identification of an NKX3.1-G9a-UTY transcriptional regulatory network 
that controls prostate differentiation," Science, vol. 352, pp. 1576-1580, 2016.  
[65]  F. Talos et al., "A computational systems approach identifies synergistic specification 
genes that facilitate lineage conversion to prostate tissue," Nature communications, vol. 8, 
no. 14662, 2017.  
[66]  K. Arumugam et al., "The Master Regulator Protein BAZ2B Can Reprogram Human 
Hematopoietic Lineage-Committed Progenitors into a Multipotent State," Cell Reports, 
vol. 33, no. 10, p. 108474, 8 December 2020.  
[67]  A. Barkal et al., "CD24 signalling through macrophage Siglec-10 is a target for cancer 
immunotherapy," Nature, vol. 572, pp. 392-396, 2019.  
[68]  D. Arik et al., "Prognostic Significance of CD24 in Clear Cell Renal Cell Carcinoma," 
Pathology & Oncology Research, vol. 23, pp. 409-416, 2017.  
[69]  H. S. Tan et al., "KRT8 upregulation promotes tumor metastasis and is predictive of a 
poor prognosis in clear cell renal cell carcinoma," Oncotarget, vol. 8, no. 44, p. 76189, 29 
September 2017.  
[70]  N. J. Farber et al., "Renal cell carcinoma: the search for a reliable biomarker," 
Translational cancer research, vol. 6, no. 3, pp. 620-632, 2017.  
336 
 
[71]  J. J. Hsieh et al., "Chromosome 3p Loss–Orchestrated VHL, HIF, and Epigenetic 
Deregulation in Clear Cell Renal Cell Carcinoma," Journal of Clinical Oncology, vol. 36, 
no. 36, p. 3533–3539, 2018.  
[72]  M. Lizio et al., "Update of the FANTOM web resource: expansion to provide additional 
transcriptomic atlases," Nucleic Acids Research, vol. 47, pp. D752-D758, 2019.  
[73]  J. Jacobs et al., "CD70: An emerging target in cancer immunotherapy," Pharmacology & 
therapeutics, vol. 155, pp. 1-10, 2015.  
[74]  L. Jilaveanu et al., "CD70 expression patterns in renal cell carcinoma," Human Pathology, 
vol. 43, pp. 1394-1399, 2012.  
[75]  L. Roumenina et al., "Tumor Cells Hijack Macrophage-Produced Complement C1q to 
Promote Tumor Growth," Cancer Immunology Research, vol. 7, pp. 1091-1105, 2019.  
[76]  A. Ramirez et al., "Functional characterization of a novel TREM2 coding variant linked to 
familial Alzheimer’s disease," Alzheimer's & Dementia, vol. 11, p. P500, 2015.  
[77]  P. Roussos et al., "The triggering receptor expressed on myeloid cells 2 (TREM2) is 
associated with enhanced inflammation, neuropathological lesions and increased risk for 
Alzheimer's dementia," Alzheimers & Dementia, vol. 11, pp. 1163-1170, 2015.  
[78]  X. Wang et al., "Overexpression of TREM2 enhances glioma cell proliferation and 
invasion: a therapeutic target in human glioma," Oncotarget, vol. 7, pp. 2354-2366, 2016.  
[79]  Y. Yao et al., "TREM-2 serves as a negative immune regulator through Syk pathway in an 
IL-10 dependent manner in lung cancer," Oncotarget, vol. 7, pp. 29620-29634, 2016.  
337 
 
[80]  Y. Katzenelenbogen et al., "Coupled scRNA-Seq and Intracellular Protein Activity Reveal 
an Immunosuppressive Role of TREM2 in Cancer," Cell, vol. 182, no. 4, pp. 872-
885.e19, 20 August 2020.  
[81]  E. Brunt et al., "cHCC‐CCA: Consensus terminology for primary liver carcinomas with 
both hepatocytic and cholangiocytic differentation," Hepatology, vol. 68, no. 1, pp. 113-
126, 2018.  
[82]  R. Dhanasekaran et al., "Treatment outcomes and prognostic factors of intrahepatic 
cholangiocarcinoma," Oncology reports, vol. 29, no. 4, pp. 1259-1267, 2013.  
[83]  A. Society et al., "Survival Rates for Bile Duct Cancer," 2021. [Online]. Available: 
https://www.cancer.org/cancer/bile-duct-cancer/detection-diagnosis-staging/survival-by-
stage.html. 
[84]  L. Fabris et al., "The tumour microenvironment and immune milieu of 
cholangiocarcinoma," Liver International, vol. 39, pp. 63-78, 2019.  
[85]  E. Loeuillard et al., "Targeting tumor-associated macrophages and granulocytic myeloid-
derived suppressor cells augments PD-1 blockade in cholangiocarcinoma," The Journal of 
clinical investigation, vol. 130, no. 10, 2020.  
[86]  S. Rizvi and G. Gores, "Pathogenesis, diagnosis, and management of 
cholangiocarcinoma," Gastroenterology, vol. 145, no. 6, pp. 1215-1229, 2013.  
[87]  K. Chang et al., "The Cancer Genome Atlas Pan-Cancer analysis project," Nature 
genetics, vol. 45, no. 10, pp. 1113-1120, 2013.  
338 
 
[88]  R. Tobin et al., "IL-6 and IL-8 are linked with myeloid-derived suppressor cell 
accumulation and correlate with poor clinical outcomes in melanoma patients," Frontiers 
in oncology, vol. 9, no. 1223, 2019.  
[89]  Z. Lopez-Bujanda et al., "TGM4: an immunogenic prostate-restricted antigen," Journal 
for immunotherapy of cancer, vol. 9, no. 6, 2021.  
[90]  M. Gonzalez-Aparicio and C. Alfaro, "Significance of the IL-8 pathway for 
immunotherapy," Human vaccines & immunotherapeutics, vol. 16, no. 10, pp. 2312-2317, 
2020.  
[91]  L. Li et al., "Human primary liver cancer organoids reveal intratumor and interpatient 
drug response heterogeneity," JCI insight, vol. 4, no. 2, 2019.  
[92]  D. Jung et al., "CG200745, an HDAC inhibitor, induces anti-tumour effects in 
cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway," Scientific 
reports, vol. 7, no. 1, pp. 1-13, 2017.  
[93]  K. Pant et al., "Role of histone deacetylases in carcinogenesis: potential role in 
cholangiocarcinoma," Cells, vol. 9, no. 3, p. 780, 2020.  
[94]  R. Ferris et al., "Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and 
Neck," New England Journal of Medicine, vol. 375, no. 19, pp. 1856-1867, 2016.  
[95]  T. Seiwert et al., "Safety and clinical activity of pembrolizumab for treatment of recurrent 
or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-
label, multicentre, phase 1b trial," Lancet Oncology, vol. 17, no. 7, pp. 956-965, 2016.  
339 
 
[96]  R. Mehra et al., "Efficacy and safety of pembrolizumab in recurrent/metastatic head and 
neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-
012," British Journal of Cancer, vol. 119, no. 2, pp. 153-159, 2018.  
[97]  B. Burtness et al., "Pembrolizumab alone or with chemotherapy versus cetuximab with 
chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck 
(KEYNOTE-048): a randomised, open-label, phase 3 study," Lancet, vol. 394, no. 10212, 
pp. 1915-1928, 2019.  
[98]  C. Feig et al., "Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts 
synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.," Proceedings of the 
National Academy of Sciences of the United States of America, vol. 110, no. 50, p. 20212, 
2013.  
[99]  C. Dominguez et al., "Single-Cell RNA Sequencing Reveals Stromal Evolution into 
LRRC15(+) Myofibroblasts as a Determinant of Patient Response to Cancer 
Immunotherapy," Cancer Discovery, vol. 10, no. 2, pp. 232-253, 2020.  
[100]  Y. Kieffer et al., "Single-Cell Analysis Reveals Fibroblast Clusters Linked to 
Immunotherapy Resistance in Cancer," Cancer Discovery, vol. 10, no. 9, pp. 1330-1351, 
2020.  
[101]  A. Costa et al., "Fibroblast Heterogeneity and Immunosuppressive Environment in 
Human Breast Cancer," Cancer Cell, vol. 33, no. 3, pp. 463-479, 2018.  
[102]  D. Ohlund et al., "Distinct populations of inflammatory fibroblasts and myofibroblasts in 
pancreatic cancer," Journal of Experimental Medicine, vol. 214, no. 3, pp. 579-596, 2017.  
340 
 
[103]  S. Puram et al., "Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor 
Ecosystems in Head and Neck Cancer," Cell, vol. 171, no. 7, pp. 1611-1624, 2017.  
[104]  A. Subramanian et al., "Gene set enrichment analysis: A knowledge-based approach for 
interpreting genome-wide expression profiles," Proceedings of the National Academy of 
Sciences of the United States of America, vol. 102, no. 43, pp. 15545-15550, 2005.  
[105]  M. E. Spector et al., "Prognostic value of tumor-infiltrating lymphocytes in head and neck 
squamous cell carcinoma," JAMA Otolaryngology–Head & Neck Surgery, vol. 145, no. 
11, pp. 1012-1019, 2019.  
[106]  R. Uppaluri et al., "Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally 
Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, 
Phase II Trial," Clinical Cancer Research, vol. 26, no. 19, pp. 5140-5152, 2020.  
[107]  N. Direkze et al., "Bone marrow contribution to tumor-associated myofibroblasts and 
fibroblasts," Cancer Research, vol. 64, no. 23, pp. 8492-5, 2004.  
[108]  A. Karnoub et al., "Mesenchymal stem cells within tumour stroma promote breast cancer 
metastasis," Nature, vol. 449, no. 7162, pp. 557-63, 2007.  
[109]  P. Mishra et al., "Carcinoma-associated fibroblast-like differentiation of human 
mesenchymal stem cells," Cancer Research, vol. 68, no. 11, pp. 4331-9, 2008.  
[110]  Y. Kojima et al., "Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) 
signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts," 
Proceedings of the National Academy of Sciences of the United States of America, vol. 
107, no. 46, pp. 20009-14, 2010.  
341 
 
[111]  H. Tan et al., "TGFbeta1 is essential for MSCs-CAFs differentiation and promotes 
HCT116 cells migration and invasion via JAK/STAT3 signaling," OncoTargets and 
Therapy, vol. 12, pp. 5323-5334, 2019.  
[112]  J. Larkin et al., "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated 
Melanoma," New England Journal of Medicine, vol. 373, no. 1, pp. 23-34, 2015.  
[113]  M. Lakins et al., "Cancer-associated fibroblasts induce antigen-specific deletion of CD8 
(+) T Cells to protect tumour cells," Nature Communications, vol. 9, no. 1, p. 948, 2018.  
[114]  L. Gorchs et al., "Human Pancreatic Carcinoma-Associated Fibroblasts Promote 
Expression of Co-inhibitory Markers on CD4(+) and CD8(+) T-Cells," Frontiers in 
Immunology, vol. 10, p. 847, 2019.  
[115]  B. Park et al., "TGFbeta1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-
Specific T Cells in Cancer," Cancer Discovery, vol. 6, no. 12, pp. 1366-1381, 2016.  
[116]  C. Hutton et al., "Single-cell analysis defines a pancreatic fibroblast lineage that supports 
anti-tumor immunity," Cancer Cell, vol. 39, no. 9, pp. 1227-1244, 2021.  
[117]  B. Ozdemir et al., "Depletion of carcinoma-associated fibroblasts and fibrosis induces 
immunosuppression and accelerates pancreas cancer with reduced survival," Cancer Cell, 
vol. 25, no. 6, pp. 719-34, 2014.  
[118]  P. Andre et al., "Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor 
Immunity by Unleashing Both T and NK Cells," Cell, vol. 175, no. 7, pp. 1731-1743, 
2018.  
[119]  N. van Montfoort et al., "NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by 
Cancer Vaccines," Cell, vol. 175, no. 7, pp. 1744-1755, 2018.  
342 
 
[120]  N. Lee et al., "HLA-E is a major ligand for the natural killer inhibitory receptor 
CD94/NKG2A," Proceedings of the National Academy of Sciences of the United States of 
America, vol. 95, no. 9, pp. 5199-204, 1998.  
[121]  G. Biffi et al., "IL1-Induced JAK/STAT Signaling Is Antagonized by TGFbeta to Shape 
CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma," Cancer Discovery, vol. 9, no. 
2, pp. 282-301, 2019.  
[122]  A. Luginbuhl et al., "Discordant treatment response in primary tumors and lymph node 
metastases after four weeks of preoperative PD-1 blockade in head and neck squamous 
cell carcinoma (HNSCC)," Journal of Clinical Oncology, vol. 37, pp. 6016-601, 2019.  
[123]  L. Zhang et al., "Lineage tracking reveals dynamic relationships of T cells in colorectal 
cancer," Nature, vol. 564, no. 7735, pp. 268-272, 2018.  
[124]  M. Lizio et al., "Gateways to the FANTOM5 promoter level mammalian expression 
atlas," Genome Biology, vol. 16, p. 22, 2015.  
[125]  D. Liu et al., "Integrative molecular and clinical modeling of clinical outcomes to PD1 
blockade in patients with metastatic melanoma," Nature Medicine, vol. 25, no. 12, pp. 
1916-1927, December 2019.  
[126]  R. Siegel et al., "Cancer statistics," CA: A Cancer Journal for Clinicians, vol. 69, pp. 7-
34, 2019.  
[127]  C. Pound et al., "Natural history of progression after PSA elevation following radical 
prostatectomy," JAMA, vol. 281, pp. 1591-7, 1999.  
343 
 
[128]  A. D'Amico et al., "Combination of the preoperative PSA level, biopsy gleason score, 
percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with 
clinically localized prostate cancer," Urology, vol. 55, pp. 572-7, 2000.  
[129]  S. Slovin et al., "Ipilimumab alone or in combination with radiotherapy in metastatic 
castration-resistant prostate cancer: results from an open-label, multicenter phase I/II 
study," Annals of Oncology, vol. 24, pp. 1813-21, 2013.  
[130]  E. Kwon et al., "Ipilimumab versus placebo after radiotherapy in patients with metastatic 
castration-resistant prostate cancer that had progressed after docetaxel chemotherapy 
(CA184-043): a multicentre, randomised, double-blind, phase 3 trial," Lancet Oncology, 
vol. 15, pp. 700-12, 2014.  
[131]  J. De Bono et al., "KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory 
metastatic castration-resistant prostate cancer (mCRPC)," J Clin Oncol 2018;36, vol. 36, 
2018.  
[132]  T. Beer et al., "Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo 
in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-
Naive Castration-Resistant Prostate Cancer," Journal of Clinical Oncology, vol. 35, pp. 
40-7, 2017.  
[133]  P. Kantoff et al., "Sipuleucel-T immunotherapy for castration-resistant prostate cancer," 
New England Journal of Medicine, vol. 363, pp. 411-22, 2010.  
[134]  K. Boudadi et al., "Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-
expressing metastatic prostate cancer," Oncotarget, vol. 9, pp. 28561-71, 2018.  
344 
 
[135]  P. Sharma et al., "Initial results from a phase II study of nivolumab (NIVO) plus 
ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer 
(mCRPC; CheckMate 650)," Journal of Clinical Oncology, vol. 37, no. 142, 2019.  
[136]  C. Drake et al., "Prostate cancer as a model for tumour immunotherapy," Nature Reviews 
Immunology, vol. 10, pp. 580-93, 2010.  
[137]  M. Haffner et al., "Comprehensive Evaluation of Programmed Death-Ligand 1 Expression 
in Primary and Metastatic Prostate Cancer," American Journal of Pathology, vol. 188, no. 
6, pp. 1478-1485, 2018.  
[138]  M. Sanda et al., "Molecular characterization of defective antigen processing in human 
prostate cancer," Journal of the National Cancer Institute, vol. 87, pp. 280-5, 1995.  
[139]  W. Su et al., "The Polycomb Repressor Complex 1 Drives Double-Negative Prostate 
Cancer Metastasis by Coordinating Stemness and Immune Suppression," Cancer Cell, 
vol. 36, pp. 139-55 , 2019.  
[140]  A. Erlandsson et al., "M2 macrophages and regulatory T cells in lethal prostate cancer," 
Prostate, vol. 79, pp. 363-9, 2019.  
[141]  A. Calcinotto et al., "IL-23 secreted by myeloid cells drives castration-resistant prostate 
cancer," Nature, vol. 559, pp. 363-9, 2018.  
[142]  B. Benzon et al., "Correlation of B7-H3 with androgen receptor, immune pathways and 
poor outcome in prostate cancer: an expression-based analysis," Prostate Cancer and 
Prostatic Diseases, vol. 20, pp. 28-35, 2017.  
[143]  M. Mercader et al., "Early effects of pharmacological androgen deprivation in human 
prostate cancer," BJU International, vol. 99, pp. 60-7, 2007.  
345 
 
[144]  H. Yano et al., "Intratumoral regulatory T cells: markers, subsets and their impact on anti-
tumor immunity," Immunology, vol. 157, pp. 232-47, 2019.  
[145]  H. Akaike et al., "Information Theory and an Extension of the Maximum Likelihood 
Principle," Springer Series in Statistics Breakthroughs in Statistics, p. 610–624, 1992.  
[146]  L. N. Sanchez-Pinto et al., "Comparison of Variable Selection Methods for Clinical 
Predictive Modeling," International Journal of Medical Informatics, vol. 116, p. 10–17, 
2018.  
[147]  E. Vittinghoff and C. Mcculloch, "Relaxing the Rule of Ten Events per Variable in 
Logistic and Cox Regression," American Journal of Epidemiology, vol. 165, no. 6, p. 
710–718, December 2007.  
[148]  M. Ammirante et al., "B-cell-derived lymphotoxin promotes castration-resistant prostate 
cancer," Nature, vol. 464, pp. 302-5, 2010.  
[149]  M. Mercader et al., "T cell infiltration of the prostate induced by androgen withdrawal in 
patients with prostate cancer," Proceedings of the National Academy of Sciences of the 
United States of America, vol. 98, no. 25, pp. 14565-14570, 2001.  
[150]  K. Hagihara et al., "Neoadjuvant sipuleucel-T induces both Th1 activation and immune 
regulation in localized prostate cancer," Oncoimmunology, vol. 8, 2019.  
[151]  L. Fong et al., "Activated lymphocyte recruitment into the tumor microenvironment 
following preoperative sipuleucel-T for localized prostate cancer," Journal of the National 
Cancer Institute, vol. 106, 2014.  
[152]  J. Fu et al., "STING Agonist Formulated Cancer Vaccines Can Cure Established Tumors 
Resistant to PD-1 Blockade," Science Translational Medicine, vol. 7, no. 283, 2015.  
346 
 
[153]  V. Bronte et al., "Boosting antitumor responses of T lymphocytes infiltrating human 
prostate cancers," Journal of Experimental Medicine, vol. 201, no. 8, pp. 1257-1268, 
2005.  
[154]  M. A. Elmonem et al., "Immunomodulatory Effects of Chitotriosidase Enzyme," Enzyme 
Research, pp. 1-9, 2016.  
[155]  S. Wada et al., "Cyclophosphamide Augments Antitumor Immunity: Studies in an 
Autochthonous Prostate Cancer Model," Cancer Research, vol. 69, no. 10, p. 4309–4318, 
December 2009.  
[156]  J. Machiels et al., "Cyclophosphamide, Doxorubicin, and Paclitaxel Enhance the 
Antitumor Immune Response of Granulocyte/Macrophage-Colony Stimulating Factor-
Secreting Whole-Cell Vaccines in HER-2/Neu Tolerized Mice," Cancer Research, vol. 
61, no. 9, May 2001.  
[157]  L. A. Emens et al., "Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, 
and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast 
Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune 
Activation," Journal of Clinical Oncology, vol. 27, no. 35, pp. 5911-5918, October 2009.  
[158]  M. Scurr et al., "Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, 
Which Associate with Survival in Metastatic Colorectal Cancer," Clinical Cancer 
Research, vol. 23, no. 22, November 2017.  
[159]  C. M. Huijts et al., "Phase 1 Study of Everolimus and Low-Dose Oral Cyclophosphamide 
in Patients with Metastatic Renal Cell Carcinoma," Cancer Immunology, Immunotherapy, 
vol. 68, no. 2, p. 319–329, September 2018.  
347 
 
[160]  J. Stultz and L. Fong, "How to turn up the heat on the cold immune microenvironment of 
metastatic prostate cancer," Prostate Cancer and Prostatic Diseases, vol. 24, no. 3, pp. 
697-717, 2021.  
[161]  M. Bilusic et al., "Immunotherapy of Prostate Cancer: Facts and Hopes," Clinical Cancer 
Research, vol. 23, no. 22, 2017.  
[162]  K. Sfanos et al., "Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and 
PD-1+," Prostate, vol. 69, no. 15, pp. 1694-1703, 2009.  
[163]  L. Vargas Roditi et al., "Single-Cell proteomics defines the cellular heterogeneity of 
localized prostate cancer," bioRxiv, 26 January 2021.  
[164]  J. Sutherland et al., "Activation of thymic regeneration in mice and humans following 
androgen blockade," Journal of Immunology, vol. 175, no. 4, pp. 2741-2753, 2005.  
[165]  P. Gannon et al., "Characterization of the intra-prostatic immune cell infiltration in 
androgen-deprived prostate cancer patients," Journal of Immunological Methods, vol. 
348, no. 1-2, pp. 9-17, 2009.  
[166]  M. Morse and D. McNeel, "Prostate cancer patients on androgen deprivation therapy 
develop persistent changes in adaptive immune responses," Human Immunology, vol. 71, 
no. 5, pp. 496-504, 2010.  
[167]  B. Greenstein et al., "Reappearance of the thymus in old rats after orchidectomy: 
inhibition of regeneration by testosterone," Journal of Endocrinology, vol. 110, no. 3, pp. 
417-422, 1986.  
[168]  A. Roden et al., "Augmentation of T cell levels and responses induced by androgen 
deprivation," Journal of Immunology, vol. 173, no. 10, pp. 6098-6108, 2004.  
348 
 
[169]  H. Kissick et al., "Androgens alter T-cell immunity by inhibiting T-helper 1 
differentiation," Proceedings of the National Academy of Sciences of the United States of 
America, vol. 111, no. 27, pp. 9887-9892, 2014.  
[170]  C. Wilson et al., "Enhanced production of B lymphocytes after castration," Blood, vol. 85, 
no. 6, pp. 1535-1539, 1995.  
[171]  K. Windmill and V. Lee, "Effects of castration on the lymphocytes of the thymus, spleen 
and lymph nodes," Tissue Cell, vol. 30, no. 1, pp. 104-111, 1998.  
[172]  C. Sorrentino et al., "Androgen deprivation boosts prostatic infiltration of cytotoxic and 
regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer 
patients," Clinical Cancer Research, vol. 17, no. 6, pp. 1571-1581, 2011.  
[173]  Y. Pu et al., "Androgen receptor antagonists compromise T cell response against prostate 
cancer leading to early tumor relapse," Science Translational Medicine, vol. 8, no. 333, 
2016.  
[174]  S. Tang et al., "Increased CD8+ T-cell function following castration and immunization is 
countered by parallel expansion of regulatory T cells," Cancer Research, vol. 72, no. 8, 
pp. 1975-1985, 2012.  
[175]  L. Brady et al., "Inter- and intra-tumor heterogeneity of metastatic prostate cancer 
determined by digital spatial gene expression profiling," Nature Communications, vol. 12, 
no. 1, pp. 1-16, 2021.  
[176]  M. He et al., "Transcriptional mediators of treatment resistance in lethal prostate cancer," 
Nature Medicine, vol. 27, no. 3, pp. 426-433, 2021.  
349 
 
[177]  J. Fox et al., "Mass cytometry reveals species-specific differences and a new level of 
complexity for immune cells in the prostate," American journal of clinical and 
experimental urology, vol. 7, no. 4, pp. 281-296, 2019.  
[178]  A. Oliver et al., "Tissue-dependent tumor microenvironments and their impact on 
immunotherapy responses," Frontiers in Immunology, vol. 9, no. JAN, p. 70, 2018.  
[179]  D. Hanahan and R. Weinberg, "Hallmarks of cancer: The next generation," Cell, vol. 144, 
no. 5, pp. 646-674, 2011.  
[180]  J. Clark and C. Cooper, "ETS gene fusions in prostate cancer," Nature Reviews Urology, 
vol. 6, no. 8, pp. 429-439, 2009.  
[181]  G. Petrovics et al., "Frequent overexpression of ETS-related gene-1 (ERG1) in prostate 
cancer transcriptome," Oncogene, vol. 24, no. 23, pp. 3847-3852, 2005.  
[182]  S. Chen et al., "Single-cell analysis reveals transcriptomic remodellings in distinct cell 
types that contribute to human prostate cancer progression," Nature Cell Biology, vol. 23, 
no. 1, pp. 87-98, 2021.  
[183]  F. Triebel et al., "LAG-3, a novel lymphocyte activation gene closely related to CD4," 
Journal of Experimental Medicine, vol. 171, no. 5, pp. 1393-1405, 1990.  
[184]  F. Balkwill et al., "TNF-α in promotion and progression of cancer," Cancer and 
Metastasis Reviews, vol. 25, no. 3, pp. 409-416, 2006.  
[185]  A. Montfort et al., "The TNF Paradox in Cancer Progression and Immunotherapy," 
Frontiers in Immunology, vol. 1818, 10 July 2019.  
[186]  E. Perez-Ruiz et al., "Prophylactic TNF blockade uncouples efficacy and toxicity in dual 
CTLA-4 and PD-1 immunotherapy," Nature, vol. 569, no. 7756, pp. 428-432, 2019.  
350 
 
[187]  Y. Zhang et al., "Overexpression of a novel candidate oncogene KIF14 correlates with 
tumor progression and poor prognosis in prostate cancer," Oncotarget, vol. 8, no. 28, pp. 
45459-45469, 2017.  
[188]  D. Wishart et al., "DrugBank: A knowledgebase for drugs, drug actions and drug targets," 
Nucleic Acids Research, vol. 36, 2008.  
[189]  D. Robinson et al., "Integrative clinical genomics of advanced prostate cancer," Cell, vol. 
161, no. 5, pp. 1215-1228, 2015.  
[190]  D. Quigley et al., "Genomic Hallmarks and Structural Variation in Metastatic Prostate 
Cancer," Cell, vol. 174, no. 3, pp. 758-769, 2018.  
[191]  B. Dong et al., "Single-cell analysis supports a luminal-neuroendocrine 
transdifferentiation in human prostate cancer," Communications Biology, vol. 3, no. 1, pp. 
1-15, 2020.  
[192]  W. Karthaus et al., "Regenerative potential of prostate luminal cells revealed by single-
cell analysis," Science, vol. 368, no. 6490, pp. 497-505, 2020.  
[193]  H. Song et al., "Single-cell analysis of human primary prostate cancer reveals the 
heterogeneity of tumor-associated epithelial cell states," bioRxiv, 2020.  
[194]  E. Shenderov et al., "Genomic and clinical characterization of pulmonary-only metastatic 
prostate cancer: A unique molecular subtype," Prostate, vol. 79, no. 13, pp. 1572-1579, 
2019.  
[195]  M. Haffner et al., "Genomic and phenotypic heterogeneity in prostate cancer," Nature 
Reviews Urology, vol. 18, no. 2, pp. 79-92, 2021.  
351 
 
[196]  H. Beltran et al., "Divergent clonal evolution of castration-resistant neuroendocrine 
prostate cancer," Nature Medicine, vol. 22, no. 3, pp. 298-305, 2016.  
[197]  E. Bluemn et al., "Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained 
through FGF Signaling," Cancer Cell, vol. 32, no. 4, pp. 474-489.e6, 2017.  
[198]  M. Labrecque et al., "Molecular profiling stratifies diverse phenotypes of treatment-
refractory metastatic castration-resistant prostate cancer," Journal of Clinical 
Investigation, vol. 129, no. 10, pp. 4492-4505, 2019.  
[199]  A. Obradovic et al., "T-cell infiltration and adaptive treg resistance in response to 
androgen deprivation with or without vaccination in localized prostate cancer," Clinical 
Cancer Research, vol. 26, no. 13, pp. 3182-3192, 2020.  
[200]  J. Grosso et al., "Functionally Distinct LAG-3 and PD-1 Subsets on Activated and 
Chronically Stimulated CD8 T Cells," The Journal of Immunology, vol. 182, no. 11, pp. 
6659-6669, 2009.  
[201]  J. Grosso and C. Drake, "Current immunotherapeutic strategies in prostate cancer," 
Surgical Oncology Clinics of North America, vol. 16, no. 4, pp. 861-871, 2007.  
[202]  E. Lipson et al., "Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line 
advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047)," 
Journal of Clinical Oncology, vol. 39, p. 9503, 2021.  
[203]  C. Zahm et al., "PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy," 
OncoImmunology, vol. 10, no. 1, 2021.  
352 
 
[204]  C. Fares et al., "Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does 
Checkpoint Inhibitor Immunotherapy Not Work for All Patients?," American Society of 
Clinical Oncology Educational Book, vol. 39, pp. 147-164, 2019.  
[205]  R. Zappasodi et al., "Rational design of anti-GITR-based combination immunotherapy," 
Nature Medicine, vol. 25, no. 5, pp. 759-766, 2019.  
[206]  L. Vence et al., "Characterization and Comparison of GITR Expression in Solid Tumors," 
Clinical Cancer Research, vol. 25, no. 21, pp. 6501-6510, 2019.  
[207]  K. Heinhuis et al., "Safety, Tolerability, and Potential Clinical Activity of a 
Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination 
With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-
Escalation and Cohort-Expansion Clinic," JAMA Oncology, vol. 6, no. 1, pp. 100-107, 
2020.  
[208]  B. Tran et al., "Dose escalation results from a first-in-human, phase 1 study of 
glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with 
advanced solid tumors," Journal for ImmunoTherapy of Cancer, vol. 6, no. 1, p. 93, 2018.  
[209]  D. Killock et al., "GITR agonism — combination is key," Nature Reviews Clinical 
Oncology, vol. 16, no. 7, p. 402, 2019.  
[210]  R. Geva et al., "First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐
induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or 
with pembrolizumab in patients with advanced solid tumors," Cancer, vol. 126, no. 22, 
pp. 4926-4935, 2020.  
353 
 
[211]  F. Balkwill et al., "Tumour necrosis factor and cancer," Nature Reviews Cancer, vol. 9, 
no. 5, pp. 361-371, 2009.  
[212]  J. E. Hawley et al., "Association between immunosuppressive cytokines and PSA 
progression in biochemically recurrent prostate cancer treated with intermittent hormonal 
therapy," The Prostate, vol. 80, no. 4, pp. 336-344, 2020.  
[213]  C. Sweeney et al., "Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate 
Cancer," New England Journal of Medicine, vol. 373, no. 8, pp. 737-746, 2015.  
[214]  C. Ager et al., "Longitudinal immune profiling reveals unique myeloid and T-cell 
phenotypes associated with spontaneous immunoediting in a prostate tumor model," 
Cancer Immunology Research, vol. 9, no. 5, pp. 529-541, 2021.  
[215]  P. Thall et al., "New statistical strategy for monitoring safety and efficacy in single-arm 
clinical trials," Journal of Clinical Oncology, vol. 14, no. 1, pp. 296-303, 1996.  
[216]  A. Obradovic et al., "PISCES: A pipeline for the Systematic, Protein Activity-based 
Analysis of Single Cell RNA Sequencing Data," bioRxiv, 1 June 2021.  
[217]  E. Chen et al., "Enrichr: Interactive and collaborative HTML5 gene list enrichment 
analysis tool," BMC Bioinformatics, vol. 14, 2013.  
[218]  A. Abeshouse et al., "The Molecular Taxonomy of Primary Prostate Cancer," Cell, vol. 
163, no. 4, pp. 1011-1025, 2015.  
[219]  T. Simpson et al., "Fc-dependent depletion of tumor-infiltrating regulatory T cells co-
defines the efficacy of anti-CTLA-4 therapy against melanoma," Journal of Experimental 
Medicine, vol. 210, pp. 1695-1710, 2013.  
354 
 
[220]  Z. Freeman et al., "A conserved intratumoral regulatory T cell signature identifies 4-1BB 
as a pan-cancer target," Journal of Clinical Investigation, vol. 130, pp. 1405-1416, 2020.  
[221]  J. Arriaga et al., "A MYC and RAS co-activation signature in localized prostate cancer 
drives bone metastasis and castration resistance," Nature Cancer, vol. 1, no. 11, pp. 1082-
1096, November 2020.  
[222]  M. LaFleur et al., "Inhibitors of the PD-1 Pathway in Tumor Therapy," Journal of 
immunology, vol. 200, pp. 375-383, 2018.  
[223]  M. De Simone et al., "Transcriptional landscape of human tissue lymphocytes unveils 
uniqueness of tumor-infiltrating T regulatory cells," Immunity, vol. 45, no. 5, pp. 1135-
1147, 2016.  
[224]  G. Plitas et al., "Regulatory T cells exhibit distinct features in human breast cancer," 
Immunity, vol. 45, no. 5, pp. 1122-1134, 2016.  
[225]  C. Zheng et al., "Landscape of infiltrating T cells in liver cancer revealed by single-cell 
sequencing," Cell, vol. 169, no. 7, pp. 1342-1356, 2017.  
[226]  A. M. Magnuson et al., "Identification and validation of a tumor-infiltrating Treg 
transcriptional signature conserved across species and tumor types," Proceedings of the 
National Academy of Sciences, vol. 115, no. 45, pp. E10672-E10681, 2018.  
[227]  M. Stubbington et al., "T cell fate and clonality inference from single-cell 
transcriptomes," Nature Methods, vol. 13, pp. 329-332, 2016.  
[228]  S. Loontiens et al., "Purification of high-quality RNA from a small number of 
fluorescence activated cell sorted zebrafish cells for RNA sequencing purposes," BMC 
Genomics, vol. 20, no. 228, 2019.  
355 
 
[229]  D. Aggen et al., "Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the 
Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses," 
Clinical Cancer Research, vol. 27, no. 2, pp. 608-621, 15 January 2021.  
[230]  M. Uhlén et al., "Proteomics. Tissue-based map of the human proteome," Science, vol. 
347, no. 6220, p. 1260419, 23 January 2015.  
 
 
 
 
 
 
 
 
